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The C1858T single nucleotide polymorphism in the human protein tyrosine phosphatase non-
receptor type 22 (PTPN22) gene encodes an R620W missense mutation in PTPN22 (PTPN22R620W) 
and is associated with an increased susceptibility to multiple autoimmune diseases including 
rheumatoid arthritis, systemic lupus erythematosus and type 1 diabetes. PTPN22 is expressed 
in all immune cells and is a negative regulator of Src and spleen tyrosine kinase (Syk) family 
kinases downstream of multiple immunoreceptors including the T cell receptor, the B cell 
receptor, the αLβ2 integrin LFA-1, Toll-like receptors and dectin-1.  
As many of the autoimmune diseases associated with the polymorphism in PTPN22 have an 
autoantibody component to their pathology, the aim of this thesis was to identify whether 
PTPN22 regulates signalling downstream of Fc receptors. Fcγ receptors (FcγRs) recognise the Fc 
region of IgG autoantibodies when they bind to autoantigens and form immune complexes. 
After immune complex binding and receptor crosslinking, FcγRs signal via Src and Syk family 
kinases, known targets of PTPN22, leading to effector functions including antigen uptake, 
antigen presentation and cytokine secretion. Bone marrow derived dendritic cells (BMDCs) from 
wild type (WT) and Ptpn22-/- mice were pulsed with ovalbumin:anti-ovalbumin immune 
complexes (ova ICs). Co-culture with WT ova specific CD4+ T cells revealed that ova IC pulsed 
Ptpn22-/- BMDCs have an enhanced capability to induce T cell proliferation.  PTPN22 was found 
to be dispensable for ova IC binding, internalisation and processing, but the enhanced T cell 
proliferation was associated with an increased capability of Ptpn22-/- BMDCs to present immune 
complex derived antigens and to form ova IC dependent BMDC-T cell conjugates. These findings 
highlight PTPN22 as a negative regulator of FcγR mediated responses and provide a link between 
the association of PTPN22R620W with autoantibody associated autoimmune diseases. Despite the 
requirement for PTPN22 in regulating T cell responses after ova IC stimulation, PTPN22 was not 
required for T cell responses after BMDCs were pulsed with OVA323-339 peptide or ova protein.  
To investigate the role of PTPN22 in autoimmunity in more detail, a mouse model of rheumatoid 
arthritis was utilised. Ptpn22-/- mice were found to develop more severe disease using the K/BxN 
serum transfer model. Despite this, WT and Ptpn22-/- arthritic mice displayed similar joint 
erosion and immune cell infiltration. In addition, PTPN22 was found to be dispensable for the in 
vitro differentiation and function of osteoclasts, the cells which are responsible for the bone 
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e. List of Abbreviations 
 
ABCs age dependent B cells 
ACPA anti-citrullinated protein antibody 
ADCC antibody dependent cell mediated cytotoxicity 
Anti-ova rabbit anti-chicken egg albumin 
APC antigen presenting cell 
Bcl-2 B cell lymphoma-2 
BCR B cell receptor 
BiP binding immunoglobulin protein 
BLC B lymphocyte chemoattractant 
Blk B cell lymphocyte kinase 
BMDC bone marrow derived dendritic cell 
BMDM bone marrow derived macrophages 
C constant domain 
CAIA collagen antibody-induced arthritis 
cDC conventional dendritic cell 
CDP common dendritic cell progenitor 
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c-Fms colony-stimulating factor-1 receptor 
CIA collagen-induced arthritis 
CLIP class II-associated invariant chain peptide 
CLR c-type lectin receptor 
cMoP common monocyte progenitor 
CMP common myeloid progenitor 
CpG unmethylated CG dinucleotides 
Csk c-terminal Src kinase 
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CTFR CellTrace Far Red 
CTV CellTrace Violet 
DAG diacylglycerol 
DAMP damage-associated molecular pattern 
DAS28 disease activity score 28 
DC dendritic cell 
DHR123 dihydrorhodamine 123 
E. coli Escherichia coli 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum 
ERK extracellular signal regulated kinase 
FBS fetal bovine serum 
FcR fragment crystalline receptor 
FcγR Fc gamma receptor 
Fgr gardner-rasheed feline sarcoma viral oncogene homologue 
Flt3 fms-like tyrosine kinases 3 
Flt3L fms-like tyrosine kinases 3 ligand 
fMLP N-Formyl-Methionyl-Leucyl-Phenylalanine 
Frk Fyn related kinase 
GlcNAc N-acetylglucosamine 
GM-CSF granulocyte macrophage-colony stimulating factor 
GMFI geometric mean fluorescent intensity 
GPI glucose-6-phosphate isomerase 
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Grb2 growth factor receptor bound protein 2 
GWAS genome wide association studies 
H heavy chain 
H+E hematoxylin and eosin 
HA heat aggregated 
Hck hematopoietic cell kinase 
HKCA heat killed Candida albicans 
HKLM heat killed Listeria monocytogenes 
HLA human leukocyte antigen 
HSC hematopoietic stem cell 
IC immune complex 
ICAM-1 intercellular adhesion molecule 1 
IFNα interferon α 
IFNαR interferon α receptor 
IFNβ interferon β 
IFNγ interferon γ 
Ig immunoglobulin 
IgG immunoglobulin G 
















IRF interferon regulatory factor 
ITAM immunoreceptor tyrosine-based activation motif 
ITAMi inhibitory ITAM signalling 
ITIM immunoreceptor tyrosine-based inhibition motif 
JAK2 janus kinase 2 
JIA juvenile idiopathic arthritis 
JNK c-Jun N-terminal kinase 
KC keratinocyte chemoattractant 
L light chain 
LAMP-1 lysosomal associated membrane protein-1 
Lck lymphocyte specific protein tyrosine kinase 
LCMV lymphocytic choriomeningitis virus 
LFA-1 lymphocyte function associated antigen 1 
Li invariant chain 
LIX liposaccharide induced CXC chemokine 
LN lymph node 
LPS lipopolysaccharide 
LY lucifer yellow 
MAPK mitogen activated protein kinase 
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mBSA methylated bovine serum albumin 
MCP-1 monocyte chemoattractant protein-1 
MDP monocyte and dendritic cell progenitor 
MHCI major histocompatibility complex class I 
MHCII major histocompatibility complex class II 
micro-CT Micro-computed tomography 
MIP-1α macrophage inflammatory protein-1α 
MIP-1β macrophage inflammatory protein-1β 
MIP-2 macrophage inflammatory protein 2 
MMP9 matrix metalloprotease 9 
NET neutrophil extracellular trap 
NK cell natural killer cell 
NLR nucleotide oligomerisation domain-like receptor 
NOD mice non-obese diabetic mice 
NP-KLH NP-Keyhole Limpet Hemocyanin 
NSF N-ethylmaleimide-sensitive fusion factor 
NSG mice NOD scid gamma mice 
OPG osteoprotegerin 
Ova ovalbumin 
Ova IC ovalbumin:anti-ovalbumin immune complex 
PAD peptidylarginine deiminase 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PCR polymerase chain reaction 
pDC plasmacytoid dendritic cell 
PEST proline-, glutamic acid-, serine- and threonine-rich 
PET positron emission tomography 
PET/CT positron emission tomography/computed tomography 
PFA paraformaldehyde 
PI3K phosphoinositide 3 kinase 
PKC protein kinase C 
PLCγ phospholipase C-γ 
PMA phorbol 12-myristate 13-acetate 
poly(I:C) polyinosine-polycytidylic acid 
polyU poly-uridine 
PRR pattern recognition receptor 
PSTPIP F-BAR-Proline-Serine-Threonine Phosphatase Interacting Protein 
PTEN phosphatase and tensin homologue 
PTPN22 protein tyrosine phosphatase non-receptor type 22 
RA rheumatoid arthritis 
Rag1 recombination activating gene 1 
RANK receptor activator of nuclear factor kappa-B 
RANK-L receptor activator of nuclear factor kappa-B ligand 
RANTES (CCL5) regulated on activation, normal T cell expressed and secreted 
RGD peptide arginine-glycine-aspartic acid peptide 
RLR retinoic acid-inducible gene I-like receptor 
ROS reactive oxygen species 
SCID severe combined immunodeficient 
SH2 src homology 2 
SH3 src homology 3 
SHIP-1 SH2-domain-containing inositol polyphosphate 5' phosphatase 1 
SHIP-2 SH2-containing inositol 5’-phosphatase 2 
SHP-1 src homology region 2 domain containing phosphatase-1 
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SLE systemic lupus erythematosus 
SNP single nucleotide polymorphism 
SPECT single-photon emission computed tomography 
Syk spleen tyrosine kinase 
T1D type 1 diabetes 
TBK1 TANK-binding kinase 1 
TCR T cell receptor 
Tfh cell T follicular helper cell 
Tfr cell T follicular regulatory cell 
Th1 type 1 helper T cells 
Th2 type 2 helper T cells 
Th17 type 17 helper T cells 
TIR toll/interleukin-1 receptor 
TLR toll-like receptor 
TNFα tumour necrosis factor α 
TNP-Ficoll trinitrophenol-Ficoll 
TNP-ova trinitrophenyl-ovalbumin 
TRAF3 TNF receptor associated factor 3 
TRAP tartrate-resistant acid phosphatase 
Tregs cells regulatory T cells 
TRIM21 tripartite motif containing protein 21 
TrkA tropomyosin receptor kinase A 
UC ulcerative colitis 
V variable domain 
WT wild type 







1.1.1 Phosphatases and kinases 
 
Protein tyrosine phosphatases dephosphorylate target proteins by removing phosphate groups 
from tyrosine residues. In this way, they oppose the actions of tyrosine kinases, which catalyse 
the addition of phosphate groups to tyrosine residues. Together, protein kinases and 
phosphatases regulate a vast array of signalling pathways, including those involved in cell 
differentiation, activation, migration and apoptosis. The importance of phosphatases in 
regulating signalling is exemplified by mice which express a loss-of-function mutation in Ptpn6 
(which encodes the hematopoietic phosphatase Src homology region 2 domain containing 
phosphatase-1, SHP-1), and display the motheaten phenotype, characterised by chronic skin 
inflammation and systemic autoimmunity1,2. In addition, a loss of balance between protein 
kinases and phosphatases is involved in the pathogenesis of human diseases including cancer3.  
 
1.1.2 The structure and function of PTPN22 
 
PTPN22 is located on human chromosome 1p13 and Ptpn22 is located on mouse chromosome 
3. These encode the protein tyrosine phosphatase non-receptor type 22 (PTPN22), a cytoplasmic 
tyrosine phosphatase belonging to the proline-, glutamic acid-, serine- and threonine-rich (PEST) 
family of phosphatases. PTPN22 is expressed in all hematopoietic cells, but different immune 
cell subsets express varying levels of the phosphatase, with natural killer (NK) cells and 
neutrophils expressing the most in mice4. The mouse protein was identified in 19925 and the 
human protein was identified a few years later in 19996. There are three splice isoforms of the 
human protein, the most abundant of which is isoform 1, which is the full length 807 amino acid 
protein. Isoforms 2 and 3 are shorter variants and have unknown functions6,7. The mouse and 
human proteins share 89% sequence homology in their catalytic domains, but are only 61% 
identical in the rest of the protein. This indicates that extrapolations between results found in 
human and mouse experiments should be carried out with caution. 
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PTPN22 is composed of an N-terminal catalytic domain, an interdomain and a C-terminal PEST 
domain containing four proline-rich regions, named P1-4 (Figure 1-1). These proline-rich regions 
can interact with Src homology 3 (SH3) containing proteins. A single nucleotide polymorphism 
(SNP) in the human gene (C1858T) causes an arginine to a tryptophan substitution at amino acid 
620 of the human protein (R620W), located in the P1 PEST domain of PTPN22. This prevents 
PTPN22 from interacting with the negative regulatory C-terminal Src kinase (Csk)8. Csk usually 
works in concert with PTPN22 to negatively regulate T cell receptor (TCR) signalling. Other 
known interactors of PTPN22 include lymphocyte specific protein tyrosine kinase (Lck)9, zeta 
chain associated protein kinase, 70 KDa (ZAP-70)9, the TCRζ chain9, tumour necrosis factor (TNF) 
receptor associated factor 3 (TRAF3)10, the adaptor molecule Growth factor receptor bound 
protein 2 (Grb2)11 and the E3 ubiquitin ligase c-Cbl6.  
 
Figure 1-1: The structure of PTPN22. 
PTPN22 is composed of an N-terminal catalytic domain, an-interdomain and a C-terminal binding domain, which 
contains 4 polyproline rich motifs (P1-4). Mouse PTPN22 is 802 amino acids in length and human PTPN22 is 807 amino 
acids in length. Diagram has been adapted from Stanford SM and Bottini N, Nature Reviews Rheumatology, 2014. 
One report indicated that although mRNA levels of Ptpn22 were similar in lymphoid organs from 
WT and Ptpn22R619W mice (which express the orthologue of the human autoimmune associated 
variant), the PTPN22R619W protein was more sensitive to calpain mediated degradation than the 
WT protein. This was shown by reduced expression of PTPN22 in thymocytes from Ptpn22R619W 
mice compared with PTPN22 expression in thymocytes from WT mice12. However, a subsequent 
report did not corroborate this finding13. 
 
1.1.3 PTPN22 and autoimmunity 
 
The C1858T (rs2476601) SNP in human PTPN22 (which encodes PTPN22R620W, with PTPN22R619W 
being the mouse orthologue) is associated with an increased susceptibility to multiple 
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autoimmune diseases including type 1 diabetes (T1D)14–21, rheumatoid arthritis (RA)14,22–27, 
systemic lupus erythematosus (SLE)28,29, Graves’ disease17,30–32 and Addison’s disease33,34. The 
first association between the SNP and autoimmune disease was discovered by Bottini and 
colleagues, in which they found, in two independent cohorts, that T1D patients were more likely 
to express the SNP than healthy controls8. Despite these associations, the C1858T SNP in PTPN22 
is not associated with an increased susceptibility to all autoimmune diseases. For example, there 
is no association or a negative association between the SNP and multiple sclerosis35,36, ulcerative 
colitis (UC)37 and Crohn’s disease37. Furthermore, carriers of PTPN22 C1858T are protected from 
tuberculosis38,39 but are more susceptible to other infections including invasive pneumococcal 
infections40. However, the SNP has no effect on susceptibility to hepatitis C infections41. 
Although the C1858T SNP in PTPN22 is the most commonly found variant, other SNPs exist in 
PTPN22 which have also been linked with autoimmunity. These include PTPN22 C1123G 
(rs2488457), which is located in the promoter region of the gene, and has been linked with an 
increased susceptibility to UC42. It has also been linked with a modestly increased risk of T1D43,44, 
juvenile idiopathic arthritis (JIA)45 and RA46,47, but not all of these associations have been 
confirmed in independent cohorts48,49. The PTPN22 C1123G and PTPN22 C1858T polymorphisms 
have also been shown to cause reduced mRNA expression of PTPN22 in RA patients compared 
to healthy controls not carrying the polymorphisms50. In addition, PTPN22 G788A (rs33996649), 
which encodes PTPN22R263Q, is located in the catalytic domain of the protein and confers reduced 
enzymatic activity51, has been associated with a slight protection against SLE51,52, RA53 and UC54.  
 
1.2 The role of PTPN22 and PTPN22R619W in murine immune cells in the steady state 
 
Despite the strong association between PTPN22 polymorphisms and autoimmune disease 
susceptibility, mice in which PTPN22 is absent do not develop spontaneous autoimmunity on a 
C57Bl/6 genetic background. PTPN22 is expressed in all hematopoietic cells and the role of 
PTPN22 has been investigated in a variety of immune cells, with its role in T cells receiving the 
most attention. How the mouse orthologue of the autoimmune associated variant 
(PTPN22R619W) affects the functions of immune cell subsets is complex, as depending on the 
cellular context and signalling pathway under investigation, both gain- and loss-of-phosphatase 




1.2.1 The role of PTPN22 in murine T cells 
 
In Ptpn22-/- mice, T cell development and TCR signalling in naïve T cells is grossly normal, 
although TCR signalling is enhanced in Ptpn22R619W naïve and memory T cells13. With age, both 
Ptpn22-/- and Ptpn22R619W mice develop larger lymph nodes (LNs) and spleens or LNs, thymus 
and spleens, respectively, with increased cellularity12,55. This may be partly due to the fact that 
Ptpn22-/- mice have increased numbers of CD44+ CD62Llo effector/memory CD4+ and CD8+ T cells 
that are hyper-responsive to TCR engagement55. This is due to a role of PTPN22 in 
dephosphorylating Src and Syk family kinases, namely Lck, Fyn and ZAP-70, downstream of the 
TCR, in addition to dephosphorylating the immunoreceptor tyrosine-based activation motifs 
(ITAMs) in the CD3ζ chain56. Ptpn22R619W mice also show an expansion in the effector/memory T 
cell compartment in lymphoid organs12.  
In addition to an expansion of effector/memory T cells, Ptpn22-/- mice also have increased 
numbers of CD25+ Foxp3+ regulatory T cells (Tregs) in the thymus57, lymph nodes58 and 
spleens57,58.  Peripheral Ptpn22-/- Tregs were found to express augmented levels of CD25 than WT 
Tregs, and this correlated with enhanced phosphorylation of STAT5 after interleukin-2 (IL-2) 
stimulation of Ptpn22-/- splenic Tregs57. Although this enhanced STAT5 phosphorylation was not 
found in Ptpn22-/- Tregs after IL-2 stimulation in a separate report58. WT and Ptpn22-/- Tregs showed 
equal phosphorylation of signalling intermediates including Src, ZAP-70 and extracellular signal 
regulated kinase (ERK), and calcium flux after anti-CD3 crosslinking. In vitro, splenic Ptpn22-/- Tregs 
were found to be equally suppressive of effector T cell proliferation as WT Tregs57. However, in 
vivo, Ptpn22-/- Tregs were found to be more suppressive than their WT counterparts, in this way 
reducing Ptpn22-/- effector T cell induced colitis58. This outgrowth of both effector/memory T 
cells and Tregs over time may provide one explanation why Ptpn22-/- mice do not develop 
spontaneous autoimmunity. Ptpn22R619W mice do not show any differences in Treg numbers or 
their suppressive capacity13. 
Alongside the expansion of effector/memory T cells and Tregs in Ptpn22-/- mice, they also have an 
increased number of T follicular helper (Tfh, CD4+ CD44hi CXCR5+ PD-1+) cells in the draining LNs 
7 days after immunisation with NP-Keyhole Limpet Hemocyanin (NP-KLH) in Complete Freud’s 
Adjuvant (CFA). The expansion of Tfh cells in Ptpn22-/- mice was not accompanied by an expansion 
of follicular regulatory T (Tfr) cells, indicating that these cells were not capable of regulating the 
proliferation of the Tfh cells, leading to an increase in B cell numbers and antibody production in 
the absence of PTPN22. The expansion of Tfh cells in Ptpn22-/- mice was shown to be due to the 
cells being more proliferative than WT Tfh cells, and because they expressed higher mRNA 
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expression of the apoptosis regulator, and master regulator of Tfh cell differentiation, Bcl2, 
suggestive of a survival advantage. Finally, Ptpn22-/- Tfh cells expressed higher Il21 and Il4 mRNA 
and interleukin-21 (IL-21) protein than WT Tfh cells. Interleukin-4 (IL-4) provides B cell help59. 
Data from our own laboratory has demonstrated that PTPN22 also regulates signalling 
downstream of the integrin lymphocyte function associated antigen-1 (LFA-1) in T cells. Both 
Ptpn22-/- and Ptpn22R619W effector T cells adhered more and migrated faster on intercellular 
adhesion molecule-1 (ICAM-1) coated glass. In addition, Ptpn22-/- effector T cells were found to 
have enhanced ERK phosphorylation after a 20 minute stimulation with ICAM-1, indicating that 
PTPN22 negatively regulates signalling downstream of LFA-1 in T cells60. In a separate report, 
Ptpn22-/- Tregs were found to express more LFA-1 and make larger contact areas with ICAM-1 
coated surfaces than WT Tregs58. 
With age, both Ptpn22-/- and Ptpn22R619W mice show an expanded CD4+ IFNγ+ T cell population 
in lymph nodes and spleen. Our laboratory described a phenotype that was also apparent in 
Ptpn22-/- mice 96 days after the induction of collagen-induced arthritis. Ptpn22-/- CD4+ T cells 
secreted enhanced IFNγ after stimulation with anti-CD3 and ICAM-1. This was not the case using 
anti-CD3/anti-CD28 stimulation, again demonstrating that PTPN22 regulates signalling 
downstream of LFA-1 in T cells. In addition, Ptpn22-/- CD4+ T cells plated on anti-CD3 and ICAM-
1 showed an enhanced ICAM-1 density at the immune synapse compared to WT CD4+ T cells, 
and were capable of forming more conjugates with WT BMDCs61. This indicates that in the 
absence of PTPN22, CD4+ T cells have an enhanced LFA-1 responsiveness, potentially resulting 
in the observed expansion of CD4+ IFNγ+ T cells.  
 
1.2.2 The role of PTPN22 in murine B cells 
 
B cell development and B cell receptor (BCR) signalling are largely normal in the absence of 
PTPN22, however, Ptpn22-/- and Ptpn22R619W mice have increased numbers of germinal 
centres12,59. In addition, Ptpn22-/- mice have increased splenic follicular B cells59. The increase in 
germinal centres has been attributed to increased Tfh cell proliferation, survival and IL-21 
secretion in Ptpn22-/- mice (as discussed above)59, and not due to a B cell specific role for PTPN22. 
In Ptpn22-/- mice, this increase in germinal centres is accompanied by enhanced serum levels of 
IgG1, IgG2a and IgE55, however in Ptpn22R619W mice, serum levels of IgM, IgG3 and IgA were 
similar to WT mice12. Despite this, after immunisation with trinitrophenol-Ficoll (TNP-Ficoll), 
Ptpn22R619W mice showed enhanced serum IgG3 and IgM anti-TNPs12.  
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Some PTPN22 dependent differences in B cells were observed when Ptpn22R619W mice were on 
a mixed background or with increased age. These included enhanced levels of autoantibodies, 
autoreactive B cells, splenic T1 B cells and age dependent B cells (ABCs), and enhanced BCR 
signalling13. A separate report also demonstrated enhanced anti-IgM stimulated BCR signalling 
using splenic CD19+ B cells from Ptpn22R619W mice. 
To further identify a role of PTPN22 in B cell tolerance, non-obese diabetic (NOD) severe 
combined immunodeficient (SCID) gamma (NSG) mice were engrafted with CD34+ 
hematopoietic stem cells (HSCs) from human foetuses expressing the PTPN22 C1858T allele. 
Once engrafted, the expression of the variant led to an abnormal central B cell tolerance 
checkpoint. This resulted in an increase in autoreactive new emigrant B cells. PTPN22R620W 
expression therefore prevents the normal removal of autoreactive B cells, thus affecting B cell 
tolerance. Using the inhibitor LTV-1 (which inhibits the phosphatase activity of human PTPN22), 
or by using shRNA directed against PTPN22, the authors were able to show that this reduced the 
frequency of autoreactive new emigrant B cells in mice transplanted with PTPN22R620W 
expressing HSCs62. This data indicates that it is the enzymatic activity of PTPN22 which is 
regulating B cell tolerance. 
 
1.2.3 The role of PTPN22 in murine neutrophils 
 
Although PTPN22 is highly expressed in neutrophils, to date there has only been one study which 
has investigated its function in this cell type in mice. PTPN22 was found to play an important 
role in positively regulating immune complex induced effector functions, such that Ptpn22-/- 
neutrophils displayed reduced adhesion, reactive oxygen species (ROS) production and 
degranulation in response to immune complex stimulation. However, PTPN22 was found to be 
dispensable for neutrophil chemotaxis to macrophage inflammatory protein 2 (MIP2) and 
neutrophil diapedesis through an endothelial cell layer. Ptpn22-/- mice were protected from 
development of arthritis using the K/BxN serum transfer model, which was attributed to a lack 
of neutrophil infiltration into the joints63. 
 
1.2.4 The role of PTPN22 in murine myeloid cells 
 
PTPN22 is also highly expressed in myeloid cells and has been found to regulate signalling 
downstream of a variety of pattern recognition receptors10,12,64. For example, PTPN22 promotes 
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type I interferon production after Toll-like receptor (TLR) engagement in dendritic cells (DCs) 
and macrophages10. Ptpn22-/- BMDCs and bone marrow derived macrophages (BMDMs), in 
addition to WT RAW 264.7 macrophages subjected to suppression of PTPN22 expression, were 
stimulated with TLR3, 4, 7 or 9 ligands, using polyinosine-polycytidylic acid (poly(I:C)), 
lipopolysaccharide (LPS), poly-uridine (polyU) and unmethylated CG dinucleotides (CpG) 
respectively. Reduced expression of TLR induced anti-inflammatory type I interferons was 
detected, however no differences in the production of LPS induced pro-inflammatory cytokines 
by WT and Ptpn22-/- BMDCs and BMDMs were observed. Ptpn22-/- BMDMs also displayed 
reduced upregulation of CD86 after 16 hours of stimulation with LPS or poly(I:C). Reduced 
interferon β (IFNβ) was also detected in the serum of Ptpn22-/- mice 4 hours after LPS injection, 
although TNFα and interleukin-6 (IL-6) levels were normal. As type I interferons are vital for anti-
viral responses, WT and Ptpn22-/- mice were infected with lymphocytic choriomeningitis virus 
(LCMV). 24 hours after infection, serum IFNβ was reduced in Ptpn22-/- mice, upregulation of 
CD40 and CD86 on splenic DCs was reduced, and LCMV specific CD8+ T cells in the spleen 7 days 
after infection were also reduced.  The proposed mechanism was that after TLR stimulation, 
PTPN22 associates with TNF receptor associated factor 3 (TRAF3) and promotes TRAF3 
ubiquitination. This in turn leads to the activation of the serine/threonine kinases TANK-binding 
kinase 1 (TBK1) and inhibitor of nuclear factor kappa epsilon (IKKε), which then phosphorylate 
interferon regulatory factors 3 and 7 (IRF3 and IRF7), which can then translocate to the nucleus 
and induce expression of type I interferons. As a result of PTPN22 promoting the expression of 
TLR induced type 1 interferons, Ptpn22-/- mice failed to suppress inflammatory arthritis after 
poly(I:C) treatment using the K/BxN model10. Reduced levels of type I interferons were also 
observed in a separate study, where Ptpn22R619W mice were injected with the TLR7/8 agonist 
R848 and serum levels of cytokines were measured after 1 hour64.   
Ptpn22-/- hematopoietic progenitor cells show augmented IFNα receptor (IFNαR) signalling, 
indicating that PTPN22 negatively regulates IFNαR signalling65. This was shown by enhanced 
STAT1 phosphorylation in Ptpn22-/- hematopoietic progenitor cells after stimulation with IFNα. 
Expression of IFN-inducible genes, such as Irf8, were found to be increased in Ptpn22-/- BMDMs 
after 4 hours of IFNα stimulation. Using an IFNα-induced mouse model of lupus, Ptpn22-/- mice 
were found to be more prone to disease, showing more anti-nuclear antibodies and increased 
mortality65. As both IFNα and PTPN22 have been previously linked to SLE in humans, this paper 
demonstrated a potential mechanism whereby expression of PTPN22R619W may be linked to an 
enhanced susceptibility to lupus development.  
The C-type lectin receptor dectin-1 recognises fungal β-glucans. Dectin-1 signals via Syk so the 
role of PTPN22 in regulating signalling downstream of this receptor in BMDCs was investigated 
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by our laboratory. Ptpn22-/- BMDCs pulsed with OVA323-339 peptide and the dectin-1 agonist 
curdlan caused enhanced interleukin-17A (IL-17A) secretion from WT CD4+ OT-II T cells, both in 
vitro and in vivo. This was found to be due to enhanced interleukin-1β (IL-1β) secretion from 
curdlan stimulated Ptpn22-/- BMDCs. Enhanced ERK and Syk phosphorylation was also observed 
in Ptpn22-/- BMDCs stimulated with the dectin-1 agonist heat killed Candida albicans (HKCA). 
Similar results were found using Ptpn22R619W BMDCs. This indicates that in the absence of 
PTPN22, or in the presence of the autoimmune associated variant of PTPN22, BMDCs show 
enhanced signalling downstream of dectin-1, thus demonstrating that PTPN22 negatively 
regulates dectin-1 signalling66. 
A recent study reported that ovalbumin (ova) pulsed Ptpn22R619W macrophages induced 
augmented WT CD4+ OT-II T cell activation and proliferation, demonstrated by enhanced CD69 
expression after 18 hours of co-culture and enhanced CFSE dilution after 5 days of co-culture. 
The authors suggested that this was caused by an enhanced phagocytic capability of Ptpn22R619W 
macrophages, by measuring uptake of fluorescent Escherichia coli (E. coli), and an increased 
expression of CD80, CD86 and major histocompatibility complex class II (MHCII)67. A further 
report showed that LPS matured Ptpn22R619W BMDCs or splenic DCs also induced enhanced WT 
CD4+ OT-II T cell proliferation when pulsed with ova or OVA323-339 peptide. This was attributed to 
increased co-stimulation rather than alterations in phagocytosis, through LPS induced 
upregulation of CD40 and CD86 and enhanced secretion of interleukin-12 (IL-12)12. This data, 
however, is in contrast with other reports using Ptpn22-/- mice, which showed that Ptpn22-/- 
BMDMs displayed reduced upregulation of CD86 after LPS stimulation10, or no difference in LPS 
induced WT and Ptpn22-/- BMDC co-stimulatory molecule expression or cytokine secretion61. 
This shows that myeloid cells respond differently either in the absence of PTPN22, or in the 
presence of PTPN22R619W. 
In addition to the role of PTPN22 in regulating LFA-1 signalling in T cells, PTPN22 has also been 
shown to induce reduced IFNγ expression by WT and Ptpn22-/- CD4+ OT-II T cells after 6 days of 
co-culture with LPS matured, OVA323-339 peptide pulsed BMDCs, followed by restimulation with 
freshly pulsed BMDCs for 2 days. This was not due to differences in LPS induced WT and Ptpn22-
/- BMDC cytokine secretion, expression of co-stimulatory molecules, or due to the release of a 
soluble factor. Instead, it was found to be as a result of an LFA-1 dependent mechanism, as 





1.3 Phenotype of Ptpn22-/- and Ptpn22R619W mice using models of autoimmunity  
 
As discussed above, Ptpn22-/- mice do not develop spontaneous autoimmunity. Despite this, 
when they are crossed with mice that express a mutated form of the phosphatase CD45, they 
do develop a lupus like disease68. In addition, when Ptpn22-/- mice are crossed onto a more 
susceptible genetic background (129/Sv), spontaneous autoimmunity does develop13. Induced 
models of autoimmunity have also been used to investigate the role of PTPN22 and these are 
summarised in Table 1-1 below. 
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No effect PTPN22 is not required 





Table 1-1: Models of autoimmunity used with PTPN22 variant mice. 
Table shows the outcomes of each model and the potential mechanisms. Mouse backgrounds are shown in brackets 
in the first column.  
 
1.4 Phenotype of Ptpn22-/- and Ptpn22R619W mice using viral infection models  
 
Due to the high prevalence of PTPN22 variants in the population, and their association with 
autoimmunity, it has been speculated that the variants should also provide an immunological 
advantage. To date, a small number of studies have been published investigating whether 
PTPN22 is involved in defending against viral infections in mice.  
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As mentioned previously, PTPN22 is required for type I interferon production after TLR 
stimulation in myeloid cells. As part of this study, the response of WT and Ptpn22-/- mice to an 
acute infection with LCMV Armstrong was tested. PTPN22 was found to promote anti-viral 
responses as LCMV infected Ptpn22-/- mice were more susceptible to infection. This was due to 
a reduction in serum type I interferons one day after infection and a reduced activation of splenic 
CD8α+ DCs and plasmacytoid DCs. Ptpn22-/- mice also showed an impaired expansion of LCMV-
specific CD8+ T cells10. A separate report also showed that Ptpn22-/- LCMV-specific CD8+ T cells 
failed to accumulate in WT hosts after acute infection with LCMV. This was accompanied by 
reduced pSTAT-1 in these T cells after stimulation with IFNα. However, in the same report, 
Ptpn22-/- CD8+ T cells showed enhanced expansion in a lymphopenic host75. 
A contrasting result was found using a different strain of LCMV which causes a chronic infection 
(clone 13). In this case, Ptpn22-/- mice were shown to be more capable of controlling the 
infection than WT mice, as shown by a lack of weight loss and reduced viral titres in the spleens 
over the course of the infection. This was accompanied by an increase in the number of LCMV-
specific CD8+ T cells, which did not display an exhausted phenotype. In addition to enhanced 
Ptpn22-/- CD8+ T cell anti-viral responses, Ptpn22-/- CD4+ T cells also showed enhanced IFNγ and 
TNFα production after infection with LCMV clone 1376. A separate report also showed that 
Ptpn22-/- mice were able to resist a chronic viral infection with LCMV clone 13. After 28 and 39 
days of infection, serum viral titres in Ptpn22-/- mice were substantially lower than those found 
in WT mice, and were also lower in the spleen, lung, liver and kidneys 14 days after infection. 
Viral clearance was found to be dependent on CD4+ T cells, as when they were depleted from 
Ptpn22-/- mice, the mice were no longer able to control the infection. 1 day post infection, 
Ptpn22-/- mice had a reduced frequency of IFNα and IFNβ producing splenic plasmacytoid DCs, 
which was accompanied by a subtle reduction in CD86 expression on splenic conventional DCs 
and plasmacytoid DCs77.  
Taken together, this data indicates that in the context of an acute viral infection, PTPN22 is 
needed for the production of anti-viral type I interferons by myeloid cells, which are required to 
induce an efficient T cell dependent adaptive response. However, PTPN22 also inhibits CD8+ T 
cell homeostatic proliferation during lymphopenia. In the case of a chronic viral infection, 





1.5 The role of PTPN22 and PTPN22R620W in human immune cells 
 
The role of PTPN22 has also been studied in humans. However, due to the unavailability of tissue 
samples, most of the experiments have focussed on immune cell populations within the 
peripheral blood. 
 
1.5.1 The role of PTPN22 in human T cells 
 
Naïve CD4+ T cells from the peripheral blood of healthy donors expressing PTPN22R620 or the 
disease associated PTPN22R620W proliferate similarly after anti-CD3/anti-CD28 stimulation. 
Despite this, bulk CD4+ T cells from healthy donors expressing PTPN22R620W (homozygous) 
produce more IFNγ, TNFα and IL-2 and less IL-17A than WT CD4+ T cells after 20 hours of TCR 
stimulation. However, suppression of IFNγ production by PTPN22R620W CD4+ T cells was impaired 
using Tregs from the same donor, indicating that PTPN22R620W Tregs are less capable of 
suppression78.  
Enhanced TCR induced IL-2 secretion was not found in a separate study. In this case, CD4+ T cells 
from children with type 1 diabetes expressing PTPN22R620W (heterozygous) secreted reduced 
levels of IL-2 after anti-CD3/anti-CD28 stimulation, compared to those patients not expressing 
the variant79. This data indicates that the variant acts as a gain-of-function mutation with respect 
to TCR signalling. This finding was confirmed by another study which showed reduced IL-2 
production, proliferation and activation of peripheral blood PTPN22R620W CD4+ T cells after TCR 
stimulation, and reduced calcium flux after PHA stimulation80. Reduced response to TCR 
stimulation by PTPN22R620W expressing human T cells was also found in a separate report. Anti-
CD3 stimulation of PTPN22R620W T cells showed reduced calcium mobilisation compared to WT T 
cells from age and disease status matched controls. In addition, PTPN22R620W (heterozygous) 
expressing T cells stimulated with irradiated antigen presenting cells (APCs) or with anti-
CD3/anti-CD28 for 3 days showed reduced upregulation of the activation marker CD25 in 
comparison to WT T cells. This was accompanied by a reduction in interleukin-10 (IL-10) 
secretion after 24 hours of anti-CD3/anti-CD28 stimulation. Phenotyping of T cells from 
PTPN22R620 and PTPN22R620W carriers showed that a higher proportion of peripheral blood CD4+ 
T cells in individuals expressing PTPN22R620W (heterozygous) were memory T cells (identified by 
their expression of CD45RO)81. 
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The kinases Lck and ZAP-70 are phosphorylated after LFA-1 engagement, and as these are 
substrates of PTPN22, the role of PTPN22 in regulating LFA-1 signalling in human T cells was 
investigated. To begin, the localisation of PTPN22 in migrating primary T cell blasts was assessed. 
PTPN22 was found to co-localise with phosphorylated Src, ZAP-70 and Vav at the leading edge. 
siRNA suppression of PTPN22 in human T cell blasts led to an increased migration velocity on 
ICAM-1 coated surfaces. In addition, human T cell blasts from healthy donors expressing 
PTPN22R620W showed increased phosphorylation of ERK after stimulation with ICAM-1. In WT 
human T cells plated on ICAM-1 coated surfaces, PTPN22 clustered at the plasma membrane, 
close to LFA-1, where it could inhibit LFA-1 signalling, however T cells expressing PTPN22R620W 
did not form clusters of PTPN22 at the plasma membrane after ICAM-1/LFA-1 engagement, thus 
preventing the regulation of LFA-1 signalling60. 
Taken together, this indicates that in the context of TCR signalling, PTPN22R620W is generally 
acting as a loss-of-function mutation, such that it negatively regulates signalling downstream of 
TCR engagement, similarly to what has been demonstrated using PTPN22 deficient mice. 
 
1.5.2 The role of PTPN22 in human B cells 
 
Humans expressing PTPN22R620W (heterozygous) have a reduced frequency of peripheral blood 
CD19+ CD27+ memory B cells. In addition, memory B cells from these subjects demonstrated a 
lower level of calcium flux after anti-IgM stimulation81. A separate report showed that healthy 
humans expressing PTPN22R620W (heterozygous) had increased frequencies of peripheral blood 
transitional CD19+ B cells (CD19+ CD27neg CD10+ CD24+ CD38hi) and anergic B cells (CD19+ CD27neg 
IgD+ IgMneg)82. In addition, healthy individuals carrying the PTPN22R620W risk allele were found to 
have more autoreactive B cells, with a 3-fold increase in the proportion of polyreactive B cells 
seen (that reacted to ssRNA, dsDNA, insulin and LPS)83. However, in a separate study, healthy 
subjects carrying the risk variant were found to have fewer autoreactive VH4-34+ transitional B 
cells, compared to healthy subjects not carrying the risk allele84. Both naïve and transitional B 
cells from PTPN22R620W (heterozygous) carriers display reduced apoptosis82. B cells from healthy 
PTPN22R620W (heterozygous) carriers also showed increased expression of genes involved in B 
cell activation, proliferation and survival, including CD40, SLAMF6, BCL2 and ICOSL. The 
increased CD40 gene expression resulted in increased CD40 expression on the surface of naïve 
B cells from people harbouring the PTPN22R620W risk allele, and these cells were more responsive 
to CD40 ligand stimulation, as judged by increased expression of CD25 and CD69 after 2 days83. 
Taken together, this data indicates that PTPN22R620W alters B cell homeostasis, potentially by 
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altering BCR signalling and resistance to BCR mediated apoptosis. This may lead to a loss of B 
cell tolerance in humans expressing the autoimmune associated variant of PTPN22. 
 
1.5.3 The role of PTPN22 in human neutrophils 
 
Neutrophils from PTPN22R620W (heterozygous) expressing RA patients or healthy donors were 
found to have enhanced effector functions compared to PTPN22R620 expressing individuals. 
Healthy human neutrophils expressing PTPN22R620W (heterozygous) transmigrated through an 
activated endothelial layer more effectively than WT neutrophils. These neutrophils also 
released more ROS after TNFα and N-Formyl-Methionyl-Leucyl-Phenylalanine (fMLP) 
stimulation. In addition, neutrophils heterozygous for PTPN22R620W from both healthy individuals 
and RA patients released more calcium after stimulation with fMLP85. These observations are 
important as neutrophils are the major immune cell infiltrate in arthritic joints, so in patients 
harbouring the R620W variant, disease may be exacerbated by the presence of overactive 
neutrophils. 
 
1.5.4 The role of PTPN22 in human natural killer cells 
 
A potential role of PTPN22 in human natural killer (NK) cells has been investigated in one report. 
Peripheral blood mononuclear cells (PBMCs) from healthy donors expressing PTPN22R620W 
(heterozygous) or PTPN22R620 were cultured in vitro in the presence of IL-2 and anti-CD3 after 
density gradient centrifugation. The proportion of CD3- CD56+ NK cells was monitored over 21 
days, and it was found that PTPN22R620W (heterozygous) cultures had a reduced proportion of 
NK cells compared to PTPN22R620 cultures. However, this may be due to a preferential expansion 
of CD3+ T cells in the PTPN22R620W (heterozygous) cultures86. 
 
1.6 Is PTPN22R620W a gain- or loss-of function mutant? 
 
As both gain- and loss-of-phosphatase function roles have been attributed to PTPN22R620W, 
depending on the cell type and the signalling pathway being investigated, this variant has 
recently been described as a switch-of-function polymorphism. In this case, the function of 
PTPN22R620W could be influenced both by its catalytic activity, but also by its cellular location, 
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giving rise to different functions depending on the signalling pathway under investigation87. The 
apparently contradicting results which have been found in different cell types and downstream 
of different immunoreceptors, highlights the utility of investigating the role of PTPN22 using 
Ptpn22-/- mice. In this case, the complete absence of the protein allows for the identification of 




1.7.1 DC development and differentiation in mice 
 
DCs were first described by Ralph Steinman and Zanvil Cohn in 197388. Their name refers to the 
presence of dendritic like protrusions, which they visualised on a phagocytic cell type in mouse 
spleens. DCs, although of myeloid lineage and closely related to macrophages and monocytes, 
develop from a DC specific committed progenitor in the bone marrow.  
DCs are a heterogenous population and can be broadly divided into two subsets, namely 
plasmacytoid DCs (pDCs) and conventional CD11c+ DCs (cDCs) (Figure 1-2). pDCs recognise 
bacterial and viral pathogens via TLR9 and TLR7 respectively, and respond to infection by 
releasing type I interferons (mainly IFNα and IFNβ), IL-6 and TNFα. Type I interferon secretion is 
dependent on expression of the transcription factor IRF7, and induces an anti-viral response in 
addition to NK cell activation. pDCs are also capable of initiating adaptive immune responses by 
presenting antigens to CD4+ and CD8+ T cells and by expressing chemokines which lead to the 
recruitment of immune cells89. pDCs differentiate from common DC progenitors (CDPs) as a 
result of fms-like tyrosine kinases 3/fms-like tyrosine kinases 3 ligand (Flt3/Flt3L) engagement 
and downstream STAT3 signalling. This in turn enhances E2-2 expression, which is the major 
transcription factor involved in the development of pDCs90, and suppresses the expression of 
ID2, a transcription factor required for cDC development91. Conversely, GM-CSF and STAT5 
signalling induces the expression of ID2, which inhibits pDC development by antagonising E2-2. 
pDCs mainly reside in the lymph nodes and spleen under non-inflammatory conditions, and 
utilise endothelial venules to enter lymph nodes, aided by the expression of L-selectin on the 
high endothelial venules and CCL19 and CCL21 expression in the lymph node. 
cDCs are superior to pDCs at internalising and presenting antigens to T cells, due to their 
enhanced endocytic capacity, higher MHCII and co-stimulatory molecule expression and 
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cathepsin S and D expression; enzymes which are required for antigen processing. As with pDCs, 
cDCs also depend on Flt3/Flt3L signalling for their development92 and all express the 
transcription factor ZBTB46. cDCs can be further subdivided into cDC1s and cDC2s. cDC1s 
express the chemokine receptor XCR1 and are further distinguished by their expression of CD8α 
in lymphoid organs and CD103 in non-lymphoid organs. Their main role is cross-presentation of 
exogenous antigens on MHCI to CD8+ T cells. There are multiple transcription factors that have 
been linked with the development of cDC1s, including ID2, BATF3, NFIL3 and IRF8. For example, 
Batf3-/- mice specifically lack XCR1+ DCs, including splenic CD8α+ cDCs, and lung, dermal and 
intestinal CD103+ cDCs93. Mouse cDC1s correspond to human CD141+ DCs94.  
cDC2s are defined by their expression of the integrin CD11b or SIRPα, and form the most 
abundant cDC population found in lymphoid organs. They present antigens in MHCII, for the 
activation of CD4+ T cells. cDC2s can be divided further into ESAMhi and ESAMlo populations, with 
ESAMhi being the major subtype. Transcription factors RelB, NOTCH2, IRF2, IRF4 and RBP-J have 
been shown to be involved in cDC2 development. For example, deletion of NOTCH2 or RBP-J in 
CD11c+ cells caused a lack of cDC2s in the spleen95,96, and this led to a reduced activation of CD4+ 
T cells96. After TLR stimulation, cDC2s produce pro-inflammatory cytokines IL-6 and interleukin-
23 (IL-23), with ESAMlo cells being the best producers. Mouse cDC2s correspond to human CD1c+ 
DCs94. 
In addition to cDCs and pDCs, there are also a subset of non-classical DCs, which include 
monocyte-derived DCs (also known as inflammatory DCs). These differentiate in both lymphoid 
and non-lymphoid organs from monocytes in the presence of inflammation or infection. 
Monocyte-derived DCs, as opposed to cDCs or pDCs, are thought to be somewhat similar to GM-







Figure 1-2: DC development in mice.  
Hematopoietic stem cells (HSC) differentiate into a variety of progenitor cells, including common myeloid progenitors 
(CMP). These in turn differentiate into monocyte and DCl progenitors (MDP). MDPs lack the potential to differentiate 
into lymphoid, megakaryocyte and granulocyte cells, but can give rise to both monocytes (and their progenitors), 
plasmacytoid DCs (pDCs) and conventional DCs (cDCs). MDPs can differentiate into common monocyte progenitors 
(cMoPs), which lack Flt3 expression and therefore can not produce DCs, but instead produce monocytes. Alternatively, 
MDPs differentiate into common DC progenitors (CDP), which express Flt3 and M-CSFR,  but have lost monocyte 
potential, so give rise to preDCs and pre-pDCs. preDCs become cDCs, which can be further divided into cDC1s (CD8α+ 
or CD103+) and cDC2s (CD11b+). cDCs can be further subdivided into ESAMhi and ESAMlo subsets. Diagram has been 
adapted from Merad M et al., Annual Review of Immunology, 2013 and Mildner A and Jung S, Immunity, 2014. 
 
1.7.2 General functions of DCs 
 
DCs are professional APCs which are critical for pathogen sensing, antigen uptake and 
presentation. Although macrophages and B cells are also capable of presenting antigen, they are 
more specialised for phagocytosis and antibody production respectively. Immature DCs are 
found in peripheral tissues (although lymphoid resident DCs also exist), where they display high 
levels of endocytosis, required for sampling antigens. Once DCs have internalised an antigen, 
they migrate to draining lymph nodes via the afferent lymph, a process which can take between 
1-3 days and is dependent on CCR7 expression98. During this period, DCs also undergo a process 
termed maturation. DC maturation involves increased expression of MHCII and co-stimulatory 
molecules, production of cytokines and chemokines, and an enhanced migratory capacity due 
to the upregulation of chemokine receptors. Once in the lymph node, the DCs present antigens 
to T and B cells, to either promote tolerance (if the antigen was internalised in the absence of 
an inflammatory signal) or to initiate an adaptive immune response. DCs are the only APC which 
can activate naïve T cells and are therefore vital in initiating an adaptive immune response. DCs 
then receive feedback from the adaptive immune cells, including via the secretion of cytokines 
and antibodies, which further shape the immune response.  
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To understand the role of DCs in immunity, mice have been engineered that lack DCs. This was 
achieved by crossing CD11c-Cre mice with mice expressing diptheria toxin under the control of 
a loxP flanked neomycin resistance (neoR) cassette from the ROSA26 locus. In the absence of 
DCs (cDCs, plasmacytoid DCs and Langerhans cells), these mice had reduced body weight, 
developed spontaneous autoimmunity, had enlarged spleens and lymph nodes (mainly as a 
result of increased neutrophil frequencies), had more activated CD4+ T cells in the spleens, 
lymph nodes and peripheral organs, and displayed enhanced serum autoantibody production99. 
In addition, 40% of mice lacking DCs died within 8 weeks of age. This demonstrates that DCs are 
required to promote immune tolerance and to therefore prevent the development of 
autoimmunity under non-inflammatory conditions. 
 
1.7.3 Antigen uptake by DCs  
 
Although lymphoid resident DCs are able to present lymph and blood derived antigens which 
drain through lymphatic vessels from the periphery to the lymph nodes and spleen, this is only 
efficient if the antigen is present at a high concentration. Alternatively, DCs present in the 
peripheral tissues can take up soluble and particulate matter from extracellular fluid using a 
process known as endocytosis, which includes both phagocytosis and macropinocytosis. As 
discussed above, these tissue resident DCs can then migrate to draining lymph nodes and 
present antigens to T and B cells.  
Receptor mediated endocytosis is aided by the presence of numerous cell surface receptors, 
referred to as pattern recognition receptors (PRRs). These include Toll-like receptors (TLRs), C-
type lectin receptors (CLRs), nucleotide oligomerisation domain (NOD)-like receptors (NLRs) and 
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). Together these receptors recognise a 
wide variety of pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs). After recognition of PAMPs and DAMPs by receptors present on 
DCs, signalling downstream of the receptor leads to its internalisation, often via the recruitment 
of clathrin, leading to the formation of clathrin coated endocytic vesicles. For larger, particulate 
antigens, receptor mediated phagocytosis is utilised, which generally uses the same receptors 
as receptor mediated endocytosis. Phagocytosis requires the actin cytoskeleton and leads to the 
formation of large intracellular vacuoles. 
Although PRRs can bind and recognise a vast array of PAMPs and DAMPs, DCs also require an 
alternative mechanism to internalise antigens. For this, they use macropinocytosis to internalise 
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large amounts of soluble antigens from their environment. Macropinocytosis is an actin 
dependent process, as preventing actin polymerisation blocks macropinocytosis in BMDMs100, 
but it does not require the presence of cell surface receptors. Macropinocytosis requires 
phosphoinositide 3 (PI3)-kinase activity, as inhibition using wortmannin or LY294002 prevented 
closure of macropinosomes in mouse BMDMs101. GTPases have also been shown to be involved 
in macropinocytosis, for example, splenic DCs expressing a dominant negative form of Rac are 
unable to form macropinosomes102.  
Extracellular material internalised via macropinocytosis enters macropinosomes, which can be 
up to 5 µm in diameter, and form as a result of membrane ruffling. Depending on the type of 
APC, macropinosomes enter different intracellular processing pathways. In human DCs, antigens 
internalised by macropinocytosis enter compartments which contain MHCII, cathepsin D and 
lysosomal associated membrane protein-1 (LAMP-1), indicating that they enter late 
endosomes/lysosomes to be degraded103, and do not enter early endosomes104. In addition, 
antigen which has been internalised via macropinocytosis can be released into the cytoplasm 
where they can be processed and cross-presented via MHCI105. As a result of PRR stimulation, 
DCs mature, and this is accompanied by a decreased capacity to internalise material via 
macropinocytosis in vitro. Despite this, mature DCs still endocytose and phagocytose, but their 
function shifts towards presentation of previously internalised antigens. The fact that mature 
DCs are still capable of endocytosis is exemplified by the fact that splenic DCs matured using LPS 
or CpG and pulsed with ova in vivo are still capable of internalising ova, as they cause similar ova 
specific CD4+ and CD8+ T cell proliferation as immature splenic DCs, after being co-cultured in 
vitro for 60 hours106. 
 
1.7.4 Antigen processing and presentation by DCs 
 
The delivery of internalised antigens into the appropriate antigen processing pathways is 
essential so that DCs can process antigens into peptides which can be presented to T cells. 
Generally, the proteasome, a multi-subunit protease, is responsible for the degradation of 
intracellular antigens found in the cytosol107, whereas lysosomal proteolysis is used to degrade 
internalised antigens108. Presentation of peptides in MHCI leads to the activation of CD8+ T cells, 
mainly for the elimination of infected cells and tumour cells. However, this also requires the 
activation of CD4+ T cells via peptides expressed in MHCII. MHCI is expressed on nearly all cell 
types, and non-immune cell expression of peptides in MHCI are derived from cytosolic proteins 
which have been processed by the ubiquitin/proteasome system. Cytosolic peptides, usually 8-
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10 amino acids in length, are loaded onto MHCI in the endoplasmic reticulum (ER) and then 
transported to the plasma membrane via the Golgi apparatus107. If the DC is immature, in the 
case of presentation of self-peptides, then this should promote tolerance. However, if the DC is 
mature, then CD8+ T cells should be activated to recognise and kill infected cells. In addition to 
presenting endogenous antigens on MHCI, DCs can also present exogenous antigens on MHCI, 
by a process known as cross-presentation.  
Instead of being processed by the proteasome, exogenous, internalised antigens enter 
endolysosomal compartments. These consist of early endosomes, late endosomes and 
lysosomes, which in turn are more acidic and proteolytically active. For example, lysosomes have 
a pH of 4-4.5 and contain cathepsin proteases which lead to the degradation of the internalised 
pathogens, allowing for the loading of peptides onto MHCII molecules, and subsequent 
presentation to CD4+ T cells.  
MHCII is assembled in the ER and relocates to endosomal compartments bound to the invariant 
chain (li, CD74). The invariant chain is also synthesised in the ER, where it forms trimers. Three 
MHCII αβ heterodimers associate with one li trimer, and this MHCII-li complex facilitates MHCII 
stabilisation, as in the absence of li, an accumulation of misfolded MHCII molecules are found in 
the ER109,110. The invariant chain also targets MHCII to endosomal compartments, via the Golgi 
and trans-Golgi network, and requires the presence of a conserved di-leucine motif in its N-
terminal cytoplasmic domain111. These leucine residues can associate with the adaptor 
molecules AP1 and AP2112, and are responsible for endocytosis of MHCII-li found on the plasma 
membrane. The invariant chain prevents peptide binding and is released from MHCII via 
progressive proteolysis in endosomes, until only the class II-associated invariant chain peptide 
(CLIP) remains in the binding grove of MHCII. In late endosomes, the non-classical MHC 
glycoprotein HLA-DM (H2-M in mice) then aids the release of CLIP from MHCII by inducing a 
conformation change. HLA-DM also stabilises empty MHCII molecules, thus preventing their 
aggregation. Once CLIP is released, antigenic peptides can be loaded onto MHCII in the late 
endosomal compartment. The MHCII groove, formed by the alpha and beta chain can 
accommodate peptides of 13-25 amino acids in length108. HLA-DM can also remove low affinity 
peptides from MHCII113. In mature DCs, peptide-MHCII complexes then traffic to the plasma 
membrane via endolysosomal tubules114, which are positive for LAMP-1, CD63 and CD82. 
Endolysosomal tubules colocalise with microtubules and do not form when LPS matured DCs are 
treated with nocodazole, which destabilises microtubules, indicating that microtubules act as 
scaffolds for endolysosomal tubules. Cytochalasin D, on the other hand, had no effect on the 




If peptide-MHCII complexes presented on the cell surface of APCs are not recognised by T cells, 
they are targeted for degradation by ubiquitination. This allows APCs to present a wider variety 
of antigens to T and B cells. In human DCs, peptide-MHCII complexes are internalised by clathrin-
independent endocytosis after ubiquitination by March-1, an E3 ubiquitin ligase115,116. After DC 
maturation, peptide-MHCII complexes are maintained on the cell surface for longer, partly due 
to an overall reduction in endocytosis, but also by the fact that peptide-MHCII complexes are no 
longer ubiquitinated by March-1116.  
In comparison to macrophages, DCs have higher endosomal pH and lower protease contents, 
which causes less antigen degradation, and therefore favours antigen presentation. The low 
antigen degradation in DCs may favour the production of longer antigenic peptides which can 
be presented in MHCII and may contribute to their ability to cross-present exogenous antigens 
on MHCI, potentially explaining why DCs are more effective APCs than macrophages117. 
 
Figure 1-3: Routes of antigen uptake, processing and presentation by DCs.   
Antigens can be internalised via phagocytosis, macropinocytosis or receptor mediated endocytosis. Once internalised, 
they enter early endosomes, late endosomes and lysosomes, which are progressively more acidic, leading to antigen 
degradation. Peptides can then be loaded onto MHCII molecules and transported to the plasma membrane, for 
presentation to CD4+ T cells. Alternatively, internalised antigens, along with self-proteins and viral proteins can be 
degraded by the proteasome and be loaded onto MHCI, for presentation to CD8+ T cells. Diagram has been adapted 






1.7.5 The role of Src and Syk family kinases in regulating antigen uptake, processing 
and presentation 
 
Protein kinases and phosphatases are essential for regulating numerous receptor signalling 
pathways present in DCs. Src and Syk family kinases are expressed in innate cells and play a 
fundamental role in initiating and regulating signalling for receptors that utilise ITAMs, including 
C-type lectin receptors and immunoreceptors118. The Src family of tyrosine kinases consists of 
Src, Yes, Fyn, Gardner-Rasheed feline sarcoma viral oncogene homologue (Fgr), Lck, 
hematopoietic cell kinase (Hck), B cell lymphocyte kinase (Blk), Lyn and Fyn related kinase (Frk), 
while innate cells predominantly express Hck, Fgr, Lyn and Src118. The Syk family of tyrosine 
kinases includes Syk and ZAP-70, but only Syk is expressed in innate cells118.  
The role of Syk in the presentation of immune complex derived antigens has been investigated 
using selective inhibitors. Syk inhibition in mouse BMDCs inhibited immune complex 
internalisation and led to the subsequent reduction in immune complex induced BMDC cytokine 
secretion119 and presentation of antigens to T cells120. In addition, Syk deficient BMDMs are 
defective in FcγR dependent phagocytosis of IgG opsonised sheep red blood cells121. In the same 
study and in a subsequent one, the role of Src family kinases was also tested, and BMDMs 
deficient for Hck, Fgr and Lyn were capable of phagocytosing opsonised red blood cells, albeit at 
a reduced rate compared to WT BMDMs121,122. BMDMs lacking either Syk or Src family kinases 
were capable of internalising latex beads and E. coli, indicating that these kinases are not 




1.8.1 FcγR expression and function  
 
Autoantibodies have long been implicated in the aetiology of autoimmune diseases including 
RA, T1D, Graves’ disease and SLE, diseases for which PTPN22R620W is also a susceptibility risk 
allele123.  Autoantibodies are produced by B cells and bind to self-antigens forming immune 
complexes (ICs) which are recognised by fragment crystalline (Fc) receptors (FcRs), thus inducing 
FcR mediated antigen uptake and cell activation.  
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FcRs are found on most innate immune cells, including DCs, and are part of the immunoglobulin 
superfamily. FcRs recognise the Fc region of immunoglobulins (Igs) and can be categorised 
depending on which class of Ig they recognise. FcγRs recognise the Fc regions of IgGs, FcεRI 
recognises IgE, FcαRs recognise IgA, FCMRs recognise IgM and FcδRs recognise IgD. IgG is the 
most abundant immunoglobulin class found in mice and humans124. IgG can be further divided 
into subclasses, namely IgG1, IgG2, IgG3 and IgG4 in humans, and IgG1, IgG2a, IgG2b and IgG3 
in mice125. These are detected by FcγRs as either monomeric, as part of an aggregate, an IC or 
opsonised particle.  There are four cell surface FcγRs expressed in mice, FcγRI, IIb, III and IV, and 
six expressed in humans, FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB (see Tables 1-2 
and 1-3). The FcγRs have different affinities for IgG subclasses. For example, mouse FcγRIV is a 
high affinity receptor for IgG2b126, but does not bind to IgG1 or IgG3. Mouse FcyRI is a high 
affinity receptor for IgG2a and a low affinity receptor for IgG2b and IgG3. FcyRIIb and FcyRIII are 
low affinity receptors for mouse IgG1, IgG2a and IgG2b. FcyRIIb, III and IV can also bind to IgE 
with low affinity, making FcyRI the only specific IgG receptor expressed in mice126. There are also 
two cytoplasmic FcγRs which recognise internalised IgGs, tripartite motif containing protein 21 
(TRIM21) and neonatal FcR (FcRn). FcγRI, III and IV are classed as activating receptors, whereas 
FcγRIIb is the only inhibitory receptor expressed in mice. Most innate immune cells express both 
activating and inhibitory FcγRs, allowing for the modulation of downstream signalling. However, 
there are exceptions, as NK cells only express FcγRIII and B cells only express FcγRIIb, which 
allows them to regulate signalling via the BCR125.  
FcγR Cell location Activating or 
inhibitory 
IgG subclass affinity 
FcγRI Plasma membrane Activating High affinity for IgG1, IgG3 and IgG4 
FcγRIIA Plasma membrane Activating Low affinity for IgG1, IgG2, IgG3 and 
IgG4 
FcγRIIB Plasma membrane Inhibitory Low affinity for IgG1, IgG3 and IgG4 
FcγRIIC Plasma membrane Activating Low affinity for IgG1, IgG3 and IgG4 
FcγRIIIA Plasma membrane Activating Low affinity for IgG1, IgG3 and IgG4 
FcγRIIIB Plasma membrane Activating Low affinity for IgG1, IgG3 and IgG4 
FcRn Intracellular IgG recycling 
and transport 
High affinity for IgG1, IgG2, IgG3 and 
IgG4 
TRIM21 Intracellular Activating and 
proteasome 
targeting 
High affinity for IgG1, IgG2, IgG3 and 
IgG4 







FcγR Cell location Activating or 
inhibitory 
IgG subclass affinity 
FcγRI Plasma membrane Activating High affinity for IgG2a, low affinity for 
IgG2b. No binding to IgG1 
FcγRIIb Plasma membrane Inhibitory Low affinity to IgG1, IgG2a and IgG2b. 
No binding to IgG3 
FcγRIII Plasma membrane Activating Low affinity to IgG1, IgG2a and IgG2b. 
No binding to IgG3 
FcγRIV Plasma membrane Activating High affinity for IgG2a and IgG2b. No 
binding to IgG1 and IgG3 
FcRn Intracellular IgG recycling 
and transport 
High affinity for IgG1, IgG2a, IgG2b and 
IgG3 
TRIM21 Intracellular Activation and 
proteasome 
targeting 
Binds to IgG2a, IgG2b and IgG3 with 
unknown affinity 
Table 1-3: IgG recognising FcR expression in mice and their IgG binding affinities.  
IgG immunoglobulins are composed of two heavy (H) chains and two light (L) chains, linked by 
disulphide bonds. The heavy chains contain an N-terminal variable domain (VH) and three 
constant domains (CH1, CH2 and CH3). The light chain consists of an N-terminal variable domain 
(VL) and a constant region (CL). The Fc region, which is recognised by FcγRs, is composed of the 
lower hinge region between CH1 and CH2, in addition to the CH2 and CH3 domains. Although the 
subclasses of IgG show high homology, there is variation in the Fc regions, and this affects IgG 
binding to FcγRs. A conserved N-linked glycosylation site between CH2 and CH3 in the heavy chain 
(N297) affects binding to FcγRs by modulating the quaternary structure of the Fc region of the 
IgG127. The presence of a glycan at this position acts to stabilise the Fc region and leads to a more 
open IgG conformation, thus enhancing FcγR binding. The glycan is composed of a core structure 
of N-acetylglucosamine (GlcNAc) and mannose groups, which can be extended by the presence 
of galactose, sialic acid, fucose and bisecting GlcNAc, the combination of which affects FcγR 
binding. The glycan is also able to directly bind to the FcγR, through glycan protein binding. The 
glycosylation state of N297 has been adapted to modulate and improve FcγR binding of 





Figure 1-4: The structure of IgG.  
IgGs are formed of two heavy (H, grey) and two light (L, orange) polypeptide chains, linked by disulphide bonds (black 
lines). These contain both constant (C, filled) and variable (V, open) regions. The Fab region is composed of the light 
chains and the VH and CH1 domains of the heavy chains. The Fc region is composed of the lower hinge region between 
CH1 and CH2, as well as the CH2 and CH3 domains of the heavy chains. An N-linked glycosylation site is located within 
the heavy chain (N297, blue circles). Diagram has been adapted from Shade K et al., Antibodies, 2013. 
When the Fc region of an IgG is recognised by an activating FcγR, this leads to receptor 
crosslinking and induces Src family kinase activation, which in turn phosphorylates two tyrosine 
residues in the ITAM, located in the associated common γ chain. Syk is then recruited via its 
tandem SH2 domains to the phosphorylated tyrosines. After Syk recruitment, downstream 
targets are phosphorylated, including LAT. Phosphorylated LAT then recruits phospholipase Cγ 
(PLCγ) which hydrolyses phosphatidyl inositol 4,5-bisphosphate to soluble inositol 1,4,5-
triphosphate (IP3) and membrane bound diacylglycerol (DAG). This results in enhanced 
intracellular calcium, leading to further downstream signalling involving ERK, p38 and c-Jun N-
terminal kinase (JNK). This signalling ultimately leads to a range of cellular processes including 
DC maturation, cytoskeletal rearrangement, oxidative burst, antibody dependent cell mediated 
cytotoxicity (ADCC) and chemokine/cytokine production125 (Figure 1-5a). The presence of Src 
and Syk family kinases downstream of FcγRs raises the possibility that PTPN22 may be involved 
in regulating signalling via its ability to dephosphorylate these kinases. 
Alternatively, if the Fc region of an IgG is recognised by the inhibitory receptor FcγRIIb, 
phosphatases such as SH2-domain-containing protein tyrosine phosphatase 1 (SHP-1) and SH2-
domain-containing inositol polyphosphate 5' phosphatase 1 (SHIP-1) are recruited to the 
phosphorylated tyrosines in the immunoreceptor tyrosine-based inhibition motif (ITIM), located 
in the cytoplasmic tail of the receptor. Co-ligation of an activating FcγR with the inhibitory 
FcγRIIb reduces activating signalling by dephosphorylation of signalling intermediates. To reduce 
signalling downstream of an activating receptor, FcyRIIb needs to be co-ligated with the same 
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immune complex129 (Figure 1-5b). Therefore, the cellular response depends on a balance 
between the positive and negative signals. Ideally, foreign antigens will promote positive signals, 
giving rise to a pro-inflammatory response, whereas in the case of self-antigens, an anti-
inflammatory response will be mounted. If this balance is not regulated appropriately, then 
pathogens may not be eliminated, or autoimmunity may ensue.  
 
Figure 1-5: Schematic showing activating and inhibitory FcγR signalling.  
(a) Activating FcγR signalling is initiated by the Fc regions of IgGs in immune complexes being recognised by FcγRs. 
This causes receptor crosslinking, which leads to Src family kinase dependent phosphorylation of the tyrosines in the 
ITAM of the associated common gamma chain (FcRγ). Syk binds to the phosphorylated tyrosines via its SH2 domains 
and leads to downstream signalling resulting in cellular processes including immune complex uptake, processing and 
presentation, cell maturation, cytokine production, and T cell activation. (b) Inhibitory FcγR signalling occurs when an 
immune complex is bound by both an activating FcγR and the inhibitory receptor FcγRIIb. Src family kinases 
phosphorylate a tyrosine in the ITIM, located in the cytoplasmic tail of FcγRIIb, leading to SHIP-1 recruitment. SHIP-1 
then negatively regulates signalling downstream of the activating receptor, leading to increased hydrolysis of PIP3 and 
ERK inhibition. Diagrams have been adapted from Takai T, Nature Reviews Immunology, 2002, Schmidt RE et al, 
Immunology Letters, 2005 and Ivashkiv LB, Immunology, 2011. 
In myeloid cells, both the activating and inhibitory FcγRs internalise IgG-containing particles 
after they are recognised. Internalisation of ICs via activating FcγRs is dependent on the presence 
of the two tyrosines in the ITAM130. However, the di-leucine motif in the intracellular domain of 
FcγRIIb is required for uptake via this receptor131. There are three isoforms of FcγRIIb in mice, 
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FcγRIIb1, FcγRIIb1’ and FcγRIIb2132. FcγRIIb1 contains an insertion of 47 amino acids in its 
cytoplasmic domain and is incapable of endocytosis, whereas this insertion is lacking in FcγRIIb2, 
and it is this isoform that mediates endocytosis and clearance of immune complexes131. FcγRIIb2 
is predominantly expressed in myeloid cells, whereas FcγRIIb1 is expressed by lymphoid cells. 
ICs taken up by activating FcγRs are thought to enter a degradative pathway, to allow for the 
production of peptides which can be presented to both CD4+ and CD8+ T cells. Uptake via the 
inhibitory FcγR is thought to cause retention of the IgG-containing particle, potentially for 
presentation of intact antigen to B cells133. The intracellular IgG receptors, TRIM21 and neonatal 
FcR are thought to play an important role in routing FcγR-IgG complexes to specific endosomes 
for either degradation or recycling134–137. TRIM21 is especially important in orchestrating the 
degradation of antibody bound viruses, by routing these to the proteasome via its E3 ubiquitin 
ligase activity137. 
The requirement for intact ITAM signalling downstream of FcγRs in BMDCs has been investigated 
and found to be required for optimal T cell responses. This was demonstrated using NOTAM 
BMDCs, which are unable to signal through ITAMs, but have normal FcγR cell surface 
expression138. NOTAM BMDCs show normal ova IC binding, but reduced uptake and degradation. 
As a result, NOTAM BMDCs are unable to present ova IC derived antigens on MHCI and MHCII 
(despite being capable of stimulating T cells when pulsed with OVA323-339 peptide or ova 
protein)139. ITAM signalling was also demonstrated to be important using DAP12 and FcRγ 
doubly deficient mice, as BMDCs from these mice were pulsed with ova coated beads and were 
unable to cause ova specific CD4+ T cell proliferation140. 
 
1.8.2 Regulation of FcyR signalling 
 
Polymorphisms have been detected in human FCGR genes and shown to be associated with 
autoimmune diseases such as SLE, RA and multiple sclerosis141, which demonstrates the 
requirement for effective regulation of FcγR signalling. The major mechanism used to regulate 
signalling downstream of activating FcγRs is the presence of the inhibitory receptor. As discussed 
above, if the inhibitory receptor is crosslinked by the same immune complex as an activating 
receptor, then the inhibitory receptor negatively regulates signalling downstream of the 
activating receptors. This is due to the recruitment of phosphatases including SHP-1, SHP-2 and 
SHIP-1 to the phosphorylated tyrosines in the ITIM in the intracellular domain of the receptor. 
SHIP-1 is thought to be the major phosphatase involved in FcγRIIb signalling and subsequent 
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inhibition of activating FcγR effector responses in mast cells and B cells142–144. SHIP 
dephosphorylates phosphatidylinositol-3,4,5-triphosphate, thus preventing the production of 
IP3 and DAG145. FcγRIII and FcγRIIb bind to IgG containing immune complexes with similar affinity 
and specificity, indicating that if FcγRIIb is present on the same cell as FcγRIII then it is likely that 
it will reduce activating FcγRIII signalling. In the steady state, the ratio of activating FcγR to 
FcγRIIb expression is low, preventing undesirable responses to immune complexes. However, 
this ratio increases during inflammation. Expression of these opposing receptors can be 
modulated in vitro using a variety of pro and anti-inflammatory cytokines. For example, IFNγ can 
enhance FcγRI and FcγRIII expression, while also reducing FcγRIIb expression on the cell surface 
of kidney mesangial cells146. Alternatively, anti-inflammatory cytokines IL-4 and TGFβ have been 
shown to increase the expression of FcγRIIb on THP-1 cells147. This demonstrates that during a 
type 2 helper T cell (Th2) mediated immune response, IL-4 enhances FcγRIIb signalling, 
preventing excessive IgG dependent inflammatory responses. Whereas, during a type 1 helper 
T cell (Th1) mediated response, IFNγ favours activating FcγR signalling. 
An additional level of modulation is provided by inhibitory ITAM signalling (ITAMi), where 
monomeric antibodies (in the absence of antigen) cause recruitment of the phosphatase SHP-1 
to the ITAM, thus suppressing cell activation downstream of other activating receptors148. 
Inhibitory signalling may be due to only one ITAM tyrosine residue being phosphorylated after 
IgG engagement with the receptor149 (Figure 1-6). This mechanism may continuously reduce 
immune cell activation and therefore contribute to maintaining immune homeostasis148. This 
can also occur as a result of chronic activating receptor stimulation. 
 
Figure 1-6: Schematic showing inhibitory ITAM FcγR signalling.  
Inhibitory ITAM signalling (ITAMi) occurs after low avidity engagement of an activating FcγR, for example, with 
monomeric IgG, which causes mono-phosphorylation of a tyrosine in the ITAM. Instead of leading to the recruitment 
of Syk (which requires that both tyrosines are phosphorylated), this leads to SHP-1 recruitment, which in turn inhibits 
signalling from activating receptors. Diagrams have been adapted from Takai T, Nature Reviews Immunology, 2002, 
Schmidt RE et al, Immunology Letters, 2005 and Ivashkiv LB, Immunology, 2011. 
Ubiquitination also provides a mechanism for negative regulation of FcyR signalling. 
Ubiquitination can lead to internalisation and/or delivery of antibody or immune complex bound 
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FcyRs to lysosomes or proteasomes for degradation. Ubiquitin is added to lysine residues in the 
target proteins, either via monoubiquitination (a single ubiquitin being added to one lysine 
residue), multiunbiquitination (ubiquitin molecules being added to multiple lysine residues), or 
polyubiquitination. Ubiquitin tagged proteins mainly become internalised via clathrin 
dependent endocytosis150.  
The complement component C5a, which forms during immune complex induced cell activation 
regulates the expression of the activating and inhibitory FcγRs. For example, binding of C5a to 
its receptor C5aR on alveolar macrophages has been shown to increase transcription of Fcgr3 
and reduce expression of FcγRIIb151,152. Regulation also occurs in the other direction, in that C5a 
production can be induced after immune complex binding to activating FcγRs in macrophages151. 
Co-stimulation of immune complexes with C5a results in enhanced FcγRIII dependent cell 
activation152.  
 
1.8.3 Association of SNPs in FCGR genes with autoimmunity 
 
Polymorphisms are present in human FCGR genes which are linked to the development of 
autoimmune diseases including SLE, RA, multiple sclerosis, Wegener’s granulomatosis and 
Guillain-Barre syndrome.  For example, the V158F (rs396991) variant of FcyRIIIA was found to 
be expressed at a higher frequency in SLE patients compared to healthy controls153. This variant 
was also found at higher frequencies in RA patients compared to healthy controls154,155. A T695C 
polymorphism in FCGR2B leads to an isoleucine to a threonine amino acid change at position 
232 of the protein, and has been associated with an enhanced susceptibility to SLE156. 
Conversely, a T559G base pair change in FCGR3A, which leads to F176V substitution in FcyRIIIA 
is associated with a reduced risk of SLE, as fewer SLE patients were found to carry the variant157. 
 
1.8.4 Phenotypes of mice lacking FcyR expression 
 
Mice that lack expression of the activating FcγRs (FcRy-/-), and therefore only express the 
inhibitory receptor FcγRIIb, are resistant to a variety of models of autoimmune diseases such as 
immune complex-induced alveolitis158, antibody-induced vasculitis159 and collagen-induced 
arthritis (CIA) (on the DBA/1 susceptible background)160, but are susceptible to infections 
including Mycobacterium tuberculosis161. Mice lacking the inhibitory receptor FcγRIIb, and 
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therefore only expressing the activating receptors, have enhanced levels of autoantibodies 
which lead to IC-induced autoimmune diseases such as methylated bovine serum albumin 
(mBSA)-induced arthritis162. They are also more susceptible to CIA (on the DBA/1 background), 
which is accompanied by enhanced anti-collagen II IgG160. FcγRIIb deletion renders arthritis 
resistant 129/SvJ and C57Bl/6 mice sensitive to disease using the CIA model163. FcγRIIb-/- mice 
are also more susceptible to immune complex-induced alveolitis158, and on a C57Bl/6 
background develop a spontaneous autoimmune phenotype which resembles SLE, including 
glomerulonephritis, anti-nuclear antibodies and proteinuria164. However, FcγRIIb-/- mice are 
more resistant to infections with Streptococcus pneumoniae as their macrophages are more 
effective at clearing the bacteria165.  
Microarrays carried out on immune complex stimulated WT, FcγRIIb-/- and FcRγ-/- mouse BMDCs 
showed that FcγRIIb regulates gene expression. The authors reported a 75% increase in 
differentially expressed genes between FcγRIIb-/- and WT immune complex stimulated BMDCs, 
indicating that FcγRIIb normally acts to limit FcγR dependent cell activation. In addition, gene 
expression profiles associated with T cell activation were seen in WT and FcγRIIb-/- BMDCs, but 
not in FcRγ-/- BMDCs. In order to activate T cells, BMDCs need to mature after immune complex 
stimulation. This includes upregulation of MHCII and co-stimulatory molecules, cytokine 
secretion and an increased migratory capacity. mRNA and protein expression of CD40 and CD86 
were all enhanced after IC stimulation in WT and FcγRIIb-/- BMDCs, but not in FcRγ-/- BMDCs. 
Immune complex induced cytokine secretion was found to be lowest by FcRγ-/- BMDCs and 
highest by FcγRIIb-/- BMDCs, both in comparison to WT BMDCs. This indicates that cytokine 
secretion is mainly due to activating FcγR signalling and that it is regulated by FcγRIIb. Immune 
complex stimulation also leads to the production of chemokines and growth factors. Genes for 
these were more highly upregulated in stimulated WT and FcγRIIb-/- BMDCs compared to FcRγ-/- 
BMDCs. This all resulted in an enhanced capacity of IC pulsed FcγRIIb-/- BMDCs to cause ova 
specific CD8+ T cell proliferation166. 
 
1.9 Rheumatoid Arthritis  
 
Rheumatoid arthritis (RA) is an autoimmune chronic disease, which, if left untreated, causes 
synovial inflammation and loss of normal joint architecture due to bone and cartilage 
destruction. It also includes extra-articular features including those associated with the 
cardiovascular and pulmonary systems. The joint infiltrating leukocytes activate synovial 
fibroblasts and macrophages. This leads to the production of a variety of pro-inflammatory 
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cytokines and soluble mediators, which lead to angiogenesis, cartilage destruction and bone 
erosion. Unlike other autoimmune diseases such as T1D, the autoantigen response of patients 
with RA is not joint specific, since autoantibodies are directed against ubiquitous antigens found 
throughout the body. Autoantibodies include those against citrullinated proteins (ACPAs), 
rheumatoid factor (directed against the Fc region of IgG), collagen II, glucose-6-phosphate 
isomerase (GPI) and binding immunoglobulin protein (BiP). These can often be detected years 
before development of synovial inflammation, in the pre-clinical phase of the disease167.  As 
autoantibodies are often detected in the blood long before the onset of clinical disease, this 
suggests that disease initiation may occur at non-articular sites. The exact mechanism behind 
the transition from the pre-clinical to the clinical phase of disease is not known, however, it 
involves the presentation of self-peptide in MHCII to autoreactive T cells.  
Both genetic and environmental factors are thought to play a role in the aetiology of the disease. 
Genome wide association studies (GWAS) have found links between RA and more than 100 loci, 
the most highly associated polymorphisms are found within the human leukocyte antigen (HLA) 
region, especially the HLA-DRB1 locus. This allele of HLA-DRB1 has a higher affinity for 
citrullinated peptides168, indicating that this may favour the presentation of modified self-
peptides, potentially leading to a breach of tolerance. In addition, there is an increased 
concordance rate in monozygotic compared to dizygotic twins (15-30% and 5% respectively); 
thus demonstrating the presence of genetic risk factors169. There is also an environmental 
influence to the disease, with smoking being the strongest environmental risk factor170. It has 
been suggested that smoking may affect the expression, particularly in the lung, of 
peptidylarginine deiminases (PADs), the enzymes responsible for citruillinating proteins171. In 
addition, infectious agents including E. coli and Epstein-Barr virus172 and the oral and gut 
microbiota173 have been linked with RA. 
 
1.10 Mouse models of rheumatoid arthritis 
 
Mouse models of rheumatoid arthritis have been instrumental in increasing our understanding 
of the mechanistic basis behind the human disease. Although they each have their limitations, 
they have underpinned the testing and advancing of a wide range of therapies and facilitated 
investigation of the pre-clinical phase and initial onset of disease, which is often not possible in 
humans. In addition, these models allow for the study of clinically relevant tissues including 
lymph nodes and joints, which are not so readily available from patients. Mouse models which 
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have been commonly used include collagen-induced arthritis (CIA), collagen antibody-induced 
arthritis (CAIA), zymosan-induced arthritis, K/BxN serum transfer model and the methylated BSA 
model. In addition, there are spontaneous models which include the K/BxN model, the TNFα 
transgenic mouse and the SKG mouse.  
 
1.10.1 Collagen-induced arthritis 
 
Collagen-induced arthritis (CIA) was first reported in 1977, where human, chicken or rat type II 
collagen in the presence of complete or incomplete Freund’s adjuvant caused inflammatory 
arthritis in 40% of rats after intradermal injection174. Mouse strains that express MHCII I-Aq, such 
as DBA/1 mice, are particularly susceptible to this model. The model shares several hallmarks of 
the human disease, including a breach of tolerance, the generation of autoantibodies against 
type II collagen, and, less commonly, the presence of rheumatoid factor or antibodies against 
citrullinated peptides. Signs of disease are visible between 21-25 days post injection and peak 
at approximately 35 days, after which mice enter a phase of remission. Both T and B cells are 
required for the initiation of CIA, resulting in the presence of collagen specific T cells and collagen 
type II antibodies, which are generally IgG2a or IgG2b. Although C57Bl/6 mice do not express 
MHCII I-Aq, and are considered to be resistant to CIA, arthritis can be induced, albeit a milder 
more chronic disease, with a lower penetrance. The role of PTPN22 has been investigated using 
this model of arthritis, where it was found to be dispensable, although Ptpn22-/- mice did develop 
a more severe disease, which did not reach statistical significance61. 
 
1.10.2 Collagen antibody-induced arthritis 
 
The collagen antibody-induced arthritis (CAIA) model is initiated by the transfer of arthritogenic 
antibodies against type II collagen from mice subjected to the CIA model175, human RA patients 
or commercially available antibody cocktails176 into recipient mice. As autoantibodies are being 
transferred, T and B cells are not required for initiation of disease, so this model does not 
completely recapitulate the complexities of the human disease. The clinical features of this 
model are similar to those found using CIA, including immune cell infiltration of the synovium, 
pannus formation, bone remodelling and cartilage damage. The CAIA model can be used in 
mouse strains which are resistant to CIA, and signs of disease are present after 8 days and mice 
enter remission within 1 month. 
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1.10.3 Zymosan-induced arthritis 
 
The zymosan-induced arthritis model is more transient than both CIA and CAIA, where signs of 
inflammatory arthritis can be seen 3 days after intraarticular injection with zymosan. Clinical 
signs include immune cell infiltration into the synovium, pannus formation and synovial 
hypertrophy177. However, one drawback of this model is that disease is only seen in the joints 
that have received the zymosan.  
 
1.10.4 K/BxN and K/BxN serum transfer model of arthritis 
 
The K/BxN model of rheumatoid arthritis was developed in the lab of Benoist and Mathis in the 
1990s178. By crossing KRN TCR transgenic mice with NOD mice, the offspring (referred to a K/BxN 
mice) developed a joint disease similar to RA after approximately 4 weeks of age. NOD mice 
express the MHCII allele I-Ag7, and this was the only requirement from the NOD mouse needed 
to cause spontaneous disease, as when they crossed KRN mice with a C57Bl/6 line expressing 
the NOD I-Ag7, the offspring also developed disease. The KRN T cell receptor recognises the 
bovine ribonuclease43-56 peptide presented in the context of I-Ak. Disease arises from the 
activation of T cells which express the KRN TCR, which also recognises a self-peptide of glucose-
6-phosphate isomerase (GPI) when presented in the NOD I-Ag7. The activated T cells then provide 
help to B cells which leads to the production of IgG1 GPI autoantibodies. GPI catalyses the 
conversion of glucose-6-phosphate to fructose-6-phosphate during glycolysis. Being a glycolytic 
enzyme, GPI does not show joint specific expression, but is ubiquitously expressed. Despite this, 
clinical signs of disease are mostly detected in the joints. This may be due to the presence of 
GPI, in close proximity to IgG and complement component C3 on the cartilage surface, along the 
thickened synovium and the pannus of arthritic mice. In healthy mice, the GPI on the cartilage 
surface was not localised with IgG179. 
Arthritis developing in K/BxN mice has some similarities to human RA, characterised by joint 
swelling and redness, leading to joint deformities and eventually causing reduced mobility.  
Histology showed leukocyte infiltration, synovial inflammation, pannus formation, cartilage and 
bone destruction, and fibrosis; all reminiscent of the human disease. The bones and joints that 
are affected include the metatarsal, tarsal, ankle and knee joints, but not the hips or the spine. 
In the initial study by Benoist and Mathis, they did not detect circulating autoantibodies such as 
those against dsDNA or rheumatoid factor. Although they did detect IgG deposits on sections of 
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many organs. T cells are required for disease initiation as by treating K/BxN mice with a non-
depleting CD4 monoclonal antibody for 1 week, they were able to prevent disease initiation. B 
cells are also required for disease development, as when they used µMT mice to create K/BxN 
mice that lacked B cells, no signs of disease were visible178.  
By harvesting serum or purified autoantibodies from arthritic K/BxN mice, disease can be 
transferred to recipient mice. This is called the K/BxN serum transfer model of arthritis and has 
the benefit that arthritis can be investigated in any mouse strain and with established gene 
deficient mouse lines. The disease observed using this model is transient, but can be maintained 
by repeated injections of GPI autoantibodies. Autoantibodies to GPI have been detected in RA 
patients180, thus demonstrating the utility of these models to investigate the human disease. As 
autoantibodies are being transferred, the serum transfer model focusses on the effector phase 
of the disease, and as such T and B cells are not required for disease initiation. Using a variety of 
gene deficient mice, it has been shown that neutrophils181 and macrophages182,183 are required 
for disease development. Mast cells were initially thought to be required for disease, as mast 
cell deficient KitW/W-v mice and mast cell deficient Kit-ligand (Kitl)-mutated KitlSl/Sl-d mice were 
found to be resistant184. However, more recent evidence has shown that mast cell deficient mice 
are able to develop disease185. Other vital factors for disease initiation include the complement 
component C5186, FcyRIII187, IL-1188 and LFA-1189,190. In addition, Syk dependent signalling has 
been found to be required, as mice lacking Syk expression in neutrophils are resistant185. Syk-/- 
neutrophils were recruited normally to the joints, but once there, produced reduced levels of 
TNFα and were more sensitive to apoptosis. Src family kinases were also found to be required 
for disease development, as mice lacking Hck, Fgr and Lyn were protected191. This was not due 
to a cell intrinsic role in leukocyte migration, but a role in establishing an inflammatory 
microenvironment, potentially due to the impact of Src family kinases in regulating immune 
complex induced neutrophil and macrophage activation. Despite the abundance of TNFα and IL-
6 in the joints of RA patients and in mouse models of arthritis, these cytokines were not required 
for disease initiation using the serum transfer model, although some TNFα-/- mice were 
protected188.  
The role of PTPN22 in the K/BxN serum transfer model of arthritis has been previously examined, 
however the results are contradictory. PTPN22 has either been found to augment63 or not 
affect10,59 disease severity. This indicates that other factors may be involved including the titre 




1.10.5 Methylated bovine serum albumin (mBSA)-induced arthritis 
 
Methylated bovine serum albumin (mBSA) in complete Freund’s adjuvant, when given 
systemically, followed by intraarticular injections of mBSA into the knee joint causes antigen-
induced arthritis192. The model represents lots of the clinical features of RA, including synovitis, 
mononuclear cell infiltration of the synovium, and bone and cartilage erosion, and has been 
used in a range of animals to induce prolonged inflammation.  
 
1.10.6 Spontaneous TNFα transgenic mouse model of arthritis 
 
In 1991, a transgenic mouse line was created in which the human TNFα (hTNFtg) was 
dysregulated through mutation of the 3’ untranslated region of the gene193. These mice develop 
spontaneous chronic inflammatory arthritis, which affects all joints and can be prevented using 
anti-TNFα treatment194. The disease closely mirrors RA in humans, and includes immune cell 
infiltration, pannus formation, cartilage damage and bone erosion, although rheumatoid factor 
is not detected in the serum of these mice. Depending on the level of TNFα overexpression, signs 
of disease are visible from 4-5 weeks of age. hTNFtg mice, when crossed onto Recombination 
activating gene (Rag1)-/- mice also develop arthritis, indicating that T and B cells are not required 
for disease initiation in these mice195. 
This model also demonstrated the important role of TNFα in RA. TNFα is highly expressed in the 
inflamed synovium of RA patients, where it can induce cartilage damage via collagenase, cause 
proliferation of fibroblast-like synoviocytes, and promote osteoclastogenesis. In addition, anti-
TNFα inhibits the production of other pro-inflammatory cytokines, and has been used as a 
successful treatment in RA for over 20 years196.   
 
1.10.7 Spontaneous arthritis using SKG mice  
 
The SKG mouse strain was established in 2003197. SKG mice develop a spontaneous T cell 
mediated chronic inflammatory arthritis. Clinical signs of disease are visible from 2 months of 
age and result in the formation of a pannus, immune cell joint infiltration, cartilage and bone 
erosion and the presence of autoantibodies including rheumatoid factor; many of which are also 
found in RA patients. SKG mice carry a mutation in the gene for the kinase Zap70, which leads 
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to a tryptophan to a cysteine substitution at position 163, located in the SH2 domain of the 
protein. This leads to a dramatic reduction in ZAP-70 protein expression, and impaired binding 
of the mutant kinase to the invariant CD3 chain subunit, and is accompanied by profound 
reductions in signalling via the TCR. This in turn reduces the threshold for thymic selection, 
leading to the positive selection of a repertoire of autoreactive T cells198.  
 
1.11 Imaging of arthritic mice 
 
Positron emission tomography (PET) in combination with computed tomography (CT) is a 
technique which can be used to image mice and humans, in a non-invasive manner. One of the 
benefits of this technique is that it can be used to monitor disease progression or the efficacy of 
therapy in a longitudinal manner. Galium-68 is a radioactive isotope with a half-life of 68 
minutes. By chelating gallium-68 to a trimeric arginine-glycine-aspartic acid (RGD) peptide, it can 
be used to visualise areas of inflammation. RGD is found in extracellular matrix proteins such as 
fibrinogen, vitronectin, von Willibrand’s factor and osteopontin. RGD binds with high affinity to 
the integrin αvβ3. αvβ3 is expressed at low levels in the steady state, but is upregulated as a 
result of inflammation. Radiolabelled RGD peptides have been used extensively in the field of 
oncology199 because tumour cells and the associated endothelial cells express αvβ3 during 
angiogenesis. New blood vessel formation is also a feature of the inflamed synovial tissue in RA 
joints. In addition, αvβ3 is highly expressed on the surface of osteoclasts, activated macrophages 
and activated endothelial cells, all of which are present in the RA joint200. Imaging of arthritis has 
been previously achieved using an indium-111 radiolabelled dimeric RGD peptide and single-
photon emission computed tomography (SPECT) imaging, using the CIA model201. 
 
1.12 The human skeleton and osteoclasts 
 
1.12.1 The skeleton and bone remodelling 
 
The human skeleton is composed of bone and cartilage. The skeleton provides a structural role, 
in which it protects internal organs and is used for locomotion, via attachment to muscle. In 
addition, the skeleton provides a calcium and phosphate source, which is required for 
maintaining serum homeostasis. There are two types of bone present in the skeleton: cortical 
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and trabecular. Cortical bone forms the outer part of the skeleton and is dense and compact, 
thus providing mechanical strength and protection. Trabecular bone is less dense, contains the 
bone marrow, and has a higher turnover rate than cortical bone202. Both cortical and trabecular 
bone are eroded during RA203. 
The skeleton is continuously remodelled to remove old bone, to adjust to mechanical needs and 
to repair microfractures. Bone remodelling is achieved in stages referred to as resorption, 
reversal and formation. This occurs because of the combined effort of osteoclasts and 
osteoblasts, which together form basic multicellular units (or bone remodelling units). After 
bone resorption by osteoclasts, the reversal stage sees the appearance of mononuclear cells on 
the bone, followed by new bone formation by osteoblasts. The new bone is finally covered in a 
layer of lining cells202. Therefore, the actions of osteoblasts and osteoclasts need to be finely 
balanced to prevent an overall change in bone mass (Figure 1-7). 
 
Figure 1-7: Schematic showing normal bone remodelling by osteoclasts and osteoblasts.  
Bone remodelling is a vital process in order to maintain the structural integrity of the skeleton and to maintain mineral 
homeostasis. Remodelling begins with a resorption phase in which osteoclasts degrade the bone matrix and solubilise 
the bone mineral, due to their ability to release enzymes and to create an acidic environment. The reversal phase 
involves removal of debris by macrophages and monocytes. Bone formation occurs as osteoblasts produce osteoid 
matrix, which becomes mineralised. Diagram has been adapted from Lian JB et al., Nature Reviews Endocrinology, 
2012. 
Osteoclasts are the only cell type capable of resorbing bone and are therefore responsible for 
removing mineralised bone. As established RA is characterised by the presence of bone erosions, 
this demonstrates the essential nature of this cell type in disease. In addition, the requirement 
for osteoclasts in bone erosion is demonstrated by the fact that mice lacking osteoclasts do not 
develop bone erosions during mouse models of arthritis204,205. The importance of osteoclasts in 
RA is also exemplified by the number of anti-rheumatic drugs that have been developed that 
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target factors involved in osteoclastogenesis or osteoclast function. These include inhibitors of 
TNFα, IL-1 and IL-6R, including Tocilizumab, Adalimumab and Anakira respectively203. 
Osteoblasts counteract the role of osteoclasts by being responsible for the formation of new 
bone matrix. Osteoblasts originate from mesenchymal cells and are found on the bone surface, 
where they produce the bone matrix constituents. Osteoblasts also become incorporated into 
the new bone matrix where they regulate mineral metabolism as osteocytes. During 
homeostasis, levels of bone resorption and formation are equal, but in RA (and in other skeletal 
diseases such as osteoporosis), excessive bone loss is caused by a loss of equilibrium between 
osteoclast and osteoblast function203.  
 
1.12.2 Osteoclast differentiation and function 
 
Osteoclasts are giant, multi-nucleated cells derived from the monocyte lineage. Hematopoietic 
stem cells differentiate into monocytes in the bone marrow. Monocytes further differentiate 
into osteoclast precursors as a result of receptor activator of nuclear factor kappa-B ligand 
(RANK-L) ligation with its receptor RANK on the precursors. RANK is a member of the TNF 
receptor superfamily. RANK-L is expressed on multiple cell types including osteoblasts, stromal 
cells and activated T cells. Both RANK and RANK-L are upregulated as a result of pro-
inflammatory cytokines such as IL-1, IL-17A and TNFα, which are found in the inflamed joint203. 
RANK-RANK-L engagement leads to NFkB and NFAT-2 activation and signalling through colony-
stimulating factor-1 receptor (c-Fms), the receptor for M-CSF. This causes osteoclast precursors 
to differentiate and fuse to become multinucleated osteoclasts203. Finally, the integrin αvβ3 is 
required for osteoclasts to adhere to bone and c-Src signalling allows them to become polarised, 
both of which cause the cells to become fully differentiated, active osteoclasts, complete with a 
ruffled border (Figure 1-8). αvβ3 is present within actin structures called podosomes. These are 
dynamic structures which continually dissolve and reform, allowing the osteoclast to move over 
the bone surface. A sealing zone is formed by podosomes, inside which is the resorption pit. 
Protons are released into the pit, creating an acidic environment, and enabling calcium to be 
solubilised. Surrounding the sealing zone are ruffled borders, through which enzymes such as 
matrix metalloprotease 9 (MMP9), tartrate-resistant acid phosphatase type 5 (TRAP) and 




Figure 1-8: Schematic showing osteoclastogenesis.  
Hematopoietic stem cells (HSCs) differentiate into monocytes. In the presence of M-CSF, these cells further 
differentiate into mononucleated osteoclasts. RANK-L engagement with its receptor RANK on the surface of 
mononucleated osteoclasts causes cell fusion, resulting in multinucleated osteoclasts. These use the integrin αvβ3 to 
adhere to the bone surface and use c-Src signalling to become polarised, thus creating fully differentiated, active 
osteoclasts which can resorb the underlying bone. Adapted from Lian JB et al., Nature Reviews Endocrinology, 2012. 
The requirement for M-CSF and RANK-L for osteoclast survival and differentiation has been 
demonstrated using mice that lack these cytokines. op/op mice display osteopetrosis as they 
lack functional M-CSF207. Mice lacking expression of RANK-L also show osteopetrosis208. In both 
cases, the dense bone phenotype was attributed to the lack of osteoclasts. The opposite 
phenotype is apparent in mice that lack expression of osteoprotegerin (OPG), which is an 
inhibitor of osteoclast differentiation, and therefore in its absence, mice suffer from 
osteoporosis209. OPG is a receptor which also recognises RANK-L, therefore it acts as a decoy 
receptor.  
In addition to M-CSF/RANK-L dependent osteoclast differentiation, osteoclastogenesis can also 
be stimulated by the presence of ACPAs. These autoantibodies are recognised by Fc receptors 
expressed on osteoclast precursors. It has been shown that FcγRs play an important role in 
osteoclast differentiation, such that FcγRIII-deficient mice show an osteoporotic phenotype, 
which is associated with an increased number of osteoclasts210. This suggest that FcγRIII has an 
inhibitory effect on osteoclastogenesis under homeostatic conditions. 
 
1.12.2.1 Regulation of osteoclast function 
 
As mentioned above, OPG binds to RANK-L, thus preventing RANK-L from binding to RANK. OPG 
is expressed by osteoblastic cells and B cells211, and its expression is induced by cytokines, 
hormones and drugs, including IL-1 and TNFα; cytokines which also induce RANK-L expression212. 
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OPG inhibits osteoclast differentiation and thus regulates bone resorption, in addition to 
inducing apoptosis of osteoclasts. This means that bone mass is affected by the RANK-L/OPG 
ratio.  
Osteoclasts and osteoclast precursors also regulate their own differentiation. RANK-L activation 
of c-Fos leads to NFATc1 activation, a transcription factor required for osteoclast differentiation, 
RANK-L activation also causes secretion of IFNβ from osteoclast precursors. IFNβ binding to its 
receptor leads to degradation of TRAF6, which normally mediates the activation of a variety of 
signalling pathways downstream of RANK. In addition, TRAF6 is an E3 ubiquitin ligase and causes 
its own degradation, again regulating osteoclast differentiation213. 
Multiple cytokines regulate osteoclast differentiation. These can be either pro-osteoclastogenic, 
such as TNFα, IL-1, IL-6, IL-17A and IL-23, or anti-osteoclastogenic such as IFNα, IFNβ, IL-4 and 
IL-10214. The balance of these cytokines needs to be tightly regulated in order to maintain a 
normal bone mass.  
TNFα leads to bone resorption by causing an increase in the ratio of RANK-L to OPG in stromal 
cells and osteoblasts and by increasing M-CSF expression on stromal cells, osteoblasts and 
activated T cells. TNFα also causes enhanced RANK expression on osteoclast precursors. In 
addition, it has been shown that TNFα works in synergy with RANK-L to promote osteoclast 
differentiation. A RANK-L independent role for TNFα in macrophage differentiation into 
osteoclasts has also been reported215. IL-6 stimulates osteoclastogenesis by causing enhanced 
RANK-L and IL-1 expression by osteoblasts, and enhanced RANK-L expression by stromal cells. 
Inhibiting IL-6 receptor signalling has been shown to prevent osteoclast formation in vitro and 
in vivo216. The pro-inflammatory cytokine IL-1β directly affects the resorptive ability of 
osteoclasts, by regulating cytoskeletal dynamics via Src/TRAF6217. It also causes bone resorption 
by inducing expression of RANK-L. Targeting IL-1 using IL-1 receptor antagonists has been 
successfully used in RA patients218. IL-17A causes the expression of TNFα, IL-1, IL-6 and 
interleukin-8 (IL-8), all of which are pro-osteoclastogenic cytokines219,220. In mouse models of RA, 
IL-17A has been shown to induce RANK-L expression, ultimately leading to osteoclast 
differentiation and bone erosion221. In synovial joints of RA patients, IL-17A and interleukin-32 
(IL-32) work synergistically to cause expression of osteoclast specific genes encoding TRAP, 
MMP9 and cathepsin K, thus inducing osteoclast differentiation222.  
Both type I interferons, IFNα and IFNβ, inhibit RANK-L induced osteoclastogenesis223. IFNγ has 
also been shown to inhibit RANK-L and TNFα induced osteoclastogenesis, and IFNγ receptor 
deficient mice show an increased number of osteoclasts and a concomitant reduction in bone 
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mass224. This indicates that both type I and type II interferons act as inhibitors of osteoclast 
differentiation. 
 
1.12.2.2 The role of kinases and phosphatases in osteoclast function 
 
Protein kinases and phosphatases are known to play vital roles in osteoclast function. Protein 
tyrosine phosphatase activity inhibitors have been shown to prevent in vitro differentiation of 
osteoclasts and osteoclast-mediated bone resorption225. Phosphorylation also regulates 
signalling downstream of RANK and c-Fms (the receptors for RANK-L and M-CSF respectively), 
both of which are essential for osteoclast differentiation226. Mice with inactive SHP-1 have 
reduced bone mass and increased numbers and activity of osteoclasts, as SHP-1 is a negative 
regulator of signalling downstream of RANK in osteoclasts227. Osteoclasts from mice lacking c-
Src are unable to form ruffled borders, have reduced cell migration and are unable to resorb 
bone228. Mice lacking the Src family kinase Hck have an osteopetrotic phenotype shown by 
decreased bone degradation229. Fyn deficiency also causes reduced osteoclast differentiation in 
vitro, indicating that Fyn positively regulates osteoclast differentiation230. In contrast, the Src 
family kinase Lyn is a negative regulator of osteoclast formation, such that Lyn-/- mice show 
enhanced bone loss due to increased osteoclastogenesis231. Finally, the phosphatase PTPN12 








As PTPN22 regulates signalling downstream of a variety of immunoreceptors, its targets Src and 
Syk family kinases are downstream of FcRs, and autoantibodies are a hallmark of many of the 
PTPN22R620W associated diseases, I hypothesise that PTPN22 regulates immune complex 
stimulated FcR responses in DCs. Therefore, in its absence, FcR signalling will be enhanced, 
leading to augmented immune complex induced effector functions. If the autoimmune 
associated variant of PTPN22 acts as a loss-of-function variant in the context of FcR signalling, 





1. To investigate if PTPN22 regulates FcyR dependent effector functions in DCs. 
2. To investigate the role of PTPN22 in DC antigen uptake, processing and presentation. 
3. To investigate whether PTPN22 plays a role in the K/BxN serum transfer model of 












Ammonium acetate, 7.5M A2706 Sigma Aldrich 
β-mercaptoethanol 21985-023 Invitrogen 
Bovine serum albumin (BSA) A7906 Sigma Aldrich 
CellTrace Violet (CTV) cell proliferation kit C34557 Invitrogen 
CellTrace Far Red (CTFR) cell proliferation 
kit 
C34564 Invitrogen 
Chloroform 404635000 Acros Organics 
DELFIA europium-N1 streptavidin 1244-360 Perkin Elmer 
DELFIA enhancement solution 4001-0010 Perkin Elmer 
DHR123 D1054 Sigma Aldrich 
Dibutyl phthalate 524980 Sigma Aldrich 
DNase free water 10977-035 Invitrogen 
DNase I 10104159001 Roche 
EDTA, 0.5M V4233 Promega 
EGTA E0396 Sigma Aldrich 
EndoGrade ovalbumin (ova) 321000 Hyglos GmbH 
Ethanol 1.08543.0250 Merck 
FBS F7524 Sigma Aldrich 
FITC F1300 Invitrogen 
Fixable viability dye eFluor 506 65-0866-14 eBioscience 
Gelatin G2500 Sigma Aldrich 
GelRed nucleic acid gel stain 41003 Biotium 
Glycoblue 10301575 Invitrogen 
GM-CSF - From B78H1/GM-CSF.1 cell 
line, from Professor Janis 
Burkhardt (University of 
Pennsylvania) 
Heat killed Candida albicans tlrl-hkca InvivoGen 
Heat killed Listeria monocytogenes tlrl-hklm InvivoGen 
HEPES 15630-080 Invitrogen 
hFlt3L 550606 BioLegend 
Hygromycin B SC-29067 Santa Cruz 
Indo-1 I1203 Invitrogen 
Ionomycin I0634 Sigma Aldrich 
Isopropanol 67-63-0 Acros Organics 
Liberase TL 54010200001 Roche 
LPS-EK tlrl-eklps InvivoGen 
Lucifer yellow CH, lithium salt L453 Invitrogen 
Monensin 420701 BioLegend 
OneComp eBeads 01-1111 eBioscience 
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OVA323-339 peptide SP1050B Abgent 
Ovalbumin-AF488 O34781 Invitrogen 
Ovalbumin-AF594 O34783 Invitrogen 
Ovalbumin-AF647 O34784 Invitrogen 
Paraformaldehyde, 32% 15714-S Electron Microscopy 
Services 
PBS (magnesium and calcium free) 21-031-CVR Corning 
PCRBIO Taq Mix Red, 2x PB10.13 PCR Biosystems 
Penicillin/streptomycin P4333 Sigma Aldrich 
Phorbol 12-myristate 13-acetate (PMA) P8139 Sigma Aldrich 
Polybead microspheres, 3 µm 17134-15 Polysciences GmbH 
Polymyxin B P4932 Sigma Aldrich 
Proteinase K 3115879001 Roche 
QIAzol 79306 Qiagen 
Rabbit anti-chicken egg albumin (anti-ova) C6534 Sigma Aldrich 
Rabbit IgG I5006 Sigma Aldrich 
Rainbow fluorescent particles (counting 
beads) 
422907 BioLegend 
Recombinant human Flt3L 550604 BioLegend 
Recombinant human glucose-6-phosphate 
isomerase (GPI) 
228-10568-1 RayBiotech 
Recombinant mouse M-CSF 576404 BioLegend 
Recombinant mouse RANK-L 577102 BioLegend 
Red blood cell lysis buffer, 10x 420301 BioLegend 
RPMI-1640 containing L-glutamine R8758 Sigma Aldrich 
Nuclease free water 20-9000-01 Severn Biotech Ltd 
Sodium azide, 1% 40-2000-01 Severn Biotech Ltd 
Src inhibitor-1 S2075 Sigma Aldrich 
Streptavidin 405229 BioLegend 
Syk inhibitor II 574712 Calbiochem 
2,4,6-Trinitrophenyl ovalbumin (TNP-ova) SC-396493 Santa Cruz Biotechnology 
Trypan blue T8154 Sigma Aldrich 
Trypsin-EDTA T3924 Sigma Aldrich 
Tween 20 P1379 Sigma Aldrich 
UltraPure agarose 16500500 Thermo Fisher Scientific 
Zombie fixable viability dye 423107 BioLegend 
Table 2-1: Source and catalogue numbers of reagents used.  
 
2.1.2 Antibodies 
Antigen Clone Source Dilution 
CD3 145-2C11 BioLegend 1:300 
CD4 RM4-5 BioLegend 1:200 
CD8 53-6.7 BioLegend 1:200 
CD11b M1/70 BioLegend 1:500 
CD11c N418 BioLegend 1:500 
CD19 6D5 BioLegend 1:300 
CD24 30-F1 BioLegend 1:200 
CD25 3C7 BioLegend 1:400 
CD40 3/23 BioLegend 1:100 
62 
 
CD45.1 A20 BioLegend 1:200 
CD45.2 104 BioLegend 1:200 
CD54 YN1/1.7.4 BioLegend 1:500 
CD69 H1.2F3 BioLegend 1:100 
CD80 16-10A1 BioLegend 1:100 
CD86 GL-1 BioLegend 1:200 
CD115 AF598 BioLegend 1:500 
CD117 2B8 BioLegend 1:100 
CD135 A2F10 BioLegend 1:200 
B220 RA3-6B2 BioLegend 1:300 
Dectin-1 (neutralising) R1-8g7 InvivoGen 1:100 
F(ab’)2 goat anti-rabbit IgG - Invitrogen 1:500 
F(ab’)2 goat anti-mouse IgG-
alkaline phosphatase  
- Jackson ImmunoResearch 1:2000 
FcγRI X545/7.1 BioLegend 1:100 
FcγRIIb K9.361 cl5 
Professor Jeffrey Ravetch 
(Rockefeller University) 
10 µg/ml 
FcγRII/III 2.4G2 BioLegend 1:500 
FcγRIV MB 1 9E9 cl27 
Professor Jeffrey Ravetch 
(Rockefeller University) 
10 µg/ml 
FcγRII/III 2.4G2 BioLegend 1:500 
Goat anti-mouse IgG  - Invitrogen 1:100 
Goat anti-hamster IgG  - AbD Serotec 1:100 
IFNγ XMG1.2 BioLegend 1:100 
IgG1 anti-TNP - 
Dr Michael Robson (King’s 
College London) 
10 µg/ml 
IgG1 anti-TNP glycoforms - 
Dr Gestur Vidarsson, 
(University of Amsterdam) 
10 µg/ml 
IL-17A TC11-18H10.1 BioLegend 1:100 
Ly6C HK1.4 BioLegend 1:300 
Ly6G 1A8 BioLegend 1:100 
MHCII I-Ab AF6-120.1 BioLegend 1:200 
NK1.1 PK136 BioLegend 1:300 
SIRPα P84 BioLegend 1:500 
TCR Vα2 B20.1 BioLegend 1:400 
TCR Vβ5.1, 5.2 MR9-4 BioLegend 1:200 
Ter119 TER-119 BioLegend 1:300 
TNFα MP6-XT22 BioLegend 1:400 
Table 2-2: Source, catalogue numbers and clone numbers of antibodies used.  
 
2.1.3 Solutions 
Solution Components Storage 
Calcium flux assay buffer 0.5% BSA in HBSS containing 
calcium and magnesium. 
Stored at 4°C. 
BMDC wash media RPMI-1640 with L-glutamine 
supplemented with 1% heat-
inactivated Fetal Bovine Serum 
(FBS) and 





BMDC culture media (GM-
CSF) 
RPMI-1640 with L-glutamine 
supplemented with 10% heat-
inactivated FBS, 
penicillin/streptomycin (100 
µg/ml), β-mercaptoethanol (50 
µM) and 1% murine GM-CSF.  
Sterile and stored at 4°C. 
BMDC culture media 
(Flt3L) 
RPMI-1640 with L-glutamine 
supplemented with 10% heat-
inactivated FBS, 
penicillin/streptomycin (100 
µg/ml), β-mercaptoethanol (50 
µM), HEPES (10 mM) and 
human Flt3L (0.2 µg/ml).  
Sterile and stored at 4°C. 
Cell line culture media 
(B78H1-GM-CSF) 
RPMI-1640 with L-glutamine 
supplemented with 10% heat-
inactivated FBS, 
penicillin/streptomycin (100 
µg/ml) and ± hygromycin B (1.2 
mg/ml). 
Sterile and stored at 4°C. 
Cell lysis buffer (for 
degradation assay) 
0.5% NP-40, 50mM Tris, 150 
mM NaCl in water. 
Made fresh and stored on 
ice. 
ELISA wash buffer (for anti-
GPI) 
0.05% Tween in PBS. Made fresh and stored at 
room temperature. 
FACS buffer 5% FBS, 1 mM EDTA, 0.01% 
sodium azide in PBS. 
Stored at 4°C. 
Freezing media 90% FBS and 10% DMSO.  Filter sterilised and stored 
at -20°C. 
Immunoassay block buffer 2% BSA in PBS. Stored at 4°C. 
Immunoassay wash buffer 0.5% Tween in PBS. Made fresh and stored at 
room temperature. 
MACS buffer 0.5% BSA, 2mM EDTA in PBS. Filter sterilised and stored 
at 4°C. 
Mouse tail/ear lysis buffer 50mM Tris (pH 8), 25mM EDTA 
(pH 8), 100mM NaCl, 1% SDS 
and 0.4mg/ml Proteinase K. 
Stored at room 
temperature. 
Neutrophil ROS buffer 0.1% gelatin in PBS. Incubated at 37°C to 
dissolve the gelatin. Stored 
at 4°C and warmed to room 
temperature before use. 
Osteoclast culture media RPMI-1640 with L-glutamine 
supplemented with 10% heat-
inactivated FBS, 
penicillin/streptomycin (100 
µg/ml), β-mercaptoethanol (50 
µM, M-CSF (50 ng/ml) and 
RANK-L (50 ng/ml).  
Sterile and stored at 4°C. 
10 x PBS (magnesium and 
calcium free) 
137mM NaCl, 2.7mM KCl, 
8.1mM Na2HPO4, 1.5mM 
KH2PO4 (pH 7.4). 
Stored at room 
temperature. 
Table 2-3: Recipes for solutions used.  
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Acid phosphatase (TRAP) kit 387A-1KT Sigma Aldrich 
BCA protein assay kit 10678484 Thermo Fisher 
Scientific 
Bio-Plex Pro mouse cytokine 23-plex assay M60009RDPD Bio-Rad 
CD4+ T cell isolation kit, mouse 130-104-454 Miltenyi Biotec 
First strand cDNA synthesis kit K1612 Thermo Fisher 
Scientific 
Foxp3/transcription factor staining buffer set 11500597 eBioscience 
IFNγ ELISA standard set 430804 BioLegend 
IL-2 ELISA standard set 431001 BioLegend 
IL-6 ELISA standard set 431301 BioLegend 
IL-12/23p40 ELISA standard set 431604 BioLegend 
IL-17A ELISA standard set 432504 BioLegend 
LEGENDplex mouse inflammation panel 740446 BioLegend 
LEGENDplex mouse proinflammatory chemokine 
panel 
740451 BioLegend 
OsteoLyse assay kit PA-1500 Lonza 
PowerUp SYBR green mastermix A25741 Applied Biosystems 
qPCRBIO cDNA synthesis kit PB30.11 PCR Biosystems 
TNFα ELISA standard set 430904 BioLegend 
Table 2-4: Source and catalogue numbers for commercial kits. 
 
2.1.5 Plastics 
Item Catalogue number Source 
6 well flat bottom tissue culture plate 140675 Thermo Fisher Scientific 
24 well flat bottom tissue culture plate 142475 Thermo Fisher Scientific 
96 well flat bottom tissue culture plate 167008 Thermo Fisher Scientific 
96 well round bottom tissue culture plate 163320 Thermo Fisher Scientific 
T25 tissue culture flask 430639 Corning 
T175 tissue culture flask 431080 Corning 
Non-TC treated 96 well plate (for dilutions) 650101 Greiner Bio-One Ltd 
96 well flat bottom ELISA plate  442404 Thermo Fisher Scientific 
96 well flat bottom assay black plate 3603 Corning 
384 well plate (for qPCR) AB-1384 Thermo Fisher Scientific 
8 strip PCR tubes 732-0545 VWR 
Cell strainers, 70 µm 542070 Greiner Bio-One Ltd 
Cryovial 430487 Corning 
LS positive selection columns 130-042-401 Miltenyi Biotec 
Petri dishes 101R20 Thermo Fisher Scientific 
Polystyrene 5ml tubes (FACS tubes) 352052 BD Falcon 








2.2.1.1 Ethics Statement 
 
All animal work has been conducted according to The Animals (Scientific Procedures) Act 1986 
under Home Office License 70/8792. The King’s College London Animal Welfare and Ethical 
Review Body (AWERB) approved the research. Animals were sacrificed using a rising 




Wild type (WT) C57Bl/6, Ptpn22-/-, Ptpn22R619, Ptpn22R619W (WT), OT-II, and OT-II x CD45.1 mice 
were housed under specific pathogen free conditions. Ptpn22-/- mice and Ptpn22R619W mutant 
mice were backcrossed for more than 10 generations to the C57Bl/6 strain. WT and Ptpn22-/- 
mice were rederived from Professor Rose Zamoyska (University of Edinburgh). Ptpn22R619 and 
Ptpn22R619W mice were rederived from Professor David Rawlings (University of Washington 
School of Medicine), and were bred as a separate colony from the WT and Ptpn22-/- mice. Mice 
used in experiments were age and gender-matched.  
 
2.2.1.3 Mouse genotyping 
 
Mouse tail tips or ear clips were digested overnight at 56°C in 375 µl tail lysis buffer (50 mM Tris 
(pH 8), 25 mM EDTA (pH 8), 100 mM NaCl, 1% SDS and 0.4 mg/ml Proteinase K (Roche)).  The 
following day, 125 µl 5M NaCl was added per sample, vortexed and centrifuged for 5 minutes at 
4°C and 13,500 rpm. The supernatants were transferred to new tubes and 250 µl isopropanol 
was added per sample, vortexed and centrifuged for 15 minutes at 4°C and 13,500 rpm. The 
supernatants were discarded and the DNA was washed with 500 µl 70% ethanol, before being 
centrifuged for 5 minutes at 4°C and 13,500 rpm. DNA was left to air dry for at least 30 minutes 
at room temperature, before being resuspended in 50 µl DNase free water.  
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All polymerase chain reactions (PCRs) were undertaken in a total volume of 25 µl, composed of 
0.5 µl forward primer (see Table 2-6 for sequences, all from Sigma Aldrich), 0.5 µl reverse primer 
(see Table 2-6 for sequences, all from Sigma Aldrich), 12.5 µl 2 x PCRBIO Taq Mix Red (PCR 
Biosystems), 9 µl DNase free water and 2.5 µl DNA. Positive (previous DNA samples of known 
genotype) and negative (no DNA) PCRs were always run alongside the samples of unknown 
genotype. 
Primer pairs Primer sequence PCR cycle Expected 
products (bp) 
PTPN22 Forward:  5' AGC CAA GTT TCT 
TTG TTG AGA A 3' 
Reverse:  5' CAG ACA CAA CAA 
AGC CCA GA 3' 
94°C for 1 min 
 
29 x 
94°C for 15s 
55°C for 15s 
72°C for 12s  
 
72°C for 10 mins 
4°C hold                                            
WT = 498 
Ptpn22-/- = 221 
R619W Forward: 5’ GAT AAG GTC TTA 
CTA CCC ATG CTG GC 3’  
Reverse: 5’ GGA AGT GA A CTA 
GAG CGC TAG GA C 3’ 
 
94°C for 1 min 
 
25 x 
94°C for 15s 
62°C for 15s 
72°C for 12s  
 
72°C for 10 mins 
4°C hold                                            
WT (Ptpn22R619) = 
482 
Ptpn22R619W = 640 
 
TCRβ Forward: 5’ GGG CAA AAA CTG 
ACC TTG AA 3’ 
Reverse: 5’ GAG CCT GGT TGT 
TTG TGG 3’ 
 
95°C for 5 mins 
 
30 x 
95°C for 1 min 
60°C for 1 min 
72°C for 1 min 
 
72°C for 5 mins 
4°C hold                                            
WT = no product  
KRN+ = 227 
Table 2-6: PCR primer sequences, cycles and expected product sizes for mouse genotyping. 
PCR products were run on a 1% agarose gel containing 1 x GelRed nucleic acid gel stain (Biotium) 
at approximately 100V for 30 minutes and bands were visualised using a Gel Doc EZ Gel 
Documentation System (Bio-Rad) (Figure 2-1). When bone marrow derived DCs (BMDCs) were 
genotyped, cells were harvested, pelleted and lysed in tail lysis buffer for 1 hour at 56°C. DNA 




Figure 2-1: Representative DNA gel showing PCR products for mouse genotyping.  
Ear clips from WT, Ptpn22-/-, Ptpn22R619 (WT) and Ptpn22R619W mice were digested and DNA was extracted. A PCR was 
run using PTPN22 specific primers. The PCR products were run on a 1% agarose gel and visualised using GelRed. The 
WT PCR product is 498bp in length and the Ptpn22-/- PCR product is 221bp in length. A DNA ladder is shown in the first 
lane, to aid with identifying the correct sized bands. A positive control (Ptpn22+/-) and a negative control (no DNA) 
were also run. PCR and agarose gel was carried out by Wing Han Wu (Cope laboratory, King’s College London). 
To screen OT-II and OT-II x CD45.1 mice by flow cytometry, blood was harvested from tail veins 
and placed into tubes containing 200 µl 50 mM EDTA in PBS, to prevent coagulation. Samples 
were centrifuged for 5 minutes at 4°C and 1600 rpm before removing the supernatant. Cell 
pellets were lysed twice using 500 µl red blood cell lysis buffer (BioLegend) for 5 minutes at room 
temperature, washed with PBS and centrifuged for 5 minutes at 4°C and 1600 rpm before 
removing the supernatant. Cells were then stained for 30 minutes at 4°C with antibodies against 
CD4 (BioLegend), TCR Vα2 (BioLegend), TCR Vβ5 (BioLegend), CD45.1 (BioLegend) CD45.2 
(BioLegend) and a fixable viability dye (eBioscience). Samples were washed with FACS buffer (5% 
FBS, 1 mM EDTA, 0.01% sodium azide in PBS) and fixed using 1% paraformaldehyde (PFA, 
Electron Microscopy Sciences) in PBS. Samples were analysed by flow cytometry, with OT-II+ T 
cells being identified as live, CD4+, TCR Vα2+, TCR Vβ5+ singlets. CD45.1 expression was then 
determined on these cells (Figure 2-2). 
 
Figure 2-2: Representative flow cytometry plots from genotyping OT-II and OT-II x CD45.1 mice.  
Blood from OT-II and OT-II x CD45.1 mice were collected and red blood cells were lysed. The remaining cells were 
stained with CD4, TCR Vα2, TCR Vβ5, CD45.1 and CD45.2 antibodies, in addition to a viability dye. Cells were analysed 




2.2.2 Cell culture and cell isolation 
 
2.2.2.1 Production of granulocyte macrophage-colony stimulating factor (GM-CSF) 
 
A vial of B78H1-GM-CSF cells (Professor Janis Burkhardt, University of Pennsylvania) was thawed 
rapidly in a 37°C water bath, before being slowly transferred to a cooled 15 ml conical tube 
containing ice cold culture media (RPMI-1640 with L-glutamine (Sigma Aldrich) supplemented 
with 10% heat-inactivated Fetal Bovine Serum (FBS, Sigma Aldrich) and penicillin/streptomycin 
(100 µg/ml)). Cells were centrifuged for 5 minutes at room temperature and 1000 rpm before 
being resuspended in fresh culture media, and transferred into a T25 tissue culture flask. The 
following day, the media was replaced with culture media containing hygromycin B (1.2 mg/ml, 
Santa Cruz), to remove any dead or non-adherent cells and to continue to select for GM-CSF 
expressing B78H1 cells. Cells were propagated by removing the media, washing with PBS and 
incubating with Trypsin-EDTA (Sigma Aldrich) to remove the adherent cells from the flask. Cells 
were expanded in the presence of hygromycin B for 1 week. Cells were washed with culture 
media lacking hygromycin B three times and five T175 flasks were seeded with cells each 
containing 100 ml culture media lacking hygromycin B (so that hygromycin B was not present in 
the harvested GM-CSF containing media) and the cells were cultured for up to a week, until they 
began to die. The media was then harvested (which contained the GM-CSF), combined and 
centrifuged for 15 minutes at 4°C and 2000 rpm, to remove any dead cells and debris. The GM-
CSF containing media was then aliquoted and stored at -80°C.  
To determine at what concentration to use the GM-CSF containing supernatant in bone marrow 
derived DCs (BMDC) cultures, the supernatant was tested at 0.1, 0.3, 1, 3 and 10% in culture 
media (see Section 2.2.2.2 for BMDC culture details). DC differentiation and response to 100 
ng/ml lipopolysaccharide (LPS, InvivoGen) was measured by blocking cells with a non-
fluorescent FcγRII/III antibody (Biolegend) and staining with anti-CD11c (BioLegend), a fixable 
viability dye (BioLegend), and antibodies against CD54, CD80, CD86 and MHCII I-Ab (all from 
BioLegend) by flow cytometry. The optimal concentration for BMDC differentiation and 
maturation in response to LPS was determined to be 1%. Once thawed, GM-CSF aliquots were 
kept at 4°C and used within a week. 
To store the B78H1-GM-CSF cells for future GM-CSF production, cells were collected using 
Trypsin-EDTA and centrifuged for 5 minutes at 4°C and 1600 rpm. Cells were resuspended in 0.5 
ml ice cold culture media and quickly mixed with 0.5 ml freezing media (90% FBS and 10% 
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DMSO). Cells were then transferred to cooled, labelled Cryovials and stored at -80°C in a 
CoolCell, before being transferred to liquid nitrogen for long term storage. 
 
2.2.2.2 Bone marrow derived DC (BMDC) culture using GM-CSF 
 
BMDCs were produced using a protocol adapted from Inaba, K. et al233. Bone marrow was 
flushed from femurs and tibias of WT, Ptpn22-/-, Ptpn22R619 or Ptpn22R619W mice with wash media 
(RPMI-1640 with L-glutamine supplemented with 1% heat-inactivated FBS and 
penicillin/streptomycin (100 µg/ml)) using a 23G needle and a 10ml syringe. Cells were pelleted 
for 5 minutes at 4°C and 1600 rpm, then resuspended in culture media (RPMI-1640 with 
glutamine supplemented with 10% heat-inactivated FBS, penicillin/streptomycin (100 μg/ml) 
and β-Mercaptoethanol (50 µM). A single cell suspension was achieved by passing the cells 
through a 70 µm filter (BD Biosciences). To deplete macrophages, bone marrow cells were 
incubated for 30 minutes at 37°C in 5% CO2 on Petri dishes. Non-adherent progenitor cells were 
collected from the dish, counted using trypan blue (Sigma Aldrich) and resuspended at 1.5 x 
106/ml in culture media. GM-CSF was added to the bone marrow cells at 1% and 1 ml was added 
per well of a 24 well tissue culture plate (Thermo Fisher Scientific). On day 3 of culture, 75% of 
the media was removed and replaced with fresh culture media supplemented with 1% GM-CSF. 
On day 4, all the media was removed, the cells were washed and cultured with 1 ml fresh culture 
media supplemented with 1% GM-CSF. BMDCs were used between days 6 and 8, when they 
were at least 85% CD11c+ as determined by flow cytometry. As the cultures are heterogenous, 
they were further phenotyped to identify GM-DCs and GM-macs, based on gating by Helft, J et 
al234. GM-DCs were identified as CD11c+ MHCIIhi CD11b+ live singlets and GM-macs were 
identified as CD11c+ MHCIIint CD11bhi live singlets. 
 
2.2.2.3 Bone marrow derived DC (BMDC) culture using Flt3L 
 
Bone marrow was flushed from femurs and tibias of WT and Ptpn22-/- mice with wash media 
(RPMI-1640 with L-glutamine supplemented with 1% heat-inactivated FBS and 
penicillin/streptomycin (100 µg/ml)) using a 23G needle and a 10ml syringe. Cells were pelleted 
for 5 minutes at 4°C and 1600 rpm and resuspended in 2 ml red blood cell lysis buffer 
(BioLegend) for 5 minutes at room temperature, washed with PBS and centrifuged for 5 minutes 
at 4°C and 1600 rpm. Cells were seeded at 1 x 106/ml in culture media (RPMI-1640 with 
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glutamine supplemented with 10% heat-inactivated FBS, penicillin/streptomycin (100 μg/ml) 
and β-Mercaptoethanol (50 µM) and HEPES (10 mM)) containing 0.2 μg/ml human recombinant 
Flt3L (BioLegend), and 5 mls was added per well of a 6 well plate (Thermo Fisher Scientific). Cells 
were cultured for 11-13 days at 37°C in 5% CO2. To harvest cells for experiments, the media was 
removed, wells were washed with PBS and 1 ml Trypsin-EDTA was added per well and left at 
room temperature for 5-10 minutes, before cells were harvested by pipetting. 
 
2.2.2.4 Isolation of splenic conventional DCs (cDCs)  
 
Spleens from WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W mice were digested in 1 ml RPMI-1640 
containing DNase I and Liberase TL (both at 0.1 mg/ml, Roche) for 30 minutes at 37°C in 5% CO2; 
10 mM EDTA was added for the final 5 minutes. Spleens were mashed through gauze and 
centrifuged for 5 minutes at 4°C and 1600 rpm. Splenocytes were resuspended in 2 ml red blood 
cell lysis buffer (BioLegend) for 5 minutes at room temperature, washed with PBS and 
centrifuged for 5 minutes at 4°C and 1600 rpm. Splenic DCs were identified by flow cytometry 
as live, CD11c+, MHCII+ singlets and were used to measure FcγR cell surface expression and for 
receptor mediated endocytosis assays. 
 
2.2.2.5 CD4+ T cell isolation from lymph nodes and spleen 
 
CD4+ T cells were isolated from lymph nodes and spleens of 8-16 week old WT OT-II mice using 
a CD4+ T cell isolation kit (Miltenyi Biotech). This technique uses negative selection, in which 
cells are first incubated with biotinylated antibodies against CD8α, CD11b, CD11c, CD19, CD45R, 
CD49b, CD105, MHCII, Ter119 and TCRγ/δ. This is followed by incubation with anti-biotin 
magnetic microbeads. By passing the cell suspension through a column mounted on a magnet, 
all non-CD4+ cells will be retained by the magnet, and the CD4+ T cells can be collected as they 
will pass through the column.  
Single cell suspensions were made from lymph nodes and spleens by mashing them through 70 
µm filters (BD Biosciences). Cells were centrifuged for 5 minutes at 4°C and 1600 rpm. 
Splenocytes were resuspended in 2 ml red blood cell lysis buffer (BioLegend) for 5 minutes at 
room temperature, washed with PBS and centrifuged for 5 minutes at 4°C and 1600 rpm. LN and 
spleen cells were combined, counted and resuspended in cold MACS buffer (0.5% BSA, 2mM 
EDTA in PBS) at 2.5 x 108/ml. 100 µl (per 1 x 108 cells) CD4+ T cell biotin antibody cocktail was 
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added to the cells and incubated for 5 minutes at 4°C. 300 µl MACS buffer and 200 µl anti-biotin 
microbeads (per 1 x 108 cells) was then added to the cells and incubated for 10 minutes at 4°C. 
Cells were washed with MACS buffer, centrifuged for 5 minutes at 4°C and 1600 rpm and 
resuspended in 500 µl MACS buffer (per 1 x 108 cells). Cells were then loaded onto an LS column 
(Miltenyi Biotech), which had been pre-wetted with MACS buffer. The column was washed three 
times with MACS buffer and CD4+ T cells were collected in the flow through.  
To verify that the isolation had been successful, an aliquot of CD4+ T cells were stained for flow 
cytometry, using antibodies against CD3, CD4, TCR Vα2 and TCR Vβ5 (all from BioLegend), and a 
fixable viability dye (eBioscience). In general, the proportion of cells that were CD4+ after the 
sorting was at least 80%, and of those, approximately 90% were OT-II+ (TCR Vα2+, TCR Vβ5+) 
(Figure 2-3). 
 
Figure 2-3: Representative flow cytometry plots showing CD4+ T cell purity pre- and post-CD4+ negative isolation. 
 Lymph nodes and spleens from WT OT-II mice were processed to make single cell suspensions, and CD4+ T cells were 
isolated using a negative selection kit. An aliquot of cells were taken pre- and post-isolation and stained using CD4, 
TCR Vα2 and TCR Vβ5 antibodies, in addition to a viability dye. Cells were analysed by flow cytometry and the 
proportion of CD4+ T cells that were OT-II+ (TCR Vα2+ TCR Vβ5+) was determined by gating on live, CD4+ singlets.  
Once isolated, CD4+ T cells were counted and resuspended at 2 x 107/ml in PBS and labelled with 
CellTrace Violet (2 µM, CTV, Invitrogen) in PBS for 20 minutes at 37°C, followed by quenching in 
culture media for 20 minutes at 37°C. CTV labelled WT CD4+ OT-II T cells were used in co-cultures 





2.2.2.6 Osteoclast culture 
 
Bone marrow from WT and Ptpn22-/- mouse femurs were flushed with wash media (RPMI-1640 
with L-glutamine supplemented with 1% heat-inactivated FBS and penicillin/streptomycin (100 
µg/ml)) using a 25G needle and a 10 ml syringe. Bone marrow cells were centrifuged for 5 
minutes at 4°C and 1600 rpm, and resuspended in 2 ml red blood cell lysis buffer (BioLegend) 
for 5 minutes at room temperature. Cells were then washed with PBS, centrifuged for 5 minutes 
at 4°C, resuspended in 8 ml osteoclast culture media (RPMI-1640 with L-glutamine 
supplemented with 10% heat-inactivated FBS, penicillin/streptomycin (100 µg/ml) and β-
mercaptoethanol (50 µM)), containing 50 ng/ml recombinant mouse M-CSF (BioLegend) and 
seeded onto a 10 cm Petri dish at 37°C and 5% CO2. Three days later, media was removed from 
Petri dishes, washed with PBS and adherent M-CSF dependent macrophages were harvested 
using a cell scraper. Harvested cells were centrifuged for 5 minutes at 4°C and 1600 rpm, 
resuspended and counted. Cells were resuspended at 1 x 106/ml in osteoclast culture media and 
50 ng/ml M-CSF (as a negative control) or 50 ng/ml M-CSF and 50 ng/ml RANK-L (BioLegend) 
was added. 100 µl (1 x 105 cells) was added per well of a 96 well flat bottom plate or an OsteoLyse 
plate (Lonza). An additional 100 µl osteoclast culture media (containing M-CSF and RANK-L at 
the original concentrations) was added at day 6. Half of the media was replaced on day 9. 
Osteoclasts were used in experiments from days 6-12. 
 
2.2.3 BMDC FcyR stimulation 
 
2.2.3.1 Production of immune complexes and heat aggregated IgG 
 
The protocol for immune complex production was based on Ellsworth, J et al235. A range of ratios 
of ova:anti-ova were initially tested for immune complex production. These were based on 
published data, and included 1:5, 1:20, 1:50 and 2:1. The upregulation of MHCII and co-
stimulatory molecules on WT BMDCs after 24 hours of incubation was then assessed. A ratio of 
1:20 was found to be most successful at inducing BMDC maturation, and was therefore used in 
all subsequent experiments.  
For immune complexes that would bind to all FcγRs, EndoGrade ovalbumin (ova, Hyglos GmbH) 
and rabbit anti-chicken egg albumin (anti-ova, Sigma Aldrich) were combined at a ratio of 1:20 
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(ova:anti-ova, as utilised by Ellsworth, J et al) in PBS and incubated at 37°C for 1 hour. Insoluble 
ova immune complexes (ova ICs) were pelleted for 30 minutes at 4°C and 13,500 rpm and 
resuspended in PBS or culture media. Total protein concentration was determined by BCA assay 
(Thermo Fisher Scientific) as per the manufacturer’s instructions, and added to BMDCs at 1 µM. 
In some experiments, ICs were added at 10 µg/ml. ICs were stored at 4°C and used within 1 week 
of production. As it was not possible to determine the proportion of ova and anti-ova in the final 
ICs, it was assumed that the initial 1:20 ratio was maintained. 
For uptake assays, immune complexes were made using ova-AF488 (Invitrogen), instead of using 
EndoGrade ova. Using fluorescent ova allowed for receptor mediated endocytosis to be 
monitored by flow cytometry. For isotype specific immune complexes, 2,4,6-Trinitrophenyl-
ovalbumin (TNP-ova, Santa Cruz Biotechnology) was combined with an IgG1 specific anti-TNP 
(Dr Michael Robson, King’s College London), and produced as above. 
To determine whether IgG glycosylation would affect the response of WT and Ptpn22-/- BMDCs, 
immune complexes were also made using TNP-ova and a panel of human IgG1 anti-TNP 
monoclonal antibodies with different glycoforms (Dr Gestur Vidarsson, University of 
Amsterdam). Immune complexes were made as per ova ICs. To produce these IgG1 glycoforms, 
the Vidarsson laboratory utilised decoy substrates to reduce fucosylation and galactosylation, 
overexpression of glycotransferases was used to increase levels of bisecting N-
acetylglucosamine (GlcNAc linked to the mannose residue at the base of the N-glycan, referred 
to as ‘bisection’), galactosylation and sialylation, and in vitro sialylation was used to increase 
sialylation. By using a combination of these techniques, they were able to engineer IgG1 











Antibody number Glycoform Name 
376 Unmodified Anti-TNP IgG1  
384 -G Anti-TNP 2FG 
341 +G Anti-TNP IgG1 + B4GALT1 + D-galactose 
353 +G +S Anti-TNP IgG1 + B4GALT1 + ST6GALT + D-galactose  
215 +B Anti-TNP IgG1 + GNTIII 
377 -F Anti-TNP IgG1 + 2FF  
212 -F +G Anti-TNP + B4GALT1 + D-galactose + 2FF 
302 -F +G +S Anti-TNP IgG1 + B4GALT1 + ST6GALT + 2FF + D-galactose 
218 -F +B Anti-TNP IgG1 + GNTIII + 2FF  
Table 2-7: IgG1 anti-TNP glycoforms.  
2FG = 2-deoxy-2-fluoro-d-galactose, an analogue of galactose, used to prevent galactosylation (this also reduced 
sialylation and fucosylation). B4GALT1 = β-1,4-galactosyltransferase 1, which adds N-linked glycans, and is expressed 
in B cells. D-galactose = this increased levels of galactosylation by providing more substrate (this also slightly increases 
sialylation). ST6GALT = β-galactoside alpha-2,6-sialyltransferase 1, when co-transfected with B4GALT1 and D-
galactose addition (to increase galactosylation), this increased levels of sialylation. BGNTIII = human N-
acetylglucosamine (GlcNAc) transferase III, which is responsible for the addition of GlcNAc to glycans, therefore used 
to enhance levels of bisecting GlcNAc (bisection). 2FF = 2-deoxy-2-fluoro-1-fucose, added as a decoy substrate to 
reduce the incorporation of fucose into the IgG1-Fc glycan, thus decreasing fucosylation, without affecting the levels 
of galactosylation, sialylation and bisection. G = galactosylation, S = sialylation, B = bisection and F = fucosylation. 
IgG1 anti-TNP glycoforms were provided by Dr Gestur Vidarsson (University of Amsterdam). 
As additional controls for some experiments, BMDCs were also stimulated with 1 µM ova pre-
incubated with rabbit IgG (using the same procedure as making ova ICs), or with 1 µM ova added 
in combination with 1 µM heat aggregated (HA) rabbit IgG (Sigma Aldrich). HA rabbit IgG was 
made by incubating rabbit IgG at 62°C for 20 minutes, cooling to 4°C and centrifuging for 10 
minutes at room temperature and 13,500 rpm to remove aggregates.  
 
2.2.3.2 Immune complex induced BMDC maturation and cytokine secretion 
 
To assess FcγR dependent BMDC maturation, 1 µM ova, anti-ova or ova ICs were added directly 
to WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W culture wells on day 7 of culture. Polymyxin B 
(25µg/ml, Sigma Aldrich) was added to neutralise the effects of any potential endotoxin 
contamination. 24 hours later, BMDCs were harvested, washed, blocked with a non-fluorescent 
FcγRII/III antibody (BioLegend) and stained with anti-CD11c (BioLegend), anti-CD54 (BioLegend), 
anti-CD80 (BioLegend), anti-CD86 (BioLegened), anti-MHCII I-Ab (BioLegend) and a fixable 
viability dye (eBioscience) for 30 minutes at 4°C. Cells were washed and fixed using 1% PFA in 
PBS prior to flow cytometry. Cell surface CD54, CD80, CD86 and MHCII expression was 
determined by gating on live, CD11c+ singlets (Figure 2-4).  
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To determine FcγR induced cytokine secretion, WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W BMDCs 
were harvested on day 6-7 of culture, counted and resuspended at 2 x 106/ml in culture media. 
100 µl (2 x 105 cells) BMDCs were added per well of a 96 well round bottom plate (Thermo Fisher 
Scientific), and stimulated with 100 µl 2 x ova (10 µg/ml final concentration), rabbit anti-ova (200 
µg/ml final concentration) or ova ICs (10 µg/ml ova final concentration) for 24 hours at 37°C and 
5% CO2. Polymyxin B (25µg/ml, Sigma Aldrich) was added to neutralise the effects of any 
potential endotoxin contamination (Figure 2-4). To analyse cytokine secretion as a result of 
signalling downstream of FcγRIII and FcγRIIb only, TNP-ova:IgG1 anti-TNP immune complexes 
were used. After 24 hours, cell-free supernatants were harvested from the wells and frozen at -
20°C before use in IL-6, TNFα and IL-12/23p40 immunoassays (BioLegend). 
 
Figure 2-4: Schematic of ova immune complex stimulation of BMDCs for upregulation of MHCII and co-stimulatory 
molecules and secretion of cytokines.  
WT, Ptpn22-/- and Ptpn22R619W BMDCs or splenic DCs were incubated for 24 hours at 37°C, 5% CO2 with ova, rabbit 
anti-ova or ova:anti-ova immune complexes (ova ICs). BMDCs were harvested, washed and stained with anti-CD11c, 
a viability dye and antibodies against MHCII and co-stimulatory molecules. Cell surface expression of these markers 
was determined by flow cytometry, gating on live, CD11c+ singlets (for BMDCs) or live, CD11c+ MHCII+ singlets (for 
splenic conventional DCs). Alternatively, cell-free supernatants were collected and immunoassays were used to 
determine the secretion of cytokines including IL-6, TNFα and IL-12/23p40. 
Immunoassays, which are generally enzyme-linked immunosorbent assays (ELISAs) can be used 
to measure the presence of an analyte in a serum, plasma or cell supernatant sample. The wells 
of a plate are first coated with a capture antibody, which will bind to the specific protein of 
interest in the sample. The proteins are then bound by labelled detection antibodies. This can 
then be detected on a plate reader, and using a standard curve, can be used to calculate the 
concentration of the analyte of interest in the original sample. 
To carry out immunoassays using supernatants from stimulated BMDCs, 96 well flat bottom 
plates (Thermo Fisher Scientific) were coated overnight at 4°C with 50 µl per well of capture 
antibodies (IL-6, TNFα, or IL-12/23p40, BioLegend) in coating buffer (BioLegend). Wells were 
washed three times with immunoassay wash buffer (0.5% Tween in PBS) and blocked with 200 
µl per well of immunoassay block buffer (2% BSA in PBS) at room temperature for 1 hour. During 
this time, supernatants were diluted 1:1 – 1:10 (depending on the expected secretion of the 
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cytokine being analysed) in culture media and standard serial dilutions were made. The top 
standard was generally 1-2 ng/ml, with 6 x 1:2 serial dilutions in culture media being made and 
0 ng/ml as the bottom standard. Wells were washed three times with immunoassay wash buffer 
and 50 µl samples or standards were added per well for 2 hours at room temperature (added in 
duplicate). Wells were washed three times with immunoassay wash buffer and 50 µl per well of 
biotinylated detection antibodies (BioLegend) in immunoassay block buffer was added for 2 
hours at room temperature. Wells were washed five times with Immunoassay wash buffer and 
100 µl per well of Europium labelled streptavidin (Delfia) in immunoassay block buffer was 
added for 1 hour at room temperature. Wells were washed five times with immunoassay wash 
buffer and 100 µl per well of Enhancer solution (Delfia) was added for at least 10 minutes at 
room temperature. Emission was measured at 615 nm (using an excitation of 340 nm) on a Victor 
Wallac plate reader (Perkin Elmer). 
The concentration of secreted cytokine was calculated using a standard curve, plotted using the 
standard concentration on the x-axis and the relative fluorescence unit on the y-axis, and the 
equation for the line of best fit, y = mx + c. The analyte concentration (x) could therefore be 
calculated using x = (y – c)/m, where y = relative fluorescence units, c = y-axis intercept and m = 
gradient of the slope. If the concentration was negative, this was manually adjusted to 0 (Figure 
2-5). 
 
Figure 2-5: Example ELISA standard curve.  
Relative fluorescence units (RFU) are averages of technical duplicates, and have been plotted against standard IL-6 
concentrations, created by serial dilution. A line of best fit has been added. The equation of the line (y = 61.65x + 495.3) 
was used to calculate the IL-6 concentration in supernatant samples of unknown concentration.  
To measure the secretion of a wider range cytokines and chemokines from immune complex 
stimulated BMDCs, a Bio-Plex pro cytokine assay (Bio-Rad) was also performed. This allowed for 
the identification of 23 analytes, and was carried out as per the manufacturer’s instructions. 
Supernatants from WT and Ptpn22-/- BMDCs were harvested after 24 hours of stimulation with 
ova (10 µg/ml), rabbit anti-ova (200 µg/ml) or ova ICs (10 µg/ml ova final concentration), in the 
presence of polymyxin B (25 µg/ml, Sigma Aldrich). All supernatants were diluted 1:3 and set up 
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as technical duplicates for the multiplex assay. Samples were collected using a Luminex 
Flexmap3D and Xponent 4.0 software (Luminex). 
 
2.2.3.3 BMDC calcium flux after immune complex stimulation 
 
The dye indo-1 can be used to measure intracellular calcium flux in real time. Indo-1 emits at 
two wavelengths, both of which are detectable by flow cytometry, depending on whether it is 
in the presence of calcium (400 nm) or not (475 nm). In these experiments, the ionophore 
ionomycin was used as a positive control as it transports calcium from intracellular stores into 
the cytoplasm. The chelator ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
(EGTA) was used as a negative control. 
WT and Ptpn22-/- BMDCs were harvested, counted and resuspended at 1 x 107/ml in calcium flux 
assay buffer (0.5% BSA in HBSS containing calcium and magnesium). Cells were stained with 
indo-1 (2 µg/ml, Invitrogen) at 37°C for 30 minutes. Cells were washed with calcium flux assay 
buffer, centrifuged for 5 minutes at 4°C and 1600 rpm and resuspended at 1 x 107/ml in calcium 
flux assay buffer. Cells were stained with anti-CD11c (BioLegend) for 30 minutes at room 
temperature. 100 µl (1 x 106) cells was added per FACS tube and taken to the flow cytometer. 
BMDCs were collected for 7 minutes, and stimulated after 1 minute with ionomycin (10 µg/ml, 
Sigma Aldrich) followed by EGTA (2 mM, Sigma Aldrich) after 4 minutes, or with ova ICs (50 µg) 
after 1 minute. Calcium flux was determined by gating on CD11c+ singlets (excluding really bright 
Indo-1 (violet and blue) cells) (Figure 2-6).  
 
Figure 2-6: Schematic of calcium flux assay.  
WT and Ptpn22-/- BMDCs were harvested, washed and resuspended at 1 x 107/ml and stained for 30 minutes at 37°C 
with indo-1. Cells were washed and stained with anti-CD11c and 1 x 106 cells (in 100 µl) were added per FACS tube. 
Samples were collected by flow cytometry for 1 minute before stimulations were added. Ionomycin was added, 




2.2.3.4 Reactive oxygen species (ROS) production by ex vivo bone marrow 
neutrophils 
 
Dihydrorhodamine 123 (DHR123) can be used to measure reactive oxygen species (ROS) 
production. DHR123 is an uncharged, non-fluorescent compound which can diffuse across 
membranes. When it becomes oxidised by the presence of ROS, it becomes fluorescent, which 
allows for the detection of ROS production by flow cytometry. DHR123 has an excitation 
wavelength of 507 nm and an emission wavelength of 529 nm.  
To prevent unintended activation of ex vivo neutrophils, all reagents need to lack calcium and 
magnesium. In addition, incubations must be carried out at room temperature. WT and Ptpn22-
/- bone marrow was flushed from mice using 0.1% gelatin in PBS and centrifuged for 5 minutes 
at room temperature and 1600 rpm and resuspended in 2 ml red blood cell lysis buffer 
(BioLegend) for 5 minutes at room temperature, washed in 0.1% gelatin in PBS and centrifuged 
for 5 minutes at room temperature and 1600 rpm. Bone marrow cells were resuspended at 1 x 
107/ml in 0.1% gelatin in PBS and blocked with a non-fluorescent FcγRII/III antibody (BioLegend) 
and stained with anti-CD11b (BioLegend), anti-Ly6G (BioLegend) and a fixable viability dye 
(eBioscience) for 20 minutes at room temperature. Cells were washed, centrifuged for 5 minutes 
at room temperature and 1600 rpm and resuspended at 1 x 107/ml in 0.1% gelatin in PBS before 
being stained with 0.01 µM DHR123 (Sigma Aldrich) for 40 minutes at room temperature in the 
dark. Cells were washed, centrifuged for 5 minutes at room temperature and 1600 rpm and 
resuspended at 1 x 107/ml in 0.1% gelatin in PBS. 100 µl (1 x 106) cells was added per FACS tube 
and ova, anti-ova and ova ICs were added (all made in 0.1% gelatin in PBS) for 45 minutes at 
room temperature. Cells were washed, centrifuged for 5 minutes at room temperature and 1600 
rpm and fixed using 1% PFA in PBS prior to flow cytometry. DHR123 expression was determined 
by gating on live, CD11b+, Ly6G+ singlets (Figure 2-7).  
 
Figure 2-7: Schematic of reactive oxygen species (ROS) production by bone marrow neutrophils.  
Bone marrow cells were flushed from WT and Ptpn22-/- mice, stained with anti-CD11c, anti-Ly6G and a viability dye 
(L/D). Cells were then washed and stained with DHR-123 and then stimulated with ova, rabbit anti-ova or ova:anti-
ova immune complexes (ova ICs) for 45 minutes at room temperature. Cells were then washed and fixed and analysed 




2.2.4 DC-T cell assays 
 
2.2.4.1 In vitro DC-T cell co-cultures  
 
WT, Ptpn22-/-, Ptpn22R619 (WT) and Ptpn22R619W BMDCs were incubated overnight at 37°C, 5% 
CO2 with LPS (100 ng/ml, InvivoGen) and 0.01 µM or 1 µM OVA323-339 (InvivoGen), 1 µM ova or 1 
µM ova ICs. In some experiments, ova and ova IC pulsed BMDCs were also matured with LPS. 
The following day, BMDCs were harvested, washed and resuspended in culture media. OT-II 
CD4+ T cells were isolated and CTV labelled as described in Section 2.2.2.5. BMDCs were co-
cultured with CTV labelled CD4+ T cells at 1:2 (1 x 105 BMDC:2 x 105 T cells) in 96 well round 
bottom plates (Thermo Fisher Scientific) for 1-6 days.  
On day 1, cell-free supernatants were harvested, and IL-2 secretion was determined by 
immunoassay (BioLegend, as per Section 2.2.3.2). In addition, cells were harvested and stained 
with anti-CD3 (BioLegend), anti-CD4 (BioLegend), anti-CD25 (BioLegend), anti-CD69 (BioLegend) 
and a fixable viability dye (eBioscience) for 30 minutes at 4°C. Cells were washed and fixed using 
1% PFA in PBS prior to flow cytometry. Cell surface CD25 and CD69 expression was determined 
by gating on live, CD3+, CD4+ singlets.  
On days 3 and 6 of co-culture, cell-free supernatants were harvested, and IFNγ, TNFα and IL-17 
secretion was determined by immunoassay (BioLegend, as per Section 2.2.3.2). In addition, cells 
were restimulated for 6 hours at 37°C, 5% CO2 with phorbol 12-myristate 13-acetate (PMA, 10 
ng/ml, Sigma Aldrich), ionomycin (500 ng/ml, Sigma Aldrich) and monensin (BioLegend). Cells 
were harvested and stained with anti-CD3 (BioLegend), anti-CD4 (BioLegend) and a fixable 
viability dye (eBioscience) for 30 minutes at 4°C. Cells were washed and incubated in 
fix/permeabilisation buffer (Foxp3/transcription factor staining buffer set, eBioscience) for 15 
minutes at room temperature, washed with perm buffer (Foxp3/transcription factor staining 
buffer set, eBioscience) and stained with anti-IFNγ, anti-TNFα and anti-IL-17 (all from BioLegend) 
in permeabilisation buffer for 45 minutes at room temperature. Cells were washed in 
permeabilisation buffer and resuspended in PBS containing 5 x 104 counting beads (BioLegend) 
per FACS tube, prior to flow cytometry. T cell proliferation (via CTV dilution) and intracellular 
expression of IFNγ, TNFα and IL-17 were determined by gating on live, CD3+, CD4+ singlets (Figure 
2-8). The total number of live, CD3+, CD4+ singlets per co-culture well was determined using cell 
80 
 
counts by trypan blue (Sigma Aldrich) exclusion and the proportion of live cells which were CD3+, 
CD4+ by flow cytometry. 
 
Figure 2-8: Schematic of in vitro BMDC:T cell co-cultures.  
WT, Ptpn22-/- and Ptpn22R619W BMDCs were incubated for 18 hours at 37°C, 5% CO2 in the presence of 100 ng/ml LPS 
and 10 µM OVA323-339, or 1 µM ova or 1 µM ova:anti-ova ICs (ova ICs). . BMDCs were harvested, washed and co-
cultured with WT CTV labelled CD4+ OT-II T cells for 1-6 days, at 1 DC: 2 T cells (1 x 105:2 x 105). Cell-free supernatants 
were collected on days 1, 3 and 6 and analysed for secretion of IL-2 (day 1), IFNγ, TNFα and IL-17 (days 3 and 6). 
Intracellular cytokines were detected after 6 hours of restimulation with PMA, ionomycin and monensin. Finally, T cell 
proliferation was assessed by CTV dilution and by calculating the total number of T cells in the co-culture wells (days 
3 and 6). 
As additional controls for some experiments, BMDCs were also stimulated with 1 µM ova pre-
incubated with rabbit IgG (using the same procedure as making ova ICs), or with 1 µM ova added 
in combination with 1 µM HA rabbit IgG (Sigma Aldrich), prior to co-culture with WT CD4+ OT-II 
T cells. 
 
2.2.4.2 DC:T-cell conjugate assay  
 
WT and Ptpn22-/- BMDCs were incubated overnight at 37°C, 5% CO2 with LPS (100 ng/ml, 
InvivoGen) and 10 µM OVA323-339 (InvivoGen), 1 µM ova or 1 µM ova ICs. The following day, 
BMDCs were harvested, washed and resuspended at 1 x 107/ml in PBS prior to staining with 1 
μM CellTrace Far Red (CTFR, Invitrogen) for 20 minutes at 37°C, followed by quenching in culture 
media for 20 minutes at 37°C. 1 x 105 CTFR labelled BMDCs and 2 x 105 CTV labelled WT OT-II T 
cells (in a total volume of 50 μl) were added to each 1.5 ml tube, centrifuged for 2 minutes at 
500 rpm and incubated at 37°C for 0-120 minutes. Cells were fixed with 3% PFA for 15 minutes 
at room temperature, transferred to FACS tubes and acquired by flow cytometry using a medium 






Figure 2-9: Schematic of DC-T cell conjugate assay.  
WT and Ptpn22-/- BMDCs were incubated for 18 hours at 37°C, 5% CO2 in the presence of 100 ng/ml LPS and 10 µM 
OVA323-339, or 1 µM ova or 1 µM ova:anti-ova ICs (ova ICs). The following day, BMDCs were washed and stained with 
CellTrace Far Red (CTFR). WT OT-II CD4+ T cells were isolated from the spleen and lymph nodes of OT-II mice and 
stained with CellTrace Violet (CTV). BMDCs and T cells were mixed at 1 DC: 2 T cells (1 x 105:2 x 105) and centrifuged 
for 2 minutes at 500 rpm. Cells were incubated at 37C for 0-2 hours for conjugates to form. Conjugates were identified 
as CTFR+ CTV+ events.   
To determine the role of Src and Syk family kinases in immune complex induced conjugate 
formation, WT BMDCs were incubated overnight at 37°C, 5% CO2 with 1 µM ova ICs. The 
following day, BMDCs were harvested and CTFR stained as above, before being incubated with 
Src inhibitor-1 (5 µM, Sigma Aldrich) or Syk inhibitor II (5 µM, Calbiochem) for 15 minutes at 
37°C. The conjugate assay was then carried out as described above. 
 
2.2.5 In vivo experiments 
 
2.2.5.1 FITC painting assay 
 
FITC (Invitrogen) was resuspended in DMSO and diluted in 1:1 acetone:dibutyl phthalate 
(irritant, Sigma Aldrich) at 1 mg/ml. WT and Ptpn22-/- mice were anaesthetised and 10 µl FITC in 
irritant was added to the dorsal side of their left ears. 10 µl irritant alone (as a negative control) 
was added to the dorsal side of their right ears. After 24 hours, auricular draining lymph nodes 
were harvested, ripped open using 26G needles and digested in RPMI-1640 containing DNase I 
and Liberase TL (both at 0.1mg/ml, Roche) for 30 minutes at 37°C in 5% CO2; 10 mM EDTA was 
added for the final 5 minutes. Single cell suspensions were obtained by mashing the digested 
lymph nodes through gauze. Cells were counted and stained with anti-CD11c (BioLegend), anti-
MHCII I-Ab (BioLegend) and a fixable viability marker (eBioscience) for 30 minutes at 4°C. Cells 
were washed and fixed using 1% PFA in PBS prior to flow cytometry. FITC uptake was measured 
in migratory DCs by gating on live, CD11c+, MHCIIhi singlets and in resident DCs by gating on live, 




Figure 2-10: Schematic of FITC painting assay.  
FITC in acetone:dibutyl phthalate (irritant) or irritant alone was added to the dorsal sides of the left and right ears 
respectively of WT and Ptpn22-/- mice. 24 hours later, draining lymph nodes were removed, digested and stained with 
anti-CD11c, anti-MHCII and a viability dye (L/D). FITC uptake by resident (gated on live, CD11chi, MHCII+ singlets) and 
migratory (gated on live, CD11c+, MHCIIhi singlets) DCs was determined by flow cytometry. 
 
2.2.5.2 Ova and ova IC induced in vivo T cell proliferation 
 
To determine if PTPN22 played a role in regulating immune complex induced T cell proliferation 
in vivo, CD4+ OT-II T cells were transferred into WT and Ptpn22-/- recipient mice. The mice were 
later immunised with ova ICs, which would be processed and presented by endogenous antigen 
presenting cells, and T cell proliferation could be monitored after 3 days by CTV dilution and by 
calculating the total number of transferred T cells in the draining lymph nodes.  
WT CD4+ OT-II T cells were isolated from the lymph nodes and spleens of OT-II CD45.1+ mice and 
stained with CTV, as described in Section 2.2.2.5. An aliquot of cells was stained with anti-CD4 
(BioLegend), anti-TCR Vα2 (BioLegend) and anti-TCR Vβ5 (BioLegend) for 30 minutes at 4 °C. 
Samples were washed with FACS buffer and fixed using 1% PFA in PBS prior to flow cytometry. 
The proportion of total cells which were OT-II+ was determined by gating on live, CD4+, TCR Vα2+, 
TCR Vβ5+ singlets. 1 x 106 CTV labelled WT CD4+ OT-II T cells were injected (i.v.) into WT or 
Ptpn22-/- mice (CD45.2+). The following day mice were immunised (s.c.) with 1 µg ova, 20 µg anti-
ova or ova ICs (containing 1 µg ova and 20 µg anti-ova), into the right footpad (in a total volume 
of 20 µl). After 3 days, draining popliteal lymph nodes (right) and non-draining popliteal lymph 
nodes (left) were harvested. Single cell suspensions were made by mashing lymph nodes 
through gauze. Cells were washed with PBS and centrifuged for 5 minutes at 4°C and 1600 rpm. 
Cells were counted, blocked with a non-fluorescent FcγRII/III antibody (BioLegend) and stained 
using antibodies against CD4, TCR Vα2, TCR Vβ5, CD45.1, CD45.2 (all from BioLegend), and a 
fixable viability dye (eBioscience). CTV dilution was determined by gating on the live, CD4+, TCR 
Vα5+, TCR Vβ2+, CD45.1+, CD45.2- singlets (Figure 2-11). In addition, the total number of 
transferred OT-II T cells was calculated using cell counts by trypan blue (Sigma Aldrich) exclusion 




Figure 2-11: Schematic of in vivo T cell proliferation assays.  
WT and Ptpn22-/- (CD45.2) mice were injected (i.v.) with CTV labelled WT CD4+ OT-II T cells (CD45.1). The following 
day, mice were injected (s.c.) into their right footpad with ova or ova ICs. 3 days later, draining (right) and non-draining 
(left) popliteal lymph nodes were removed and T cell proliferation was assessed by flow cytometry. 
 
2.2.5.3 Transfer of ova IC pulsed BMDCs into recipient mice for in vivo T cell 
proliferation 
 
An alternative assay to investigate the role of PTPN22 in immune complex induced T cell 
proliferation in vivo was to transfer ova IC pulsed WT and Ptpn22-/- BMDCs into OT-II recipient 
mice and to monitor T cell proliferation in the draining lymph nodes.  
WT and Ptpn22-/- BMDCs were pulsed overnight with 1 µM ova ICs. The following day, BMDCs 
were harvested, washed, counted and resuspended at 2.5 x 107/ml in PBS. 5 x 105 BMDCs were 
injected (s.c.) into the right footpad of recipient WT OT-II mice (in a total volume of 20 µl). After 
6 days, draining (right) and non-draining (left) popliteal lymph nodes were harvested. Single cell 
suspensions were made by mashing the lymph nodes through gauze. Cells were counted, 
blocked with a non-fluorescent FcγRII/III antibody (BioLegend) and stained using antibodies 
against CD4, TCR Vα2, TCR Vβ5 (all from BioLegend) and a fixable viability dye (eBioscience). 
Cells were washed with FACS buffer and resuspended in PBS containing 5 x 104 counting beads 
(BioLegend) per FACS tube, prior to flow cytometry (Figure 2-12). The total number of OT-II T 
cells per lymph node was calculated using cell counts by trypan blue (Sigma Aldrich) exclusion 





Figure 2-12: Schematic of in vivo T cell proliferation assay.  
WT and Ptpn22-/- BMDCs DCs were incubated for 24 hours at 37°C, 5% CO2 with ova or ova:anti-ova immune complexes 
(ova ICs). The following day, BMDCs were harvested, washed and injected (s.c.) into the right footpad of recipient WT 
OT-II mice. 6 days later, draining (right) and non-draining (left) popliteal lymph nodes were removed and T cell 
proliferation was assessed by flow cytometry. 
 
2.2.6 Uptake, processing and presentation assays  
 
2.2.6.1 Macropinocytosis assay 
 
In order to identify whether PTPN22 was required for BMDC macropinocytosis, assays were 
conducted using Lucifer yellow CH (LY), a water-soluble dye. The polar properties of LY mean 
that it cannot passively pass through cell membranes, however it can be internalised by DCs 
during non-specific uptake of their surrounding environments, via macropinocytosis. LY is 
fluorescent and can therefore be detected by flow cytometry and thus provides a simple method 
for monitoring macropinocytosis. 
WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W BMDCs were stimulated overnight in the presence or 
absence of LPS (100 ng/ml, InvivoGen). The following day, BMDCs were harvested, washed and 
counted and 2 x 105 were added to each FACS tube. BMDCs were cooled on ice and incubated 
with Lucifer yellow (1 mg/ml, Invitrogen) at 37°C for 0-30 minutes. Samples were returned to ice 
and washed twice with cold PBS to prevent further uptake. Cells were blocked with a non-
fluorescent FcγRII/III antibody (BioLegend) and stained with anti-CD11c and a fixable viability 
dye (BioLegend) for 30 minutes on ice. Cells were washed with FACS buffer and fixed using 1% 




Figure 2-13: Schematic of Lucifer yellow uptake.  
WT, Ptpn22-/- and Ptpn22R619W BMDCs were incubated with Lucifer yellow for 0-30 minutes at 37°C. In some 
experiments, BMDCs were matured overnight with 100 ng/ml lipopolysaccharide (LPS) prior to the uptake assay. Cells 
were washed with cold PBS to prevent further uptake, and were stained with anti-CD11c and a viability dye (L/D). 
Internalisation was measured by flow cytometry, gating on live, CD11c+ singlets.  
 
2.2.6.2 Receptors mediated endocytosis of heat killed Listeria monocytogenes and 
heat killed Candida albicans 
 
Listeria monocytogenes is a Gram-positive bacteria which is mainly recognised by Toll-like 
receptor 2 (TLR2). Candida albicans is a fungus which contains β-glucans in its cell wall. β-glucans 
are recognised by the C-type lectin receptor, dectin-1. Heat killed preparations of these agonists 
can be used to monitor receptor mediated endocytosis via TLR2 and dectin-1 respectively. 
Heat killed Listeria monocytogenes (HKLM, InvivoGen) or heat killed Candida albicans (HKCA, 
InvivoGen) were stained with Zombie UV Fixable Viability dye (BioLegend, diluted 1:50 in PBS) 
at room temperature in the dark for 20 minutes. Labelled HKLM and HKCA was then washed 
with PBS, centrifuged for 5 minutes at room temperature and 13,500 rpm and resuspended in 
PBS at 1 x 108/ml. 
WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W BMDCs were harvested, counted and resuspended in 
FACS buffer at 8 x 106/ml. 2 x 105 BMDCs were added to FACS tubes, cooled on ice and incubated 
with 6 x 106 UV labelled heat killed Listeria monocytogenes (1 DC:30 HKLM) or 2 x 106 heat killed 
Candida albicans (1 DC:10 HKCA) on ice for 45 minutes. Cells were washed with cold FACS buffer 
and incubated at 37°C for 0-60 minutes. Samples were returned to ice and washed with cold PBS 
to prevent further uptake. Cells were blocked with a non-fluorescent FcγRII/III antibody 
(BioLegend) and stained with anti-CD11c (BioLegend) for 30 minutes on ice. Cells were washed 
with FACS buffer and fixed using 1% PFA in PBS prior to flow cytometry. Uptake was identified 




Figure 2-14: Schematic of HKLM and HKCA antigen uptake assays.  
WT and Ptpn22-/- BMDCs were incubated with heat killed Listeria monocytogenes (HKLM) or heat killed Candida 
albicans (HKCA) on ice for 45 minutes, before being washed and incubated at 37°C for 0-60 minutes. Cells were washed 
with cold PBS to prevent further uptake, and were stained with anti-CD11c and a viability dye (L/D). Internalisation 
was measured by flow cytometry, gating on live, CD11c+ singlets.  
 
2.2.6.3 Receptor mediated endocytosis of ovalbumin 
 
Ovalbumin (ova) is internalised via mannose receptor mediated endocytosis. By pre-incubating 
BMDCs with fluorescent ova on ice, this allows for binding to the mannose receptors. Transfer 
of the DCs to 37°C allows for receptor mediated endocytosis. This assay can therefore be used 
to identify whether PTPN22 is required for receptor mediated endocytosis of ova. 
WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W BMDCs were stimulated overnight in the presence or 
absence of LPS (100 ng/ml, InvivoGen). The following day, BMDCs were harvested, counted and 
resuspended in FACS buffer at 8 x 106/ml. 2 x 105 BMDCs were added to FACS tubes, cooled on 
ice and incubated with ova-AF488 (10 µg/ml, Invitrogen) on ice for 45 minutes. Cells were then 
incubated at 37°C for 0-60 minutes. Samples were returned to ice and washed with cold PBS to 
prevent further uptake. Cells were blocked with a non-fluorescent FcγRII/III antibody 
(BioLegend) and stained with anti-CD11c (BioLegend) and a fixable viability dye (eBioscience) for 
30 minutes on ice. Cells were washed with FACS buffer and fixed using 1% PFA in PBS prior to 






Figure 2-15: Schematic of ova uptake assays.  
WT, Ptpn22-/- and Ptpn22R619W BMDCs or splenocytes were incubated with ova-AF488 or ova-AF647 on ice for 45 
minutes, before being incubated at 37°C for 0-60 minutes. In some experiments, BMDCs were matured overnight with 
100 ng/ml lipopolysaccharide (LPS) prior to the uptake assay. Cells were washed with cold PBS to prevent further 
uptake, and were stained with anti-CD11c and a viability dye (L/D) for BMDCs or with anti-CD11c, anti-MHCII and a 
viability dye (L/D) for splenocytes. Internalisation was measured by flow cytometry, gating on live, CD11c+ singlets (for 
BMDCs) or gating on live, CD11c+, MHCII+ singlets (for splenic conventional DCs). 
To measure ova uptake by splenic DCs, spleens from WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W 
mice were digested in 1 ml RPMI-1640 containing DNase I and Liberase TL (both at 0.1mg/ml, 
Roche) for 30 minutes at 37°C in 5% CO2; 10 mM EDTA was added for the final 5 minutes. 
Splenocyte cell suspensions were resuspended in 2 ml red blood cell lysis buffer (BioLegend), 
washed in PBS and centrifuged for 5 minutes at 4°C and 1600 rpm. Splenocytes were counted 
and 5 x 106 were added per FACS tube. Splenocytes were cooled on ice and incubated with ova-
AF647 (50 μg/ml, Invitrogen) for 45 minutes on ice. Cells were washed and transferred to 37°C 
for 45 minutes to allow for uptake. Samples were returned to ice and washed with cold PBS to 
prevent further uptake. Cells were blocked with a non-fluorescent FcγRII/III antibody 
(BioLegend) and stained to identify splenic DCs, washed with FACS buffer and fixed using 1% PFA 
in PBS prior to flow cytometry. Splenic DCs were identified as live, lineage- (to exclude CD3+, 
CD19+, Ter119+, NK1.1+, GR1+, B220+ splenocytes), CD11c+, MHCII+ singlets.  
 
2.2.6.4 Receptor mediated endocytosis of ova immune complexes 
 
Ova:anti-ova immune complexes (ova ICs) were made as described in Section 2.2.3.1. As rabbits 
do not have IgG subtypes, these ova ICs will bind to all FcγRs expressed on the cell surface of 
BMDCs. By using fluorescent ova (ova-AF488) in the ova ICs, FcγR mediated endocytosis could 
be monitored by flow cytometry. 
WT and Ptpn22-/- BMDCs were harvested, counted and resuspended in FACS buffer at 8 x 106/ml. 
2 x 105 BMDCs were added to FACS tubes, cooled on ice and incubated with ova-AF488 (10 
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µg/ml, Invitrogen) immune complexes (ova ICs) on ice for 45 minutes. Cells were washed with 
cold FACS buffer and incubated at 37°C for 0-60 minutes. Samples were returned to ice and 
washed with cold PBS to prevent further uptake. Cells were blocked with a non-fluorescent 
FcγRII/III antibody (BioLegend) and stained using anti-CD11c (BioLegend), F(ab’)2 goat anti-
rabbit IgG-AF647 (Invitrogen) and a fixable viability dye (BioLegend). Cells were washed and 
fixed using 1% PFA in PBS prior to flow cytometry. Cell surface ova-AF488 ICs were identified as 
F(ab’)2 goat anti-rabbit IgG-AF647+, as this would bind to rabbit anti-ova-containing ICs. BMDCs 
with internalised ova ICs were identified as live, CD11c+, F(ab’)2 goat anti-rabbit IgG-AF647- 
singlets (Figure 2-16).  
 
Figure 2-16: Schematic of ova:anti-ova immune complex uptake assays.  
WT and Ptpn22-/- BMDCs were incubated with ova-AF488:anti-ova immune complexes (ova-AF488 ICs) on ice for 45 
minutes, before being washed and incubated at 37°C for 0-60 minutes. Cells were washed with cold PBS to prevent 
further uptake, and were stained with anti-CD11c, a viability dye (L/D) and F(ab’)2 anti-rabbit-AF647 (to identify non-
internalised ova-AF488 ICs). Internalisation was measured by flow cytometry, gating on live, CD11c+, F(ab’)2 anti-
rabbit-AF647- singlets.  
 
2.2.6.5 Ova and ova immune complex degradation assay 
 
To investigate whether PTPN22 may regulate the degradation of internalised antigens by 
BMDCs, polystyrene beads were coated with fluorescent ova and rabbit anti-ova. The intensity 
of the ova signal is lost over time, which can be used as a measure of antigen degradation.  
3µm polystyrene beads (Polysciences) were coated overnight at 4°C with ovalbumin-AF594 (0.5 
mg/ml, Invitrogen). For ova-AF594:anti-ova coated beads, beads were washed the following day 
and incubated with rabbit anti-ova (50 μg/ml, Sigma Aldrich) for 20 minutes on ice. 1 x 105 
BMDCs and 2 x 106 beads were added to wells of a 96 well round bottom plate (1 DC:20 beads, 
Thermo Fisher Scientific), centrifuged for 5 minutes at 2000 rpm and incubated at 37°C and 5% 
CO2 for 0-7 hours. To exclude non-internalised beads, BMDCs were washed and stained with 
rabbit anti-ova (50 μg/ml, Sigma Aldrich, only for ova coated beads), and F(ab’)2 goat anti-rabbit 
IgG-AF647 (4 μg/ml, Invitrogen) for 20 minutes on ice. Cells were washed with FACS buffer and 
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lysed for 10 minutes on ice in lysis buffer (0.5% NP-40, 50mM Tris, 150 mM NaCl). Beads were 
washed twice with FACS buffer and transferred to FACS tubes. Internalised beads were identified 
as F(ab’)2 goat anti-rabbit IgG-AF647- (Figures 2-17 and 2-18). 
 
Figure 2-17: Schematic of ova coated bead degradation assay.  
WT and Ptpn22-/- BMDCs were incubated with ova-AF594 coated beads for 0-7 hours at 37°C, 5% CO2. BMDCs were 
washed and stained with rabbit anti-ova, followed by F(ab’)2 anti-rabbit-AF647 (to identify non-internalised beads). 
BMDCs were lysed and beads were analysed by flow cytometry. The ova-AF594 fluorescence was determined on 
internalised beads by gating on single, F(ab’)2 anti-rabbit-AF647- beads.  
 
Figure 2-18: Schematic of ova:anti-ova coated bead degradation assay.  
WT and Ptpn22-/- BMDCs were incubated with ova-AF594:anti-ova coated beads for 0-7 hours at 37°C, 5% CO2. BMDCs 
were washed and stained with followed by F(ab’)2 anti-rabbit-AF647 (to identify non-internalised beads). BMDCs were 
lysed and beads were analysed by flow cytometry. The ova-AF594 fluorescence was determined on internalised beads 
by gating on single, F(ab’)2 anti-rabbit-AF647- beads.  
 
2.2.6.6 Immune complex derived antigen presentation assay 
 
The antibody YAe can be used to monitor cell surface presentation of immune complex derived 
antigens. The antibody is specific for I-Ab restricted presentation of a peptide from Eα (Eα52-68), 
so by incubating BMDCs with immune complexes containing Eα, the antibody can be utilised to 
compare expression of processed antigens on the surface of BMDCs, in the presence or absence 
of PTPN22. 
WT and Ptpn22-/- BMDCs were harvested, counted and resuspended in culture media at 2 x 
106/ml. 100 µl (2 x 105) BMDCs were incubated on 96 well round bottom plates (Thermo Fisher 
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Scientific) with GFP, GFP-Eα (Erwan Boëdec, Paris 7 University), GFP:anti-GFP immune 
complexes or immune complexes containing 0.3 mg/ml GFP-Eα  and anti-GFP (Invitrogen) for 18 
hours at 37°C, 5% CO2. BMDCs were harvested, washed and stained with anti-CD11c 
(BioLegend), anti-Eα52-68-biotin (YAe, eBioscience) and a fixable viability dye (eBioscience) for 30 
minutes on ice. Cells were washed with FACS buffer and stained with PBS containing 
streptavidin-APC (BioLegend) at room temperature for 10 minutes. Cells were washed and fixed 
using 1% PFA in PBS prior to flow cytometry. BMDCs were identified as live, CD11c+ singlets 
(Figure 2-19). To determine MHCII cell surface expression on WT and Ptpn22-/- BMDCs, separate 
wells (which did not receive any antigen or immune complex) were also stained with anti-CD11c 
(BioLegend), anti-MHCII I-Ab (BioLegend) and a fixable viability dye (eBioscience). 
 
Figure 2-19: Schematic of immune complex derived antigen presentation assay.  
WT and Ptpn22-/- BMDCs were incubated with GFP, GFP-Eα, GFP:anti-GFP ICs or GFP-Eα:anti-GFP ICs for 18 hours at 
37°C, 5% CO2. BMDCs were washed and stained with anti-CD11c, anti-YAe-biotin (which recognises Eα52-68 in I-Ab) and 
a viability dye (L/D). BMDCs were washed and incubated with streptavidin-APC. Antigen or IC internalisation was 
determined by measuring GFP expression on live, CD11c+ singlets. Cell surface presentation of Eα52-68 in I-Ab was 
determined by YAe fluorescence, after gating on live, CD11c+ singlets.  
 
2.2.6.7 Using blocking antibodies and kinase inhibitors in uptake and degradation 
assays 
 
To verify that the ova ICs were being internalised via FcγRs, BMDCs were pre-incubated with 
anti-FcγRI (BioLegend), FcγRII/III (BioLegend) and FcγRIV (Professor Jeffrey Ravetch, Rockefeller 
University) for 15 minutes at 4°C, prior to incubation with ova ICs. To determine the role of Src 
and Syk family kinases in ova IC uptake, BMDCs were pre-incubated with Src inhibitor-1 (5 µM, 
Sigma Aldrich) for 15 minutes at 37°C, or Syk inhibitor II (5 µM, Calbiochem) for 15 minutes at 
37°C, prior to incubation with LY, ova or ova ICs. To verify that the HKCA was being internalised 
via dectin-1, BMDCs were pre-incubated with anti-dectin-1 (10 µg/ml, InvivoGen) for 30 minutes 
on ice, prior to incubation with the UV labelled HKCA. 
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2.2.7 FcyR expression on BMDCs 
 
2.2.7.1 Cell surface expression of FcγRs on DCs by flow cytometry 
 
For cell surface FcγR expression, isolated splenocytes and BMDCs from WT, Ptpn22-/-, Ptpn22R619 
and Ptpn22R619W mice were harvested, washed and stained using the following antibodies: FcγRI-
APC (BioLegend), FcγRII/III-FITC (BioLegend), FcγRIIb (Professor Jeffrey Ravetch, Rockefeller 
University) followed by goat anti-mouse AF488 (Invitrogen) and FcγRIV (Professor Jeffrey 
Ravetch, Rockefeller University) followed by goat anti-hamster FITC (AbD Serotec). FcγRIII 
expression was determined by using anti-FcγRIIb followed by FcγRII/III-FITC. Cells were washed 
with FACS buffer and fixed using 1% PFA in PBS prior to flow cytometry. FcγR expression was 
determined by gating on live, CD11c+ singlets (for BMDCs) and live, CD11c+, MHCII+ singlets (for 
splenic cDCs). 
Cell surface expression of FcγRIIb on bone marrow preDCs and CDPs was also investigated. Bone 
marrow was flushed from WT and Ptpn22-/- mice, centrifuged for 5 minutes at room temperature 
and 1600 rpm and resuspended in 2 ml red blood cell lysis buffer (BioLegend) for 5 minutes at 
room temperature, washed with PBS and centrifuged for 5 minutes at room temperature and 
1600 rpm. 5 x 106 bone marrow cells were stained with FcγRIIb (Professor Jeffrey Ravetch, 
Rockefeller University) followed by goat anti-mouse AF488 (Invitrogen), washed, blocked with a 
non-fluorescent FcγRII/III antibody (BioLegend) and stained with antibodies to identify common 
DC precursors (CDPs) and preDCs. Cells were washed and fixed using 1% PFA in PBS prior to flow 
cytometry. FcγRIIb expression was determined by gating on live, CD115+, cKit (CD117)-, Flt3 
(CD135)+ singlets (for CDPs) and live, CD11c+, MHCII-, SIRPαlow, Flt3 (CD135)+ singlets (for 
preDCs). 
 
2.2.7.2 Cell surface bone marrow neutrophil FcγR expression by flow cytometry 
 
To determine cell surface FcγR expression on neutrophils, WT, Ptpn22-/-, Ptpn22R619 and 
Ptpn22R619W bone marrow was flushed from mice, centrifuged for 5 minutes at room 
temperature and 1600 rpm and resuspended in 2 ml red blood cell lysis buffer (BioLegend) for 
5 minutes at room temperature, washed with PBS and centrifuged for 5 minutes at room 
temperature and 1600 rpm. Bone marrow cells were stained as described above (Section 
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2.2.7.1). Cells were washed and fixed using 1% PFA in PBS prior to flow cytometry. FcγR 
expression was determined by gating on live, CD11b+, Ly6G+ singlets.  
 
2.2.7.3 BMDC Fcgr mRNA expression  
 
To determine mRNA levels of Fcgrs, BMDCs were harvested, washed with PBS and lysed in 700 
µl QIAzol (Qiagen) for 5 minutes at room temperature, before being stored at -80°C. To extract 
RNA, samples were thawed and 200 µl chloroform was added per sample and shaken vigorously 
by hand for 15 seconds before being incubated at room temperature for 5 minutes. Samples 
were centrifuged for 20 minutes at 4°C and 13,500 rpm and the clear aqueous phase (containing 
the RNA) was transferred to a new RNase free eppendorf tube on ice (carried out in the fume 
hood). 500 µl ice-cold isopropanol and 1 µl Glycoblue (Invitrogen) was added per tube and 
shaken for 15 seconds. Samples were incubated for at least 30 minutes at -20°C before being 
centrifuged for 30 minutes at 4°C and 13,500 rpm. The supernatants were discarded and 
replaced with 1 ml ice-cold 70% ethanol and mixed. Samples were centrifuged for 10 minutes at 
4°C and 13,500rpm before discarding the supernatant. RNA was washed twice with 250 µl 70% 
ice-cold ethanol. RNA was air dried for at least 15 minutes on ice and resuspended in 20-30 µl 
cooled nuclease free water for at least 15 minutes on ice. Finally, the NanoDrop (Thermo Fisher 
Scientific) was used to determine the amount and quality of RNA present.  
cDNA was reverse transcribed using a First Strand cDNA synthesis kit (Thermo Fisher Scientific). 
Each reaction was in a final volume of 20 µl, composed of 10 µl mastermix (reaction buffer, 
RNase inhibitor, dNTPs, reverse transcriptase and oligo (dT) 18 primer) and 1 µg mRNA (in 10 µl 
nuclease free water). Samples were incubated at 37°C for 60 minutes followed by 5 minutes at 
70°C on a Thermal Cycler. cDNA was stored at -20C before use in qPCR.  
Gene expression was measured by TaqMan quantitative real-time PCR. qPCRs were set up on 
ice, with each reaction containing 5 µl 2 x qPCRBIO probe (PCR Biosystems), 0.5 µl probe (FAM 
labelled Fcgr1: Mm00438874_m1, Fcgr2b: Mm00438875_m1 or Fcgr3: Mm00438882_m1, or a 
VIC labelled eukaryotic 18S probe: Hs99999901_s1, all from Applied Biosystems), 3.5 µl nuclease 
free water and 1µl cDNA. Each condition was set up on a 384 well plate (Thermo Fisher Scientific) 
in duplicate.   
Acquisition was conducted using the ABI 7900HT fast real-time PCR system (Applied 
Biosystems), using the following settings: 94°C for 2 minutes, 50 x (95°C for 5 seconds and 65°C 
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for 30 seconds), 95°C for 15 seconds, 60°C for 1 minute and 95°C for 15 seconds. Relative 
abundance of gene expression was calculated using 18S as the endogenous control, and the 
formula: relative abundance = 2(-ΔCT). 
 
2.2.8 Osteoclast analysis 
 
2.2.8.1 Tartrate-resistant alkaline phosphatase (TRAP) staining 
 
To ascertain whether PTPN22 was required for osteoclast differentiation in vitro, bone marrow 
cultures from WT and Ptpn22-/- mice were grown in the presence of M-CSF only or M-CSF and 
RANK-L (to induce osteoclast differentiation). A commercial staining kit was used to identify cells 
which expressed the osteoclast enzyme tartrate-resistant acid phosphatase (TRAP). The assay 
utilises Naphthol AS-BI phosphoric acid solution which is hydrolysed by TRAP to produce 
naphthol AS-BI, which then couples with fast garnet GBC to form insoluble maroon coloured 
crystals at the location of TRAP activity. As osteoclasts fuse and become multinucleated during 
differentiation, the cells could also be assessed for the number of nuclei they had. This therefore 
provided a simple assay to measure osteoclast differentiation in vitro. Using this method, 
osteoclasts were defined as TRAP+ and having 3 or more nuclei. 
On day 10 of osteoclast culture (see Section 2.2.2.6 for culture details), media was removed from 
the wells and cells were fixed for 5 minutes at room temperature using 150 µl per well of 4% 
PFA in dI water. Wells were washed three times with dI water. 150 µl per well of a solution to 
identify TRAP (Sigma Aldrich) was added, which contained 1.5 µl naphthol AS-BI phosphate 
solution, 6 µl acetate solution, 3 µl fast garnet GBC base solution, 3 µl sodium nitrite solution, 7 
µl tartrate solution and 129.5 µl dI water. After 5 minutes, the wells were washed with dI water 
and left in dI water to image. Cells were scored using a light microscope by assigning them into 
3 categories: TRAP-, TRAP+ with 1-2 nuclei and TRAP+ with 3 or more nuclei (osteoclasts). 
 
2.2.8.2 Expression of osteoclast specific genes 
 
In order to investigate if PTPN22 was required for osteoclast differentiation in a more 
quantitative manner than TRAP staining, the expression of osteoclast specific genes was 
measured in WT and Ptpn22-/- osteoclast cultures. On day 12 of osteoclast culture (see Section 
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2.2.2.6 for culture details), media was removed from the wells and the cells were washed with 
PBS. 200 µl per well 0.05M EDTA in PBS was added for 30 minutes at room temperature. To 
harvest the cells, they were pipetted up and down, centrifuged at 1600 rpm for 5 minutes at 4°C 
and lysed in 700 µl QIAzol for 5 minutes at room temperature. Samples were then stored at -
80°C before use. To extract RNA, samples were thawed and 200 µl chloroform was added per 
sample and shaken vigorously by hand for 15 seconds before being incubated at room 
temperature for 5 minutes. Samples were centrifuged for 20 minutes and 4°C at 13,500 rpm and 
the clear aqueous phase (containing the RNA) was transferred to a new RNase free eppendorf 
tube on ice. 500 µl ice-cold isopropanol and 1 µl Glycoblue (Invitrogen) was added per tube and 
shaken for 15 seconds. Samples were incubated for at least 30 minutes at -20°C before being 
centrifuged for 30 minutes and 4°C at 13,500 rpm. The supernatants were discarded and 
replaced with 1 ml ice-cold 70% ethanol and mixed. Samples were centrifuged for 10 minutes 
and 4°C at 13,500rpm before discarding the supernatant. RNA was washed twice with 250 µl 
70% ice-cold ethanol. RNA was air dried for at least 15 minutes on ice and resuspended in 20 – 
30 µl cooled nuclease free water for at least 15 minutes on ice. Finally, the nanodrop was used 
to determine the amount and quality of RNA present.  
cDNA was reverse transcribed using first strand cDNA synthesis using random hexamers (PCR 
Biosystems). Each reaction was in a final volume of 20 µl, composed of 4 µl 5 x cDNA synthesis 
mix, 1 µl 20 x RTase and 100 ng mRNA (made up to 20 µl using nuclease free water). Samples 
were incubated at 42°C for 30 minutes followed by 10 minutes at 85°C on a Thermal Cycler. 
cDNA was stored at 4°C before use in qPCRs. qPCRs were set up on ice, with each reaction 
containing 5 µl 2 x mastermix (Applied Biosystems PowerUp SYBR green), 0.5 µl forward and 
reverse primers (at 100 µM, see table 2-8 for details), 3 µl nuclease free water and 1µl cDNA 
(diluted 1:5). Each condition was set up on a 384 well plate (Thermo Fisher Scientific) in 
duplicate.  




Forward: 5’ AGT TTG CCA GTG AAT 
TTC TGA AGC 3’ 
Reverse: 5’ TGA TAT TCT TGG GCC 
TCT GAG C 3’ 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
58°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Acp5 Forward: 5’ TCC TCG GAG AAA ATG 
CAT CAT 3’ 
50°C for 2 mins 
95°C for 2 mins 
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Reverse: 5’ GCA GTT AAG CTC CTG 
GAC CAA 3’ 
 
40 x 
95°C for 15s 
50°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Mmp9 Forward: 5’ CAC CTT CAC CCG CGT 
GTA C 3’ Reverse: 5’ GCT CCG CGA 
CAC CAA ACT 3’ 
 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
50°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Ctsk Forward: 5’ GCT GTG GAG GCG GCT 
ATA TG 3’ 
Reverse: 5’ AGA GTC AAT GCC TCC 
GTT CTG 3’ 
 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
51°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Itgb3 Forward: 5’ GGA AGC AGC GCC CAG 
ATC AC 3’ 
Reverse: 5’ TTG TCC ACG AAG GCC 
CCA AA 3’  
 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
51°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Tnfsf11a Forward: 5’ TGC CTA CAG CAT GGG 
CTT T 3’ Reverse: 5’ AGA GAT GAA 
CGT GGA GTT ACT GTT T 3’ 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
50°C for 15s  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
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B2m Forward: 5‘ CAG CAA GGA CTG GTC 
TTT CTA TAT CCT GGC 3’ 
Reverse: 5‘ TCT CGA TCC CAG TAG 
ACG GTC TTG GG 3‘ 
 
50°C for 2 mins 
95°C for 2 mins 
 
40 x 
95°C for 15s 
50-58°C for 15s (depending on 
what other primers were being 
used)  
72°C for 1 min  
 
95°C for 15s 
60°C for 1 min 
95°C for 15s                                     
Table 2-8: PCR primer sequences and cycles used for Fcgr mRNA expression in BMDCs.  
Acquisition was conducted using the ABI 7900HT fast real-time PCR system (Applied 
Biosystems). Relative abundance of gene expression was calculated using B2m mRNA as an 
endogenous control, and the formula: relative abundance = 2(-ΔCt).  
 
2.2.8.3 OsteoLyse assay 
 
The OsteoLyse assay kit allows for the measurement of collagen degradation by osteoclasts. The 
OsteoLyse plate contains wells which are coated with Europium labelled collagen. As the 
osteoclasts differentiate and become resorptive, they will degrade the underlying collagen. This 
leads to the release of Europium labelled collagen fragments into the media. The media can be 
harvested and the amount of collagen in the media can be measured on a plate reader.  
On days 6 and 11 of osteoclast culture (see Section 2.2.2.6 for culture details), 20 µl cell-free 
supernatant was removed from the wells of WT and Ptpn22-/- bone marrow cells grown in the 
presence of M-CSF only, or M-CSF and RANK-L, on an OsteoLyse plate (Lonza). Supernatants 
were stored at -20°C before use.  
To carry out the OsteoLyse assay, 10 µl cell-free supernatant was added per well of a black 96 
well flat bottom assay plate (Corning). 200 µl room temperature Fluorophore Releasing Reagent 
(Lonza) was added per well and the plate was rotated for 5 minutes at room temperature to 
mix. The fluorescence of each well was determined using an excitation of 340 nm and an 





2.2.9 K/BxN serum transfer model of arthritis 
 
The K/BxN serum transfer model is described in Kouskoff V et al., 1996178. The model can be 
established in a wide range of mouse strains, and is initiated by the transfer of arthritogenic 
serum containing IgG1 autoantibodies to glucose-6-phosphate isomerase (GPI). The 
arthritogenic serum is harvested from K/BxN mice, which express the KRN TCR transgene and 
the MHCII I-Ag7 and develop spontaneous disease. The KRN TCR transgene recognises a peptide 
from the bovine pancreas ribonuclease when presented in MHCII I-Ak and also a peptide of GPI 
when presented in MHCII I-Ag7. The K/BxN model is similar to human RA in that they both show 
symmetrical distribution and a chronic progressive disease with joint destruction.  
 
2.2.9.1 Arthritogenic serum collection and anti-GPI ELISA 
 
Mice expressing the KRN TCR transgene were bred to NOD mice, which express I-Ag7. The 
offspring of this cross (K/BxN mice) spontaneously develop arthritis at 4-6 weeks of age. At 8 
weeks of age, cardiac punctures (under anaesthetic) were performed on arthritic mice. The 
arthritogenic serum, containing autoantibodies to GPI was pooled, aliquoted and stored at -80°C 
before use (Figure 2-20).  
 
Figure 2-20: Schematic showing production of arthritogenic serum for the K/BxN serum transfer model of arthritis.  
Male mice expressing the KRN transgene are bred with female NOD mice expressing I-Ag7. Offspring from this cross 
develop spontaneous arthritis between 4-6 weeks of age. Cardiac punctures are performed on arthritic mice at 8 weeks 
of age. The blood is centrifuged and the arthritogenic serum is pooled and stored at -80°C. This serum can be used to 
induce arthritis in recipient mice. 
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To ensure that the arthritogenic serum contained autoantibodies to GPI, an ELISA was 
performed, comparing the anti-GPI levels in different batches of serum. A 96 well flat bottom 
plate (Thermo Fisher Scientific) was coated overnight at 4°C with 50 µl 5 µg/ml recombinant 
human glucose-6-phosphate isomerase (GPI, RayBiotech). The following day, the wells were 
washed three times with wash buffer (0.05% Tween in PBS). Wells were then blocked with 250 
µl ELISA block buffer (1% BSA in PBS) for 30 minutes at room temperature, and washed three 
times with wash buffer. 50 µl serum samples (diluted 1:2700, 1:5400, 1:21600 and 1:86400 with 
PBS) were added to the wells and incubated for 1 hour at room temperature. Wells were washed 
3 times with wash buffer and 50 µl alkaline phosphatase-conjugated F(ab’)2 goat anti-mouse 
IgG (1:2000 in PBS, Jackson ImmunoResearch) added per well for 30 minutes at room 
temperature. The wells were washed 3 times with wash buffer and 100 µl phosphatase substrate 
was added per well and incubated for 10 minutes at room temperature, before measuring the 
absorbance at 405 nm on a Victor Wallac plate reader (Perkin Elmer).  
 
2.2.9.2 Establishing disease using the K/BxN serum transfer model of arthritis 
 
Arthritogenic serum was diluted 1:1 with PBS and 150 µl was injected (i.p.) into WT, Ptpn22-/-, 
Ptpn22R619 and Ptpn22R619W mice on days 0 and 2. Mice receiving PBS were used as controls. 
Disease progression was monitored daily for 10 days by assigning clinical scores to each limb, 
using a scale of 0-3 per paw, where 0 = no reddening or swelling, 1 = slight swelling and/or 
reddening, 2 = pronounced swelling, 3 = pronounced swelling leading to joint stiffness 
(maximum per mouse = 12). Paw swelling was also measured using calipers (Kroeplin) and mice 







Figure 2-21: Schematic showing the K/BxN serum transfer model of arthritis.  
WT, Ptpn22-/- and Ptpn22R619W mice were injected (i.p) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) 
on days 0 and 2. Tail bleeds for serum were performed on days 1 and 3. At the peak of disease (on day 5), LNs, spleens 
and joints were harvested for immune cell phenotyping. Cardiac punctures were performed on days 5, 9 and 10 for 
serum. Paws were harvested on days 9 and 10 for histology. Mice were monitored daily by assigning clinical scores, 
taking paw caliper measurements and taken their weights. 
 
Figure 2-22: Example photos showing paws of WT healthy and arthritic mice on day 6 of the K/BxN serum transfer 
model of arthritis. 
 
2.2.9.3 Serum collection from healthy and arthritic mice 
 
Tail bleeds were performed on days 1 and 3 of the model, or cardiac punctures (under 
anaesthetic) were performed on days 5 and 9 (at the end of the experiments) from WT and 
Ptpn22-/- mice who had received arthritogenic serum or PBS. Blood was transferred to 1.5 ml 
tubes, allowed to clot at room temperature for at least 30 minutes, centrifuged for 20 minutes 
at room temperature and 13,500 rpm and the serum was transferred to new tubes and stored 




2.2.9.4 Analysis of serum cytokines and chemokines 
 
Serum cytokines and chemokines were measured using a LEGENDplex mouse proinflammatory 
chemokine panel and a LEGENDplex mouse inflammation panel, each of which could identify 13 
analytes (both from BioLegend). These are bead based immunoassays in which differentially 
sized and fluorescent beads are bound to antibodies specific for each analyte. These act as 
capture beads for the analytes present in the samples. A biotinylated detection antibody cocktail 
is then added, which contains antibodies specific for each analyte bound to a capture antibody 
on the beads. Finally, streptavidin-PE is added, which will bind to the biotinylated detection 
antibodies, which allows for fluorescent detection of each analyte, proportional to the amount 
of analyte present in the original sample. This fluorescence can be detected using flow 
cytometry. 
The assays were carried out as per the manufacturer’s instructions. Serum samples were 
thawed, vortexed for 5 seconds and centrifuged for 2 mins and 4°C at 13,500 rpm, before being 
diluted 1:1 with assay buffer. The top standard was reconstituted and serially diluted 1:4 to 
create the standards. 25 µl diluted samples and standards were loaded onto a 96 well V bottom 
plate in duplicate. Beads were vortexed and 25 µl was added to each well and the plate was 
rotated for 2 hours at room temperature at 800 rpm. The plate was centrifuged for 5 minutes at 
1050 rpm and the supernatant was flicked out. The beads were washed with wash buffer and 
centrifuged as above. 25 µl detection antibodies were added to each well and the plate was 
rotated for 1 hour at room temperature at 800 rpm. 25 µl streptavidin-PE was added to each 
well and the plate was rotated for 30 minutes at room temperature at 800 rpm. The plate was 
centrifuged for 5 minutes at 1050 rpm and the supernatant was removed. The beads were 
washed with wash buffer and transferred to microFACS tubes, before being collected by flow 
cytometry. Cytokine and chemokine serum concentrations were determined using standard 
curves for each analyte.  
 
2.2.9.5 Hematoxylin and eosin staining of joint sections 
 
Hematoxylin and eosin staining is a histological stain which allows for the visualisation of joint 
architecture and cell infiltration. Hematoxylin in combination with a metal cation (for example 
aluminium ions) is positively charged and can interact with negatively charged, acidic cell 
components including nucleic acids. This results in purple/blue nuclei, ribosomes and the rough 
endoplasmic reticulum. Eosin is acidic and negatively charged and can therefore react with 
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positively charged, basic parts of the tissue, such as amino groups in proteins in the cytoplasm, 
which become pink/red. As a result, different immune cells can be identified using this staining 
technique. 
On day 9 or 10 of the K/BxN serum transfer model of arthritis, WT, Ptpn22-/-, Ptpn22R619 and 
Ptpn22R619W mice were culled and hind paws were removed and fixed in formalin. 1-2 weeks 
later, fixed paws were transferred to tubes containing PBS and sent to Pathology Core Facilities 
at either Imperial College London or Queen Mary University London. Here the paws were 
decalcified over a period of 2 weeks, using EDTA, embedded into paraffin blocks, sectioned along 
the sagittal plane of the ankle joint, and stained using hematoxylin and eosin. Joints were scored 
in a blinded fashion using a light microscope by Professor Andrew Cope (King’s College London) 
using a scale of 0-3 for cell infiltration and joint erosion. 
 
2.2.9.6 Immunophenotyping of joints and joint draining LNs 
 
At day 5 of the K/BxN serum transfer model of arthritis WT and Ptpn22-/- mice were culled and 
spleens, popliteal dLNs, brachial/axiallary dLNs, wrist and ankle joints were removed. Joints 
were only removed if they were visibly arthritic. If two wrists (or two ankles) of a mouse were 
both similarly arthritic, these were combined into one sample. If only one ankle (or one wrist) 
was arthritic, then this joint was processed individually. Tissue from ankle and wrists joints were 
not combined. As each joint sample was from a different amount of tissue, I did not calculate 
the absolute cell numbers for each of the immune cell populations. To process the joints, they 
were first cut into small pieces, before being digested in 1ml RPMI-1640 containing DNase I and 
Liberase TL (both at 0.1mg/ml, Roche) for 2 hours at 37°C in 5% CO2; 10 mM EDTA was added 
for the final 5 minutes. Single cell suspensions were made by mashing the joint pieces and 
released cells through gauze. All the recovered cells were then transferred into FACS tubes, 
washed in PBS and centrifuged for 5 minutes at 4°C and 1600 rpm, and stained as described 
below.  
To process lymph nodes and spleens, the lymph nodes were first disrupted using 26G needles 
and then both lymph nodes and spleens were digested in 1 ml RPMI-1640, containing DNase I 
and Liberase TL (both at 0.1mg/ml, Roche) for 30 minutes at 37°C in 5% CO2; 10 mM EDTA was 
added for the final 5 minutes. Single cell suspensions were obtained by mashing the digested 
organs through gauze.  Splenocyte cell suspensions were resuspended in 2 ml red blood cell lysis 
buffer (BioLegend) for 5 minutes at room temperature, washed in PBS and centrifuged for 5 
minutes 4°C and 1600 rpm. Splenocytes were counted and 5 x 106 were added per FACS tube. 
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Lymphocyte cell suspensions were transferred into FACS tubes, counted, washed in PBS and 
centrifuged for 5 minutes at 4°C and 1600 rpm. Cells were then stained as described below. 
For staining, cells were blocked with a non-fluorescent FcγRII/III antibody (BioLegend) and 
stained with 100 µl per tube of an antibody cocktail containing anti-Ter119, anti-CD19, anti-
B220, anti-NK1.1, anti-MHCII I-Ab, anti-CD11b, anti-CD11c, anti-Ly6G, anti-Ly6C, anti-CD3, anti-
CD4, anti-CD8 (all from BioLegend) and a fixable viability dye (eBioscience) in PBS for 30 minutes 
at 4°C. Cells were washed with FACS buffer and stained with 100 µl per tube streptavidin in FACS 
buffer for 10 minutes at room temperature. Finally, cells were washed with FACS buffer and 
fixed using 1% PFA in PBS containing 5 x 104 counting beads (BioLegend), prior to flow cytometry. 
Cell were first gated on live, lineage- (to exclude Ter119+, CD19+, B220+ and NK1.1+ cells) singlets 
and then the following cell subsets were identified: Ly6Clo to med monocytes (CD11c- Ly6Clow to med, 
SSC-Alo), Ly6Chi monocytes (CD11c-, Ly6Chi, SSC-Alo), neutrophils (CD11c-, CD11b+, Ly6G+), CD4+ T 
cells (CD3+, CD4+), CD8+ T cells (CD3+, CD8+), conventional DCs (cDCs, CD11c+, MHCII+), cDC1s 
(CD11c+, MHCII+, CD8+) and cDC2s (CD11c+, MHCII+, CD11b+) (Figure 2-23).  
 
Figure 2-23: Flow cytometry plots showing example gating for K/BxN immune cell phenotyping at the peak of 
disease (day 5).  
Single cell suspensions were made from spleens, lymph nodes and joints of WT and Ptpn22-/- mice on day 5 of the 
K/BxN serum transfer model of arthritis. Cells were stained with antibodies for detection of immune cell subsets by 
flow cytometry. Cell were first gated on live, lineage- (to exclude Ter119+, CD19+, B220+ and NK1.1+ cells) singlets and 
then the following cell subsets were identified: Ly6Clo to med monocytes (CD11c- Ly6Clow to med, SSC-Alo), Ly6Chi monocytes 
(CD11c-, Ly6Chi, SSC-Alo), neutrophils (CD11c-, CD11b+, Ly6G+), CD4+ T cells (CD3+, CD4+), CD8+ T cells (CD3+, CD8+), 




2.2.9.7 Micro-computed tomography analysis 
 
Leg bones were removed from WT and Ptpn22-/- mice on day 10 of the K/BxN serum transfer 
model of arthritis. Bones were fixed overnight at room temperature in 4% PFA in PBS and then 
transferred to 70% ethanol the following day. Bones were shipped to the lab of Dr Nicole 
Horwood (University of Oxford) where micro-computed tomography (micro-CT) analysis was 
carried out. Bones were scanned using a Skyscan 1174 scanner (Bruker) and images were 
analysed using Skyscan CT analyser software version 1.13.2.1. 
 
2.2.9.8 Positron emission tomography/computed tomography (PET/CT imaging of 
arthritic mice using the radiotracer 68Ga(HP3-RGD3) 
 
In order to visualise areas of inflammation in whole mice, we utilised a Galium-68 labelled RGD 
trimeric peptide (68Ga(HP3-RGD3)). The RGD (arginine-glycine-aspartic acid) peptide, found in 
multiple extracellular matrix proteins binds to the integrin αvβ3, which is expressed at low levels 
in the steady state, but is upregulated in areas of angiogenesis and inflammation. Radiolabelling 
of the RGD trimeric peptide was carried out by Dr Michelle Ma (King’s College London). 
Hydrochloric acid (0.1 M, 5 mls) was passed through a 68Ge/68Ga generator (Eckert and Ziegler) 
and the eluate was fractionated into 1 ml fractions. The second 1 ml fraction was added to HP3-
RGD3 in a 1:1 ethanol:water solution (50-100 µl), immediately followed by ammonium acetate 
(1 M, 300 µl). High performance liquid chromatography was used to determine the labelling 
efficiency.  
 The K/BxN serum transfer model of arthritis was established in WT and Ptpn22-/- mice, and on 
day 6 the mice were injected (i.v.) with 4 µg 68Ga(HP3-RGD3), containing 8-14 Mbq (under 
anaesthetic). One hour post injection, mice were either culled and imaged dead, or mounted 
onto the nanoScan PET/CT bed (Mediso Medical Imaging Systems) set at 37°C with continuous 
anaesthetic. PET images were collected for 15 minutes, followed by a CT image (to gain 
anatomical information). After imaging (or using separate mice), mice were culled and organs 
were collected for biodistribution. All organ collection tubes were weighed before and after 
adding the organ, so that the weight of each organ could be calculated. The radioactivity of each 
organ was determined using a gamma counter. These experiments were carried out with Dr 




Figure 2-24: Schematic showing induction and experimentation of PET/CT and biodistribution analysis of arthritis 
in WT and Ptpn22-/- mice using the K/BxN serum transfer model of arthritis.  
WT and Ptpn22-/- mice were injected (i.p) with 150 µl PBS or high titre arthritogenic serum (diluted 1:1 with PBS) or 
low titre arthritogenic serum (diluted 1:8 with PBS on days 0 and 2. On day 6 or 8, mice were injected (i.v.) with gallium-
68 labelled RGD peptide. 1 hour later, mice were culled and imaged using PET/CT and organs were harvested for 
biodistribution. Mice were monitored daily by assigning clinical scores, taking paw caliper measurements and taken 
their weights. 
 
2.2.10 Data acquisition and analysis  
 
Flow cytometry samples were acquired using a Fortessa II or FACSCanto II with FACS Diva 
software (all from BD). Data were analysed using FlowJo software version 10 (TreeStar). Gates 
were determined by fluorescence minus one (FMO) controls. All graphs were plotted using Prism 
version 7 (GraphPad) and analysed for statistical significance using a 2-way ANOVA followed by 
Sidak’s or Tukey’s multiple comparisons test, Wilcoxon matched-pairs signed ranks test, or 




3. Results: Investigating the regulation of immune complex induced DC 




PTPN22 is a non-receptor protein tyrosine phosphatase which regulates signalling downstream 
of a range of immunoreceptors, generally via its ability to dephosphorylate Src and Syk family 
kinases237. DCs (DCs) express a range of pattern recognition receptors (PRRs) including Toll-like 
receptors (TLRs), C-type lectin receptors (CLRs), nucleotide oligomerisation domain (NOD)-like 
receptors (NLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and Fc gamma 
receptors (FcγRs), and use these to bind and internalise soluble and particulate matter from 
their surroundings238. FcγRs are expressed on most innate immune cells and recognise the Fc 
region of IgG immunoglobulins. These can be as part of an antibody:antigen immune complex 
or as part of an opsonised particle, and engagement of these with FcγRs leads to receptor 
crosslinking and downstream signalling involving Src and Syk family kinases. This ultimately leads 
to a variety of cellular processes including immune complex internalisation, antigen processing 
and presentation, antibody-dependent cellular cytotoxicity (ADCC), cytokine and chemokine 
secretion, cell maturation and release of reactive oxygen species (ROS)125; all of which shape the 
immune response. As polymorphisms in PTPN22 are associated with autoimmune diseases, and 
the majority of the associated diseases have an autoantibody component to their pathology, the 
experiments described in this Chapter set out to investigate whether PTPN22 regulates DC 
effector responses after FcγR engagement. Firstly, I compared immune complex induced 
effector functions in WT and Ptpn22-/- bone marrow derived DCs (BMDCs), including DC 
upregulation of co-stimulatory molecules, cytokine secretion and T cell activation. BMDCs from 
mice expressing the autoimmune associated variant of Ptpn22 (Ptpn22R619W) were then studied, 
to investigate whether FcR stimulation was dysregulated by the autoimmune associated variant 
of PTPN22 (PTPN22R620W). Finally, the role of PTPN22 in antigen processing and presentation in 








This Chapter aimed to determine whether PTPN22 is required for: 
1. BMDC differentiation and FcγR expression. 
2. Immune complex induced BMDC maturation. 




3.3.1 PTPN22 does not regulate BMDC differentiation in vitro 
 
As BMDCs have been extensively used throughout this thesis, I first wanted to ascertain whether 
PTPN22 affected differentiation of BMDCs from bone marrow. Wild type (WT) and Ptpn22-/- 
bone marrow was cultured in the presence of granulocyte-macrophage colony stimulating factor 
(GM-CSF) for 7 days and flow cytometry was used to identify the proportion of the cultures that 
had differentiated into CD11c+ DCs. This was found to be similar in the presence or absence of 
PTPN22 (Figure 3-1b). As GM-CSF induced BMDC cultures do not form a homogenous 
population, additional analysis was carried out to distinguish between cells which were more 
DC-like (GM-DCs, identified as CD11c+, MHCIIhi, CD11b+ live singlets) and macrophage-like (GM-
macs, identified as CD11c+, MHCIIint, CD11bhi live singlets), based on gating by Helft J. et al234. 
Verification of these distinct populations was also achieved by measuring the expression of DC 
and macrophage specific cell surface markers including CD24 and CD64 respectively (Figure 3-
1d). The proportions of both GM-DCs and GM-macs were similar in WT and Ptpn22-/- bone 
marrow cultures (Figure 3-1b), indicating that PTPN22 does not regulate bone marrow 
differentiation into BMDCs in the presence of GM-CSF in vitro.   
Bone marrow differentiation was also assessed from mice expressing the orthologue of the 
human associated variant of Ptpn22 (Ptpn22R619W). As with the Ptpn22-/- cultures, Ptpn22R619W 




Figure 3-1: PTPN22 does not affect BMDC differentiation in vitro.  
(a-d) Bone marrow from WT (white) and Ptpn22-/- (black) (a-b) or Ptpn22R619 (WT, white) and Ptpn22R619W (black) (c) 
mice was cultured in the presence of GM-CSF for 7 days. Cells were stained to identify CD11c+ cells, CD11c+ MHCII+ 
cells, CD11c+ MHCIIhi CD11b+ (GM-DCs) and CD11c+ MHCIIint CD11bhi (GM-macs), all gated on live singlets. 
Representative flow cytometry plots (a) and combined data (b-c) are shown. n = 6-7 + s.d. (d) Representative flow 
cytometry plots of CD24 (left, GM-DC marker) and CD64 (right, GM-mac marker), gated on CD11c+ MHCIIhi CD11b+ 
(GM-DCs, grey) and CD11c+ MHCIIint CD11bhi (GM-macs, white) live singlets. 
These observations show that PTPN22 does not modulate BMDC differentiation in vitro, which 
indicated that any differences found in the response of WT and Ptpn22-/- BMDCs in subsequent 
experiments is not due to any initial differences in their differentiation. 
 
3.3.2 Ptpn22-/- BMDCs express normal levels of activating FcγRs, but reduced 
expression of the inhibitory receptor FcγRIIb  
 
Four FcγRs are expressed in mice: FcγRI, FcγRIIb, FcγRIII and FcγRIV126. Before beginning to 
investigate a potential role of PTPN22 in regulating FcγR dependent effector responses in DCs, 
BMDC cell surface expression of FcγRs was measured. Cell surface expression of the activating 
receptors FcγRI, FcγRIII and FcγRIV was similar on WT and Ptpn22-/- BMDCs (as judged by % 
positive and geometric mean fluorescence intensity, GMFI), however Ptpn22-/- BMDCs were 
found to have reduced expression of the inhibitory FcγRIIb on their cell surface (Figure 3-2a), 
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while the proportion of WT and Ptpn22-/- BMDCs expressing FcγRIIb was similar (Figure 3-2b). 
Expression of the autoimmune associated variant of Ptpn22 (Ptpn22R619W) did not affect BMDC 
FcγR expression (Figure 3-2c). Despite the reduced expression of FcγRIIb on Ptpn22-/- BMDCs, 
when WT and Ptpn22-/- BMDCs were matured with LPS, their FcγR expression was found to be 
similar (Figure 3-2d). 
To identify at what point during DC differentiation the difference in FcγRIIb expression occurred, 
bone marrow from WT and Ptpn22-/- mice was harvested and stained to identify common DC 
progenitors (CDPs) and preDCs. FcγRIIb expression was similar on WT and Ptpn22-/- CDPs and 
preDCs (Figure 3-2e), indicating that PTPN22 may regulate FcγRIIb expression at a later stage of 
DC development. 
To investigate this further, WT and Ptpn22-/- BMDCs were lysed, mRNA was extracted, cDNA was 
reverse transcribed, and expression of Fcgr1, Fcgr2b and Fcgr3 was determined using qRT-PCR. 
Expression of these genes was found to be similar between WT and Ptpn22-/- BMDCs (Figure 3-
2f), indicating that the difference in cell surface expression of FcγRIIb between WT and Ptpn22-
/- BMDCs was not due to differences in Fcgr2b gene expression.  
Expression of FcγRs was also measured on conventional DCs derived from the spleens of WT, 
Ptpn22-/- and Ptpn22R619W mice. As with the BMDCs, splenic DCs from the different genotypes of 
mice expressed similar levels of the activating receptors (Figure 3-2g-h). Although there was a 
trend in some experiments towards reduced expression of FcγRIIb on Ptpn22-/- splenic DCs 
compared to WT splenic DCs, overall, the difference was not significant (Figure 3-2g). Similar 
FcγR expression was also seen on splenic DCs from Ptpn22R619 (WT) and Ptpn22R619W mice (Figure 




Figure 3-2: Ptpn22-/- BMDCs express normal levels of activating FcγRs, but reduced expression of the inhibitory 
receptor FcγRIIb.  
(a) FcγR surface expression on WT (white) and Ptpn22-/- (black) BMDCs (geometric mean fluorescence intensity, GMFI, 
gated on CD11c+ live singlets). n = 16-18 + s.d; ***p<0.005 using a 2-way ANOVA with Sidak’s multiple comparisons 
test. (b) FcγR surface expression on WT (white) and Ptpn22-/- (black) BMDCs (% positive, gated on CD11c+ live singlets). 
n = 10 + s.d. (c) FcγR surface expression on Ptpn22R619 (WT, white) and Ptpn22R619W (black) BMDCs (GMFI, gated on 
CD11c+ live singlets). n = 7 + s.d. (d) FcγR surface expression on WT (white) and Ptpn22-/- (black) LPS matured BMDCs 
(GMFI, gated on CD11c+ live singlets). n = 4 + s.d. (e) FcγRIIb surface expression on WT (white) and Ptpn22-/- (black) 
CDPs and preDCs (GMFI, gated on CD115+, cKit-, Flt3+ live singlets for CDPs and CD11c+, MHCII-, SIRPαlow, Flt3+ live 
singlets for preDCs). n = 6 + s.d. (f) Fcgr mRNA expression from WT (white) and Ptpn22-/- (black) BMDCs, relative to 
18S. n  = 5 + s.d. (g) FcγR surface expression on WT (white) and Ptpn22-/- (black) splenic DCs (gated on CD11c+, MHCII+ 
live singlets). n = 1 (for FcγRI), 3 (for FcγRIII and IV), 11 (for FcγRIIb) + s.d. (h) FcγR surface expression on Ptpn22R619 
(WT, white) and Ptpn22R619W (black) splenic DCs (gated on CD11c+, MHCII+ live singlets). n = 5 (for FcγRI), 8 (for FcγRIIb, 
III and IV) + s.d.  
 
3.3.3 PTPN22 does not regulate FcγR expression on bone marrow neutrophils 
 
In addition to DCs, most other innate immune cells also express FcγRs. Bone marrow neutrophils 
from WT, Ptpn22-/- and Ptpn22R619W mice were analysed to determine their FcγR expression. This 
was found to be similar between the different genotypes (Figure 3-3a-b), indicating that PTPN22 




Figure 3-3: Ptpn22-/- and Ptpn22R619W neutrophils express normal levels of FcγRs.  
(a) FcγR surface expression on WT (white) and Ptpn22-/- (black) bone marrow neutrophils (geometric mean 
fluorescence intensity, GMFI, gated on CD11b+, Ly6G+ live singlets). n = 10 + s.d. (b) FcγR surface expression on 
Ptpn22R619 (WT, white) and Ptpn22R619W (black) bone marrow neutrophils (GMFI, gated on CD11b+, Ly6G+ live singlets). 
n = 8 + s.d.  
 
3.3.4 PTPN22 is dispensable for FcγR induced BMDC maturation 
 
Immune complex crosslinking of FcγRs causes BMDC maturation, which leads to increased cell 
surface expression of the major histocompatibility complex class II (MHCII) and co-stimulatory 
molecules including CD54, CD80 and CD86; expression of which can affect T cell activation166. 
WT and Ptpn22-/- BMDCs were incubated with ovalbumin (ova), rabbit anti-ova (anti-ova), ova 
pre-incubated with rabbit IgG (ova + rabbit IgG, and produced as per an immune complex), ova 
and heat aggregated (HA) rabbit IgG (ova + HA IgG) and ova:anti-ova immune complexes (ova 
ICs) for 24 hours at 37°C, 5% CO2. After 24 hours, BMDCs were harvested and stained for cell 
surface expression of MHCII and co-stimulatory molecules (see Materials and Methods Figure 2-
4 for experimental setup). Expression of these molecules was unchanged from unstimulated 
conditions after incubation with ova, anti-ova, ova pre-incubated with rabbit IgG, and ova added 
in combination with HA IgG (Figure 3-4a-f). Only incubation with ova ICs caused BMDC 
maturation, as determined by a moderate increase in CD54, CD80 and CD86 expression (Figure 
3-4a-f). This indicates that the addition of an antigen and antibody is insufficient to induce BMDC 
maturation, but that it requires the presence of an antigen:antibody immune complex. The 
response to ova IC stimulation between WT and Ptpn22-/- BMDCs was similar (Figure 3-4a-f), 




Figure 3-4: PTPN22 does not regulate immune complex induced maturation of BMDCs.  
(a-c) WT and Ptpn22-/- BMDCs were stimulated in the presence of ova, anti-ova or ova IC. After 24 hours, BMDCs were 
harvested and surface stained for CD80, CD86 and MHCII. WT (white) and Ptpn22-/- (black) BMDC cell surface 
expression (geometric mean fluorescence intensity, GMFI, gated on CD11c+ live singlets) of CD80 (a), CD86 (b) and 
MHCII (c). n = 6-8 + s.d. ***p<0.005, **p<0.01 using a 2-way ANOVA with Tukey’s multiple comparisons test. All WT v 
Ptpn22-/- comparisons were non-significant (n.s.). Bars on graphs only show comparisons of ova IC v unstim/ova/anti-
ova for Ptpn22-/- BMDCs (for simplicity). (d-f) WT and Ptpn22-/- BMDCs were stimulated in the presence of ova, ova 
pre-incubated with rabbit IgG (ova + rabbit IgG), ova with heat aggregated IgG (ova + HA IgG), or ova IC. After 18 
hours, BMDCs were harvested and surface stained for CD54, CD80 and CD86. GMFI (gated on CD11c+ live singlets) are 
shown for WT (white) and Ptpn22-/- (black) BMDC CD54 (d), CD80 (e) and CD86 (f) expression. n = 4 + s.d. ***p<0.005, 
**p<0.01, *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test. All WT v Ptpn22-/- comparisons were 
non-significant (n.s.). Bars on graphs only show comparisons of ova IC v ova/ova + rabbit IgG/ova + HA IgG for Ptpn22-
/- BMDCs (for simplicity). 
 To determine whether expression of the autoimmune associated variant of PTPN22 would 
affect BMDC maturation in response to immune complex stimulation, Ptpn22R619 (WT) and 
Ptpn22R619W BMDCs were stimulated with ova ICs for 24 hours (with ova and anti-ova being used 
as controls). Although immune complex stimulation did cause a subtle increase in CD54 and 
CD86 expression, the expression was similar between WT and Ptpn22R619W BMDCs (Figure 3-5a-
c). This indicates that PTPN22 does not regulate expression of co-stimulatory molecules after 




Figure 3-5: PTPN22R619W expression does not affect immune complex induced maturation of BMDCs.  
(a-c) Ptpn22R619 (WT) and Ptpn22R619W BMDCs were stimulated in the presence of ova, anti-ova or ova IC. After 24 
hours, BMDCs were harvested and surface stained for CD54, CD80 and CD86. (a-c) WT (white) and Ptpn22R619W (black) 
BMDC cell surface expression (geometric mean fluorescence intensity, GMFI, gated on CD11c+ live singlets) of CD54 
(a), CD80 (b) and CD86 (c). n = 4 + s.d. ***p<0.005, *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons 
test. All WT v Ptpn22R619W comparisons were non-significant (n.s.). Bars on graphs only show comparisons of ova IC v 
unstim/ova/anti-ova for Ptpn22R619W BMDCs (for simplicity). 
As GM-CSF induced BMDCs are not equivalent to in vivo DCs, I wanted to test whether PTPN22 
may be playing a role in FcγR BMDC effector functions in Flt3L induced BMDCs, which are more 
reflective of in vivo DCs. WT and Ptpn22-/- Flt3L cultures differentiated similarly to produce DC1-
like (CD24+) and DC2-like (SIRPα+) DCs (Figure 3-6a). WT and Ptpn22-/- Flt3L BMDCs were 
stimulated for 24 hours with ova, ova ICs or LPS and expression of CD54, CD80 and MHCII was 
determined by flow cytometry. Ova ICs only induced a modest upregulation of these markers, 
whereas expression was highly upregulated after LPS stimulation. In agreement with the GM-







Figure 3-6: PTPN22 is dispensable for Flt3L BMDC differentiation and effector functions.  
(a-d) WT (white) and Ptpn22-/- (black) bone marrow cells were grown in the presence of Flt3L for 12-13 days. (a) BMDCs 
were harvested and stained for immunophenotyping, by gating on CD11c+ live singlets, CD11c+ CD24+ live singlets 
(DC1-like cells) and CD11c+ SIRPα+ (DC2-like cells) live singlets. n = 3 + s.d. (representative of 8 independent 
experiments). (b-c) BMDCs were stimulated for 24 hours with ova, ova ICs or LPS, harvested and stained for expression 
of CD54, CD80 and MHCII (gated on CD11c+, CD24+ (b) or CD11c+, SIRPα+ (c) live singlets). n = 3 + s.d.  
 
3.3.5 PTPN22 does not regulate immune complex induced maturation of splenic DCs 
Splenic DCs from WT and Ptpn22-/- mice were stimulated ex vivo with ova or ova ICs. After 24 
hours, cell surface upregulation of CD40, CD54 and CD86 was measured. As with the in vitro 
BMDCs, lack of PTPN22 did not affect expression of these molecules on splenic DCs (Figure 3-
7a-c). Taken together, this indicates that PTPN22 does not play a role in modulating splenic DC 






Figure 3-7: PTPN22 does not regulate immune complex induced maturation of splenic DCs.  
(a-c) WT and Ptpn22-/- splenic DCs were stimulated in the presence of ova or ova IC. After 24 hours, splenic DCs were 
harvested and surface stained for CD40, CD54 and CD86. Data shows WT (white) and Ptpn22-/- (black) splenic DC cell 
surface expression (mean fluorescence intensity, MFI, gated on CD11c+, MHCII+ live singlets) of CD40 (a), CD54 (b) and 
CD86 (c). n = 4 + s.d. ***p<0.005, **p<0.01, *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test. 
All WT v Ptpn22-/- comparisons were non-significant (n.s.). Bars on graphs only show comparisons of ova IC v 
unstim/ova for Ptpn22-/- BMDCs (for simplicity). 
 
3.3.6 PTPN22 is dispensable for FcγR induced BMDC cytokine secretion 
 
In addition to causing upregulation of MHCII and co-stimulatory molecules, immune complex 
stimulation also induces the secretion of T cell polarising cytokines by BMDCs127,239. To 
determine whether PTPN22 was required for this process, WT and Ptpn22-/- BMDCs were 
harvested, counted and stimulated in the presence of ova, anti-ova or ova ICs for 24 hours at 
37°C, 5% CO2. After 24 hours, supernatants were harvested and the secretion of interleukin-6 
(IL-6), tumour necrosis factor α (TNFα) and interleukin-12/23p40 (IL-12/23p40) was measured 
by immunoassay (see Materials and Methods Figure 2-4 for experimental setup). Ova and anti-
ova stimulation caused very low levels of cytokine secretion from both WT and Ptpn22-/- BMDCs 
(Figure 3-8a-c). BMDCs stimulated with ova ICs secreted significantly more IL-6, TNFα and IL-
12/23p40 compared to BMDCs incubated with ova or anti-ova alone, however, both WT and 
Ptpn22-/- BMDCs secreted similar levels of these cytokines in response to immune complex 





Figure 3-8: PTPN22 is dispensable for BMDC cytokine secretion after immune complex stimulation.  
(a-c) WT (white) and Ptpn22-/- (black) BMDCs were stimulated with ova, anti-ova or ova IC, in the presence of 
polymyxin B. After 24 hours, cell-free supernatants were harvested and secretion of IL-6 (a), TNFα (b) and IL-12/23p40 
(c) was determined by immunoassay. n = 3 + s.d. (representative of 10 independent experiments).  
Cytokine secretion was also measured from immune complex stimulated Ptpn22R619 (WT) and 
Ptpn22R619W BMDCs. Only low levels of IL-6, TNFα and IL-12/23p40 were detected in the 
supernatants of BMDCs incubated in the presence of ova alone for 24 hours (Figure 3-9a-c). 
Whilst enhanced cytokine secretion was observed after stimulation with ova ICs, WT and 
Ptpn22R619W BMDCs secreted similar levels (Figure 3-9a-c).  
 
Figure 3-9: Expression of Ptpn22R619W does not affect BMDC cytokine secretion after immune complex stimulation.  
(a-c) Ptpn22R619 (WT, white) and Ptpn22R619W (black) BMDCs were stimulated with ova or ova IC, in the presence of 
polymyxin B. After 24 hours, cell-free supernatants were harvested and secretion of IL-6 (a), TNFα (b) and IL-12/23p40 
(c) was determined by immunoassay. n = 4 + s.d. 
In order to look at the secretion of a wider array of cytokines and chemokines after immune 
complex stimulation, a Luminex assay was performed. Of the 23 analytes that were detected, 8 
showed immune complex induced secretion, above that secreted by ova or anti-ova stimulated 
BMDCs. These were IL-6, monocyte chemoattractant protein-1 (MCP-1), interleukin-1α (IL-1α), 
regulated on activation, normal T cell expressed and secreted (RANTES, CCL5), keratinocyte 
chemoattractant (KC, CXCL1), macrophage inflammatory protein-1β (MIP-1β), interleukin-
12p40 (IL-12p40) and macrophage inflammatory protein-1α (MIP-1α). However, the secretion 
of these analytes was similar between WT and Ptpn22-/- ova IC stimulated BMDCs (Figure 3-10a-
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h). This again indicates that PTPN22 is dispensable for cytokine and chemokine secretion after 
immune complex stimulation. 
 
Figure 3-10: PTPN22 is dispensable for BMDC cytokine secretion after immune complex stimulation.  
(a-h) WT (white) and Ptpn22-/- (black) BMDCs were stimulated with ova, anti-ova or ova IC. After 24 hours, cell-free 
supernatants were harvested and secretion of IL-6 (a), MCP-1 (b), IL-1α (c), RANTES (d), KC (e), MIP-1β (f), IL-12p40 (g) 
and MIP-1α (h) was determined using a Luminex assay. n = 1 (unstim, ova, anti-ova) and 3 (ova IC) + s.d.  
Ova ICs bind to all FcγRs expressed on the surface of mouse BMDCs because the anti-ova is 
raised in rabbits, and rabbit IgG does not have different subclasses. To further investigate 
whether PTPN22 may be required for cytokine secretion downstream of specific FcγRs, 
monoclonal anti-TNP antibodies of the IgG1 isotype were combined with TNP-ova to form TNP-
ova:IgG1 anti-TNP immune complexes. These ICs preferentially bind to FcγRIIb and FcγRIII126, 
and were used to induce cytokine secretion from WT and Ptpn22-/- BMDCs. As with the ova ICs, 
the TNP-ova:IgG1 anti-TNP immune complex stimulation led to enhanced secretion of IL-6 and 




Figure 3-11: PTPN22 is dispensable for BMDC cytokine secretion after IgG1 specific immune complex stimulation. 
 (a-b) WT (white) and Ptpn22-/- (black) BMDCs were stimulated with TNP-ova, IgG1 anti-TNP or TNP-ova:IgG1 anti-
TNP IC (TNP-ova IC), in the presence of polymyxin B. After 24 hours, cell-free supernatants were harvested and 
secretion of IL-6 (a) and TNFα (b) was determined by immunoassay. n = 3 + s.d. 
In contrast to rabbits, there are four IgG subclasses in mice: IgG1, IgG2a, IgG2b and IgG3. These 
have different affinities for FcγRs, for example, FcγRI is a high affinity receptor for IgG2a, 
whereas FcγRIV has no affinity for IgG3127. An additional factor that affects IgG binding to FcγRs 
is the presence of an N-linked glycan at asparagine 297 in the Fc domain of IgGs. The glycan is 
composed of fucose, galactose, sialic acid and bisecting N-acetylglucosamine, in varying 
proportions128. The composition of the glycan affects IgG binding to FcγRs, for example, the lack 
of fucose in the glycan enhances IgG binding to human FcγRIII240. The lab of Dr Gestur Vidarsson 
(University of Amsterdam) kindly provided me with engineered human IgGs with defined Fc-
glycans236 (see Materials and Methods Table 2-7 for antibody details). Although they have been 
verified to bind to mouse FcγRs, not many of the IgG glycoforms caused BMDC cytokine 
secretion as part of an immune complex that was higher than the secretion caused by the IgG 
antibody alone. Focussing on those IgG glycoforms which did induce BMDC cytokine secretion, 
there was no difference in the response of WT and Ptpn22-/- BMDCs (Figure 3-12a-c). This is in 
agreement with my previous experiments showing that PTPN22 does not regulate immune 





Figure 3-12: PTPN22 is dispensable for BMDC cytokine secretion after IgG1 specific immune complex stimulation.  
(a-c) WT (white) and Ptpn22-/- (black) BMDCs were stimulated with TNP-ova, glycosylation variants of IgG1 anti-TNP 
or TNP-ova:IgG1 anti-TNP ICs, in the presence of polymyxin B. IgG1 anti-TNP glycosylation variants used were 
unmodified IgG1 anti-TNP (376), IgG1 anti-TNP +2FF (377) and IgG anti-TNP + B4galT1 + St6galT + 2FF + d-gal (302); 
see Materials and Methods Table 2-7 for more details. After 24 hours, cell-free supernatants were harvested and 
secretion of IL-6 (a), TNFα (b) and IL-12/23p40 (c) was determined by immunoassay. n = 3 + s.d. IgG1 anti-TNP 
glycoforms were provided by Dr Gestur Vidarsson (University of Amsterdam). 
Taken together, this data therefore indicates that PTPN22 is not required for immune complex 
induced BMDC maturation, including upregulation of co-stimulatory molecules and cytokine 
secretion. 
 
3.3.7 Immune complex stimulation can induce calcium flux in BMDCs 
 
An earlier response to FcγR crosslinking than DC cytokine secretion and maturation, is calcium 
flux. After receptor crosslinking, phospholipase Cγ2 becomes stimulated which then cleaves 
phosphatidylinositol-(4,5)-bisphosphate to diacylglycerol and inositol-(1,4,5)-trisphosphate. 
Inositol-(1,4,5)-trisphosphate binds to IP3 receptors located in the endoplasmic reticulum, 
resulting in the release of calcium from intracellular stores. Indo-1 is a sensitive ratiometric dye 
which can be used to measure intracellular calcium flux as it emits light at different wavelengths 
depending on whether it is in the absence or presence of calcium. In the absence of calcium, 
indo-1 displays a main emission peak at 500 nm, whereas in the presence of calcium, this shifts 
to 390 nm. By staining BMDCs with indo-1, the calcium flux in response to stimulation can be 
monitored in real time by flow cytometry. The response of WT and Ptpn22-/- BMDCs to immune 
complex stimulation was measured in multiple experiments, however, the results were not 
consistent. Although the ionophore ionomycin always induced a robust calcium flux, and the 
chelator EGTA reduced this back to baseline, immune complex stimulation only caused a 
measurable flux in calcium in some experiments (Figure 3-13). Therefore, it was not possible 
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from these experiments to conclude whether PTPN22 was required for calcium flux after FcγR 
crosslinking.  
 
Figure 3-13: Immune complex stimulation can cause calcium flux in BMDCs.  
BMDCs were stained with indo-1 and collected by flow cytometry. Ionomycin, followed by EGTA (top) or ova ICs 
(bottom) were used added to BMDCs (arrows on the right hand plots indicate the time of addition of stimulations), 
and calcium flux was measured in real time. 
 
3.3.8 PTPN22 does not regulate immune complex induced reactive oxygen species 
production by neutrophils    
 
The production of reactive oxygen species (ROS) is one of the mechanisms that phagocytes use 
to destroy invading pathogens. Although DCs can produce ROS, neutrophils and macrophages 
are far more efficient at using this to destroy pathogens241. This is because the phagocytic 
pathway in DCs focuses more on antigen presentation as opposed to pathogen killing238. I 
therefore compared the ability of ex vivo neutrophils (identified as CD11b+, Ly6G+ live singlets) 
from the bone marrow of WT and Ptpn22-/- mice to produce ROS after immune complex 
stimulation, using dihydrorhodamine 123 (DHR123). DHR123 is a derivative of rhodamine and is 
an uncharged and non-fluorescent dye. When it is incubated with cells, it can passively diffuse 
across membranes, and when it becomes oxidised by ROS, it is converted into rhodamine 123, 
which fluoresces green and can be detected by flow cytometry.  Ova and anti-ova stimulation 
caused no increase in ROS production (as shown by no change in the percentage of DHR123+ 
neutrophils) relative to unstimulated bone marrow cells (Figure 3-14). Although ova ICs caused 
a subtle increase in ROS production, a similar increase was observed in both WT and Ptpn22-/- 




Figure 3-14: PTPN22 is not required for immune complex induced ROS production by bone marrow neutrophils. 
Bone marrow from WT and Ptpn22-/- mice was flushed, red blood cell lysed, stained with DHR123 and incubated with 
ova, anti-ova and ova ICs for 45 minutes at room temperature. DHR123 expression (% positive, relative to the 
unstimulated condition) in WT (white) and Ptpn22-/- (black) neutrophils was determined by flow cytometry (gated on 
CD11b+, Ly6G+ live singlets). n = 3 + s.d. *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test. All WT 
v Ptpn22-/- comparisons were non-significant (n.s.). Bars on graphs only show comparisons of ova IC v unstim/ova/anti-
ova for Ptpn22-/- BMDCs (for simplicity). 
 
3.3.9 PTPN22 is dispensable for T cell proliferation after co-culture with LPS matured, 
OVA323-339 peptide pulsed BMDCs 
 
Before identifying whether PTPN22 was required for presentation of immune complex derived 
peptide to T cells, its potential role in the presentation of a non-internalised antigen was first 
investigated. LPS matured BMDCs are more efficient at causing T cell proliferation when 
presenting OVA323-339 peptide, than immature BMDCs242. This is due to the increased expression 
of MHCII on the surface of mature DCs, allowing for enhanced presentation of OVA323-339 
peptide. Therfore, I first wanted to determine whether PTPN22 was required for T cell 
proliferation by mature BMDCs presenting OVA323-339 peptide. WT and Ptpn22-/- BMDCs were LPS 
matured and pulsed with OVA323-339 peptide overnight, prior to co-culture with ova specific WT 
CD4+ OT-II T cells for 1-6 days (see Materials and Methods Figure 2-8 for experimental setup).  
Increasing concentrations of OVA323-339 peptide caused enhanced upregulation of CD25 and 
CD69 on T cells after 1 day of co-culture, but expression of these early activation markers was 
not dependent on the genotype of the BMDC (Figure 3-15a-b). In addition, interleukin-2 (IL-2) 
secretion was measured at day 1 and found to be similar between WT T cells co-cultured with 
WT or Ptpn22-/- BMDCs (Figure 3-15c). T cell proliferation after 6 days of co-culture, measured 
by CellTrace Violet (CTV) dilution was similar regardless of the BMDC genotype (Figure 3-15d-e), 
and secretion of interferon γ (IFNγ) was also found to be similar (Figure 3-15f). This indicates 
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that PTPN22 is not required for the presentation to T cells of OVA323-339 peptide by LPS matured 
BMDCs. Consistent with these data, I have previously observed no differences in MHCII 
expression on LPS matured WT or Ptpn22-/- BMDCs (Figure 3-16). 
 
Figure 3-15: PTPN22 is dispensable for T cell proliferation caused by LPS matured, OVA323-339 peptide pulsed BMDCs. 
(a-f) WT and Ptpn22-/- BMDCs were LPS matured and pulsed overnight in the presence of OVA323-339 peptide (or left 
unpulsed) prior to co-culture with CTV labelled WT CD4+ OT-II T cells for 6 days. (a-b) CD25 (a) and CD69 (b) cell surface 
expression (geometric mean fluorescence intensity, GMFI) on WT OT-II T cells after 1 day of co-culture with WT (white) 
or Ptpn22-/- (black) BMDCs (gated on CD3+, CD4+ live singlets). n = 2-3 + s.d. (c) At day 1 of co-culture, cell-free 
supernatants were assessed for IL-2 by immunoassay. n = 3 + s.d. (d-e) Proportions of WT OT-II T cells in each 
generation of cell division after 6 days of co-culture with 0.01 µM (d) and 1 µM (e) OVA323-339 peptide pulsed WT (white) 
or Ptpn22-/- (black) BMDCs (gated on CD3+, CD4+ live singlets). n = 2-3 + s.d. (f) At day 6 of co-culture, cell-free 
supernatants were assessed for IFNγ by immunoassay. n = 3 + s.d. Experiments were carried out with Dr Harriet Purvis 




Figure 3-16: PTPN22 does not regulate LPS induced maturation of BMDCs.  
WT and Ptpn22-/- BMDCs were stimulated in the presence or absence (unstim) of LPS. After 24 hours, BMDCs were 
harvested and surface stained for CD80, CD86 and MHCII. (a-c) WT (white) and Ptpn22-/- (black) BMDC cell surface 
expression (geometric mean fluorescence intensity, GMFI, gated on CD11c+ live singlets) of CD80 (a), CD86 (b) and 
MHCII (c). (d-f) WT (white) and Ptpn22-/- (black) BMDC cell surface expression (% positive, gated on CD11c+ live singlets) 
of CD80 (d), CD86 (e) and MHCII (f). n = 5 + s.d.  
To determine whether expression of the autoimmune associated variant of PTPN22 would affect 
BMDC presentation of OVA323-339 peptide to T cells, co-cultures were also carried out using 
Ptpn22R619 (WT) and Ptpn22R619W LPS matured BMDCs. IL-2 secretion after 1 day of co-culture 
and IFNγ secretion after 6 days of co-culture were similar between T cells co-cultured with WT 
and Ptpn22R619W LPS matured BMDCs (Figure 3-17a-b), indicating that expression of PTPN22R619W 







Figure 3-17: Expression of PTPN22R619W does not affect T cell cytokine secretion after co-culture with LPS matured, 
OVA323-339 peptide pulsed BMDCs.  
(a-b) Ptpn22R619 (WT) and Ptpn22R619W BMDCs were LPS matured and pulsed overnight in the presence of OVA323-339 
peptide (or left unpulsed) prior to co-culture with CTV labelled WT CD4+ OT-II T cells for 6 days. (a) At day 1 of co-
culture, cell-free supernatants from T cells co-cultured with Ptpn22R619 (WT, white) and Ptpn22R619W (black) BMDCs 
were assessed for IL-2 by immunoassay. n = 4 + s.d. (b) At day 6 of co-culture, cell-free supernatants from T cells co-
cultured with Ptpn22R619 (WT, white) and Ptpn22R619W (black) BMDCs were assessed for IFNγ by immunoassay. n = 4 + 
s.d.  
 
3.3.10 Immune complex pulsed Ptpn22-/- BMDCs cause enhanced T cell proliferation 
 
Once immune complexes have been internalised via FcγRs, they enter the endosomal processing 
pathway such that immune complex derived antigens can be presented to CD4+ T cells on MHCII. 
The cross-presentation pathway also allows for the presentation of antigens derived from 
exogenous material on MHCI to CD8+ T cells, but this process was not investigated here. To 
determine whether PTPN22 modulates the ability of BMDCs to present immune complex 
derived antigens and in turn activate CD4+ T cells, in vitro co-culture assays were performed. WT 
and Ptpn22-/- BMDCs were pulsed overnight with ova, ova pre-incubated with rabbit IgG (ova + 
rabbit IgG), ova added in combination with heat aggregated rabbit IgG (ova + HA IgG), or ova ICs 
and the following day were co-cultured with ova specific WT CD4+ OT-II T cells for 1-6 days (see 
Materials and Methods Figure 2-8 for experimental setup).  
At early stages of the co-culture, T cells co-cultured with ova IC pulsed BMDCs responded more 
robustly that those co-cultured with ova alone, as judged by an increase in CD25 and CD69 
expression, IL-2 and IFNγ secretion, and T cell proliferation (Figure 3-18a-e). On day 1 of culture, 
WT T cells that had been co-cultured with ova IC pulsed Ptpn22-/- BMDCs expressed higher levels 
of the early activation markers CD25 and CD69, and secreted enhanced levels of IL-2, in 
comparison to T cells co-cultured with ova IC pulsed WT BMDCs (Figure 3-18a-c). At day 3, T cell 
proliferation was measured by calculating the total number of T cells per co-culture well. 
Enhanced T cell proliferation was found after co-culture with ova IC pulsed Ptpn22-/- BMDCs 
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(Figure 3-18d), but this was not accompanied by changes in IFNγ cytokine secretion (Figure 3-
18e).  
 
Figure 3-18: Ova IC pulsed Ptpn22-/- BMDCs cause enhanced T cell activation and proliferation after 1-3 days of co-
culture.  
(a-e) WT and Ptpn22-/- BMDCs were pulsed overnight in the presence of ova, ova pre-incubated with rabbit IgG (ova + 
rabbit IgG), ova with heat aggregated IgG (ova + HA IgG), or ova IC prior to co-culture with CTV labelled WT CD4+ OT-
II T-cells for 1-3 days. (a-b) CD25 (a) and CD69 (b) cell surface expression (geometric mean fluorescence intensity, 
GMFI) on WT OT-II T cells after 1 day of co-culture with WT (white) or Ptpn22-/- (black) BMDCs (gated on CD3+, CD4+ 
live singlets). n = 4; ****p<0.001, ***p<0.005 using a 2-way ANOVA with Sidak’s multiple comparisons test. (c) At day 
1 of co-culture, cell-free supernatants were assessed for IL-2 by immunoassay. n = 4; ****p<0.001 using a 2-way 
ANOVA with Sidak’s multiple comparisons test. (d) The number of T cells per co-culture well was counted after 3 days 
of co-culture with WT (white) or Ptpn22-/- (black) BMDCs (gated on CD3+, CD4+ live singlets). n = 4 + s.d; ****p<0.001 
using a 2-way ANOVA with Sidak’s multiple comparisons test. (e) At day 3 of co-culture, cell-free supernatants were 
assessed for IFNγ by immunoassay. n = 4 + s.d. 
After 6 days, T cell proliferation was assessed by CTV dilution. It has been previously 
demonstrated that complexed antigen is more efficient at inducing T cell proliferation than 
antigen alone243. This was confirmed as T cells co-cultured with ova IC pulsed BMDCs proliferated 
more than those with ova pulsed BMDCs (Figure 3-19b-c). I next compared the ability of ova IC 
pulsed WT or Ptpn22-/- BMDCs to induce T cell proliferation. In agreement with the findings from 
days 1 and 3 of co-culture, ova IC pulsed Ptpn22-/- BMDCs induced enhanced T cell proliferation 
after 6 days, in comparison to WT BMDCs (Figure 3-19c). This was also accompanied by 




Figure 3-19: Ptpn22-/- BMDCs enhance immune complex induced T cell proliferation after 6 days of co-culture.  
(a-d) WT and Ptpn22-/- BMDCs were pulsed overnight in the presence of ova or ova IC (or left unpulsed, no ova) prior 
to co-culture with CTV labelled WT CD4+ OT-II T cells for 6 days. Proportions of WT OT-II T cells in each generation of 
cell division after 6 days of co-culture with unpulsed (a), ova (b) and ova IC (c) pulsed WT (white) or Ptpn22-/- (black) 
BMDCs (gated on CD3+, CD4+ live singlets). n=7-11 ± s.d.; **p<0.01, *p<0.05 using a Wilcoxon matched-pairs signed 
ranks test. (d) The number of cells per well were counted after 6 days of co-culture with ova IC pulsed WT (white) or 
Ptpn22-/- (black) BMDCs. n = 6; *p<0.05 using a paired t-test.  
As a control, unpulsed BMDCs were also co-cultured with ova specific T cells, and, as expected, 
these caused very little T cell proliferation or cytokine secretion (Figure 3-19a, 3-20a-c and 3-
21a-c). As additional controls, BMDCs were pulsed with ova pre-incubated with rabbit IgG, or 
ova added in combination with HA rabbit IgG. BMDCs pulsed with these antigen/antibody 
combinations did not induce T cell proliferation, upregulation of CD25 or CD69, or cytokine 
secretion, higher than those seen by ova pulsed BMDCs alone (Figure 3-18a-e). This indicates 
that it is the presence of an antibody:antigen immune complex which is causing enhanced T cell 
responses by Ptpn22-/- BMDCs, and that just the combined presence of an antibody and antigen 
is not sufficient.  
Although T cells co-cultured for 6 days with ova IC pulsed BMDCs secreted enhanced levels of 
IFNγ, TNFα and IL-17 in comparison to those induced by ova pulsed BMDCs (Figure 3-20a-c), 
expression or secretion of these cytokines was not dependent on the genotype of the BMDC 
(Figures 3-20a-c and 3-21a-c). Together, these data demonstrate that PTPN22 negatively 
regulates the ability of BMDCs to induce immune complex dependent T cell activation and 




Figure 3-20: PTPN22 is dispensable for T cell cytokine secretion after 6 days of co-culture with BMDCs.  
(a-c) WT and Ptpn22-/- BMDCs were pulsed overnight in the presence of ova or ova IC prior to co-culture with CTV 
labelled WT CD4+ OT-II T-cells for 6 days. At day 6 of co-culture, cell-free supernatants were assessed for IFNγ (a), TNFα 
(b) and IL-17 (c) by immunoassay. n = 3-9. Connecting lines indicate WT or Ptpn22-/- BMDCs co-cultured with the same 
WT OT-II T cells.  
 
Figure 3-21: PTPN22 is dispensable for T cell cytokine expression after 6 days of co-culture with BMDCs.  
(a-c) WT and Ptpn22-/- BMDCs were pulsed overnight in the presence of ova or ova IC prior to co-culture with CTV 
labelled WT CD4+ OT-II T-cells for 6 days. At day 6, T cells co-cultured with ova or ova IC pulsed WT (white) or Ptpn22-
/- (black) BMDCs were restimulated for 6 hours with PMA and ionomycin in the presence of monensin and intracellular 
expression of IFNγ (a), TNFα (b) and IL-17 (c) was determined (gated on CD3+, CD4+ live singlets). n = 4-9. Connecting 
lines indicate WT or Ptpn22-/- BMDCs co-cultured with the same WT OT-II T cells.  
To determine whether lacking PTPN22 expression in the T cell would cause an additive or 
synergistic effect to lacking PTPN22 expression in the BMDC, co-cultures were performed using 
ova IC pulsed Ptpn22-/- BMDCs and WT or Ptpn22-/- CD4+ OT-II T cells. The lack of PTPN22 in the 
T cell did not further enhance the rate of T cell proliferation (Figure 3-22), indicating that PTPN22 
plays an important role in BMDCs to regulate T cell proliferation, regardless of the genotype of 




Figure 3-22: Lacking PTPN22 expression in T cells does not affect T cell proliferation after co-culture with ova IC 
pulsed Ptpn22-/- BMDCs.  
Ptpn22-/- BMDCs were pulsed overnight in the presence of ova ICs prior to co-culture with CTV labelled WT (black) or 
Ptpn22-/- (dark grey) CD4+ OT-II T cells for 6 days. Data shows proportions of OT-II T cells in each generation of cell 
division (gated on CD3+, CD4+ live singlets). n = 6-10 ± s.d. 
 
3.3.11 PTPN22 is dispensable for immune complex induced T cell proliferation and 
cytokine secretion by LPS matured BMDCs 
 
During infection, or autoimmunity, it is unusual for immune cells to be exposed to immune 
complexes alone, as the co-cultures discussed above have modelled. Instead, it is more likely 
that immune cells will interact with both TLR and FcγR ligands. For example, endogenous ligands 
such as damage associated molecular patterns (DAMPs) and autoantibodies are often present 
simultaneously in rheumatoid arthritis patients. To investigate whether PTPN22 also played a 
role in the presentation of immune complex derived antigens by LPS matured BMDCs, co-
cultures were performed using ova and ova IC pulsed LPS matured WT and Ptpn22-/- BMDCs and 
WT CD4+ OT-II T cells. Although I have found that PTPN22 negatively regulates immune complex 
induced T cell proliferation (Figure 3-19c), in the presence of LPS, PTPN22 was no longer 
required. Both ova IC pulsed WT and Ptpn22-/- LPS matured BMDCs caused similar T cell 






Figure 3-23: LPS matured Ptpn22-/- BMDCs cause normal immune complex induced T cell proliferation.  
(a-c) WT and Ptpn22-/- BMDCs were LPS matured and pulsed overnight in the presence of ova or ova IC (or left 
unpulsed, no ova) prior to co-culture with CTV labelled WT CD4+ OT-II T cells for 6 days. Proportions of WT OT-II T cells 
in each generation of cell division after 6 days of co-culture with unpulsed (a), ova (b) and ova IC (c) pulsed WT (white) 
or Ptpn22-/- (black) BMDCs (gated on CD3+, CD4+ live singlets). n= 6-7 ± s.d. 
In addition, production and secretion of IFNγ, TNFα and IL-6 was similar between T cells co-
cultured with mature WT and Ptpn22-/- BMDCs (Figures 3-24a-c and 3-25a-c).  
 
Figure 3-24: PTPN22 is dispensable for T cell cytokine secretion after 6 days of co-culture with LPS matured BMDCs.  
(a-f) WT and Ptpn22-/- BMDCs were LPS matured and pulsed overnight in the presence of ova or ova IC prior to co-
culture with CTV labelled WT CD4+ OT-II T-cells for 6 days. At day 6 of co-culture, cell-free supernatants were assessed 
for IFNγ (a), TNFα (b) and IL-17 (c) by immunoassay. n = 4-7. Connecting lines indicate WT or Ptpn22-/- BMDCs co-








Figure 3-25: PTPN22 is dispensable for T cell cytokine expression after 6 days of co-culture with LPS matured BMDCs.  
(a-c) WT and Ptpn22-/- BMDCs were LPS matured and pulsed overnight in the presence of ova or ova IC prior to co-
culture with CTV labelled WT CD4+ OT-II T-cells for 6 days. At day 6, T cells co-cultured with ova or ova IC pulsed LPS 
matured WT (white) or Ptpn22-/- (black) BMDCs were restimulated for 6 hours with PMA and ionomycin in the presence 
of monensin and intracellular expression of IFNγ (d), TNFα (e) and IL-17 (f) was determined (gated on CD3+, CD4+ live 
singlets). n = 4-6. Connecting lines indicate WT or Ptpn22-/- BMDCs co-cultured with the same WT OT-II T cells.  
 
3.3.12 PTPN22 is dispensable for immune complex induced T cell proliferation in vivo 
 
I next wanted to determine whether PTPN22 was required for antigen presenting cell (APC) 
mediated T cell proliferation in vivo.  For this, I took two approaches, firstly, CTV labelled WT 
CD4+ CD45.1+ OT-II T cells were adoptively transferred into WT or Ptpn22-/- CD45.2+ recipient 
mice and the following day mice were injected with ova or ova ICs into their right footpad. Three 
days later, the draining (right) and non-draining (left) popliteal lymph nodes were extracted and 
proliferation of the transferred T cells was assessed (see Materials and Methods Figure 2-11 for 
experimental setup). Only low numbers of transferred T cells were found in the non-draining 
lymph nodes, as expected (Figure 3-26b). More transferred T cells were found in the draining 
LNs, and ova IC immunisation enhanced T cell proliferation in comparison with ova alone (Figure 
3-26c), consistent with my in vitro experiments. Despite this, proliferation of the transferred WT 
OT-II T cells was similar in WT and Ptpn22-/- mice (Figure 3-26b-c). This indicates that PTPN22 is 




Figure 3-26: PTPN22 is dispensable for immune complex induced antigen presentation and T cell proliferation in 
vivo.  
(a-c) CTV labelled WT CD4+ OT-II CD45.1+ T cells were transferred (i.v.) into WT and Ptpn22-/- CD45.2+ recipient mice. 
The following day, ova or ova IC were injected (s.c.) into the right footpad. 3 days later, T cell proliferation was 
measured in the draining (right, dLN) and non-draining, control (left, cLN) popliteal lymph nodes. (a) Representative 
flow cytometry plots showing gating to identify transferred WT CD4+ TCR Vα2+ CD45.1+ T cells in the dLNs of CD45.2+ 
recipient mice. (b-c) Total number of transferred WT CD4+ TCR Vα2+ CD45.1+ T cells in the non-draining (b) and draining 
(c) lymph nodes of WT (white) and Ptpn22-/- (black) CD45.2+ recipient mice (gated on CD4+, TCR Vα2+, CD45.1+ live 
singlets). n = 6-9 (ova) and 15-17 (ova IC) recipient mice.  
Secondly, to try to ascertain whether PTPN22 may regulate BMDC ova IC induced T cell 
proliferation in a more in vivo setting, WT and Ptpn22-/- BMDCs were pulsed with ova ICs in vitro 
and then transferred into the right footpad of WT OT-II recipient mice (see Materials and 
Methods Figure 2-12 for experimental setup). As the responding T cells were endogenous in the 
recipient mice, CTV could not be used to track T cell proliferation. Instead, the total number of 
OT-II T cells were calculated in the draining (right) and non-draining (left) popliteal lymph nodes 
6 days after BMDC transfer. Only a low number of T cells were present in the non-draining lymph 
node compared to the draining LN (Figure 3-27). Similar numbers of T cells were present in the 
draining LNs of mice that received WT and Ptpn22-/- ova IC pulsed BMDCs (Figure 3-27), 




Figure 3-27: PTPN22 is dispensable for ova IC pulsed BMDC induced T cell proliferation in vivo.  
WT (white) and Ptpn22-/- (black) BMDCs were stimulated in the presence of ova ICs. The following day, BMDCs were 
injected (s.c.) into the right footpad of WT OT-II recipient mice. 6 days later, T cell proliferation was measured in the 
draining (dLN) and non-draining, control (cLN) popliteal lymph nodes. Data shows the total number of transferred WT 
CD4+ OT-II T cells in the lymph nodes (gated on CD4+, TCR Vα2+, TCR Vα2+ live singlets). n = 3-4 recipient mice. 
 
3.3.13 PTPN22 is dispensable for in vivo migration of migratory DCs  
 
Not only do DCs need to be able to recognise, internalise, process and present antigens in order 
to cause T cell activation, they must also be capable of migrating from peripheral tissues to 
lymph nodes, so that they can interact with T cells244. Therefore, the role of PTPN22 in DC 
migration was assessed. FITC in 1:1 acetone:dibutyl phthalate (irritant) was added to the dorsal 
side of the left ears of WT and Ptpn22-/- mice (irritant alone was added as a negative control to 
the right ears). 24 hours later, the proportion of FITC+ migratory and resident DCs in the draining 
auricular lymph nodes was assessed (see Materials and Methods Figure 2-10 for experimental 
setup). Similar proportions of FITC+ migratory DCs were found in the draining lymph nodes of 
both WT and Ptpn22-/- mice (Figure 3-28b). This indicates that PTPN22 is dispensable for DC 




Figure 3-28: PTPN22 is not required for in vivo migration of skin resident DCs to the draining lymph nodes.  
(a-b) FITC in 1:1 acetone:dibutyl phthalate (FITC in irritant) was added to the dorsal side of the left ears of WT and 
Ptpn22-/- mice. Irritant alone (as a negative control) was added to the dorsal side of the left ears of WT and Ptpn22-/- 
mice. After 24 hours, auricular draining lymph nodes were harvested, digested and stained to identify resident and 
migratory DCs. (a) Representative flow cytometry plots showing FITC expression in resident (white) and migratory 
(grey) DCs in the draining LNs of a mouse receiving FITC in irritant (top) or irritant alone (bottom). (b) Combined data 
showing FITC uptake in resident (gated on CD11chi, MHCII+ live singlets) and migratory DCs (gated on CD11c+, MHCIIhi 
live singlets) in WT (white) and Ptpn22-/- (black) mice, after receiving FITC in irritant (circle) or irritant alone (triangle). 
n = 10-12 recipient mice. 
 
3.4 Overall findings 
 
The main findings of this Chapter were: 
1. PTPN22 is dispensable for BMDC differentiation in vitro. 
2. Ptpn22-/- BMDCs express reduced cell surface FcγRIIb. 
3. PTPN22 is dispensable for immune complex induced upregulation of co-stimulatory 
molecules and cytokine secretion. 
4. PTPN22 negatively regulates immune complexed induced T cell proliferation in vitro. 
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This data has been published in: 
1. Clarke F, Purvis HA, Sanchez-Blanco C, Gutiérrez-Martinez E, Cornish GH, Zamoyska R, 
Guermonprez P, Cope AP. The protein tyrosine phosphatase PTPN22 negatively 





The aim of this Chapter was to investigate whether PTPN22 was regulating DC effector functions 
after FcγR engagement. Src and Syk family kinases are downstream of FcγRs and have been 
shown to be dephosphorylated after ligand engagement with other immunoreceptors. In 
addition, autoantibodies are present in most of the PTPN22R620W associated autoimmune 
diseases. Together, these suggested a potential role of PTPN22 in regulating cellular processes 
after FcγR crosslinking.  
The data presented in this Chapter demonstrate that PTPN22 is dispensable for immune 
complex induced BMDC effector functions, including upregulation of co-stimulatory molecules 
and cytokine secretion. This finding is somewhat surprising, as Syk, a target of PTPN22, has 
previously been shown to be required for upregulation of CD40 and CD86 on BMDCs after FcγR 
crosslinking245. In addition, my data contrasts with the role identified for PTPN22 in regulating 
FcγR signalling in mouse neutrophils. In this cell type, PTPN22 is required for immune complex 
induced effector responses including ROS production, adhesion and degranulation63. This 
difference may reflect cell specific roles for PTPN22, or it may be due to different immune 
complex stimulations being used. I did however find that PTPN22 negatively regulates immune 
complex induced T cell proliferation. 
 
3.5.1 Using GM-CSF induced BMDCs as an in vitro model of DCs 
 
Most of the data presented in this Chapter was generated using GM-CSF induced BMDCs. These 
cultures have the major advantage of being able to produce millions of cells from the bones of 
a single mouse. They also provide a simple model to investigate DC function in vitro. However, 
they do not directly model an in vivo DC population, meaning that extrapolation from BMDC 
cultures to the situation in vivo should be undertaken with caution. As shown in the phenotyping 
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in Figure 3-1, the GM-CSF bone marrow cultures are comprised of both conventional DCs and 
monocyte-derived macrophages (referred to as GM-DCs and GM-macs respectively). An 
alternative cell culture protocol is the differentiation of bone marrow progenitors using Flt3 
ligand (Flt3L)246. These cultures more closely mirror in vivo DC populations as they differentiate 
into the 3 main DC subsets: pDCs, cDC1s and cDC2s. Alternatively, in the future, it would be 
interesting to see the response of in vivo DC populations to immune complex stimulation. This 
could be achieved by injecting WT and Ptpn22-/- mice with immune complexes and measuring 
upregulation of MHCII and co-stimulatory molecules on the DCs present in the draining lymph 
nodes.  
Despite the caveats associated with the use of GM-CSF induced BMDCs, I did nevertheless find 
that PTPN22 did not affect their differentiation into CD11c+ cells, or when they were further 
classified as GM-DCs and GM-macs. In the future, it would be worthwhile sorting the GM-DCs 
and GM-macs from WT and Ptpn22-/- cultures to see if they responded differently to immune 
complex stimulation. It is possible that the requirement for PTPN22 to negatively regulate 
immune complex induced T cell proliferation may be due to its role in more DC or macrophage 
like cells. Despite there being a shift in the balance of GM-DCs and GM-macs between WT v 
Ptpn22-/- and WT v Ptpn22R619W cultures, the composition of the cultures were always similar 
when comparing cultures produced side-by-side. 
 
3.5.2 FcγR expression  
 
Ptpn22-/- BMDCs do show a different balance in their cell surface expression of activating and 
inhibitory FcγRs compared to WT BMDCs. As the expression of Fcgr1, Fcgr2b and Fcgr3 were 
found to be similar between WT and Ptpn22-/- BMDCs, this indicates that PTPN22 may be 
regulating FcγRs post-transcriptionally. This may include regulating trafficking of FcγRs to the 
cell surface, their retention there, or rates of receptor internalisation. Intracellular expression of 
FcγRs and their transport was not investigated, so it is not possible to determine exactly why 
Ptpn22-/- BMDCs express a lower level of the inhibitory receptor, FcγRIIb on their cell surface. 
Reduced expression of the inhibitory receptor may alter the activating/inhibitory (A/I) ratio, 
which could lead to an overall increase in positive signalling downstream of FcγRs in Ptpn22-/- 
BMDCs, and this could partly be responsible for the enhanced immune complex induced T cell 
proliferation that I have observed. However, as the difference in FcγRIIb expression is subtle, 
and only observed at the level of expression and not percent positivity, it is unlikely that this is 
the only mechanism. In addition, if PTPN22 is regulating the expression of FcγRIIb, this only 
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appears to occur in differentiated DCs, as FcγRIIb expression was found to be similar on the cell 
surface of bone marrow preDCs and CDPs. Other phosphatases have been shown to regulate 
the cell surface expression of receptors. For example, the non-receptor tyrosine phosphatase 
PTP-MEG2 is required for the transport of the neurotrophin receptor tropomyosin receptor 
kinase A (TrkA) to the cell surface of neurons247. PTP-MEG2 contains a Sec14 domain in its N-
terminal which targets it to secretory vesicles248, PTP-MEG2 can then dephosphorylate N-
ethylmaleimide-sensitive fusion factor which causes vesicle fusion and transport to the plasma 
membrane. PTPN22 does not contain a Sec14 domain, so it may not be capable of regulating 
expression of FcγRIIb via this mechanism.  
 
3.5.3 FcγR signalling and effector responses 
 
Some of the responses I detected after immune complex stimulation, including the upregulation 
of co-stimulatory molecules, ROS production and calcium flux, were subtle. This may have been 
because the ova ICs bind to all FcγRs present on the cells, so these will crosslink both the 
activating and inhibitory receptors. As a result, the inhibitory receptor FcγRIIb may dampen 
down the response through the activating receptors. To circumvent this issue, it would have 
been interesting to repeat these assays in the presence of a FcγRIIb blocking antibody, such that 
only signalling downstream of the activating receptors would be measured.  
Due to the unavailability of reagents, I had to use an ova antibody to make the ova ICs which 
was not guaranteed to be endotoxin free. For this reason, I also included polymyxin B in the 
stimulations to try to reduce the potential endotoxin contamination. This allowed me to be more 
confident that I was looking at FcγR signalling, and not a combination of responses downstream 
of FcγRs and TLR4. Although I did not directly test the level of endotoxin in the anti-ova, when 
the anti-ova was given to the cells with polymyxin B, the resulting BMDC maturation and 
cytokine secretion was similar to unstimulated conditions, indicating that the majority of the 
results seen with the ova ICs were due to FcγR dependent responses, as opposed to any 
potential endotoxin contamination. Also, PTPN22 was found to be dispensable for immune 
complex induced T cell proliferation when the BMDCs were LPS matured, whereas it was 
required to modulate T cell proliferation in the absence of LPS. This indicates that LPS is not 
contributing greatly to the results seen in the assays using ova ICs alone. 
For analysing BMDC immune complex induced calcium flux, I was not able to get consistent 
results. In addition to using ova ICs added in suspension as the stimulation, I also tried heat 
aggregated rabbit IgG (which should efficiently crosslink FcγRs) and a commercial BSA:anti-BSA 
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IC (OxyBURST), but I was still unsuccessful in measuring robust immune complex induced 
calcium flux. The role of PTPN22 in neutrophil ROS production after FcγR engagement was 
investigated in a recent paper. They found that Ptpn22-/- bone marrow neutrophils showed 
lower calcium flux in response to immobilised BSA:anti-BSA immune complexes63. I did not try 
to use immobilised immune complexes, but it would be interesting to see if I could observe 
robust BMDC calcium flux using this protocol. 
If time had permitted, it would have been worthwhile to look at signalling after FcγR 
engagement in the presence or absence of PTPN22. This could be achieved by using immune 
complexes or antibodies to crosslink FcγRs and then monitoring the phosphorylation status of 
signalling intermediates including Src, Syk and ERK by western blotting. I would hypothesise that 
in the absence of PTPN22, you would see enhanced phosphorylation of signalling intermediates 
after FcγR engagement. 
 
3.5.4 The role of PTPN22 in DCs on T cell proliferation 
 
I did not find a role for PTPN22 in inducing T cell proliferation after BMDC ova or OVA323-339 
peptide pulsing. It has been shown previously that CD11b+ splenic macrophages expressing 
Ptpn22R619W and pulsed with ova, are more efficient at causing T cell activation and 
proliferation67. This was attributed to enhanced macrophage expression of MHCII, CD80 and 
CD86, and an enhanced phagocytic capacity after LPS treatment. This is in contrast to my data 
using Ptpn22-/- BMDCs. In addition, I have not observed any differences in cell surface expression 
of MHCII and co-stimulatory molecules on WT and Ptpn22-/- BMDCs in response to LPS (Figure 
3-16). These differences may be due to PTPN22 playing a different role in macrophages and DCs, 
and/or it may be that lacking the gene has no affect whereas expression of the autoimmune 
associated variant of PTPN22 is important. For example, B cell receptor signalling is unaffected 
in Ptpn22-/- mice, but is enhanced in Ptpn22R619W mice13.  
Despite finding that PTPN22 is dispensable for immune complex induced BMDC maturation, and 
in inducing T cell proliferation after ova and OVA323-339 pulsing, I did find that PTPN22 negatively 
regulates processes leading to immune complex induced T cell activation. It was somewhat 
surprising that the lack of BMDC PTPN22 expression affected T cell proliferation and CD25 and 
CD69 expression, but that it had no effect on cytokine secretion after 6 days of co-culture. It has 
however been shown that T cell proliferation and cytokine secretion can be uncoupled. For 
example, the TCR-CD3 complex contains ten ITAMs, and phosphorylation of the tyrosine 
residues in the CD3 ITAMs leads to the recruitment of ZAP-70. In turn, this aids the 
137 
 
phosphorylation of SLP-76 and Lat, allowing for further downstream signalling involving Vav1 
(for cytoskeletal rearrangement), Erk and the translocation of transcription factors such as NFAT 
to the nucleus. Although lots of these signalling events are required for cytokine production, the 
exact signals required for T cell proliferation are less well understood. It has however been 
shown that the number of ITAMs present in the TCR-CD3 complex directly correlates with T cell 
proliferation, but that this is not the case for cytokine production249. This indicates that 
depending on the signal strength received by the T cell from the APC, T cell proliferation and 
cytokine secretion could be differentially affected. In addition, it has been shown that T cells in 
vivo which are in the G1 phase of the cell cycle (i.e. not actively cycling) are still capable of 
producing IFNγ, showing that proliferation and cytokine secretion are not always linked250. 
Finally, it has been demonstrated using LPS stimulated human DCs that inhibition of the kinases 
c-Src and Lyn (using the small molecular inhibitor PP1) leaves the cells less capable of inducing 
T cell IFNγ secretion, while still being able to cause T cell proliferation. This was shown to be due 
to a role of Src family kinases in stabilising the transcription factor c-Jun, which is needed for the 
transcription of cytokine genes251. 
Although PTPN22 has been previously shown to play an important regulatory role downstream 
of the TCR in T cells, by dephosphorylating kinases including Lck and ZAP-70, I found that lacking 
expression of PTPN22 in the OT-II T cells used in the co-cultures did not further effect their ova 
IC induced proliferation. I had hypothesised that Ptpn22-/- T cells would show enhanced 
proliferation after presentation of immune complexed derived peptides by Ptpn22-/- BMDCs, as 
compared to WT T cells, but this is not what I have found. This indicates that in relation to 
immune complex induced T cell proliferation, PTPN22 may be playing a more important role in 
the BMDC compared to the T cell.  
When immune complex induced T cell proliferation assays were conducted in vivo, I found that 
PTPN22 expression in BMDCs or endogenous APCs was not required to modulate T cell 
proliferation. There are many reasons why the results from the in vitro co-cultures were not 
corroborated in vivo. These include the fact that the in vitro co-cultures are a reductionist 
approach where only BMDCs and ova specific T cells are present. The situation in vivo is a lot 
more complex, with multiple cell types being capable of presenting antigen to the responding T 
cells. If PTPN22 is not required for antigen processing and presentation in certain cell types, then 
this may compensate for a potential role of PTPN22 in a different cell type in vivo. Another 
difference between the in vitro co-cultures and the in vivo situation is that GM-CSF induced 
BMDCs do not represent an in vivo DC population, and as PTPN22 has been shown to play 
different roles in different immune cell subsets, this discrepancy may be explained by the fact 
that PTPN22 may function differently in GM-CSF induced BMDCs compared to in vivo DC 
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populations. In addition, the results from the FITC painting experiment indicated that PTPN22 
was not required for migration of APCs from the footpad to the draining popliteal LN. This may 
go some way towards explaining why transferred T cells proliferated normally in vivo in WT and 
Ptpn22-/- mice after immunisation with ova ICs, as the APCs would have been capable of 
internalising the immune complexes, and migrating to the draining LNs, in order to come into 
contact with the ova specific T cells. 
 
3.5.5 Crosstalk between FcγR and TLR4 signalling  
 
The difference in the requirement for PTPN22 to regulate T cell proliferation in the absence or 
presence of LPS may be due to a variety of factors. The strength of signalling downstream of 
TLR4 engagement may be more than downstream of FcγR engagement, therefore the presence 
of LPS may mask the role that PTPN22 is playing in regulating FcγR signalling. Signal strength 
would be affected by the proportion of TLR4 and FcγRs which are bound by their ligands, and 
also on the affinity of the receptors for their ligands.  It has been demonstrated that TLR4 is 
involved in FcγRIII signalling. This indicates that these receptor signalling pathways are 
connected. Lysates from immune complex stimulated neutrophils and macrophages were 
immunoprecipitated with anti-TLR4 and by immunoblotting, FcγRIII was found to be associated. 
This association was not detected after LPS stimulation alone, but was enhanced by combined 
LPS and immune complex stimulation. In addition, IL-6 and TNFα secretion after immune 
complex stimulation was diminished from neutrophils and macrophages from TLR4 mutant mice 
(which have a missense mutation in Tlr4). This was accompanied by reduced tyrosine 
phosphorylation of FcRγ in TLR4 mutant cells. However, neutrophils and macrophages from 
FcγRIII-/- mice were equally capable as WT cells to secrete cytokines in response to LPS 
treatment. This indicates that a functional TLR4 is required for phagocytes to respond to immune 
complex stimulation, but that FcγRIII is not required for TLR4 signalling252. In addition, BMDCs 
treated with LPS for 48 hours have been shown to have a reduced ability to subsequently cause 
immune complex induced CD8+ T cell proliferation, whereas 18 hours of LPS pre-treatment 
enhanced immune complex induced CD8+ T cell proliferation253. This demonstrates that FcγR 





3.5.6 PTPN22 potential redundancy with other phosphatases 
 
A potential reason why some of the data presented in this Chapter show that PTPN22 is not 
required, may be due to the presence of other phosphatases with functional redundancy. For 
example, PTPN12 is a protein tyrosine phosphatase which belongs to the same family as 
PTPN22254. As I have found for PTPN22, PTPN12 is also dispensable for ova induced T cell 
proliferation, but it is required for the induction of optimal IFNγ secretion by T cells232. This may 
explain why there was no difference in IFNγ secretion by T cells co-cultured with Ptpn22-/- 
BMDCs compared to WT BMDCs, as both will express PTPN12. The Src homology region 2 
domain-containing phosphatase-1 (SHP-1, also known as PTPN6) is also expressed in DCs and 
has been shown to regulate T cell proliferation after DC ova pulsing. Splenic CD11c+ DCs lacking 
SHP-1 expressed higher levels of CD86 and CCR7 (but not MHCII, CD40 or CD80) ex vivo. These 
SHP-1 deficient DCs also secreted enhanced TNFα, IL-6, IL-1β, IL-10 and IFNβ at steady state, but 
also after 24 hours of LPS treatment. Overtime, these mice lacking expression of SHP-1 in DCs, 
showed an expansion of activated (CD62Llo CD44hi) CD4+ and CD8+ T cells in the spleen, which 
was accompanied by an increased ability of SHP-1 deficient DCs to induce OT-II T cell 
proliferation after ova pulsing in vitro255.  
The SH2-containing inositol 5’-phosphatase 1 (SHIP-1) has been shown to negatively regulate 
signalling downstream of the Fc receptor for IgE, FcεR1, such that SHIP-1 deficient mast cells 
require less stimulation to degranulate, flux calcium and phosphorylate ERK256. The SH2-
containing inositol 5’-phosphatase 2 (SHIP-2) has also been found to regulate signalling 
downstream of FcγRs. Over expression of SHIP-2 in the human monocyte THP-1 cell line 
prevented Nfkb mediated gene transcription and activation of the serine/threonine kinase Akt 
(also known as protein kinase B) after FcγRIIa clustering257. 
An additional protein tyrosine phosphatase which is expressed in DCs is CD45. The role of CD45 
in FcγR induced effector functions has been investigated in neutrophils. Crosslinking CD45 
caused a reduction in FcγR induced calcium flux by human neutrophils258. A later study found 
that the addition of anti-CD45 to human neutrophils on which FcγRs had been crosslinked, led 
to a reduction in antibody-dependent cell-mediated cytotoxicity (ADCC), indicating that CD45 
negatively regulates this neutrophil effector function after FcγR signalling. Crosslinking CD45 
also led to an overall reduction in protein tyrosine phosphorylation and F-actin polymerisation 
after FcγR stimulation259.   
The inositol 3-phosphatase, phosphatase and tensin homologue (PTEN) has been shown to 
regulate FcγR signalling in mouse macrophages. In the absence of PTEN, mouse peritoneal 
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macrophages display enhanced Akt and ERK phosphorylation after FcγR signalling. Additionally, 
FcγR induced cytokine secretion, including TNFα, IL-6 and IL-10 was enhanced in the absence of 
PTEN expression260. 
As Ptpn22-/- BMDCs would express SHP-1, SHIP-1, SHIP-2, CD45 and PTEN, this indicates that 
other phosphatases may be compensating for the lack of PTPN22, and could partially explain 
why PTPN22 was not required for some of the immune complex induced effector functions 
which were investigated in this Chapter.  
 
3.5.7 Differences between Ptpn22-/- and Ptpn22R619W BMDCs 
 
The data presented in this Chapter indicates that expression of the autoimmune associated 
variant of PTPN22 does not affect the ability of BMDCs to differentiate, express FcγRs, or to 
upregulate co-stimulatory molecules, secrete cytokines or induce T cell proliferation in response 
to immune complex stimulation. Therefore, the variant is not working as a gain- or loss-of-
function variant in these instances. The immune cell phenotypes in Ptpn22-/- and Ptpn22R619W 
mice do not always match, for example, Ptpn22-/- mice show an expansion of Tregs with age57,58, 
but this is not found in Ptpn22R619W mice13. 
141 
 
4. Results: Investigating the role of PTPN22 in antigen uptake, processing 




DCs are professional antigen presenting cells, sampling their surroundings and scanning for 
antigens. They are able to initiate an immune response, or cause tolerance, by internalising, 
processing and presenting antigens to T cells on MHCI and MHCII. If the antigens are recognised 
in the context of an inflammatory signal, then the DC begins a process known as maturation261. 
This includes upregulating cell surface expression of MHCII and co-stimulatory molecules, 
acidification of lysosomal compartments, a reduction in macropinocytosis, and migration to 
draining lymph nodes – all of which aid in the initiation of an effective adaptive immune 
response. Although mature DCs downregulate their macropinocytotic capacity, they are still 
capable of receptor mediated endocytosis242.  
In Chapter 3, I demonstrated that Ptpn22-/- BMDCs pulsed with ova IC are more efficient at 
inducing ova specific T cell proliferation. In this Chapter, the potential mechanism(s) behind this 
were explored in more detail. The ability of WT and Ptpn22-/- BMDCs to bind, internalise, process 
and present a variety of antigens, including immune complexes was investigated. Regulation of 
any of these processes by PTPN22 would provide a mechanism by which ova IC pulsed Ptpn22-/- 




This Chapter aimed to determine specifically whether PTPN22 is required for: 
1. BMDC antigen binding and uptake. 
2. BMDC antigen processing. 







4.3.1 PTPN22 is dispensable for Lucifer yellow macropinocytosis  
 
Before studying immune complex uptake via FcyRs, I explored pathways of BMDC antigen 
uptake via macropinocytosis and receptor mediated endocytosis, starting with 
macropinocytosis. BMDCs utilise macropinocytosis to constitutively and non-selectively engulf 
particles. These include nutrients, soluble molecules and circulating antigens from their 
surrounding environment262,263. The process requires the actin cytoskeleton for the production 
of lamellipodia. These extend and retract from the plasma membrane and a proportion fold back 
and fuse with the membrane, thus forming a vesicle called a macropinosome which engulfs 
particles from the environment. Macropinocytosis does not require the expression of specific 
cell surface receptors and is also independent of clathrin264. Once particles are internalised via 
macropinocytosis, they can be presented on MHCI and MHCII molecules103,105,263. I chose as a 
model for studying this process Lucifer yellow (LY) because it is a water-soluble dye which can 
also function as a fluid phase marker for macropinocytosis, where uptake can be easily 
measured by flow cytometry.  
The requirement for Src and Syk family kinases for macropinocytosis was first determined. WT 
BMDCs were pre-incubated with Src and Syk family kinase inhibitors before being incubated 
with LY for 0-30 minutes at 37°C. Inhibition of Src and Syk kinases had no effect on LY uptake by 
WT BMDCs, indicating that these kinases are not involved in the process (Figure 4-1a). Next, to 
determine whether PTPN22 was required for macropinocytosis, WT and Ptpn22-/- BMDCs were 
incubated with LY for 0-30 minutes at 37°C (see Materials and Methods Figure 2-13 for 
experimental setup). Over time, the LY geometric mean fluorescent intensity (GMFI) signal 
increased, as expected (Figure 4-1b). However, LY internalisation was similar between WT and 
Ptpn22-/- BMDCs (Figure 4-1b).  
Following Toll-like receptor (TLR) induced BMDC maturation, the rate of macropinocytosis is 
decreased103,242,262, although there is a transient increase in macropinocytosis within 30-45 
minutes of TLR stimulation, due to enhanced membrane ruffling. This allows for a temporary 
enhancement in antigen capture and presentation in the presence of an inflammatory signal265. 
Given that PTPN22 regulates signals transduced by pattern recognition receptors, notably 
dectin-1, I tested whether Ptpn22-/- BMDCs were equally capable of downregulating LY uptake 
after TLR stimulation. WT and Ptpn22-/- BMDCs were matured overnight using LPS. As expected, 
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LPS treatment reduced LY uptake, in comparison to immature BMDCs (Figure 4-1c), which is in 
agreement with previously published data103. However, WT and Ptpn22-/- BMDCs displayed a 
similar capacity to reduce LY internalisation after LPS treatment (Figure 4-1c-d).  
Finally, expression of the autoimmune associated variant of PTPN22 was tested to see if it 
affected macropinocytosis of LY by BMDCs. Both Ptpn22R619 (WT) and Ptpn22R619W BMDCs 
internalised LY to a similar extent over 30 minutes at 37°C (Figure 4-1e). In keeping with the 
findings from the Src and Syk inhibitor experiment (Figure 4-1a), these data confirmed that 
PTPN22 is not required for BMDC macropinocytosis. 
 
Figure 4-1: PTPN22 is dispensable for macropinocytosis of Lucifer yellow.  
(a) WT BMDC Lucifer yellow (LY) uptake after pre-treatment with DMSO (vehicle control, white), Src inhibitor (dark 
grey) or Syk inhibitor (grey); n = 3 ± s.d. (b) LY uptake by WT (white) and Ptpn22-/- (black) immature BMDCs. Data 
shown are geometric mean fluorescence intensity (GMFI) relative to maximal WT uptake at 30 minutes; n = 4 ± s.d. (c) 
LY uptake by immature (-LPS) or LPS matured (+LPS) WT (white) and Ptpn22-/- (black) BMDCs, showing representative 
LY GMFI of 3 independent experiments. (d) LY uptake by LPS matured WT (white) and Ptpn22-/- (black) BMDCs, showing 
GMFI relative to maximal WT uptake at 30 minutes; n = 3 ± s.d. (e) LY uptake by WT (white) and Ptpn22R619W (black) 
immature BMDCs. Data shown are GMFI relative to maximal WT uptake at 30 minutes; n = 3 ± s.d. All data is gated 
on CD11c+ live singlets. 
 
4.3.2 PTPN22 does not regulate antigen uptake via TLR2 or dectin-1 
 
After determining that PTPN22 is dispensable for non-selective antigen uptake via 
macropinocytosis, I next investigated whether PTPN22 was required for receptor mediated 
endocytosis of specific antigens. DCs use a vast array of pattern recognition receptors (PRRs) to 
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recognise pattern associated molecular patterns (PAMPs) within microbial and mammalian 
antigens266. PRRs include TLRs, C-type lectin receptors (CLRs), nucleotide oligomerisation 
domain (NOD)-like receptors (NLRs) and retinoic acid inducible gene-I (RIG-I) like receptors 
(RLRs). Two PRR ligands were used to investigate whether PTPN22 may regulate receptor 
mediated endocytosis: Listeria monocytogenes, which is phagocytosed via TLR2 and Candida 
albicans, which is internalised by the CLR dectin-1.  
The requirement for Src family kinases in TLR2 mediated endocytosis has been previously 
investigated. Src was found to be required for efficient internalisation of Listeria monocytogenes 
by the human epithelial Caco-2 cell line267. This paper also reported that Src family kinase 
inhibition using PP1 subtly reduced entry of Listeria monocytogenes into HEK293 cells. After 
ligand binding to TLR2, the tyrosine kinases Btk and Fyn (a Src family kinase) have been shown 
to phosphorylate tyrosine residues Y616 and Y761 within the TLR2 Toll/interleukin-1 receptor 
(TIR) domain. Phosphorylation of these residues is required for the recruitment of PI3K and Rac-
1, and for NFκB activation268, identifying a role of tyrosine phosphorylation in TLR2 signalling. 
The role of Syk in receptor mediated endocytosis via TLR2, on the other hand, has not been 
investigated. However, Syk has been shown to partially mediate LPS-dependent endocytosis of 
TLR4 and to play a role in downstream signalling in mouse BMDMs269. This was also shown in a 
more recent paper, where Syk inhibition led to a reduction in TLR4 endocytosis of E. coli by 
mouse BMDCs270.  
The requirement for Src and Syk family kinases in dectin-1 dependent phagocytosis appears to 
vary depending on the species and cell type under investigation. This is despite the fact that Src 
family kinases are responsible for the phosphorylation of the tyrosine within the hemi-ITAM 
motif in the cytoplasmic tail of dectin-1, which then recruits Syk, ultimately leading to 
downstream signalling. Syk has been found to be dispensable for dectin-1 dependent 
phagocytosis of fluorescent zymosan particles by RAW 264.7 macrophages, using the Syk 
inhibitor piceatannol, and by using Syk-/- mouse bone marrow macrophages271. A separate paper 
used piceatannol to inhibit Syk and showed a 50% reduction in zymosan uptake by RAW 264.7 
macrophages272. The authors also inhibited Src family kinases using PP2 and showed a dramatic 
reduction in zymosan uptake by RAW 264.7 macrophages272. A more recent study found that 
Syk, but not Src was required for phagocytosis of fluorescent zymosan by primary human 
monocytes, using small molecule inhibitors273. In a separate report using WT and Syk-/- mouse 
BMDCs, Syk was again found to be required for internalisation of fluorescent zymosan274.  
As a role of Src and Syk family kinases in TLR2 mediated endocytosis has not been proven 
definitively, I first wanted to determine whether they were required for BMDC TLR2-mediated 
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ligand internalisation. A heat killed preparation of Listeria monocytogenes (HKLM) was stained 
with a fluorescent viability dye, in which all HKLM would be stained, and incubated with WT 
BMDCs, after pre-treatment with Src and Syk family inhibitors. The proportion of internalised 
HKLM increased with increasing time at 37°C, but the pre-treatment with either inhibitor had 
no effect, indicating that these kinases are not required for HKLM uptake by BMDCs (Figure 4-
2a).  
 
Figure 4-2: PTPN22 is dispensable for heat killed Listeria monocytogenes (HKLM) uptake.  
(a) WT BMDCs were pre-treated with DMSO (vehicle control, white), Src inhibitor (dark grey) or Syk inhibitor (grey), 
before being incubated with HKLM (1 DC:30 HKLM) for 0-60 minutes at 37°C. Data shows HKLM uptake (gated on 
CD11c+ singlets). n = 5 ± s.d. (b) WT (white) and Ptpn22-/- (black) BMDCs were incubated with HKLM (1 DC:30 HKLM) 
for 0-60 minutes at 37°C. Data shows HKLM uptake (gated on CD11c+ singlets). n = 4 ± s.d.  
To identify a role of PTPN22 in endocytosis via TLR2 and dectin-1, HKLM and heat killed Candida 
albicans (HKCA) were stained with a fluorescent dye and incubated with WT and Ptpn22-/- 
BMDCs for 0-60 minutes at 37°C (see Materials and Methods Figure 2-14 for experimental 
setup). Internalisation of both HKLM and HKCA increased over time at 37°C, but no difference in 
uptake was observed depending on the BMDC genotype (Figures 4-2b and 4-3a). To ensure that 
the HKCA was being internalised via dectin-1, WT BMDCs were pre-incubated with a dectin-1 
blocking antibody, prior to incubation with HKCA. Uptake of HKCA was greatly reduced by the 
presence of the dectin-1 antibody, indicating that HKCA was internalised via this receptor (Figure 
4-3a).  
To determine whether expression of PTPN22R619W would affect the ability of BMDCs to 
internalise HKCA, endocytosis assays were performed using Ptpn22R619 (WT) and Ptpn22R619W 
BMDCs. As with Ptpn22-/- BMDCs, expression of PTPN22R619W did not affect HKCA uptake (Figure 
4-3b). Together these data indicate that despite evidence for a potential requirement for Src 
and Syk family kinases in TLR2 and dectin-1 dependent uptake, PTPN22 is not required for 




Figure 4-3: PTPN22 is dispensable for heat killed Candida albicans (HKCA) uptake.  
(a) Uptake of HKCA uptake by WT (white) and Ptpn22-/- (black) BMDCs or WT BMDCs pre-treated with anti-Dectin1 
(grey) (1 DC:10 HKCA). n = 6 (WT and Ptpn22-/-) or 3 (WT + anti-Dectin1) ± s.d. (b) Uptake of HKCA uptake by WT 
(white) and Ptpn22R619W (black) BMDCs. (1 DC:10 HKCA). n = 4 ± s.d. 
 
4.3.3 PTPN22 does not regulate mannose receptor mediated antigen uptake  
 
The mannose receptor (CD206) is a C-type lectin receptor which recognises mannose, fucose 
and N-acetylglucosamine present in glycans275. The requirement for the mannose receptor in 
soluble ovalbumin (ova) internalisation was demonstrated using BMDCs from Mr-/- mice (which 
lack expression of the mannose receptor), in which case, ova was not internalised, and ova 
specific CD8+ T cells were not activated276. The C-terminal intracellular domain does not contain 
specific signalling motifs277, indicating that endocytosis via the mannose receptor may not 
require Src and Syk family kinases. However, Src family kinases are required for actin protrusions 
needed during early receptor mediated phagocytosis267. 
Before assessing whether PTPN22 was required for ova internalisation, I first ascertained the 
cell surface expression of the mannose receptor. This was found to be similar on WT and Ptpn22-






Figure 4-4: WT, Ptpn22-/- and Ptpn22R619W BMDCs have similar cell surface expression of the mannose receptor.  
(a-b) CD206 (mannose receptor) geometric mean fluorescence intensity (GMFI) on WT (white) and Ptpn22-/- (white) 
(a) and WT (white) and Ptpn22R619W (black) (b) BMDCs (gated on CD11c+ live singlets). n = 5 + s.d. (a), n = 3 + s.d. (b).  
To determine whether Src and Syk family kinases were required for ova uptake, WT BMDCs were 
pre-incubated with Src and Syk family kinases inhibitors, prior to incubation with fluorescent ova 
(ova-AF488) at 37°C for 0-60 minutes. Ova-AF488 uptake was measured by flow cytometry and 
although ova-AF488 internalisation at 37°C increased over time, it was not affected by Src and 
Syk family kinase inhibition, indicating that these kinases are not required for the process (Figure 
4-5a).  
I next assessed if PTPN22 was required for receptor mediated endocytosis of ova via the 
mannose receptor. WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W BMDCs were incubated with ova-
AF488 at 37°C for 0-60 minutes and uptake was monitored (see Materials and Methods Figure 
2-15 for experimental setup). Over time, the proportion of ova-AF488+ BMDCs increased, but 
uptake at all time points by WT and Ptpn22-/- BMDCs and by WT and Ptpn22R619W BMDCs was 
quantitatively similar (Figure 4-5b-c). These data indicate that PTPN22 is not required for 
mannose receptor mediated endocytosis and demonstrates that WT and Ptpn22-/- BMDCs used 
in the in vitro co-cultures (in Chapter 3), would have been capable of internalising similar 
amounts of ova, prior to culture with ova specific CD4+ T cells.  
During maturation, the endocytic capacity of DCs is altered. As already discussed, this includes 
a dramatic reduction in macropinocytosis. However, DCs are still capable of receptor mediated 
endocytosis, albeit at a reduced rate242. To determine whether mature Ptpn22-/- BMDCs 
endocytose ova via the mannose receptor at a similar rate to WT BMDCs, cells were matured 
with LPS and the ova uptake assay was performed. Although there was a slight reduction in the 
rate of ova internalisation after LPS treatment, uptake was similar by WT and Ptpn22-/- BMDCs 




Figure 4-5: PTPN22 is not required for binding and internalisation of ova via mannose receptor mediated 
endocytosis and macropinocytosis.  
(a) WT BMDC ova uptake after pre-treatment with DMSO (vehicle control, white), Src inhibitor (dark grey) or Syk 
inhibitor (grey). Graph shows % ova-AF488+ (gated on CD11c+ live singlets). n = 3 ± s.d. (b) WT (white) and Ptpn22-/- 
(black) BMDCs were incubated with ovalbumin-AF488 for 0-60 minutes at 37°C. Graph shows % ova-AF488+ (gated 
on CD11c+ live singlets). n = 5 ± s.d. (c) WT (white) and Ptpn22R619W (black) BMDCs were incubated with ovalbumin-
AF488 for 0-60 minutes at 37°C. Graph shows % ova-AF488+ (gated on CD11c+ live singlets). n = 3 ± s.d. (d) WT (white) 
and Ptpn22-/- (black) immature (circle) and LPS matured (triangle) BMDCs were incubated with ovalbumin-AF488 for 
0-60 minutes at 37°C. Graph shows % ova-AF488+ (gated on CD11c+ live singlets). n = 3 (technical replicates) ± s.d.  
As ova can be internalised via the mannose receptor and macropinocytosis, I carried out uptake 
assays in which the unbound ova-AF488 was removed by washing, prior to uptake at 37°C. In 
this case, ova uptake should be solely via the mannose receptor. As with the previous uptake 






Figure 4-6: PTPN22 is not required for internalisation of ova via the mannose receptor.  
WT (white) and Ptpn22-/- (black) BMDCs were incubated with ovalbumin-AF488 for 45 minutes on ice, after which 
unbound ova was removed by washing (such that uptake should be via the mannose receptor, and not via the mannose 
receptor and macropinocytosis). BMDCs were then incubated for 0-60 minutes at 37°C for uptake. Graph shows % 
ova-AF488+ (gated on CD11c+ live singlets). n = 8-11 ± s.d.   
Finally, as GM-CSF BMDCs do not represent in vivo DC subsets, I carried out an ova uptake assay 
using WT and Ptpn22-/- Flt3L BMDCs. Again, PTPN22 was found to be dispensable for ova uptake 
(Figure 4-7). 
 
Figure 4-7: PTPN22 is dispensable for Flt3L BMDC ova internalisation.  
WT (white) and Ptpn22-/- (black) Flt3L induced BMDCs were incubated with ovalbumin-AF488 for 45 minutes on ice, 
then incubated for 0-60 minutes at 37°C for uptake. Graph shows ova-AF488 GMFI (gated on CD11c+, CD24+ (circle) or 
CD11c+, SIRPα+ (square) live singlets). n = 2 ± s.d. (representative of 5 independent experiments).  
 
4.3.4 Splenic conventional DC ovalbumin uptake does not require PTPN22  
 
To determine whether PTPN22 may play a role in receptor mediated endocytosis of ova by ex 
vivo DCs, the spleens of WT, Ptpn22-/-, Ptpn22R619 (WT) and Ptpn22R619W mice were digested and 
red blood cells were lysed. Splenocytes were incubated with ova-AF647 for 45 minutes either 
on ice or at 37°C. Ova internalisation was monitored by flow cytometry, by gating on 
conventional (CD11c+ MHCII+) splenic DCs (cDCs). WT, Ptpn22-/-, Ptpn22R619 and Ptpn22R619W 
splenic DCs internalised more ova-AF647 when incubated at 37°C compared to the 
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internalisation observed on ice, but the genotype of the DC did not affect ova-AF647 uptake 
(Figure 4-8a-c). This is in agreement with my data using BMDCs (Figure 4-5), and shows that 
PTPN22 is dispensable for mannose receptor mediated endocytosis of ova by DCs.   
 
Figure 4-8: PTPN22 is dispensable for uptake of ova by splenic DCs.  
(a) Representative flow cytometry plot showing ova-AF647 uptake by CD11c+ MHCII+ splenic DCs incubated with ova-
AF647 on ice (white) or at 37°C (grey) for 45 minutes. (b-c) WT (white) and Ptpn22-/- (black) (b) or WT (white) and 
Ptpn22R619W (black) (c) splenocytes were incubated with ova-AF647 for 45 minutes at 37°C. Data shows ova-AF647 
uptake by splenic DCs (GMFI, gated on lineage-, CD11c+, MHCII+ live singlets). n = 4 + s.d.  
 
4.3.5 FcγR-mediated binding and internalisation of immune complexes occurs 
independently of PTPN22 
 
As ova IC pulsed Ptpn22-/- BMDCs caused enhanced ova specific CD4+ T cell proliferation (Figures 
3-18d and 3-19c), I next wanted to determine if PTPN22 regulated ova IC induced T cell 
proliferation by affecting FcγR dependent binding and uptake of ova ICs. To begin, the 
dependency on FcγRs was tested for ova IC uptake. WT BMDCs were pre-incubated with 
antibodies against FcγRI, FcγRII/III and FcγRIV before being incubated with ova-AF488:anti-ova 
ICs (ova-AF488 ICs). Pre-incubation with FcγR antibodies greatly reduced uptake of the 
fluorescent ova ICs, indicating that ova IC internalisation is FcγRs dependent (Figure 4-9a). The 
requirement for Src and Syk family kinases on uptake of ova-AF488 ICs was next tested. WT 
BMDCs were incubated with inhibitors of Src and Syk family kinases before being incubated with 
ova-AF488 ICs. This also led to a significant reduction in ova IC internalisation (Figure 4-9b), 
which is in agreement with previous published data demonstrating a role for Src and Syk family 
kinases in IC internalisation121,122.  
Having confirmed the requirement for Src and Syk family kinases in mediating ova-AF488 IC 
uptake, I next assessed if PTPN22 was required for ova-AF488 IC binding and internalisation. WT 
and Ptpn22-/- BMDCs were incubated with ova-AF488 ICs for 60 minutes on ice and cell surface 
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binding was assessed by flow cytometry (see Materials and Methods Figure 2-16 for 
experimental setup). A similar proportion of WT and Ptpn22-/- BMDCs had ova-AF488 ICs bound 
to their cell surface (Figure 4-9c). Next, ova-AF488 IC internalisation was assessed. The 
proportion of BMDCs that internalised ova-AF488 ICs increased over time at 37°C, but both WT 
and Ptpn22-/- BMDCs internalised similar amounts of ova-AF488 ICs (Figure 4-9d). This data 
shows that PTPN22 is dispensable for FcγR mediated binding and endocytosis of ova-AF488 ICs, 
therefore differences in these processes do not explain the enhanced T cell proliferation caused 
by ova IC pulsed Ptpn22-/- BMDCs (Figure 3-19c).  
 
Figure 4-9: PTPN22 is dispensable for FcyR dependent immune complex binding and uptake.  
(a) WT BMDC ova-AF488 IC internalisation with (grey) or without (white) pre-incubation with anti-FcγRs (%, gated on 
CD11c+, anti-rabbit- live singlets). n = 3 ± s.d.; ****p<0.0001 using 2-way ANOVA with Sidak’s multiple comparisons 
test. (b) WT BMDC ova-AF488 IC internalisation after pre-treatment with DMSO (vehicle control, white), Src inhibitor 
(dark grey) or Syk inhibitor (grey) (%, gated on CD11c+, anti-rabbit- live singlets). n = 7, 4, 3 ± s.d.; **p<0.01, 
****p<0.0001 using 2-way ANOVA with Tukey’s multiple comparisons test. (c) WT (white) and Ptpn22-/- (black) BMDCs 
were incubated with ova-AF488 ICs for 1 hour on ice. Cell surface ova-AF488 IC binding was determined (gated on 
CD11c+, anti-rabbit+ live singlets). n = 3-5 + s.d. (d) Combined ova-AF488 IC internalisation by WT (white) and Ptpn22-
/- (black) BMDCs was determined (gated on CD11c+, anti-rabbit- live singlets). n = 3-5 ± s.d. 
 
4.3.6 Ova degradation occurs independently of PTPN22 
 
Having established that PTPN22 was dispensable for immune complex binding and uptake, the 
next step to investigate was immune complex degradation. After antigens are internalised they 
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enter phagocytic endosomes which can fuse with acid rich lysosomes, allowing for antigen 
degradation. Once degraded into peptides, these can be presented in the context of MHCI and 
MHCII, as peptide-MHC complexes. 
To assess antigen processing, BMDCs were incubated with ovalbumin-AF594 coated polystyrene 
beads for 0-5 hours at 37°C. Internalised beads were identified by staining with rabbit anti-
ovalbumin followed by F(ab’)2 goat anti-rabbit IgG-AF647, such that internalised beads could be 
identified as F(ab’)2 goat anti-rabbit IgG-AF647- (see Materials and Methods Figure 2-17 for 
experimental setup). To determine antigen degradation, loss of ovalbumin-AF594 fluorescence 
was assessed by flow cytometry on internalised beads278. In agreement with uptake of 
ovalbumin-AF488 (Figure 4-5b), both WT and Ptpn22-/- BMDCs were equally capable of 
internalising ovalbumin-AF594 coated beads (Figure 4-10b). Over time at 37°C, the intensity of 
ovalbumin-AF594 fluorescence on beads internalised by the BMDCs reduced (Figure 4-10c), 
indicative of antigen degradation. However, the amount of degradation (Figure 4-10c) and the 
proportion of internalised beads with degraded ova (Figure 4-10d) were similar for WT and 








Figure 4-10: PTPN22 is not required for degradation of internalised ova.  
(a-d) WT and Ptpn22-/- BMDCs were incubated with ova-AF594 coated beads for 0-5 hours at 37°C. (a) Representative 
flow cytometry plots showing ova-AF594 coated bead internalisation and ova degradation by BMDCs. (c-d) Graphs 
shows the proportion of ova-AF594 coated beads that were internalised (b), ova-AF594 geometric mean fluorescence 
intensity (GMFI) of internalised ova-AF594 coated beads (c), and the proportion of internalised ova-AF594 coated 
beads that have degraded ova-AF594 on them (d) by WT (white) and Ptpn22-/- (black) BMDCs (%, gated on single, anti-
rabbit- beads). n = 2 ± s.d. (representative of 7 independent experiments).  
 
4.3.7 Immune complex degradation occurs independently of PTPN22 
 
To determine whether PTPN22 may regulate degradation of immune complex derived antigens, 
WT and Ptpn22-/- BMDCs were incubated with ova-AF594:anti-ova coated polystyrene beads for 
0-7 hours at 37°C, and antigen degradation was again measured on internalised beads by flow 
cytometry (see Materials and Methods Figure 2-18 for experimental setup). The rate of antigen 
degradation can affect the number of peptides which are available for MHCII presentation. 
PTPN22 is required for TRAF3 ubiquitination, which is needed for TLR induced production of type 
I interferons in myeloid cells10, and FcγR ubiquitination aids internalisation and degradation of 
immune complexes150. Therefore, PTPN22 may be involved in immune complex internalisation 
and degradation.  
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The proportion of internalised ova-AF594:anti-ova coated beads was similar for WT and Ptpn22-
/- BMDCs (Figure 4-11b). This agrees with previous experiments showing that PTPN22 is 
dispensable for ova IC uptake (Figure 4-9d). In addition, the proportions of internalised ova-
AF594:anti-ova coated beads with degraded ova and the magnitude of ova degradation were 
similar by WT and Ptpn22-/- BMDCs (Figure 4-11c-d). This indicates that PTPN22 is not required 
for ova-AF594 degradation when coated to beads in the presence of anti-ova (to mimic an 
immune complex). Differences in immune complex processing are therefore unlikely to be the 
mechanism behind the enhanced immune complex induced T cell proliferation caused by 
Ptpn22-/- BMDCs. 
To determine whether Src and Syk family kinases were required for internalisation of ova-
AF594:anti-ova coated beads, WT BMDCs were pre-incubated with Src and Syk family inhibitors, 
prior to the degradation assay described above. Internalisation of ova-AF594:anti-ova coated 
beads was reduced after kinase inhibition, especially as a result of Syk kinase inhibition (Figure 
4-11e). This indicates that Syk kinase is required for efficient phagocytosis of ova-AF594:anti-







Figure 4-11: PTPN22 is not required for degradation of ova:anti-ova coated beads.  
(a-e) WT and Ptpn22-/- BMDCs were incubated with ova-AF594:anti-ova coated beads for 0-7 hours at 37°C. (a) 
Representative flow cytometry plots showing ova-AF594:anti-ova coated bead internalisation and ova degradation by 
BMDCs. (b-d) WT (white) and Ptpn22-/- (black) BMDC ova-AF594:anti-ova coated bead internalisation (b), proportion 
of internalised ova-AF594:anti-ova coated beads that have degraded ova-AF594 on them (c) and ova-AF594 GMFI of 
internalised ova-AF594:anti-ova coated beads (d) (%, gated on single, anti-rabbit- beads). n = 3 ± s.d. (technical 
repeats, representative of 10 independent experiments). (e) WT BMDC ova-AF594:anti-ova coated bead 
internalisation after pre-treatment with DMSO (vehicle control, white), Src inhibitor (dark grey) or Syk inhibitor (grey), 
(%, gated on single, anti-rabbit- beads). n = 3 ± s.d; *p<0.05, ****p<0.0001 using a 2-way ANOVA with Tukey’s multiple 
comparisons test (comparisons shown are between WT + DMSO and WT + Src/Syk inhibitors).  
 
4.3.8 PTPN22 is dispensable for soluble antigen presentation, but negatively 
regulates presentation of immune complexed derived antigens  
 
As antigen uptake and processing were found to occur independently of PTPN22 in BMDCs, I 
next assessed whether PTPN22 was required for presentation of peptides in MHCII. Firstly, WT 
and Ptpn22-/- BMDCs were incubated for 18 hours at 37°C with GFP-Eα (or GFP as a negative 
control), a soluble fusion protein containing the Eα peptide epitope. Cell surface MHCII 
restricted presentation of Eα peptide was determined using a biotinylated antibody specific for 
the Eα52-68-I-Ab peptide-MHCII complex, followed by streptavidin-APC279 (see Materials and 
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Methods Figure 2-19 for experimental setup). Whilst more than 50% of the BMDCs expressed 
Eα52-68 in MHCII on their cell surface after 18 hours, PTPN22 expression had no effect on the 
presentation of Eα peptides (Figure 4-12a-b).  
 
Figure 4-12: Ptpn22-/- BMDCs express similar levels of Eα derived peptides in MHCII on their cell surface.  
(a) Representative flow cytometry plots of Eα52-68 expression in I-Ab by WT (top) and Ptpn22-/- (bottom) BMDCs after 
18 hour incubation with GFP (left) and GFP-Eα (right). (b) Combined proportion (left) and geometric mean fluorescence 
intensity (GMFI, right) of Eα52-68 expression in I-Ab by WT (white) and Ptpn22-/- (black) BMDCs after 18 hour incubation 
with GFP and GFP-Eα (gated on CD11c+ live singlets). n = 3 + s.d.  
I next wanted to determine whether PTPN22 may be required for the specific presentation of 
immune complex derived peptides, as PTPN22 was only found to regulate T cell proliferation 
after ova IC, and not ova pulsing of BMDCs. To address this, WT and Ptpn22-/- BMDCs were 
incubated for 18 hours with GFP-Eα:anti-GFP immune complexes (or GFP:anti-GFP immune 
complexes as a negative control) and cell surface presentation of Eα52-68 in I-Ab was again 
determined by flow cytometry. Similar proportions of WT and Ptpn22-/- BMDCs expressed Eα52-
68 peptide-MHCII complexes (Figure 4-13a-b), however, Ptpn22-/- BMDCs expressed higher levels 
of cell surface Eα52-68 peptide (as demonstrated by increased GMFI, Figure 4-13b). To verify that 
this enhanced Eα52-68 presentation was not due to differences in MHCII expression on WT and 
Ptpn22-/- BMDCs, BMDCs that did not receive the Eα containing immune complexes were 
analysed for cell surface MHCII expression by flow cytometry. WT and Ptpn22-/- BMDCs were 
found to express similar levels of MHCII on their cell surface (Figure 4-13c).  Internalisation of 
the GFP-Eα:anti-GFP immune complexes could also be measured using GFP fluorescence. In 
agreement with previous endocytosis assays showing no role for PTPN22 in immune complex 
uptake, uptake of the GFP-Eα:anti-GFP immune complexes was comparable by WT and Ptpn22-
/- BMDCs (Figure 4-13d). Taken together, my data suggest that enhanced presentation of 
immune complex derived antigens could provide one potential mechanism for the increased T 




Figure 4-13: Ptpn22-/- BMDCs express more immune complex derived peptides in MHCII on their cell surface.  
(a) Representative flow cytometry plots of Eα52-68 expression in I-Ab by WT (top) and Ptpn22-/- (bottom) BMDCs after 
18 hour incubation with GFP/anti-GFP ICs (left) and GFP-Eα/anti-GFP ICs (right). (b) Combined proportion (left) and 
GMFI (right) of Eα52-68 expression in I-Ab by WT (white) and Ptpn22-/- (black) BMDCs after 18 hour incubation with 
GFP:anti-GFP ICs and GFP-Eα:anti-GFP ICs (gated on CD11c+ live singlets). n = 3 + s.d; *p<0.05 using a 2-way ANOVA 
with Sidak’s multiple comparisons test. (c) MHCII expression on WT (white) and Ptpn22-/- (black) BMDCs (GMFI, gated 
on CD11c+ live singlets). n = 3 + s.d. (d) GFP:anti-GFP IC and GFP-Eα:anti-GFP IC uptake after 18 hours by WT (white) 
and Ptpn22-/- (black) BMDCs (% GFP+, gated on CD11c+ live singlets). n = 3 + s.d. 
 
4.3.9 PTPN22 is required for efficient immune complex induced conjugate formation, 
but is dispensable when using OVA323-339 peptide or ova 
 
For DCs to initiate T cell activation and proliferation, they must be capable of forming productive 
conjugates. First, I investigated whether PTPN22 was needed for conjugate formation between 
LPS matured, OVA323-339 peptide pulsed or ova pulsed BMDCs and ova specific WT CD4+ OT-II T 
cells. WT and Ptpn22-/- BMDCs were pulsed with OVA323-339 peptide or ova (or left unpulsed, as a 
negative control), and labelled with CellTrace Far Red (CTFR). CTFR labelled BMDCs were then 
incubated with CellTrace Violet (CTV) labelled WT CD4+ OT-II T cells for 0-120 mins at 37°C. 
Conjugates were identified by flow cytometry as CTV+ CTFR+ events (see Materials and Methods 
Figure 2-9 for experimental setup). Neither unpulsed or ova pulsed WT and Ptpn22-/- BMDCs 
produced a high number of conjugates with T cells (Figure 4-14a-c). LPS matured OVA323-339 
peptide pulsed BMDCs produced more conjugates, the proportion of which increased over time 
(Figure 4-14d). Despite this, conjugate formation was similar using both WT and Ptpn22-/- OVA323-
339 peptide pulsed BMDCs (Figure 4-14d). This indicates that PTPN22 is dispensable for conjugate 
formation when BMDCs are unpulsed or pulsed with ova or OVA323-339 peptide. These results 
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were not completely surprising as PTPN22 was not required for T cell proliferation when BMDCs 
were pulsed with OVA323-339 peptide or ova (Figures 3-15d-e and 3-19b).  
As Ptpn22-/- BMDCs were found to display enhanced immune complex derived cell surface 
peptide-MHCII presentation (Figure 4-13b), I next wanted to determine whether immune 
complex pulsed Ptpn22-/- BMDCs would be capable of forming more DC-T cell conjugates. WT 
and Ptpn22-/- BMDCs were pulsed overnight with ova ICs, labelled with CTFR and incubated with 
CTV labelled WT CD4+ OT-II T cells. Ova IC pulsed BMDCs formed conjugates with T cells, and the 
proportion of which increased over time (Figure 4-14e). In agreement with the ability of Ptpn22-
/- BMDCs to express more immune complex derived antigens on their cell surface, ova IC pulsed 
Ptpn22-/- BMDCs had a significantly enhanced capability to form conjugates with WT CD4+ OT-II 
T cells than WT BMDCs (Figure 4-14e). This data, in addition to the enhanced immune complex 
derived antigen presentation, could explain the augmented immune complex induced T cell 
proliferation caused by Ptpn22-/- BMDCs.  
 
Figure 4-14: Ova IC pulsed Ptpn22-/- BMDCs form more conjugates with ova specific WT T cells.  
(a-e) Representative flow cytometry plots (a) and combined data (b-e) showing the proportion of WT OT-II T cells in 
conjugates with unpulsed (no ova) (b), 1 µM ova pulsed (c), 10 µM OVA323-339 peptide and 100 ng/ml LPS pulsed (d), 
and 1 µM ova IC pulsed (e) WT (white) and Ptpn22-/- (black) BMDCs over time. Conjugates were identified as CTV+ 
CTFR+ events (%, gated on CTV+ total T cells). n = 4 ± s.d; **p<0.01 using a 2-way ANOVA with Sidak’s multiple 
comparisons test.  
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To further determine how PTPN22 may be regulating conjugate formation, WT BMDCs were 
pulsed overnight with ova ICs and treated with Src and Syk family kinase inhibitors, prior to the 
DC-T cell conjugate assay. Inhibition of Src and Syk family kinases led to a drastic reduction in 
conjugate formation (Figure 4-15a-b). This may indicate that PTPN22 is modulating conjugate 
formation by regulating the phosphorylation states of these kinases. 
 
Figure 4-15: Src and Syk family kinases are required for efficient ova IC induced BMDC-T cell conjugate formation.  
(a-b) Representative flow cytometry plots (a) and combined data (b) for the proportion of WT OT-II T cells in conjugates 
with ova IC pulsed WT BMDCs, after pre-treatment with DMSO (vehicle control, white), Src inhibitor (dark grey) or Syk 
inhibitor (grey). Conjugates were identified as CTV+ CTFR+ events (%, gated on CTV+ total T cells). n = 3 ± s.d.; 
****p<0.0001 using a 2-way ANOVA with Tukey’s multiple comparisons test.  
 
4.4 Overall findings 
 
The main findings of this Chapter were: 
1. PTPN22 is not required for BMDC internalisation of antigens via macropinocytosis or 
receptor mediated endocytosis via dectin-1, TLR2 or the mannose receptor. 
2. PTPN22 is dispensable for FcγR dependent ova IC binding, internalisation and 
processing. 
3. PTPN22 negatively regulates presentation of IC derived peptides in MHCII and ova IC 
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The aim of this Chapter was to identify a mechanism(s) behind the enhanced immune complex 
induced T cell proliferation by Ptpn22-/- BMDCs, described in Chapter 3. A systematic approach 
was taken to first determine whether PTPN22 was required for endocytosis via a variety of 
receptors, including FcγRs. PTPN22 was found to be dispensable for internalisation of Lucifer 
yellow, heat killed Listeria monocytogenes, heat killed Candida albicans, ova, ova ICs, ova coated 
beads, ova:anti-ova coated beads, GFP-Eα and GFP-Eα ICs. This is in contrast with previously 
published data showing that M1 polarised, LPS treated Ptpn22R619W peritoneal macrophages 
were more efficient at phagocytosing heat killed fluorescent E.coli than WT macrophages67. This 
discrepancy may be due to using different antigens to measure phagocytosis, PTPN22 playing 
distinct roles in DCs compared to macrophages, and differences resulting from the expression 
of the autoimmune associated variant of PTPN22 compared to lacking expression of PTPN22 
completely. 
 
4.5.1 Receptor mediated endocytosis 
 
Although ova is internalised by the mannose receptor, it can also enter cells via 
macropinocytosis104. This has been shown by the fact that the addition of excess mannan prior 
to incubation with ova only partially reduces ova uptake, indicating that it is also taken up by 
macropinocytosis280. During the ova uptake assay, excess, unbound ova was not washed off the 
BMDCs prior to being moved to the water bath for uptake, meaning that the ova may have been 
internalised by a combination of mannose receptor mediated endocytosis and 
macropinocytosis. I purposely did not wash off the unbound ova, as this would then model more 
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closely what is happening when BMDCs are pulsed overnight with ova, prior to the co-cultures. 
I did however also carry out endocytosis assays where unbound ova was washed off prior to 
uptake, such that the majority of the internalisation would be via the mannose receptor. In these 
experiments, PTPN22 was still found to be dispensable for ova internalisation. It has been 
shown, using mannose receptor knock out mice, that BMDCs utilise the mannose receptor to 
internalise ova destined to be presented as peptides in MHCI, for the activation of CD8+ T cells, 
whereas they use macropinocytosis to internalise ova for MHCII presentation, and for the 
subsequent activation of CD4+ T cells104. This indicates that ova uptake via macropinocytosis was 
more important for the CD4+ T cell proliferation observed in the co-cultures. As PTPN22 was also 
found to be dispensable for uptake of Lucifer yellow by macropinocytosis, this is still consistent 
with the fact that PTPN22 was found to be dispensable for T cell proliferation after co-culture 
with ova pulsed BMDCs. 
Although PTPN22 was found to be dispensable for dectin-1 dependent internalisation of heat 
killed Candida albicans, our lab has demonstrated that the phosphatase regulates signalling 
downstream of the receptor. Ptpn22-/- BMDCs pulsed with OVA323-339 and the dectin-1 agonist 
curdlan caused enhanced OT-II T cell IL-17 secretion, which was found to be dependent on IL-1β 
secretion from the BMDCs. In addition, after dectin-1 stimulation, Ptpn22-/- BMDCs showed 
enhanced Syk and ERK phosphorylation66. This shows that PTPN22 is required to regulate specific 
facets of receptor signalling, which is similar to the regulation that PTPN22 appears to play in 
FcγR signalling, despite being dispensable for FcγR-dependent immune complex internalisation. 
 
4.5.2 Antigen processing 
 
As PTPN22 was found to be dispensable for endocytosis of antigens, the next step was to assess 
its role in antigen processing. For this, polystyrene beads were coated with ova or ova:anti-ova 
and the reduction of the ova fluorescence was assessed over time. Again, PTPN22 was found to 
be dispensable for this process. I did not investigate trafficking of internalised antigens in WT 
and Ptpn22-/- BMDCs, so it is possible that although PTPN22 was not required for their 
internalisation and processing, it may be required for intracellular vesicular trafficking of 
antigens, to allow for efficient presentation. A potential drawback of the bead processing assay 
is that it is based on the assumption that the reduction in ova-AF594 fluorescence is directly 
correlated with degradation of the ova or ova ICs. It is possible that the AF594 may be degraded 
at a different rate, or via a different pathway to the ova or ova ICs. To ensure that the loss of 
AF594 signal does correlate with antigen processing, it would be possible to repeat the assays 
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in the presence of an inhibitor of phagolysosomal degradation, for example chloroquine. 
Chloroquine prevents acidification of endosomes, inhibits lysosomal enzymes and prevents 
endosome-lysosome fusion, so if the loss of AF594 fluorescence was due to antigen degradation, 
then using this inhibitor should result in no loss of AF594 signal. It has been shown by the lab of 
Dr Pierre Guermonprez (King’s College London) that during uptake of ova coated beads, ova-
AF594 colocalises with LAMP-1+ vesicles and that with increasing time at 37°C, the AF594 is 
reduced (Appendix Figure 8-1). The BMDCs were only incubated with the ova or ova:anti-ova 
coated beads for a maximum of 7 hours at 37°C, after which point the AF594 signal was reduced, 
but still detectable. This indicates that complete antigen degradation had not occurred by this 
time point. In the future, it would be interesting to repeat the assays, but allowing the BMDCs 
longer to process the antigens. In addition, microscopy could have been utilised to visualise the 
location and degradation of the ova and ova ICs, including co-staining with antibodies for 
endosomal organelles, to see whether the ova and ova:anti-ova coated beads are being 
trafficked similarly in WT and Ptpn22-/- BMDCs.    
The use of the F(ab’)2 goat anti-rabbit IgG made it simple to distinguish between internalised 
and external ova ICs, ova coated beads or ova:anti-ova coated beads, as any cells that were 
F(ab’)2 goat anti-rabbit IgG+ could be excluded as having external antigens. However, the 
disadvantage of this technique is that cells which had both internalised and external ova ICs 
were excluded. Therefore, only cells which had no external ova ICs were included in the analysis. 
An alternative technique could have been to conjugate the ova ICs with a pH sensitive dye, such 
as pHrodo, which would fluoresce differently depending on whether the ova ICs had been 
internalised into the more acidic endosomes/lysosomes, or whether they remained on the cell 
surface.  
 
4.5.3 Antigen presentation 
 
In order to induce T cell proliferation, internalised antigens need to be processed and presented 
on the cell surface. Using immune complexes containing the Eα protein, peptide presentation in 
MHCII was monitored. In this case, lacking expressing of PTPN22 led to a subtle, but significant 
increase in cell surface expression of Eα52-68 expression in I-Ab. This may provide some 
explanation as to why immune complex pulsed Ptpn22-/- BMDCs caused enhanced T cell 
proliferation. I did not analyse intracellular levels of Eα52-68 in MHCII, although this would have 
been interesting. From these experiments, it is therefore not possible to distinguish between a 
potential role of PTPN22 in Eα52-68-MHCII formation and cell surface presentation. In the future, 
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microscopy experiments could be utilised to identify whether the peptide-MHC complexes were 
being formed and utilising similar pathways of vesicular trafficking in WT and Ptpn22-/- BMDCs. 
A potential drawback of this antigen presentation assay is that I was not able to look directly at 
presentation of ova IC derived antigens in MHCII, as the reagents are not available, so the results 
from the GFP-Eα containing immune complex presentation assays have been extrapolated to 
the co-cultures. Alternatively, it would have been useful to be able to carry out the co-culture 
assays using the GFP-Eα containing immune complexes, to ensure that these still induced 
enhanced T cell proliferation, when presented by Ptpn22-/- BMDCs. However, there are not 
transgenic mice available whose T cell receptors are specific for peptides from Eα.  
In addition, if PTPN22 is involved in trafficking and/or retention of peptide-MHCII complexes to 
the plasma membrane, then monitoring cell surface Eα52-68 presentation in I-Ab over more time 
points could have been informative. It may be possible that PTPN22 is not required for initial 
peptide-MHCII complex formation and trafficking to the surface, but that it is required for cell 
surface retention. My data demonstrates that after 18 hours of incubation PTPN22 negatively 
regulates antigen presentation. This time point corresponds to the point when ova IC pulsed 
BMDCs are harvested for co-cultures with WT CD4+ OT-II T cells, so this indicates that at this time 
point, Ptpn22-/- BMDCs are presenting more immune complex derived antigens to T cells, 
compared to WT BMDCs, resulting in enhanced T cell proliferation.  
 
4.5.4 T cell:BMDC conjugate formation 
 
Finally, the ability of WT and Ptpn22-/- BMDCs to form conjugates with T cells was assessed. 
Similar conjugate formation was found when BMDCs were left unpulsed, or pulsed with ova or 
OVA323-339, however enhanced conjugate formation was observed when Ptpn22-/- BMDCs were 
pulsed with ova ICs; a process found to be dependent on Src and Syk family kinases. This 
observation provided a potential mechanism behind the enhanced immune complex induced T 
cell proliferation. How PTPN22 is regulating BMDC immune complex derived antigen 
presentation and conjugate formation is unclear but these data suggest that PTPN22 acts to 
negatively regulate FcγR induced immune responses, reducing the capability of DCs to activate 
T cells. One potential drawback of the conjugate assays is that they only model the first two 
hours of the interaction between BMDCs and T cells, so although in this timeframe Ptpn22-/- 
BMDCs pulsed with ova ICs were able to form more conjugates with ova specific WT CD4+ T cells, 




4.5.5 PTPN22 potential redundancy with other phosphatases 
 
A potential reason why PTPN22 was found to be dispensable for ova IC uptake, may be due to 
the presence of other phosphatases which may compensate for the loss of PTPN22. Other 
phosphatases which are expressed in DCs, have been shown to regulate FcγR signalling in 
macrophages. For example, in the absence of the inositol 3-phosphatase PTEN, mouse 
peritoneal macrophages show an enhanced phagocytic ability260. The phosphatase SHIP-1 has 
also been shown to regulate FcγR dependent phagocytosis. Overexpression of SHIP-1 in RAW 
LR5 macrophages inhibited phagocytosis of IgG opsonised sheep red blood cells, whereas Ship1-
/- mouse macrophages showed enhanced phagocytosis281. Similar results were found when 
investigating the role of SHIP-2 in FcγR dependent phagocytosis. Transient overexpression of 
SHIP-2 in RAW 264.7 macrophages reduced the ability of these cells to internalise IgG opsonised 
sheep red blood cells, whereas knock down of SHIP-2 led to enhanced phagocytosis282. The 
mechanism behind this regulation was shown to be by SHIP-2 suppressing the activation of Rac 
after FcγR crosslinking. Rac is required for actin polymerisation and cytoskeletal rearrangement, 
both of which are needed for phagocytosis. This data indicates that PTEN, SHIP-1 and SHIP-2 can 
negatively regulate FcγR dependent phagocytosis in macrophages, potentially explaining the 
lack of requirement for PTPN22 in immune complex uptake. 
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5. Results: Investigating the role of PTPN22 in a model of rheumatoid 




To further understand the association of PTPN22R620W in humans with an enhanced susceptibility 
to multiple autoimmune diseases such as RA, I used the K/BxN serum transfer model of 
arthritis178. This model allows the effector phase of arthritis to be examined, after 
autoantibodies have been produced, and so does not require T and B cells for its initiation. The 
transferred arthritogenic serum contains autoantibodies to the glycolytic enzyme glucose-6-
phosphate isomerase (GPI) and allows arthritis to be studied in non-autoimmune prone strains 
of mice. Although T and B cells are dispensable for disease induction using this model, it has 
been shown that neutrophils181 and macrophages182,283 are required. In addition, the 
complement component C5186, FcγRIII187, IL-1188 and LFA-1189,190 have been shown to be 
necessary. Mice are injected with arthritogenic serum on days 0 and 2 and clinical signs of 
disease are visible within a few days. The disease is transient, usually peaking at 4-6 days and 
resolving by 10-12 days. Signs of disease are monitored daily, which involves assigning clinical 
scores to each paw, measuring paw swelling and weighing the mice. Although this model has 
been previously used in Ptpn22-/- mice by three independent groups, the results were 
contradictory, with two showing that PTPN22 was dispensable for disease development10,59 and 
the other showing that PTPN22 exacerbated disease63. For this reason, I was interested to carry 
out the model not only using WT and Ptpn22R619W mice, but also comparing WT with Ptpn22-/- 
mice. 
Osteoclasts are multinucleated cells which differentiate from hematopoietic stem cells, usually 
in the presence of M-CSF and RANK-L. Osteoclasts function in concert with osteoblasts to allow 
for physiological bone remodelling, whereby osteoclasts erode bone and osteoblasts form new 
bone. However, in inflammatory diseases such as RA, the balance between the activity of 
osteoclasts and osteoblasts is dysregulated, leading to excessive bone erosion. Osteoclasts are 
the only cell type capable of eroding bone and are therefore responsible for the bone erosion 
seen in RA284. This has been demonstrated in mouse models of arthritis, whereby osteoclast 
deficient mice show no signs of joint destruction and are osteopetrotic285. There is evidence 
showing that kinases and phosphatases are essential for normal osteoclast differentiation and 
function. For example, if protein tyrosine phosphatase activity is inhibited, this prevents in vitro 
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differentiation of osteoclasts, and their subsequent ability to resorb bone225. In addition, 
tyrosine phosphorylation regulates signalling downstream of receptors required for osteoclast 
differentiation and function, including c-Fms226 (the receptor for M-CSF), RANK (the receptor for 
RANK-L)286,287 and integrins288,289, which are required for adhesion of osteoclasts to cartilage and 
bone matrix. Finally, the PTPN22 family member, PTPN12, has been shown to be required for 
RANK-L dependent fusion of macrophages into osteoclasts232. For these reasons, this Chapter 




This Chapter aimed to determine whether PTPN22 plays a role in: 
1. Disease development using the K/BxN serum transfer mouse model of rheumatoid 
arthritis. 




5.3.1 The absence of PTPN22 enhances disease severity using the K/BxN serum 
transfer model of arthritis 
 
To begin to understand whether PTPN22 plays a role in arthritis development, the K/BxN mouse 
serum transfer model of arthritis was utilised. WT and Ptpn22-/- mice were injected with PBS or 
arthritogenic serum (diluted 1:1 with PBS) on days 0 and 2, and disease development was 
monitored daily for 9 days (see Materials and Methods Figure 2-20 for experimental setup). As 
expected, mice that received PBS did not display any signs of disease throughout the experiment 
(Figure 5-1a-c). However, mice that received the arthritogenic serum developed robust disease, 
shown by increasing clinical scores, which peaked at days 5-7 (Figure 5-1a). This was 
accompanied by a steady increase in paw thickness and in weight loss over time (Figure 5-1b-c). 
Ptpn22-/- mice developed more severe disease, as demonstrated by augmented clinical scores, 
paw swelling and weight loss in comparison to WT mice (Figure 5-1a-c). This indicates that 




Figure 5-1: Ptpn22-/- mice develop more severe disease using the K/BxN serum transfer model of arthritis.  
(a-c) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. Clinical scores, paw swelling measurements and weight were collected daily for 9 days. Average clinical scores 
(a), paw swelling (left ankle shown as an example) (b) and weight change (c) are shown for WT (white) and Ptpn22-/- 
(black) mice injected with PBS (square) or arthritogenic serum (circle). n = 6 (PBS) and 9 (serum) + s.d; ***p<0.005, 
**p<0.01, *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test (shown for arthritogenic serum WT 
v Ptpn22-/- only). 
 
5.3.2 Expression of PTPN22R619W is not sufficient to cause enhanced disease when 
using the K/BxN serum transfer model of arthritis 
 
After revealing a role of PTPN22 in reducing disease severity using the K/BxN serum transfer 
model of arthritis, I next wanted to identify whether expression of the autoimmune associated 
variant of PTPN22 would also affect disease severity. Ptpn22R619 (WT) and Ptpn22R619W mice were 
injected with PBS or arthritogenic serum (diluted 1:1 with PBS) on days 0 and 2, and disease 
progression was monitored daily for 10 days. Once again, clinical signs of disease were present 
in mice that had received arthritogenic serum.  In these experiments, disease severity peaked at 
day 7 and plateaued until the end of the experiment on day 10 (Figure 5-2a-c). As expected, no 
disease was seen in mice that received PBS (Figure 5-2a-c). WT and Ptpn22R619W mice developed 
similar levels of disease based on clinical scores, paw swelling measurements and weight loss 
(Figure 5-2a-c). This shows that expression of the autoimmune associated variant of PTPN22 is 




Figure 5-2: Expression of Ptpn22R619W does not affect disease progression in the K/BxN serum transfer model of 
arthritis.  
(a-c) Ptpn22R619 (WT) and Ptpn22R619W mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 
with PBS) on days 0 and 2. Clinical scores, paw swelling measurements and weight were collected daily for 10 days. 
Average clinical scores (a), paw swelling (left ankle shown as an example) (b) and weight change (c) are shown for WT 
(white) and Ptpn22R619W (black) mice injected with PBS (square) or arthritogenic serum (circle). n = 7 (PBS) and 12 
(serum) + s.d.  
 
5.3.3 Serum cytokines and chemokines are similar in arthritic WT and Ptpn22-/- mice 
 
To begin to understand the mechanism behind the enhanced disease seen in the absence of 
PTPN22, serum was harvested from WT and Ptpn22-/- mice by tail bleeds or cardiac punctures 
on days 1, 3, 5 and 9 of the model. Multiplex assays capable of identifying 13 analytes 
simultaneously were used to interrogate serum samples for a range of chemokines and 
cytokines. This included cytokines which are known to play a role in the pathogenesis of arthritis, 
including IL-1, IL-6, IL-17 and TNFα290. At day 1 and 3, mice that had received the arthritogenic 
serum had similar levels of cytokines in their serum as mice that had received PBS, except for IL-
23, which was highest in healthy WT mice (Figure 5-3a-b). This difference was maintained at day 
3 (Figure 5-3b), but IL-23 was not detected on days 5 and 9 (Figure 5-3c-d). On day 3, IL-27 and 
IFNβ expression was enhanced in the serum of Ptpn22-/- mice compared to WT mice, but this 
was found to be independent of the disease status (Figure 5-3b), indicating that this does not 
explain the enhanced disease seen in Ptpn22-/- mice. On day 5, IL-27 was also higher in the serum 
of arthritic Ptpn22-/- mice compared to WT mice (Figure 5-3c), but this difference was not 




Figure 5-3: WT and Ptpn22-/- serum cytokines are similar at multiple time points of the K/BxN serum transfer model 
of arthritis.  
(a-d) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. Tail bleeds were carried out on days 1 (a) and 3 (b) and cardiac punctures were carried out on day 5 (c) and 9 
(d). Serum cytokines were measured in from WT (grey and black) and Ptpn22-/- (pink and red) mice after injections 
with PBS (grey and pink) or arthritogenic serum (black and red) using a LEGENDplex inflammation panel. n = 3-4 (PBS) 
and 5-8 (arthritogenic serum) + s.d; *p<0.05, **p<0.01, ***p<0.005 using a 2way ANOVA and Tukey’s multiple 
comparisons test.  
Serum chemokines were analysed on days 5 and 9. Most of the analytes were undetectable, 
which may have been due to the late time points investigated, but those that were detectable, 
including Eotaxin and B lymphocyte chemoattractant (BLC, also known as CXCL13) were found 
at similar levels in the serum of both healthy and arthritic WT and Ptpn22-/- mice (Figure 5-4a-
b). Liposaccharide induced CXC chemokine (LIX, also known as CXCL5) was also detectable and 
found to be reduced in the serum of arthritic Ptpn22-/- mice compared to arthritic WT mice on 
days 5 and 9 (Figure 5-4a-b). This analysis indicates that the enhanced disease seen in Ptpn22-/- 





Figure 5-4: WT and Ptpn22-/- serum chemokines are similar at days 5 and 9 of the K/BxN serum transfer model of 
arthritis.  
(a-b) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. Cardiac punctures were carried out on days 5 (a) and 9 (b). Serum chemokines were measured in from WT 
(grey and black) and Ptpn22-/- (pink and red) mice after injections with PBS (grey and pink) or arthritogenic serum 
(black and red) using a LEGENDplex proinflammatory chemokine panel. n = 3 (PBS) and 5-6 (arthritogenic serum) + 
s.d; *p<0.05, **p<0.01, ****p<0.0001 using a 2way ANOVA and Tukey’s multiple comparisons test.  
 
5.3.4 Joint architecture is similar in WT, Ptpn22-/- and Ptpn22R619W mice  
 
To identify whether there were any microscopic differences between the arthritic joints of WT 
and Ptpn22-/- and WT and Ptpn22R619W mice, ankle joints were removed at days 9 and 10 
respectively, fixed, decalcified and stained using hematoxylin and eosin (H+E). H+E staining 
allows for the visualisation of the joint architecture and cell infiltration (see Figure 5-5b for 
examples). H+E stained joints were blindly scored by assigning a score of 0-3 for joint erosion 
and 0-3 for cell infiltration. Mice that received PBS did not show any signs of joint erosion or cell 
infiltration, as expected (Figure 5-5c-d). Mice that received the arthritogenic serum showed 
higher joint erosion and cell infiltration scores (Figure 5-5c-d). Despite the difference in external 
signs of disease between WT and Ptpn22-/- mice (Figure 5-5a), the joint erosion and cell 
infiltration scores were similar, although there was a trend towards enhanced cell infiltration in 




Figure 5-5: WT and Ptpn22-/- mice have similar ankle joint erosion and cell infiltration at day 9 of the K/BxN serum 
transfer model of arthritis.  
(a-d) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. On day 9, mice were culled and ankle joints were removed before being fixed, decalcified, embedded in 
paraffin, sectioned and stained with hematoxylin and eosin (H+E). (a) Average clinical scores are shown for WT (white) 
and Ptpn22-/- (black) mice injected with PBS (square) or arthritogenic serum (circle). n = 3 (PBS) and 5 (serum) + s.d.; 
*p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test (shown for arthritogenic serum WT v Ptpn22-/- 
only). (b) Representative H+E stained healthy (left) and arthritic (right) ankle joints, showing cell infiltration (arrow), 
bone erosion (star) and cartilage destruction (cross). (c-d) WT (white) and Ptpn22-/- (black) ankle joint sections were 
scored from 0-3 for joint erosion (c) and cell infiltration (d). Scores shown are averages of 2 ankle joints per mouse. n 
= 1 (PBS) and 5 (arthritogenic serum), and were assigned blinded to clinical scores and genotypes. 
Similar levels of joint erosion and cell infiltration were seen in WT and Ptpn22R619W mice on day 
10 (Figure 5-6a-b). This was consistent with the macroscopic measurements taken during the 
course of the disease. This again indicates that the presence of the autoimmune associated 





Figure 5-6: Ptpn22R619 (WT) and Ptpn22R619W mice have similar ankle joint erosion and cell infiltration at day 10 of 
the K/BxN serum transfer model of arthritis.  
(a-b) WT and Ptpn22R619 mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. On day 10, mice were culled and ankle joints were removed before being fixed, decalcified, embedded in 
paraffin, sectioned and stained with Hematoxylin and Eosin. WT (white) and Ptpn22R619W (black) ankle joint sections 
were scored from 0-3 for joint erosion (a) and cell infiltration (b). Scores shown are averages of 2 ankle joints per 
mouse. n = 2 (PBS) and 12 (arthritogenic serum), and were assigned blinded to clinical scores and genotypes.  
 
5.3.5 Immune cell populations are similar in the spleens and joint draining LNs of WT 
and Ptpn22-/- mice 
 
To identify whether changes in immune cell populations in the spleens or joint draining lymph 
nodes of WT and Ptpn22-/- arthritic mice could account for the observed differences in disease 
severity, mice were culled at the peak of disease and spleens and axial/brachial (wrist draining) 
and popliteal (ankle draining) lymph nodes were removed. Single cell suspensions were stained 
with antibodies to identify immune cell subsets including T cells, DCs, monocytes and 
neutrophils (see Materials and Methods Figure 2-23 for example gating). Similar numbers of T 
cells, monocytes and neutrophils were found in the wrist draining LNs and the spleens of WT 
and Ptpn22-/- mice, regardless of disease status (Figure 5-7b-c). Ptpn22-/- mice showed enhanced 
cDC and cDC2 populations in these organs, but this was also independent of disease status 
(Figure 5-7b-c). In contrast, enhanced numbers of T cells, monocytes, DCs and neutrophils were 
found in the ankle draining lymph nodes of arthritic compared to healthy mice (Figure 5-7d). 
Despite this, the numbers of these populations were not dependent on the genotype of the mice 
(Figure 5-7d). This shows that although disease state can be distinguished by the enhanced 
numbers of immune cells in the ankle draining lymph nodes, it does not provide an explanation 




Figure 5-7: WT and Ptpn22-/- healthy and arthritic mice have equivalent numbers of immune cells in their draining 
lymph nodes and spleens on day 5 of the K/BxN serum transfer model of arthritis.  
(a-d) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. (a) Average clinical scores are shown for WT (white) and Ptpn22-/- (black) mice injected with PBS (square) or 
arthritogenic serum (circle). n= 3 (PBS) and 6 (arthritogenic serum) + s.d; *p<0.05, **p<0.01 using a 2-way ANOVA 
with Tukey’s multiple comparisons test (shown for arthritogenic serum WT v Ptpn22-/- only). (b-d) On day 5, mice were 
culled and joint draining lymph nodes and spleens were removed and stained for immune cell phenotyping by flow 
cytometry. Data shows total cell numbers for each population in the axial/brachial draining lymph nodes (b), spleens 
(c), and popliteal draining lymph nodes (d) of WT (grey and black) and Ptpn22-/- (pink and red) mice. n = 3 (PBS) and 6 
(arthritogenic serum) + s.d.  
 
5.3.6 There is a trend towards an enhanced neutrophil frequency in the ankle joints 
of Ptpn22-/- arthritic mice 
 
Since the immunophenotyping of spleens and LNs from healthy and arthritic mice did not show 
any striking differences between WT and Ptpn22-/- mice, I next wanted to study the site of 
inflammation, by phenotyping the immune cells present in the joints of the mice. Only joints 
that were visually swollen were removed for analysis on day 5, because, based on the H+E 
staining, there is no cell infiltration in the joints of healthy mice (Figures 5-5d and 5-6b). Ankle 
joints and wrist joints were processed separately, but if a mouse had both ankle joints (or wrist 
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joints) that were swollen, then the cells from both joints were pooled. As different amounts of 
tissue were analysed for each mouse, absolute cell numbers for each immune population could 
not be calculated. Instead, the cell frequency of each subset within the total live cell population 
was calculated. CD4+ T cells, monocytes and neutrophils could be detected in the joints, with the 
near complete absence of DCs and CD8+ T cells (Figure 5-8a-b). Similar frequencies of CD4+ T 
cells and monocytes were found in arthritic WT and Ptpn22-/- joints (Figure 5-8a-b). However, 
there was a trend towards an enhanced frequency of neutrophils in Ptpn22-/- ankle joints (Figure 
5-8a). This observation was discovered in an independent experiment, but the number of mice 
analysed was low. If it is true that there are more neutrophils in the joints of Ptpn22-/- mice, this 
may provide an explanation for the enhanced disease observed.  
 
Figure 5-8: WT and Ptpn22-/- arthritic mice have equivalent numbers of immune cells in their joints on day 5 of the 
K/BxN serum transfer model of arthritis.  
(a-b) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl arthritogenic serum (diluted 1:1 with PBS) on days 0 and 
2. On day 5, mice were culled and joints were removed and stained for immune cell phenotyping by flow cytometry. 
Data shows frequency of live for each population in the ankle joints (a) and wrist joints (b) of WT (white) and Ptpn22-
/- (black) mice. n= 2 (WT ankle) or 3 (WT wrist) and 5 (Ptpn22-/-) + s.d. 
 
5.3.7 Micro-CT analysis reveals an increase in bone volume and trabecular thickness 
in Ptpn22-/- arthritic mice 
 
To identify whether there were differences in the structure of the bones in WT and Ptpn22-/- 
mice after the K/BxN serum transfer model of arthritis, ankle joints were removed from healthy 
and arthritic mice on day 10 after disease induction, and transferred to the lab of Dr Nicole 
Horwood (University of Oxford) for micro-CT analysis of the calcaneal bones. WT arthritic mice 
showed a reduction in bone volume and trabecular thickness compared to healthy WT mice 
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(who received PBS) (Figure 5-9b-c). This reduction was not observed between Ptpn22-/- healthy 
and arthritic mice (Figure 5-9b-c).  
 
Figure 5-9: Micro-CT analysis of bones from WT and Ptpn22-/- healthy and arthritic mice.  
(a-c) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. Clinical scores were collected daily and bones were subjected to micro-CT scanning on day 10. (a) Average 
clinical scores are shown for WT (white) and Ptpn22-/- (black) mice injected with PBS (square) or arthritogenic serum 
(circle). n = 3 (PBS) and 4-5 (serum) + s.d; *p<0.05 using a 2-way ANOVA with Tukey’s multiple comparisons test (shown 
for arthritogenic serum WT v Ptpn22-/- only). (b-c) Micro-CT analysis of the calcaneal bone from WT (white) and Ptpn22-
/- (black) mice on day 10, showing % bone volume of total volume (BV/TV) (b) and trabecular thickness (Tb.Th) (c). n = 
3 (PBS) and 4-5 (serum), where each point is an individual mouse; *p<0.05 using a 2-way ANOVA with Sidak’s multiple 
comparisons test. All micro-CT analysis was performed by the lab of Dr Nicole Horwood (University of Oxford). 
 
5.3.8 Using a novel PET radionuclide imaging tool to detect and quantify disease in 
whole animals 
 
To visualise disease using the K/BxN transfer model of arthritis on the level of the whole 
organism, I utilised Positron Emission Tomography/Computed Tomography (PET/CT) imaging, a 
non-invasive imaging technique (see Materials and Methods Figure 2-24 for experimental 
setup). Using a trimeric RGD peptide chelated to a radioisotope (68Ga(HP3-RGD3)), which binds 
to the integrin αvβ3, this technique allowed for the visualisation of areas of inflammation in an 
intact mouse. The integrin αvβ3 is expressed at low levels in healthy tissue, but is upregulated 
in sites of inflammation, on cells including angiogenic endothelium, osteoclasts and myeloid 
cells. PET/CT imaging was combined with biodistribution, which is invasive and terminal, but is 
more sensitive than PET imaging.  
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Initially, healthy and arthritic WT mice were imaged by PET, and uptake of 68Ga(HP3-RGD3) was 
measured in different organs by biodistribution. Uptake was similar between healthy and 
arthritic mice in non-target organs including the blood, muscle, lung, spleen, pancreas, stomach, 
gut, liver and femur, although uptake in the kidney was higher in arthritic mice (Figure 5-10a). 
In the ankle and wrist joints, uptake was higher in the arthritic mice compared to the healthy 
mice (Figure 5-10a), and this was also apparent in the knees and the shoulders, which do not 
show obvious inflammation macroscopically. 68Ga(HP3-RGD3) uptake in the hands and wrists, 
and feet and ankles was correlated with paw swelling (from the caliper measurements), to 
determine whether the use of this radiolabelled peptide was appropriate for monitoring disease 
severity. Both the hands and wrists, and the feet and ankles showed positive correlations 
between 68Ga(HP3-RGD3) uptake and paw swelling (Figure 5-10b). In addition to analysing 
68Ga(HP3-RGD3) uptake by biodistribution, whole body PET/CT images were acquired. These 
showed non-specific uptake in the kidneys and bladder, due to normal excretion of the 
radiolabelled peptide, but there were also areas of RGD peptide uptake which were visible in 







Figure 5-10: PET/CT imaging and biodistribution of WT mice.  
(a-c) WT mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 0 and 2. Clinical 
scores were collected daily and mice were injected with 68Ga(HP3-RGD3) (i.v.) on day 8. 1 hour post injection, mice 
were culled and subjected to PET/CT imaging and biodistribution. (a) % 68Ga(HP3-RGD3) uptake in non-target organs 
(% of injected dose, ID, corrected for organ weight, in grams, top) and target organs (% of injected dose, ID, bottom) 
is shown for WT mice that received PBS (white) and WT mice that received arthritogenic serum (black). n = 3 + s.d; 
*p<0.05,***p<0.005, ****p<0.0001 using a 2-way ANOVA with Tukey’s multiple comparisons test. (b) Correlation 
showing % 68Ga(HP3-RGD3) uptake in hands and wrists (circle) and feet and ankles (square) (% of injected dose, ID) 
with caliper measurements (for feet and ankles, the footpad and ankle measurements have been added together), 
from all mice, where each point represents an individual joint from a mouse; Pearson’s r2 = 0.762 (hands and wrists) 
and 0.8784 (feet and ankles). (c) Example PET images of a mouse that received PBS (left) and a mouse that received 
arthritogenic serum (right). Note the signal detected in the wrists and ankles of the arthritic mouse (indicated by 
arrows). All experiments were carried out with Dr Samantha Terry and Dr Michelle Ma (King’s College London). 
To investigate whether this technique could be used to identify differences in disease in the 
absence and presence of PTPN22, similar experiments were carried out with WT and Ptpn22-/- 
mice. Uptake of 68Ga(HP3-RGD3) in non-target organs was the same regardless of the genotype 
of the mice and the disease status (Figure 5-11a). In the joints, there was enhanced uptake in 
arthritic mice compared to healthy mice in the feet and ankles (p<0.05 for WT mice and p< 
0.0001 for Ptpn22-/- mice) (Figure 5-11a). In addition, there was enhanced uptake of 68Ga(HP3-
RGD3) in the hands and wrists, feet and ankles, and shoulders of Ptpn22-/- arthritic mice 
compared to WT arthritic mice (Figure 5-11a). This suggests that expression of αvβ3 is higher in 
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the joints of arthritic Ptpn22-/- mice compared to WT mice. Finally, uptake of the radiolabelled 
RGD peptide positively correlated with paw swelling measurements for both WT and Ptpn22-/- 
mice (Figure 5-11b). Enhanced 68Ga(HP3-RGD3) uptake is due to higher integrin αvβ3 expression, 
and this could indicate that there are more osteoclasts present in the joints of arthritic Ptpn22-
/- mice, which would then result in more bone erosion, thus correlating with the more severe 
arthritis that I have observed.  
 
Figure 5-11: Biodistribution of WT and Ptpn22-/- healthy and arthritic mice after injection with 68Ga(HP3-RGD3).  
(a-b) WT and Ptpn22-/- mice were injected (i.p.) with 150 µl PBS or arthritogenic serum (diluted 1:1 with PBS) on days 
0 and 2. Clinical scores were collected daily and mice were injected with 68Ga(HP3-RGD3) (i.v.) on day 6. 1 hour post 
injection, mice were culled and subjected to biodistribution. (a) % 68Ga(HP3-RGD3) uptake in non-target organs (% of 
injected dose, ID, corrected for organ weight, in grams, left) and target organs (% of injected dose, ID, right) is shown 
for WT mice WT (grey and black) and Ptpn22-/- (pink and red) mice. n = 3 (PBS) and 5 (arthritogenic serum) + s.d; 
*p<0.05,**p<0.01, ****p<0.0001 using a 2-way ANOVA with Tukey’s multiple comparisons test (only WT v Ptpn22-/- 
comparisons for either PBS or arthritogenic serum are shown, for simplicity). (b) Correlation showing % 68Ga(HP3-
RGD3) uptake in feet and ankles (left) and hands and wrists (right) (% of injected dose, ID) with caliper measurements 
(for feet and ankles, the footpad and ankle measurements have been added together), from WT (white) and Ptpn22-/- 
(black) mice, where each point represents an individual joint from a mouse; Pearson’s r2 = 0.3713 (WT hands and 
wrists), 0.4679 (Ptpn22-/- hands and wrists), 0.2768 (WT feet and ankles) and 0.6452 (Ptpn22-/- feet and ankles). All 






5.3.9 PTPN22 is dispensable for osteoclast differentiation in vitro 
 
Osteoclasts are responsible for the bone erosion seen during arthritis, and as the enhanced 
uptake of 68Ga(HP3-RGD3) in the joints of arthritic Ptpn22-/- mice suggests that there are more 
osteoclasts present in these mice, I next wanted to investigate whether PTPN22 played a role in 
their differentiation and/or function. WT and Ptpn22-/- bone marrow cells were differentiated in 
vitro, in the presence of M-CSF alone (as a negative control) and M-CSF and RANK-L (to 
differentiate osteoclasts). On day 10 of culture, a commercial kit was used to stain for the 
osteoclast specific enzyme tartrate-resistant acid phosphatase (TRAP). As osteoclasts are 
multinucleated cells, they are characterised as being TRAP positive, and having three of more 
nuclei. Quantification of the proportion of the cultures that were either TRAP-, TRAP+ with 1 or 
2 nuclei, and TRAP+ with three or more nuclei (osteoclasts), showed that the lack of PTPN22 
expression did not affect osteoclast differentiation in vitro based on these readouts (Figure 5-
12a-b).  
 
Figure 5-12: PTPN22 is dispensable for osteoclast differentiation in vitro.  
(a-b) WT and Ptpn22-/- bone marrow progenitor cells were differentiated in the presence of M-CSF and RANK-L for 10 
days. TRAP staining was carried out to visualise differentiated osteoclasts. (a) Example images of TRAP stained WT 
(left) and Ptpn22-/- (right) cultures, taken using a 40x objective. The stars indicate osteoclasts (TRAP+, with 3 or more 
nuclei). (b) Combined quantification of TRAP stained WT (white) and Ptpn22-/- (black) TRAP stained cultures. n = 14 + 
s.d. 
In order to measure osteoclast differentiation in a more quantitative manner, RNA was 
extracted from osteoclast cultures at day 12 of culture and reverse transcribed into cDNA. 
Expression of Ptpn22 was first analysed, to verify that WT osteoclasts expressed the gene and 
that Ptpn22-/- osteoclasts did not (Figure 5-13a). After this, qRT-PCR was carried out to look at 
the expression of osteoclast specific genes Itgb3, Ctsk, Tnfrs11a and Mmp9. cDNA from WT and 
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Ptpn22-/- bone marrow cells grown in the presence of M-CSF only were used as negative controls. 
Both WT and Ptpn22-/- bone marrow cells differentiated in the presence of M-CSF and RANK-L 
expressed higher levels of the osteoclast specific genes compared to M-CSF dependent 
macrophages, grown in the presence of M-CSF only (Figure 5-13b-e). Both WT and Ptpn22-/- cells 
expressed similar levels of these genes, indicating that PTPN22 is dispensable for osteoclast 
differentiation in vitro, which is consistent with the quantification of TRAP staining.  
 
Figure 5-13: PTPN22 is dispensable for osteoclast differentiation in vitro.  
(a-d) WT and Ptpn22-/- bone marrow progenitor cells were differentiated in the presence of M-CSF alone or M-CSF and 
RANK-L for 12 days. Cells were lysed and mRNA was extracted and reverse transcribed into cDNA. qRT-PCR was carried 
out to look at expression of osteoclast specific genes. Expression was determined using 2(-ΔCt), all relative to B2m. WT 
(white) and Ptpn22-/- (black) cell expression of Ptpn22 (a), Itgb3 (b), Ctsk (c), Tnfrs11a (d), and Mmp9 (e). n = 7 + s.d.  
 
5.3.10 PTPN22 is not required for osteoclast function in vitro 
 
Although I have found that PTPN22 is not required for osteoclast differentiation in vitro, I wanted 
to investigate whether the phosphatase is required for their function. c-Src is needed for normal 
osteoclast structure and function, as osteoclasts from mice lacking c-Src expression are unable 
to form ruffled borders, have reduced cell migration and are unable to resorb bone228.  
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To investigate a potential role of PTPN22 in osteoclast function, WT and Ptpn22-/- bone marrow 
cells were cultured in the presence of M-CSF or M-CSF and RANK-L in wells coated with Europium 
labelled collagen. As the cells differentiate, they will become capable of degrading the 
underlying collagen. This will cause the release of Europium labelled collagen fragments from 
the bottom of the wells, into the media. The released collagen fragments can be measured on a 
plate reader and used as a measure of osteoclast differentiation and degradation. Over the 
course of the culture, more collagen fragments were released from the bottom of the wells by 
the cells, and the level of collagen degradation was highest in the presence of M-CSF and RANK-
L, compared to M-CSF alone (Figure 5-14). However, both WT and Ptpn22-/- cells released similar 
levels of collagen into the media, indicating that PTPN22 is not required for osteoclast function 
in vitro (Figure 5-14). 
 
Figure 5-14: PTPN22 is dispensable for osteoclast dependent collagen degradation.  
WT and Ptpn22-/- bone marrow progenitor cells were differentiated in the presence of M-CSF alone or M-CSF and 
RANK-L for 11 days in wells coated with Europium labelled collagen. Cell-free supernatants were removed on days 6 
and 11 and the amount of collagen fragments present in the media was determined using an OsteoLyse assay and 
measured using a plate reader. Collagen fragments detected in media from WT (white) and Ptpn22-/- (black) cells 
grown in the presence of M-CSF and RANK-L relative to cells grown in the presence of M-CSF alone. n = 3 + s.d.  
 
5.4 Overall findings 
 
The main findings of this Chapter were: 
1. Lack of PTPN22 expression causes more severe disease using the K/BxN serum transfer 
model of arthritis. 
2. This is not associated with detectable changes in serum cytokines, chemokines, joint 
damage or immune cell infiltration in the joints and joint draining lymph nodes. 
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3. PET imaging of a 68Ga labelled RGD peptide can be used to image areas of inflammation 
in whole animals, and enhanced 68Ga(HP3-RGD3) uptake was detected in the joints of 
arthritic Ptpn22-/- mice. 
4. PTPN22 is dispensable for osteoclast differentiation and function in vitro. 
 
Some of these data have been published in: 
2. Imberti C, Terry SY, Cullinane C, Clarke F, Cornish GH, Ramakrishnan NK, Roselt P, 
Cope AP, Hicks RJ, Blower PJ, Ma MT. Enhancing PET Signal at Target Tissue in Vivo: 
Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging 




This Chapter has investigated whether PTPN22 plays a role in a mouse model of rheumatoid 
arthritis and whether it is required for osteoclast differentiation and function. Ptpn22-/- mice 
were found to be more susceptible to the K/BxN serum transfer model of arthritis. As Chapters 
3 and 4 demonstrated that PTPN22 is required to negatively regulate DC effector responses after 
immune complex engagement, and disease using this model is initiated by the transfer of 
autoantibodies, this suggests that dysregulated responses to autoantibodies/immune 
complexes in the absence of PTPN22 could account for the enhanced disease that I have 
observed.  
My observation that Ptpn22-/- mice show enhanced disease using the K/BxN serum transfer 
model of arthritis is in contrast with published data showing that PTPN22 either augments63 or 
has no effect on disease development10,59. There are multiple reasons for this discrepancy, 
including differences in the titre of the arthritogenic serum administered. It has been shown in 
CD8+ T cells that PTPN22 negatively regulates TCR signalling by weak antigens, but has no effect 
on responses to strong antigens291, so it may be possible that PTPN22 is regulating signalling 
downstream of FcγRs differently depending on the amount of autoantibodies/immune 
complexes present, which would be dependent on the titre of the serum used. In addition, it has 
been shown that the prevalence and severity of arthritis in the K/BxN model and the K/BxN 
serum transfer model of arthritis are regulated by the microbiota, such that after antibiotic 
treatment, arthritis severity is reduced292,293. The reduction in disease severity has been 
attributed to a deficiency of peripheral Th17 cells in the absence of the microbiota, especially 
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segmented filamentous bacteria294. Therefore, it is possible that differences in mouse housing 
between research groups could account for the disparity in results. In agreement with this, I 
have found that disease severity is drastically different between mice that have been bred in-
house and C57Bl/6 mice that has been bought in from a commercial supplier. When I injected 
mice from our colony and C57Bl/6 mice from Charles River (age and sex matched) 
simultaneously, using the same batch of arthritogenic serum, the Charles River mice developed 
a more severe disease, with higher penetrance (unpublished observations).  
Despite expression of PTPN22R620W in humans being associated with an enhanced susceptibility 
to multiple autoimmune diseases, I did not find an increased incidence of arthritis in Ptpn22R619W 
mice compared to WT mice. This result is not entirely unexpected, as although humans 
harbouring the PTPN22 variant have an increased risk of autoimmune disease, it is not 
considered to be a causative allele. There are more than 100 risk alleles which have been 
associated with RA295,296, with the odds ratio of PTPN22R620W for RA being 1.3-2.13295. In addition, 
environmental factors affect the likelihood of disease, and these are more varied in humans 
compared to inbred mice housed in a controlled environment. The K/BxN serum transfer model 
of arthritis has been previously reported using Ptpn22R619W mice, where, in agreement with my 
data, they also displayed similar disease to WT mice10.   
Changes in serum cytokines and chemokines during the disease could not account for the 
difference in WT and Ptpn22-/- disease. The difference in cytokine secretion between healthy 
and arthritic mice was not striking, which was surprising as it has been shown that enhanced 
expression of pro-inflammatory cytokines such as IL-17, IL-1 and TNFα in the joints can lead to 
tissue destruction290. However, as cytokines act locally, in a regulated manner, it would be 
beneficial in the future to look at cytokine secretion in the joints, as opposed to systemically. I 
did however find enhanced expression of IFNβ and IL-27 in the serum of Ptpn22-/- mice on day 
3, independent of disease status. Enhanced IL-27 has been found in the serum of RA patients, 
and this positively correlated with disease activity297. IL-27 is secreted by antigen presenting cells 
and can bind to its receptor on T cells and NK cells. In this way, IL-27 can promote the 
differentiation of naïve CD4+ T cells into Th1 cells, thus inducing a pro-inflammatory response. It 
is therefore possible that by expressing enhanced IL-27 in the steady state, Ptpn22-/- mice are 
more likely to show a more pro-inflammatory phenotype, as shown by enhanced disease after 
transfer of the arthritogenic serum. However, anti-inflammatory effects of IL-27 have also been 
documented. I did also detect reduced serum levels of LIX in arthritic Ptpn22-/- mice compared 
to arthritic WT mice. LIX has been found to be elevated in the synovial fluid of RA patients 
compared to osteoarthritis patients298. It has also been shown to cause human neutrophil 
chemotaxis299 and anti-LIX treatment reduced arthritis in mice300. This indicates that LIX is 
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involved in driving inflammation during arthritis, which is at odds with the fact that I found 
reduced serum levels of LIX in Ptpn22-/- mice, which showed enhanced clinical signs of disease 
compared to WT mice. This may be because I measured chemokine expression in the serum and 
not in the joints of the mice. 
Histological analysis of the joints of healthy and arthritic mice demonstrated that joint cell 
infiltration and erosion were similar between WT and Ptpn22-/- mice. This may have been partly 
because in the experiment used for the histology, the Ptpn22-/- mice developed disease more 
rapidly and had begun to resolve by the end of the experiment. This meant that on day 9, the 
WT and Ptpn22-/- mice showed similar disease severity. There was however a slight trend 
towards enhanced cell infiltration in the ankle joints of Ptpn22-/- mice, but due to the low number 
of samples analysed, no conclusion could be made on this potential difference. By analysing 
more ankle joints in the future, it should be possible to draw more firm conclusions regarding a 
potential increase in joint cell infiltration in Ptpn22-/- mice. No difference in joint cell infiltration 
or joint erosion was observed between WT and Ptpn22R619W mice, but this was not surprising, as 
there was no difference in disease severity.  
Immune phenotyping of cells in the joints and joint draining lymph nodes revealed a trend 
towards an increased frequency of neutrophils in the ankle joints of arthritic Ptpn22-/- mice, but 
this was not significant, most likely due to the low number of samples. Neutrophils are pivotal 
in acute and chronic disease as they can release a variety of mediators which cause inflammation 
and tissue damage. This includes releasing pro-inflammatory cytokines, reactive oxygen species, 
secreting degradative enzymes (including MMP-8, MMP-9, cathepsin G, neutrophil elastase and 
proteinase 3) and releasing neutrophil extracellular traps (NETs)301. In addition, neutrophils have 
also been found to be indispensable for the K/BxN serum transfer model of arthritis181.  
In my experiments I found that the immune cell populations were greatly expanded in the ankle 
joint draining lymph nodes of arthritic mice compared to the healthy mice, although this was 
not the case in the wrist draining lymph nodes (except for neutrophils) or the spleens. The spleen 
is probably too systemic to see any changes. In the future, it would be interesting to look at 
these immune cell populations at different time points during the disease, as the different cell 
types do not enter the joints simultaneously. In addition, solely looking at changes in total cell 
numbers may not lead to a correlation with disease severity. Alternatively, it may be more 
revealing to do more in depth phenotyping, for example, to identify T cell subsets which are 
important in disease progression such as Th17 cells. It has been shown that blocking IL-17 in 
K/BxN mice causes reduced disease294, mice lacking expression of IL-17 have reduced 
development of CIA302 and that Th17 cells are elevated in the synovial fluid of RA patients 
compared to peripheral blood303. To further characterise the immune cells present in the joints 
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and joint draining lymph nodes, single cell suspensions could be stimulated in vitro with PMA 
and ionomycin such that expression of cytokines could be detected. In addition, specific cell 
populations could be isolated, and their function could be tested in vitro. It may be possible that 
PTPN22 regulates the function of immune cells present in the joints and/or draining lymph 
nodes, without affecting the cell frequencies or total cell numbers.  
PET/CT imaging was found to be a useful technique to visualise areas of inflammation at the 
whole organism level using the K/BxN serum transfer model of arthritis. Uptake of 68Ga(HP3-
RGD3) by PET positively correlated with clinical scores, demonstrating that the technique 
provides a robust way of non-invasively monitoring disease in mice, especially those joints that 
are difficult to assess clinically (e.g. shoulders). In the future it would interesting to image mice 
at multiple time points, especially in very early disease, in order to identify whether the 
technique is sensitive enough to identify areas of inflammation before clinical signs are visible. 
It would also be beneficial to see whether the technique could be used to monitor resolution of 
disease and responses to therapies. If this was successful, then this technique could potentially 
be used to monitor patients to see whether a treatment was efficacious or not, thus potentially 
reducing the time before an alternative treatment could be administered.  
By using biodistribution, uptake of the radiolabelled RGD peptide was found to be higher in the 
joints of Ptpn22-/- arthritic mice compared to WT arthritic mice. This indicates that expression of 
the integrin αvβ3 is higher in these mice. αvβ3 is expressed on a variety of cells in the arthritic 
joint including activated macrophages, activated endothelial cells and osteoclasts. It would be 
particularly interesting to evaluate the number of osteoclasts present in the joints, to see 
whether these may be responsible for the enhanced αvβ3 expression, and therefore could be 
responsible for the more severe disease seen in Ptpn22-/- mice. Visualisation of osteoclasts could 
be achieved by carrying out TRAP staining on joint sections. 
As osteoclasts are the only bone resorbing cell type, the role of PTPN22 in their differentiation 
and function was assessed. Bone marrow cells lacking PTPN22 were found to differentiate 
normally into osteoclasts. In addition, Ptpn22-/- osteoclasts were equally capable of degrading 
collagen as WT osteoclasts. One of the reasons why PTPN22 may be dispensable for osteoclast 
differentiation, may be due to the presence of other protein tyrosine phosphatases of the PTP-
PEST family, such as PTPN12. PTPN12 has been shown to be required for RANK-L dependent 
fusion of macrophages into osteoclasts232. One caveat of these in vitro cultures was that only a 
proportion of the bone marrow cells differentiated into osteoclasts, indicating that the culture 
conditions were not optimal. In the future, it would be interesting to test different osteoclast 
differentiation protocols, for example, differentiation using immune complexes304,305. In 
addition, the cells could have been differentiated for longer, to see whether this could increase 
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the proportion of osteoclasts in the cultures. Alternatively, the M-CSF and RANK-L 
concentrations could have been tested to see if a different concentration could have been more 
effective. Differentiating osteoclasts in tissue culture plates is not optimal as osteoclasts need 
to come into contact with bone in order to become fully functional osteoclasts, with a resorptive 
capacity. I could have instead cultured the progenitor cells on dentine slices, which more closely 
mimic differentiation of cells in vivo. The non-optimal culture conditions may provide a reason 
why the expression of osteoclast specific genes and the collagen degradation was not too 





6.1 New insights into the role of PTPN22 in mice, and potential implications for 
PTPN22R620W expression in humans 
 
When I started this research project, the majority of the published data reporting on the role of 
PTPN22 in regulating immune receptors in mice was focused on the TCR and BCR. More recently, 
its role in regulating myeloid cell receptor signalling has been investigated, and my studies have 
contributed to this knowledge. Table 6-1 lists the signalling pathways which have been 
investigated to date. 
Signalling 
Pathway 
Role of PTPN22 in 
regulating pathway 
Likely substrates Reference 
TCR Negative regulator Lck, Fyn, ZAP-70 Hasegawa K, Science, 200455 
BCR No affect/negative 
regulator 
Lyn, Fyn, Blk, Syk Hasegawa K, Science, 200455 and 
Dai X, JCI, 201313 
TLR Positive regulator TRAF3 (not via its 
enzymatic function) 
Wang Y, Immunity, 201310 
Dectin-1 Negative regulator Syk Purvis HA, EJI, 201866 
LFA-1 Negative regulator Lck, ZAP-70 Brownlie RJ, Science Signaling, 
201258, Burn GL, Science 
Signaling, 201660 and Sanchez-
Blanco C, Journal of 
Autoimmunity, 201861 
FcγR Negative regulator Src, Hck, Fgr, Lyn, Syk  Clarke F, Scientific Reports, 
2018306 
Table 6-1: Signalling pathways in mice in which the role of PTPN22 has been investigated. 
Previous mouse and human data have provided multiple explanations as to why expression of 
PTPN22R620W could increase the risk of autoimmunity. These include alterations in B cell 
development, leading to an increased frequency of autoreactive B cells13,81, enhanced BCR 
signalling13, which in turn activate autoreactive T cells, promoting the production of germinal 
centres12 and subsequent autoantibody production by plasma cells13, reduced BCR dependent B 
cell apoptosis13, expansion of memory T cell populations12,13,81 and altered T cell skewing58, 
leading to a reduction in the ratio of Tregs to effector T cells57, and changes in innate responses, 
such as reduced type I interferon production by myeloid cells after TLR stimulation10.  
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My data compliments these findings by firstly showing that lacking PTPN22 expression, or 
expression of the autoimmune associated variant of PTPN22 does not regulate antigen 
endocytosis or processing by in vitro generated mouse BMDCs or ex vivo splenic DCs. This 
indicates that changes in antigen uptake and processing by DCs are unlikely to be responsible 
for promoting autoimmunity in humans harbouring the PTPN22R620W risk allele. However, I have 
found that DC expression of PTPN22 negatively regulates immune complex induced T cell 
proliferation. If PTPN22R620W acts as a loss-of-function mutation in the context of FcγR signalling, 
then a lack of regulation of immune complex signalling in DCs could cause enhanced T cell 
activation, potentially augmenting immune responses to self-antigens. In the future it would be 
beneficial to investigate FcγR dependent immune responses in DCs from humans expressing 
PTPN22R620W, which would be especially important due to the presence of autoantibodies in 
most of the associated autoimmune diseases, such as SLE and RA. 
Using the K/BxN serum transfer model of arthritis, mice expressing the orthologue of the human 
autoimmune associated variant did not develop more severe disease than WT mice. The fact 
that expression of PTPN22R619W did not affect disease progression is not all together surprising, 
as although the human variant is associated with an enhanced susceptibility to arthritis, it is not 
a causative allele, and so not all people harbouring the variant develop arthritis. Other genetic 
and environmental factors play a role in disease development, which are not recapitulated in 
the experiments using Ptpn22R619W mice. It is likely that investigating the role of the autoimmune 
associated variant of PTPN22, in both mouse and human cells may not provide a conclusive 
explanation for the enhanced disease susceptibility associated with PTPN22R620W expression in 
humans. It may be more informative to investigate the role of this polymorphism in combination 
with additional risk alleles, for example those involved in TCR, BCR and co-stimulatory molecule 
signalling, which are also associated with an enhanced risk of autoimmune diseases307,308. 
I did however find that mice lacking expression of PTPN22 were more susceptible to arthritis 
using this model. This indicates that the impact of phosphatase deficiency is distinct to that 
associated with expression of the autoimmune associated variant of the phosphatase in this 
situation. This may be partly because the R619W/R620W mutation will affect the ability of 
PTPN22 to interact with other proteins but may not detrimentally affect its catalytic activity. In 
fact, it has been suggested that PTPN22R620W has an increased catalytic activity compared to the 
WT protein79. This could indicate that PTPN22 may be affecting disease via its ability to 
dephosphorylate kinases, and not via its ability to interact with other proteins, which would 
explain why lacking the phosphatase affects disease severity whereas expression of the 
autoimmune associated variant does not.  
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It has been shown that human monocyte derived DCs which are differentiated in the presence 
of immune complexes express higher levels of CD40, CD83 and CD86 and that LPS treatment did 
not further enhance their expression. These DCs also showed low endocytic activity and were 
less able to induce T cell proliferation309, indicating that immune complexes regulate DC 
differentiation and maturation. The phenotype of DCs grown in the presence of immune 
complexes was found to be similar to DCs from SLE patients. This suggests that in diseases that 
involve autoantibodies and immune complexes, such as those associated with PTPN22R620W 
expression, altered responses of DCs and DC progenitors to FcγR engagement may play a role in 
the disease pathogenesis.  
 
6.2 PTPN22 does not regulate antigen uptake or processing 
 
Although Src and Syk family kinases are involved in multiple stages of antigen uptake and 
processing, I have found that PTPN22, which dephosphorylates these kinases, is dispensable for 
these processes. The role of PTPN22 in the internalisation of Lucifer yellow (via 
macropinocytosis) and HKLM, HKCA and ova (via receptor mediated endocytosis) by BMDCs was 
tested and PTPN22 was found not to be required. In addition, the expression of PTPN22R619W 
was tested for its ability to affect BMDC internalisation of LY, HKCA and ova and again found not 
to play a role. This is in contrast with a published report that showed enhanced uptake of 
Escherichia coli (E.coli) by Ptpn22R619W macrophages67. One likely explanation for this 
discrepancy may be the differences between macrophage and DC antigen uptake. Alternatively, 
PTPN22 may specifically regulate phagocytosis of E. coli, rather than regulating receptor 
mediated endocytosis more broadly.  
 
6.3 PTPN22 is dispensable for OVA323-339 peptide or ova induced T cell proliferation 
 
When BMDCs were pulsed with OVA323-339 peptide or ova, I found that PTPN22 was dispensable 
for WT CD4+ T cell proliferation. PTPN22R619W expression by BMDCs was also found to be 
dispensable for T cell proliferation after the BMDCs were pulsed with OVA323-339 peptide. This is 
contrary to published reports, which showed that OVA323-339 peptide or ova pulsed Ptpn22R619W 
BMDCs induced enhanced T cell proliferation after 4 days12, and that ova pulsed Ptpn22R619W 
macrophages caused enhanced expression of CD69 on WT CD4+ T cells after 18 hours of co-
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culture and enhanced T cell proliferation after 5 days67.  The reason for these observed 
differences in T cell activation between my experiments and these previous studies could be due 
to a variety of factors. One difference is the concentration of ova which has been used. I used 
10 µg/ml ova, whereas the Ptpn22R619W macrophages were pulsed with 10-100 µg/ml, with little 
difference in CD69 expression seen at 10 µg/ml and a greater difference being observed at 100 
µg/ml67. For the ova pulsed Ptpn22R619W BMDCs experiments, 100 µg/ml ova was used, and the 
ratio of T cells to DCs was also different, such that I used 1 DC:2 T cells, and the published report 
used 1 DC:4 T cells12.  Finally, the length of the co-culture was not the same between the 
experiments, as I assessed T cell proliferation after 6 days of co-culture and the other groups 
used 4 or 5 days.  
 
6.4 PTPN22 is required to regulate immune complex induced T cell proliferation 
 
Investigating the role of PTPN22 in regulating FcγR dependent BMDC responses was a logical 
strategy because a major feature of the autoimmune diseases associated with PTPN22R620W is 
the presence of autoantibodies. These autoantibodies bind to antigens to form immune 
complexes, the internalisation of which is mediated by FcRs, ultimately leading to the production 
of a T cell dependent immune response. Although my data have shown that PTPN22 is 
dispensable for immune complex binding, uptake and processing, I did however find that 
immune complex pulsed Ptpn22-/- BMDCs were more effective at inducing T cell proliferation. 
This was accompanied by an enhanced capacity to form BMDC-T cell conjugates, and to present 
immune complex derived antigens. The absence of PTPN22 may confer a subtle increase in FcγR 
dependent inflammatory signals that target immune complexed antigen for MHCII presentation. 
This increase could potentially be due to PTPN22 mediated changes to the balance of 
activating/inhibitory FcγR expression on the DC surface. This data shows that PTPN22 negatively 
regulates FcγR dependent T cell activation by BMDCs, and indicates that perturbations to 
PTPN22 in humans could affect immune complex induced DC effector responses. 
The role of PTPN22 in the regulation of FcγR signalling has been previously addressed in 
neutrophils, where PTPN22 is required for optimal immune complex induced ROS production, 
adhesion and degranulation63. Contrary to this, I found no differences in BMDC effector 
functions after immune complex stimulation, including the upregulation of co-stimulatory 
molecules or cytokine secretion. This indicates that the requirement for PTPN22 in the context 
of FcγR signalling may differ depending on the cell type. Neutrophils are also capable of 
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mediating MHCII antigen presentation310, and so in the future it would be interesting to test 
whether in neutrophils, where PTPN22 has been demonstrated to positively regulate multiple 
effector functions, FcγR mediated antigen presentation is positively or negatively regulated by 
PTPN22.  
The role of Src and Syk family kinases in Fcγ receptor mediated endocytosis has been 
established311. Syk is essential for FcγR mediated uptake in macrophages312, neutrophils312 and 
DCs245, and Src family kinases are not essential but are required for optimal uptake of IgG 
opsonised particles by macrophages122. By using small molecule inhibitors, I have also found that 
immune complex uptake via FcγRs requires Src and Syk family kinases. The discovery that 
PTPN22, which dephosphorylates these proteins, was dispensable for immune complex uptake 
may be due to the presence of other phosphatases such as SHP-1, SHP-2, SHIP-1 and SHIP-2 in 
Ptpn22-/- BMDCs. Alternatively, PTPN22 may regulate signalling downstream of FcγRs such that 
it specifically regulates MHCII antigen presentation, rather than broader BMDC effector 
functions. In the future, it would be useful to carry out pulldown assays which would allow me 
to determine whether PTPN22 was physically interacting with Src and Syk family kinases after 
FcγR crosslinking. If PTPN22 does not interact with its targets after FcγR engagement, then this 
would provide an explanation as to why PTPN22 is not required for FcγR mediated antigen 
internalisation and processing. It may then be possible to identify if different PTPN22 family 
members may instead be regulating FcγR signalling.  
In order to identify whether PTPN22 was important in immune complex derived antigen 
presentation, I carried out assays using immune complexes containing GFP-Eα. I found that in 
the absence of PTPN22, BMDCs presented more Eα52–68 peptide-MHCII complexes on their 
cell surface. However, these assays do not allow me to distinguish between PTPN22 playing a 
role in the formation of Eα52–68 peptide-MHCII complexes, their trafficking to the cell surface, 
or presentation of these complexes on the cell surface. DCs use endolysosomal tubules to 
transport peptide-MHCII complexes to the cell surface for presentation to T cells114. Syk was 
shown to be required for efficient formation of peptide-MHCII complexes in a murine B cell 
line313, and ITAM signalling is required to maintain peptide-MHCII complexes on the surface 
of DCs140. It is therefore possible that in the absence of PTPN22 mediated dephosphorylation, 
that Syk is more active and could therefore cause enhanced formation of peptide-MHCII 
complexes on the cell surface, explaining the enhanced immune complex derived antigen 
presentation that I have observed using Ptpn22-/- BMDCs. To look more closely at the 
formation and trafficking of peptide-MHCII complexes in WT and Ptpn22-/- BMDCs, it would 
be useful in the future to carry out experiments in which the localisation of GFP-Eα could be 
visualised in combination with antibodies against MHCII and organelle markers by confocal 
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microscopy; this would be straightforward due to the presence of the GFP tag. In addition, 
pulse-chase experiments could be used to shed light on peptide-MHCII complex presentation 
on the cell surface and recycling. It is possible that Ptpn22-/- BMDCs present more Eα52–
68 peptide-MHCII complexes on their cell surface due to an increased rate of formation and/or 
trafficking, and/or a reduced rate of peptide-MHCII complex recycling. It is possible that by 
analysing the PTPN22 interactome in BMDCs, that this could provide some idea as to where 
in the presentation pathway PTPN22 is important. 
As internalised immune complexes can also be presented on MHCI243,253, via cross-presentation, 
it would be interesting to determine whether PTPN22 in DCs also reduces immune complex 
induced CD8+ T cell responses. This pathway could be investigated using ova specific OT-I CD8+ 
T cells. In addition, an antibody exists which detects the OVA peptide SIINFEKL when bound to 
MHCI (25-D1.16314), so this would allow for the role of PTPN22 in immune complex derived 
antigen cross-presentation to be investigated. 
PTPN22 has also been shown to negatively regulate the fungal receptor dectin-166, although I 
have found that PTPN22 is not required for phagocytosis of C. albicans via dectin-1. It is possible 
that PTPN22 may regulate MHCII presentation of antigens derived from C. albicans and 
subsequent C. albicans specific T cell activation, but I have not tested this to date.  
 
6.5 Potential redundancy of protein tyrosine phosphatase family members with 
PTPN22 
 
As other PTP family members will be expressed in Ptpn22-/- mice, it is possible that redundancy 
of these phosphatases with PTPN22 could explain some of my data where PTPN22 has been 
found to be dispensable, despite the fact that Src and Syk family kinases have been implicated 
in the majority of the processes that I have investigated. PTP family members include PTPN2 
(also known as T cell protein tyrosine phosphatase, TCPTP), PTPN6 (also known as SHP-1), 
PTPN11 (also known as SHP-2), PTPN12 (also known as PTP-PEST) and PTPN18 (also known as 
PTP-HSCF). Many of these phosphatases have been shown to play roles in processes that I have 
investigated. For example, PTPN6 has been shown to be important in negatively regulating 
signalling downstream of the C-type lectin receptor Siglec-G, leading to reduced expression of 
peptide-MHCI complexes on mouse CD8α+ splenic DCs for cross-presentation315. In addition, 
PTPN6 has been shown to be required for phagosome acidification in mouse macrophages316. 
Like PTPN22, PTPN12  is also dispensable for BMDC ova protein induced T cell proliferation and 
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OVA323-339 peptide induced DC-T cell conjugate formation, but is required for the induction of 
optimal IFNγ secretion by T cells317. These data indicate that members of the same phosphatase 
family can regulate specific and independent DC effector functions. Indeed, as Ptpn22-/- BMDCs 
will express PTPN12, this may also explain why IFNγ secretion was similar by T cells co-cultured 
with ova pulsed WT and Ptpn22-/- BMDCs. In addition, other non-PTP family member 
phosphatases will also be expressed in Ptpn22-/- BMDCs. These include phosphatases such as 
CD45 (PTPRC) and SHIP-1, which have been shown to regulate processes required for antigen 
uptake and processing281,318.  
As with my data investigating the role of PTPN22 in DCs, it may also be the case that PTPN22 is 
dispensable for osteoclast differentiation and function due to the presence of alternative 
phosphatases. For example, it has been shown that Ship-/- mice have increased numbers of 
osteoclast precursors and osteoclasts, due to enhanced signalling downstream of RANK and c-
Fms (the receptors for RANK-L and M-CSF respectively). Ship-/- osteoclasts are more resorptive 
than WT osteoclasts and cause enhanced bone loss319. This shows that SHIP negatively regulates 
osteoclast development and function. In addition, Shp-1-/- mice have reduced bone density due 
to an increase in osteoclast numbers which have an increased resorptive ability227, indicating 
that SHP-1 inhibits osteoclast differentiation and function. PTPN12 has also been shown to be 
required for IL-4 induced macrophage fusion into multinucleated giant cells and for RANK-L 
dependent fusion of RAW 264.7 macrophages into osteoclasts in vitro232. 
 
6.6 The drawbacks of using GM-CSF induced bone marrow derived DCs  
 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and fms-like tyrosine kinases 3 
ligand (Flt3L) have been shown to be capable of inducing DC expansion in vivo320,321, which is 
why these cytokines have been used as part of a simple protocol to generate BMDCs in vitro. 
GM-CSF and Flt3L play different roles in DC development, as mice that lack GM-CSF have normal 
DC numbers in lymphoid tissues322, but these cells are not capable of activating B and T cells323. 
Whereas, mice that lack Flt3L expression have a reduced number of DCs in the spleen, lymph 
nodes and thymus92.  
Signalling downstream of the GM-CSF receptor involves the phosphorylation of the tyrosine 
kinase janus kinase 2 (JAK2) and Src family kinases including Lyn, Fyn and Hck324. Downstream 
signalling involves the JAK/STAT, Ras/Raf/MEK/ERK and the PI3K/Akt pathways, all of which 
induce cell survival and proliferation325. Flt3L binding to Flt3 causes the receptor to dimerise, 
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which in turn causes receptor phosphorylation, potentially leading to the recruitment of Src 
family kinases326,327. Downstream signalling is mainly via the PI3K/Akt and JAK/STAT pathways, 
and signalling is negatively regulated by SHIP and SHP-2328. This indicates that PTPN22 may play 
a role in regulating signalling downstream of the GM-CSF receptor and Flt3. However, despite 
the presence of potential PTPN22 targets downstream of these receptors, I did not identify a 
role of PTPN22 in DC differentiation in response to either GM-CSF of Flt3L.  
GM-CSF induced BMDCs have been used as a model of DCs for decades. They provide an 
abundant source of cells for experiments, and allow for experiments to be carried out which 
could not otherwise be performed using ex vivo isolated DCs. More recently, their suitability as 
a model of in vivo DCs, and inferring results from BMDCs to in vitro DCs has come under 
increasing scrutiny. It has become apparent that although the cultures are composed of CD11c+ 
MHCII+ cells, which broadly characterise DCs, they are a heterogenous population including both 
DC-like and macrophage-like cells234. It has also been shown that the concentration of GM-CSF 
affects the proportion of DC-like and macrophage-like cells in the cultures, such that with 
increased GM-CSF the proportion of DC-like cells decreases and macrophage-like cells 
increases329. As I kept the concentration of GM-CSF unchanged throughout my experiments, my 
cultures should have contained a consistent composition of both cell types. GM-CSF bone 
marrow cultures have been also found to contain basophils, eosinophils and monocytes329. This 
means that extrapolations between GM-CSF derived DCs and in vivo DC populations should be 
interpreted with caution. The functions of these DC-like and macrophage-like cells were tested 
and macrophage-like cells were found to have an enhanced phagocytic capability and to produce 
more pro-inflammatory cytokines in response to TLR stimulation, whereas DC-like cells induced 
enhanced T cell proliferation329. This affects the interpretation of my data, such that PTPN22 
may not play a role in antigen uptake, which in these cultures is preferentially being carried out 
by macrophage-like cells, but may play a role in T cell proliferation, primarily induced by DC-like 
cells within the cultures. It is possible that PTPN22 is required for specific aspects of DC function, 
but that the presence of macrophage-like cells also in the cultures could mask this (if PTPN22 
was dispensable for the same function in macrophage-like cells).  
An alternative to using GM-CSF to differentiate DCs in vitro, is to use Flt3L instead. Flt3L induced 
BMDCs have been shown to produce cells which are more similar to in vivo DC subsets, as both 
CD8α+ (CD24+, DC1-like cells) and CD11b+ (SIRPα+, DC2-like cells) DCs are present in the 
cultures246. I carried out initial experiments with these cultures, but found once again that 
PTPN22 was dispensable for in vitro DC differentiation, ova uptake and immune complex 
induced co-stimulatory molecule upregulation. In the future it would be interesting to use Flt3L 
induced BMDCs in more assays, and to distinguish between the role of PTPN22 in both DC 
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subsets present within the cultures. This could be achieved by sorting the CD8α+ and CD11b+ 
DCs prior to the assays. DC1s and DC2s have different functions, for example, it is known that 
DC2s are more proficient at presenting internalised antigens to CD4+ T cells, whereas DC1s are 
more effective at inducing CD8+ T cell proliferation. This was found to correlate with an increased 
expression of proteins required for MHCI and MHCII processing in DC1s v DC2s respectively. In 
addition, by using antigens targeted to the specific DC subsets, DC2s were found to present more 
peptide-MHCII complexes on their cell surface compared to DC1s330. I found that ova uptake was 
much higher by CD11b+ DCs within the cultures, despite the fact that it has been previously 
shown that DC1 and DC2-like cells from Flt3L cultures or splenic DC1s and DC2s are equally 
capable of binding and internalising biotin conjugated ova331. A separate report showed that out 
of the splenic DC populations, only CD8α+ DCs expressed the mannose receptor104; however this 
may not be the case with in vitro differentiated DCs. Additional experiments using Flt3L BMDCs 
would be needed to explore this further. 
One difference between the GM-CSF and Flt3L induced BMDC cultures was the way in which the 
cells were harvested. The GM-CSF BMDCs were harvested by pipetting, whereas Trypsin-EDTA 
was used for the Flt3L BMDCs. The use of Trypsin-EDTA may have affected the cell surface 
expression of receptors, including the receptors used for phenotyping the cultures, FcγRs, and 
the mannose receptor. If the mannose receptor was not expressed at high levels on the surface 
of the Flt3L BMDCs, then the observed ova-AF488 uptake may have been mainly via 
macropinocytosis and not receptor mediated endocytosis. In the future, it would be beneficial 
to rest the harvested Flt3L induced BMDCs after harvesting, and prior to use in an assay, so that 
the expression of cell surface receptors would have time to recover.  
 
6.7 The role of PTPN22 in vivo 
 
Although I found that PTPN22 was required for immune complex induced T cell proliferation in 
vitro, I was unable to replicate these findings in vivo. There are multiple potential reasons for 
this difference. For example, there are other antigen presenting cells in vivo that would be 
capable of presenting immune complex derived antigens to the T cells. The in vitro co-cultures 
demonstrated a reductionist approach in which only BMDCs and T cells were present.  
A potential drawback of the FITC painting experiment, was that I used CD11c and MHCII 
expression to distinguish between resident and migratory DCs, such that migratory DCs express 
more MHCII and lower levels of CD11c. Although this gating is appropriate in the steady state, it 
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is less straight forward during inflammation. This is because resident DCs will also become 
activated and will therefore increase their MHCII expression332. However, as I applied the FITC 
in irritant locally, and only waited 24 hours before analysing FITC uptake by DCs, it is possible 
that I may still be able to use this gating strategy to distinguish between the migratory and 
resident DCs present in the draining LNs.  
 
6.8 Lack of PTPN22 expression leads to an enhanced disease using the K/BxN serum 
transfer model of arthritis 
 
I found that Ptpn22-/- mice develop more severe disease using the K/BxN serum transfer model 
of arthritis. Through my investigations, I was not able to determine a mechanism behind this, 
although there was a trend towards increased neutrophil infiltration in the ankle joints of 
Ptpn22-/- arthritic mice compared to WT mice. If this is true, the infiltrating neutrophils may be 
responsible for the enhanced disease seen, and therefore it would be important in the future to 
investigate how PTPN22 was regulating neutrophil function and/or migration. For example, 
PTPN22 may reduce their migration, such that in its absence there is an enhanced neutrophil 
influx into sites of inflammation. Neutrophils require LFA-1 to adhere to endothelial cells (via 
ICAM-1 or ICAM-2), prior to diapedesis from the blood into tissues333, and as PTPN22 has been 
shown to negatively regulate LFA-1 signalling60, this could provide a potential mechanism behind 
this. However, an enhanced neutrophil influx into the joints in the absence of PTPN22 would 
contradict a published report which showed that there was a reduced neutrophil population in 
the joints of Ptpn22-/- mice; interestingly, this report also showed a reduced severity of disease 
in Ptpn22-/- mice63. Although this paper demonstrated that PTPN22 positively regulates 
neutrophil effector functions in mice, a separate report has shown that expression of 
PTPN22R620W in human neutrophils enhances cell migration, calcium flux and ROS production, 
indicating that in this context, enhanced neutrophil responses may contribute to the joint 
damage seen in RA patients expressing the variant85. My biodistribution data showed that there 
was an enhanced 68Ga(HP3-RGD3) uptake in the wrists, ankles and shoulders of Ptpn22-/- arthritic 
mice, which correlates with the trend towards enhanced neutrophil frequencies found in the 
ankles of Ptpn22-/- arthritic mice by flow cytometry. 
Although I did not observe any differences in serum cytokine and chemokine levels between WT 
and Ptpn22-/- mice, this may have been in part because analysis of serum analytes might only 
detect evidence of systemic inflammation. It is possible that I may have observed differences if 
I had measured these analytes in the joints and joint draining lymph nodes of the mice. This 
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could be achieved by either using cell suspensions from digested joints, or by analysing mRNA 
levels of cytokines and chemokines from the joint tissue. I also found little differences between 
the levels of cytokines and chemokines in the serum of healthy compared to arthritic mice, 
which was surprising. Again, this indicates that it would be more beneficial in the future to look 
specifically in areas of inflammation.  
Using PET/CT imaging allowed me to visualise areas of inflammation at a whole body level. The 
addition of biodistribution analysis complemented this, by allowing for the quantitative analysis 
of 68Ga(HP3-RGD3) uptake in specific organs. Initial experiments using WT mice showed that this 
radiolabelled peptide could be used to accurately visualise areas of inflammation. Further 
experiments showed that uptake of the peptide was higher in the joints of Ptpn22-/- mice 
compared to WT mice, indicating that cell infiltration and/or angiogenesis was enhanced in 
these animals.  
A study using a radionuclide labelled RGD peptide has recently been investigated in humans as 
part of the INIRA-1 study (led by Dr Toby Garrood and colleagues, King’s College London). This 
used 99mTechnetium labelled NC100692 peptide (mariciclatide), originally developed for 
detecting cancer cell metastases, and single-photon emission computed tomography (SPECT) 
imaging to see if uptake could be detected in the joints of patients with RA. Whole body and 
hands and feet SPECT/CT images were acquired from 5 RA patients and uptake of the 
99mTechnetium labelled peptide was seen in all joints. Uptake positively correlated with disease 
activity scores for 28 joints (DAS28). Example SPECT images are shown in the Appendix (Figure 
8-2). This indicates that the use of radiolabelled RGD peptides to visualise areas of inflammation 
is a promising technique to monitor patients in a non-invasive manner, in order to monitor 
response to treatment and disease status. This data also indicates that further analysis of 
radiolabelled RGD peptide uptake in mouse models could have merit, including measuring tracer 
uptake at early stages during disease development.  
 
6.9 PTPN22 is dispensable for osteoclast differentiation and function in vitro 
 
As osteoclasts are responsible for the bone erosion seen during human RA, but also during 
mouse models of RA, I wanted to determine whether PTPN22 may have a role in their 
differentiation and function. As osteoblasts do not develop from hematopoietic progenitors, 
they will not express PTPN22, and so any PTPN22 dependent changes in bone turnover will be 
due to PTPN22 expression in osteoclast precursors and osteoclasts. PTPN22 targets Src and Syk 
family kinases are involved in osteoclast development and function, including downstream of c-
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Fms and RANK, so it is possible that PTPN22 may regulate these kinases. In addition, the F-BAR-
proline-serine-threonine phosphatase interacting proteins 1 and 2 (PSTPIP1/2) have been shown 
to interact with PTPN22 and that they are required for the disassembly and assembly of 
podosomes in osteoclasts334. This may indicate that PTPN22 may play a role in osteoclast 
function via an indirect mechanism. I have not to date tested a potential direct or indirect role 
of PTPN22 in the formation of a podosome-rich sealing zone in osteoclasts. The sealing zone is 
essential for osteoclasts to release hydrogen ions and degradative enzymes, so this structure is 
essential for their bone resorbing capacity. This could be achieved in the future using microscopy 
and staining with phalloidin, to identify filamentous actin. It has been shown previously that 
RAW 264.7 macrophages differentiated into osteoclasts and when PTPN22 was silenced using 
siRNA these cells were incapable of forming sealing zones and were subsequently unable to 
resorb calcium phosphate334. These data suggested that PTPN22 may play a role in osteoclast 
function. Finally, I did not investigate a role of PTPN22 in regulating αvβ3 signalling. The integrin 
αvβ3 is required for adhesion of osteoclasts to bone, and is vital to allow for full osteoclast 
differentiation and their subsequent degradative capacity. There is precedent for PTPN22 in 
regulating integrin signalling, as in the context of LFA-1 in T cells, PTPN22 has been shown to 
negatively regulate signalling60,61. The increased radiolabelled RGD tracer uptake I observed in 
the joints of arthritic Ptpn22-/- mice also raised the possibility of a role of PTPN22 in osteoclasts. 
Despite these potential associations between PTPN22 and osteoclasts, my in vitro experiments 
indicate that PTPN22 is not required for their differentiation or function. However, there are 
some caveats associated with these experiments. For example, full osteoclast differentiation 
only occurs when multinucleated osteoclasts are in contact with bone, so this would account for 
the fact that only a small proportion of my in vitro cultures differentiated into TRAP+ cells with 
three or more nuclei. In addition, I used M-CSF and RANK-L to induce osteoclast differentiation, 
however it has been shown that the presence of TGFβ can increase the number of TRAP+ 
cells335,336, so this is something that would be interesting to investigate. An alternative 
differentiation pathway involves the differentiation of osteoclasts from osteoclast precursors in 
the presence of autoantibodies to citrullinated vimentin304, so this method would be worthwhile 
investigating. I have found that PTPN22 regulates signalling downstream of FcγRs in BMDCs, and 
it has been published that PTPN22 is important for immune complex induced effector functions 
in neutrophils63, so it is possible that PTPN22 may regulate osteoclast differentiation after 
autoantibody or immune complex stimulation. It has previously been shown that osteoclast 
precursors and osteoclasts express peptidylarginine deiminases (PADs) which citrullinate 
proteins. They also express vimentin and citrullinated vimentin, the expression of which 
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increases with osteoclast differentiation. Furthermore, autoantibodies against citrullinated 






In this thesis I have provided new evidence identifying the hematopoietic phosphatase PTPN22 
as a negative regulator of FcγR dependent effector functions in mouse DCs. In the absence of 
PTPN22, this resulted in enhanced immune complex induced T cell proliferation, accompanied 
by augmented presentation of immune complex derived peptides in MHCII and DC-T cell 
conjugate formation. In addition, I have found that PTPN22 reduces disease severity using a 
mouse model of arthritis. This data has added to our knowledge of the function of PTPN22 in 
mice, and could have implications for people harbouring the PTPN22R620W autoimmune 





Figure 8-1: Internalised ova-AF568 coated beads co-localise with LAMP-1 and ova-AF568 fluorescence reduces over 
time, with a concomitant increase in LAMP-1 fluorescence.  
(a) Flow cytometry analysing the remaining ova-AF568 fluorescence intensity on phagocytosed beads after 3 hours at 
37°C, isolated from Rab32+/+ (WT) and Rab32-/- BMDCs. b) Mean fluorescence intensity of ova-AF568 in isolated beads 
after different times of phagocytosis by WT (white) and Rab32-/- (black) BMDCs. The initial time point represents the 
values of undegraded ova, the different times after phagocytosis show the values of the remaining ova in the degraded 
fraction. (c-f) WT and Rab32-/- BMDCs were pulsed for 30 minutes with ova-AF568 coated beads. At 30 minutes and 2 
hours after the pulse, BMDCs were fixed and stained with anti-LAMP1 and analysed by confocal microscopy. (c) 
Example images of ova-AF568 and LAMP-1. An non-internalised bead is shown (star). (d) Ova-AF568 intensities in 
individual phagosomes. (e) Correlation between ova-AF568 and LAMP-1 fluorescence in individual phagosomes. (f) 
LAMP-1 intensities in individual phagosomes. Data is from one representative experiment in which a least 470 
individual phagosomes in 10 different cells per condition were analysed (c-f). All data was created by Dr Enrique 
Gutiérrez-Martinez (undertaken in the Guermonprez laboratory, King’s College London), and are presented with 




Figure 8-2: Single-photon emission computed tomography (SPECT) images of RA patients.  
Example SPECT images of the hands of 5 RA patients after injection with 99mTechnetium labelled NC100692 peptide 
(mariciclatide), which contains the RGD peptide. Darker areas indicate areas of uptake. These were produced as part 





1. Clarke F, Purvis HA, Sanchez-Blanco C, Gutiérrez-Martinez E, Cornish GH, Zamoyska R, 
Guermonprez P, Cope AP. The protein tyrosine phosphatase PTPN22 negatively 
regulates presentation of immune complex derived antigens. Scientific Reports 8 
(2018).  
2. Sanchez-Blanco C, Clarke F, Cornish GH, Depoil D, Thompson SJ, Dai X, Rawlings DJ, 
Dustin ML, Zamoyska R, Cope AP, Purvis HA. Protein tyrosine phosphatase PTPN22 
regulates LFA-1 dependent Th1 responses. Journal of Autoimmunity 94 (2018). 
3. Clarke F, Jordan, CK, Gutierrez-Martinez E, Bibby JA, Sanchez-Blanco C, Cornish GH, 
Dai X, Rawlings DJ, Zamoyska R, Guermonprez P, Cope AP, Purvis HA. Protein Tyrosine 
Phosphatase PTPN22 is dispensable for DC antigen processing and promotion of T-
cell activation by DCs. PLoS ONE 12 (2017). 
4. Purvis HA, Clarke F, Sanchez-Blanco C, Cornish GH, Rawlings DJ, Zamoyska R, Cope AP. 
Protein Tyrosine Phosphatase PTPN22 regulates IL-1β dependent Th17 responses by 
modulating dectin-1 signaling in mice. European Journal of Immunology 48 (2017).  
5. Imberti C, Terry SY, Cullinane C, Clarke F, Cornish GH, Ramakrishnan NK, Roselt P, 
Cope AP, Hicks RJ, Blower PJ, Ma MT. Enhancing PET Signal at Target Tissue in Vivo: 
Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging 
of αvβ3 Integrin Expression with Gallium-68. Bioconjugate Chemistry 28 (2017). 
6. Burn GA, Cornish GH, Potrzebowska K, Samuelsson M, Griffié J, Minoughan S, Yates 
M, Ashdown G, Pernodet N, Morrison VL, Sanchez-Blanco C, Purvis H, Clarke F, 
Brownlie RJ, Vyse TJ, Zamoyska R, Owen DM, Svensson LM, Cope AP. Superresolution 
imaging of the cytoplasmic phosphatase PTPN22 links integrin-mediated T cell 




1. Minton, K. Unravelling the motheaten phenotype. Nat. Rev. Immunol. 13, 307–307 
(2013). 
2. Kozlowski, M. et al. Expression and catalytic activity of the tyrosine phosphatase PTP1C 
is severely impaired in motheaten and viable motheaten mice. J. Exp. Med. 178, 2157–
63 (1993). 
3. Östman, A., Hellberg, C. & Böhmer, F. D. Protein-tyrosine phosphatases and cancer. 
Nat. Rev. Cancer 6, 307–320 (2006). 
4. Arimura, Y. & Yagi, J. Comprehensive Expression Profiles of Genes for Protein Tyrosine 
Phosphatases in Immune Cells. Sci. Signal. 3, 1–11 (2010). 
5. Matthews, R. J., Bowne, D. B., Flores, E. & Thomas, M. L. Characterization of 
hematopoietic intracellular protein tyrosine phosphatases: description of a 
phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-
, serine-, and threonine-rich sequences. Mol. Cell. Biol. 12, 2396–405 (1992). 
6. Cohen, S., Dadi, H., Shaoul, E., Sharfe, N. & Roifman, C. M. Cloning and Characterization 
of a Lymphoid-Specific, Inducible Human Protein Tyrosine Phosphatase, Lyp. Blood 6, 
2013–2024 (1999). 
7. Wang, S. et al. Identification of a variant form of tyrosine phosphatase LYP. BMC Mol. 
Biol. 11, 78 (2010). 
8. Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated 
with type I diabetes. Nat. Genet. 36, 337–338 (2004). 
9. Wu, J. et al. Identification of substrates of human protein-tyrosine phosphatase 
PTPN22. J. Biol. Chem. 281, 11002–10 (2006). 
10. Wang, Y. et al. The Autoimmunity-Associated Gene PTPN22 Potentiates Toll-like 
Receptor-Driven, Type 1 Interferon-Dependent Immunity. Immunity 39, 111–122 
(2013). 
11. Hill, R. J. et al. The lymphoid protein tyrosine phosphatase Lyp interacts with the 
adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp. 
Hematol. 30, 237–244 (2002). 
12. Zhang, J. et al. The autoimmune disease–associated PTPN22 variant promotes calpain-
mediated Lyp/Pep degradation associated with lymphocyte and DC 
hyperresponsiveness. Nat. Genet. 43, 902–907 (2011). 
13. Dai, X. et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in 
murine models. J. Clin. Invest. 123, 2024–2036 (2013). 
14. Gomez, L. M. et al. PTPN22 C1858T polymorphism in Colombian patients with 
autoimmune diseases. Genes Immun. 6, 628–31 (2005). 
15. Douroudis, K. et al. Protein tyrosine phosphatase non-receptor type 22 gene variants at 
position 1858 are associated with type 1 and type 2 diabetes in Estonian population. 
Tissue Antigens 72, 425–30 (2008). 
16. Fedetz, M. et al. The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 
diabetes in a Ukrainian population. Tissue Antigens 67, 430–433 (2006). 
17. Smyth, D. et al. Replication of an Association Between the Lymphoid General 
205 
 
Autoimmunity Locus. Diabetes 53, 10–13 (2004). 
18. Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated 
with type I diabetes. Nat. Genet. 36, 337–8 (2004). 
19. Zhernakova,  a et al. Differential association of the PTPN22 coding variant with 
autoimmune diseases in a Dutch population. Genes Immun. 6, 459–61 (2005). 
20. Zheng, W. & She, J.-X. Genetic Association Between a Lymphoid Tyrosine Phosphatase 
(PTPN22) and Type 1 Diabetes. Diabetes 54, 906–908 (2005). 
21. Kahles, H. et al. Sex-specific association of PTPN22 1858T with type 1 diabetes but not 
with Hashimoto’s thyroiditis or Addison’s disease in the German population. Eur. J. 
Endocrinol. 153, 895–899 (2005). 
22. Simkins, H. M. A. et al. Association of the PTPN22 locus with rheumatoid arthritis in a 
New Zealand Caucasian cohort. Arthritis Rheum. 52, 2222–2225 (2005). 
23. Hinks, A. et al. Association between the PTPN22 gene and rheumatoid arthritis and 
juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an 
autoimmunity gene. Arthritis Rheum. 52, 1694–1699 (2005). 
24. Plenge, R. M. et al. Replication of Putative Candidate-Gene Associations with 
Rheumatoid Arthritis in 14,000 Samples from North America and Sweden: Association 
of Susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet 77, 1044–1060 
(2005). 
25. Seldin, M. F. et al. Finnish case-control and family studies support PTPN22 R620W 
polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no 
effect in juvenile idiopathic arthritis. Genes Immun. 6, 720–2 (2005). 
26. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a 
protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J 
Hum Genet 75, 330–337 (2004). 
27. Wesoly, J. et al. Association of the PTPN22 C1858T single-nucleotide polymorphism 
with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum. 52, 
2948–2950 (2005). 
28. Kyogoku, C. et al. Genetic association of the R620W polymorphism of protein tyrosine 
phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75, 504–7 (2004). 
29. Orozco, G. et al. Association of a functional single-nucleotide polymorphism of PTPN22 , 
encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus 
erythematosus. Arthritis Rheum. 52, 219–224 (2005). 
30. Velaga, M. R. et al. The Codon 620 Tryptophan Allele of the Lymphoid Tyrosine 
Phosphatase (LYP) Gene Is a Major Determinant of Graves’ Disease. J. Clin. Endocrinol. 
Metab. 89, 5862–5865 (2004). 
31. Skorka, A., Bednarczuk, T., Bar-Andziak, E., Nauman, J. & Ploski, R. Lymphoid tyrosine 
phosphatase (PTPN22/LYP) variant and Graves’ disease in a Polish population: 
association and gene dose-dependent correlation with age of onset. Clin. Endocrinol. 
(Oxf). 62, 679–682 (2005). 
32. Zhebrun, D. et al. Association of PTPN22 1858T/T genotype with type 1 diabetes, 
Graves’ disease but not with rheumatoid arthritis in Russian population. Aging (Albany. 
NY). 3, 368–73 (2011). 
33. Roycroft, M. et al. The tryptophan 620 allele of the lymphoid tyrosine phosphatase 
206 
 
(PTPN22) gene predisposes to autoimmune Addison’s disease. Clin. Endocrinol. (Oxf). 
70, 358–362 (2009). 
34. Skinningsrud, B. et al. Mutation screening of PTPN22: association of the 1858T-allele 
with Addison’s disease. Eur. J. Hum. Genet. 16, 977–982 (2008). 
35. Begovich, A. B. et al. The R620W polymorphism of the protein tyrosine phosphatase 
PTPN22 is not associated with multiple sclerosis. Am. J. Hum. Genet. 76, 184–7 (2005). 
36. Matesanz, F. et al. Protein tyrosine phosphatase gene (PTPN22) polymorphism in 
multiple sclerosis. J Neurol 252, 994–995 (2005). 
37. Hedjoudje, A. et al. rs2476601 polymorphism in PTPN22 is associated with Crohn’s 
disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 
controls. Ann. Gastroenterol. 30, 197–208 (2017). 
38. Lamsyah, H. et al. Association of PTPN22 gene functional variants with development of 
pulmonary tuberculosis in Moroccan population. Tissue Antigens 74, 228–232 (2009). 
39. Gomez, L. M., Anaya, J.-M. & Martin, J. Genetic Influence of PTPN22 R620W 
Polymorphism in Tuberculosis. Hum. Immunol. 66, 1242–1247 (2005). 
40. Chapman, S. J. et al. PTPN22 and invasive bacterial disease. Nat. Genet. 38, 499–500 
(2006). 
41. Montes-Cano, M. A. et al. PTPN22 C1858T Polymorphism and the Outcome of Hepatitis 
C Virus Infection. Viral Immunol. 21, 491–494 (2008). 
42. Chen, Z. et al. Association of PTPN22 gene (rs2488457) polymorphism with ulcerative 
colitis and high levels of PTPN22 mRNA in ulcerative colitis. Int. J. Colorectal Dis. 28, 
1351–1358 (2013). 
43. El-Kafoury, A. A., Haroun, M., Embaby, A. M. & Dawoods, A. S. The association of 
polymorphic sites in some genes with type 1 diabetes mellitus in a sample of Egyptian 
children. Egypt. J. Med. Hum. Genet. 15, 265–272 (2014). 
44. Kawasaki, E. et al. Systematic search for single nucleotide polymorphisms in a lymphoid 
tyrosine phosphatase gene (PTPN22): Association between a promoter polymorphism 
and type 1 diabetes in Asian populations. Am. J. Med. Genet. Part A 140A, 586–593 
(2006). 
45. Fan, Z.-D. et al. STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms 
influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients. 
PLoS One 10, e0117389 (2015). 
46. Feng, X. et al. Association of the PTPN22 gene (-1123G &gt; C) polymorphism with 
rheumatoid arthritis in Chinese patients. Tissue Antigens 76, 297–300 (2010). 
47. Huang, J.-J. et al. A PTPN22 promoter polymorphism −1123G&gt;C is associated with RA 
pathogenesis in Chinese. Rheumatol. Int. 32, 767–771 (2012). 
48. Zoledziewska, M. et al. Further evidence of a primary, causal association of the PTPN22 
620W variant with type 1 diabetes. Diabetes 57, 229–34 (2008). 
49. Dieudé, P. et al. Testing for linkage and association with rheumatoid arthritis a ptpn22 
promoter polymorphism reported to be associated and linked with type 1 diabetes in 
the Caucasian population. Ann. Rheum. Dis. 67, 900–1 (2008). 
50. Remuzgo-Martínez, S. et al. Protein tyrosine phosphatase non-receptor 22 and C-Src 
tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. Sci. 
207 
 
Rep. 7, (2017). 
51. Orrú, V. et al. A loss-of-function variant of PTPN22 is associated with reduced risk of 
systemic lupus erythematosus. Hum. Mol. Genet. 18, 569–79 (2009). 
52. López-Cano, D. J. et al. The PTPN22 R263Q polymorphism confers protection against 
systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers 
susceptibility to Graves’ disease in a Mexican population. Inflamm. Res. 66, 775–781 
(2017). 
53. Rodríguez-Rodríguez, L. et al. The PTPN22 R263Q polymorphism is a risk factor for 
rheumatoid arthritis in Caucasian case-control samples. Arthritis Rheum. 63, 365–372 
(2010). 
54. Diaz-Gallo, L.-M. et al. Differential association of two PTPN22 coding variants with 
Crohnʼs disease and ulcerative colitis. Inflamm. Bowel Dis. 17, 2287–2294 (2011). 
55. Hasegawa, K. et al. PEST Domain–Enriched Tyrosine Phosphatase (PEP) Regulation of 
Effector/Memory T Cells. Science (80-. ). 303, 685–689 (2004). 
56. Stanford, S. M., Rapini, N. & Bottini, N. Regulation of TCR signalling by tyrosine 
phosphatases: from immune homeostasis to autoimmunity. Immunology 137, 1–19 
(2012). 
57. Maine, C. J. et al. PTPN22 Alters the Development of Regulatory T Cells in the Thymus. 
J. Immunol. 188, 5267–5275 (2012). 
58. Brownlie, R. J. et al. Lack of the Phosphatase PTPN22 Increases Adhesion of Murine 
Regulatory T Cells to Improve Their Immunosuppressive Function. Sci. Signal. 5, ra87-
ra87 (2012). 
59. Maine, C. J., Marquardt, K., Cheung, J. & Sherman, L. A. PTPN22 controls the germinal 
center by influencing the numbers and activity of T follicular helper cells. J. Immunol. 
192, 1415–24 (2014). 
60. Burn, G. L. et al. Superresolution imaging of the cytoplasmic phosphatase PTPN22 links 
integrin-mediated T cell adhesion with autoimmunity. Sci. Signal. 9, (2016). 
61. Sanchez-Blanco, C. et al. Protein tyrosine phosphatase PTPN22 regulates LFA-1 
dependent Th1 responses. J. Autoimmun. (2018). doi:10.1016/J.JAUT.2018.07.008 
62. Schickel, J.-N. et al. PTPN22 inhibition resets defective human central B cell tolerance. 
Sci. Immunol. 1, (2016). 
63. Vermeren, S. et al. PTPN22 Is a Critical Regulator of Fcγ Receptor–Mediated Neutrophil 
Activation. J. Immunol. 197, 4771–4779 (2016). 
64. Wang, Y. et al. PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-
Induced Type I Interferon in Systemic Lupus Erythematosus. Arthritis Rheumatol. 67, 
2403–2414 (2015). 
65. Holmes, D. A. et al. Autoimmunity-associated protein tyrosine phosphatase PEP 
negatively regulates IFN-alpha receptor signaling. J Exp Med 212, 1081–1093 (2015). 
66. Purvis, H. A. et al. Protein tyrosine phosphatase PTPN22 regulates IL-1β dependent 
Th17 responses by modulating dectin-1 signaling in mice. Eur. J. Immunol. 48, 306–315 
(2018). 
67. Li, M. et al. The common, autoimmunity-predisposing 620Arg &gt; Trp variant of 




68. Zikherman, J. et al. PTPN22 deficiency cooperates with the CD45 E613R allele to break 
tolerance on a non-autoimmune background. J. Immunol. 182, 4093–106 (2009). 
69. Zheng, P. & Kissler, S. PTPN22 Silencing in the NOD Model Indicates the Type 1 
Diabetes-Associated Allele Is Not a Loss-of-Function Variant. Diabetes 62, 896–904 
(2013). 
70. Yeh, L.-T. et al. Different Modulation of Ptpn22 in Effector and Regulatory T Cells Leads 
to Attenuation of Autoimmune Diabetes in Transgenic Nonobese Diabetic Mice. J. 
Immunol. 191, 594–607 (2013). 
71. Lin, X. et al. CRISPR-Cas9-Mediated Modification of the NOD Mouse Genome With 
Ptpn22R619W Mutation Increases Autoimmune Diabetes. Diabetes 65, 2134–8 (2016). 
72. Fousteri, G. et al. PTPN22 controls virally-induced autoimmune diabetes by modulating 
cytotoxic T lymphocyte responses in an epitope-specific manner. Clin. Immunol. 156, 
98–108 (2015). 
73. Sood, S. et al. Autoimmune Arthritis in SKG Mice PTPN22 Reduces Mannan-Induced 
Loss of the Protein Tyrosine Phosphatase. J. Immunol. (2016). 
doi:10.4049/jimmunol.1502656 
74. Wu, D. J. et al. Autoimmunity-Associated LYP-W620 Does Not Impair Thymic Negative 
Selection of Autoreactive T Cells. PLoS One 9, e86677 (2014). 
75. Jofra, T. et al. Protein tyrosine phosphatase PTPN22 has dual roles in promoting 
pathogen versus homeostatic-driven CD8 T-cell responses. Immunol. Cell Biol. 95, 121–
128 (2017). 
76. Jofra, T. et al. Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals 
Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic 
Choriomeningitis Virus Infection. Front. Immunol. 8, 811 (2017). 
77. Maine, C. J., Teijaro, J. R., Marquardt, K. & Sherman, L. A. PTPN22 contributes to 
exhaustion of T lymphocytes during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. 
113, E7231–E7239 (2016). 
78. Vang, T. et al. The autoimmune-predisposing variant of lymphoid tyrosine phosphatase 
favors T helper 1 responses. Hum. Immunol. 74, 574–585 (2013). 
79. Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-
function variant. Nat. Genet. 37, 1317–1319 (2005). 
80. Aarnisalo, J. et al. Reduced CD4+T cell activation in children with type 1 diabetes 
carrying the PTPN22/Lyp 620Trp variant. J. Autoimmun. 31, 13–21 (2008). 
81. Rieck, M. et al. Genetic variation in PTPN22 corresponds to altered function of T and B 
lymphocytes. J. Immunol. 179, 4704–10 (2007). 
82. Habib, T. et al. Altered B cell homeostasis is associated with type I diabetes and carriers 
of the PTPN22 allelic variant. J. Immunol. 188, 487–96 (2012). 
83. Menard, L. et al. The PTPN22 allele encoding an R620W variant interferes with the 
removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635 (2011). 
84. Metzler, G. et al. The Autoimmune Risk Variant PTPN22 C1858T Alters B Cell Tolerance 
at Discrete Checkpoints and Differentially Shapes the Naive Repertoire. J. Immunol. 
199, 2249–2260 (2017). 
209 
 
85. Bayley, R. et al. The autoimmune-associated genetic variant PTPN22 R620W enhances 
neutrophil activation and function in patients with rheumatoid arthritis and healthy 
individuals. Ann. Rheum. Dis. 74, 1588–1595 (2015). 
86. Douroudis, K., Shcherbakova, A., Everaus, H. & Aints, A. PTPN22 gene regulates natural 
killer cell proliferation during in vitro expansion. Tissue Antigens 76, 315–318 (2010). 
87. Vang, T., Nielsen, J. & Burn, G. L. A switch-variant model integrates the functions of an 
autoimmune variant of the phosphatase PTPN22. Sci. Signal. 11, eaat0936 (2018). 
88. Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid 
organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142–
62 (1973). 
89. Swiecki, M. & Colonna, M. The multifaceted biology of plasmacytoid DCs. Nat. Rev. 
Immunol. 15, 471–485 (2015). 
90. Cisse, B. et al. Transcription Factor E2-2 Is an Essential and Specific Regulator of 
Plasmacytoid DC Development. Cell 135, 37–48 (2008). 
91. Ghosh, H. S., Cisse, B., Bunin, A., Lewis, K. L. & Reizis, B. Continuous Expression of the 
Transcription Factor E2-2 Maintains the Cell Fate of Mature Plasmacytoid DCs. 
Immunity 33, 905–916 (2010). 
92. McKenna, H. J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting 
hematopoietic progenitor cells, DCs, and natural killer cells. Blood 95, (2000). 
93. Hildner, K. et al. Batf3 Deficiency Reveals a Critical Role for CD8alpha+ DCs in Cytotoxic 
T Cell Immunity. Science (80-. ). 322, 1097–1100 (2008). 
94. Gurka, S., Hartung, E., Becker, M. & Kroczek, R. A. Mouse Conventional DCs Can be 
Universally Classified Based on the Mutually Exclusive Expression of XCR1 and SIRPα. 
Front. Immunol. 6, 35 (2015). 
95. Caton, M. L., Smith-Raska, M. R. & Reizis, B. Notch-RBP-J signaling controls the 
homeostasis of CD8- DCs in the spleen. J. Exp. Med. 204, 1653–64 (2007). 
96. Lewis, K. L. et al. Notch2 receptor signaling controls functional differentiation of DCs in 
the spleen and intestine. Immunity 35, 780–91 (2011). 
97. Xu, Y., Zhan, Y., Lew, A. M., Naik, S. H. & Kershaw, M. H. Differential development of 
murine DCs by GM-CSF versus Flt3 ligand has implications for inflammation and 
trafficking. J. Immunol. 179, 7577–84 (2007). 
98. Förster, R. et al. CCR7 Coordinates the Primary Immune Response by Establishing 
Functional Microenvironments in Secondary Lymphoid Organs. Cell 99, 23–33 (1999). 
99. Ohnmacht, C. et al. Constitutive ablation of DCs breaks self-tolerance of CD4 T cells and 
results in spontaneous fatal autoimmunity. J. Exp. Med. 206, 549–59 (2009). 
100. Racoosin, E. L. & Swanson, J. A. Macrophage colony-stimulating factor (rM-CSF) 
stimulates pinocytosis in bone marrow-derived macrophages. J. Exp. Med. 170, 1635–
48 (1989). 
101. Araki, N., Johnson, M. T. & Swanson, J. A. A role for phosphoinositide 3-kinase in the 
completion of macropinocytosis and phagocytosis by macrophages. J. Cell Biol. 135, 
1249–60 (1996). 
102. West, M. A., Prescott, A. R., Eskelinen, E.-L., Ridley, A. J. & Watts, C. Rac is required for 
constitutive macropinocytosis by DCs but does not control its downregulation. Curr. 
210 
 
Biol. 10, 839–848 (2000). 
103. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. DCs Use Macropinocytosis and the 
Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility 
Complex Class 1I Compartment: Downregulation by Cytokines and Bacterial Products. 
doi:10.1084/jem.182.2.389 
104. Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Distinct pathways of antigen 
uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316, 612–6 
(2007). 
105. Norbury, C. C., Chambers, B. J., Prescott, A. R., Ljunggren, H. G. & Watts, C. Constitutive 
macropinocytosis allows TAP-dependent major histocompatibility compex class I 
presentation of exogenous soluble antigen by bone marrow-derived DCs. Eur. J. 
Immunol. 27, 280–288 (1997). 
106. Drutman, S. B. & Trombetta, E. S. DCs continue to capture and present antigens after 
maturation in vivo. J. Immunol. 185, 2140–6 (2010). 
107. Kloetzel, P.-M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2, 179–
188 (2001). 
108. ten Broeke, T., Wubbolts, R. & Stoorvogel, W. MHC class II antigen presentation by DCs 
regulated through endosomal sorting. Cold Spring Harb. Perspect. Biol. 5, a016873 
(2013). 
109. Anderson, M. S. & Miller, J. Invariant chain can function as a chaperone protein for class 
II major histocompatibility complex molecules. Proc. Natl. Acad. Sci. U. S. A. 89, 2282–6 
(1992). 
110. Marks, M. S., Germain, R. N. & Bonifacino, J. S. Transient aggregation of major 
histocompatibility complex class II chains during assembly in normal spleen cells. J. Biol. 
Chem. 270, 10475–81 (1995). 
111. Bonifacino, J. S. & Traub, L. M. Signals for Sorting of Transmembrane Proteins to 
Endosomes and Lysosomes. Annu. Rev. Biochem. 72, 395–447 (2003). 
112. Hofmann, M. W. et al. The leucine-based sorting motifs in the cytoplasmic domain of 
the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their 
medium chains. J. Biol. Chem. 274, 36153–8 (1999). 
113. Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of Antigen Processing. Annu. Rev. 
Immunol. 31, 443–473 (2013). 
114. Vyas JM, Kim YM, Artavanis-Tsakonas K, Love JC, V. der V. A. and P. H. Tubulation of 
class II MHC compartments is microtubule dependent and involves multiple 
endolysosomal membrane proteins in primary DCs. J Immunol 178, 7199–7210 (2007). 
115. Furuta, K., Walseng, E. & Roche, P. A. Internalizing MHC class II-peptide complexes are 
ubiquitinated in early endosomes and targeted for lysosomal degradation. Proc. Natl. 
Acad. Sci. U. S. A. 110, 20188–93 (2013). 
116. Walseng, E. et al. Ubiquitination regulates MHC class II-peptide complex retention and 
degradation in DCs. Proc. Natl. Acad. Sci. U. S. A. 107, 20465–70 (2010). 
117. Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential Lysosomal 
Proteolysis in Antigen-Presenting Cells Determines Antigen Fate. Science (80-. ). 307, 
1630–1634 (2005). 
118. Lowell, C. A. Src-family and Syk kinases in activating and inhibitory pathways in innate 
211 
 
immune cells: signaling cross talk. Cold Spring Harb. Perspect. Biol. 3, (2011). 
119. Matsubara, S. et al. Syk Activation in DCs Is Essential for Airway Hyperresponsiveness 
and Inflammation. Am. J. Respir. Cell Mol. Biol. 34, 426–433 (2006). 
120. Nakashima, K. et al. A novel Syk kinase-selective inhibitor blocks antigen presentation 
of immune complexes in DCs. Eur. J. Pharmacol. 505, 223–228 (2004). 
121. Crowley, M. T. et al. A Critical Role for Syk in Signal Transduction and Phagocytosis 
Mediated by Fcγ Receptors on Macrophages. J. Exp. Med. 186, 1027–1039 (1997). 
122. Fitzer-Attas, C. J. et al. Fcgamma receptor-mediated phagocytosis in macrophages 
lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J. Exp. Med. 191, 669–82 
(2000). 
123. Fousteri, G., Liossis, S. C. & Battaglia, M. Roles of the protein tyrosine phosphatase 
PTPN22 in immunity and autoimmunity. Clin. Immunol. 149, 556–565 (2013). 
124. Schroeder, H. W., Cavacini, L. & Cavacini, L. Structure and function of immunoglobulins. 
J. Allergy Clin. Immunol. 125, S41-52 (2010). 
125. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. 
Immunol. 8, 34–47 (2008). 
126. Bruhns, P. Properties of mouse and human IgG receptors and their contribution to 
disease models. Blood 119, 5640–5650 (2012). 
127. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H. & Lambrecht, B. N. The function of Fcγ 
receptors in DCs and macrophages. Nat. Rev. Immunol. 14, 94–108 (2014). 
128. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to 
Effector Functions. Front. Immunol. 5, 520 (2014). 
129. Daëron, M. et al. The same tyrosine-based inhibition motif, in the intra-cytoplasmic 
domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. 
Immunity 3, 635–646 (1995). 
130. Amigorena, S., Salamero, J., Davoust, J., Fridman, W. H. & Bonnerot, C. Tyrosine-
containing motif that transduces cell activation signals also determines internalization 
and antigen presentation via type III receptors for IgG. Nature 358, 337–341 (1992). 
131. Miettinen, H. M., Rose, J. K. & Mellman, I. Fc receptor isoforms exhibit distinct abilities 
for coated pit localization as a result of cytoplasmic domain heterogeneity. Cell 58, 
317–327 (1989). 
132. Daëron, M. Fc receptor biology. Annu. Rev. Immunol. 15, 203–234 (1997). 
133. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. Cell Surface Recycling of Internalized 
Antigen Permits DC Priming of B Cells. Immunity 23, 503–514 (2005). 
134. Qiao, S.-W. et al. Dependence of antibody-mediated presentation of antigen on FcRn. 
Proc. Natl. Acad. Sci. U. S. A. 105, 9337–42 (2008). 
135. Baker, K. et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG 
immune complexes by CD8-CD11b+ DCs. Proc. Natl. Acad. Sci. 108, 9927–9932 (2011). 
136. McEwan, W. A. et al. Intracellular antibody-bound pathogens stimulate immune 
signaling via the Fc receptor TRIM21. Nat. Immunol. 14, 327–36 (2013). 
137. Mallery, D. L. et al. Antibodies mediate intracellular immunity through tripartite motif-
containing 21 (TRIM21). Proc. Natl. Acad. Sci. U. S. A. 107, 19985–90 (2010). 
212 
 
138. de Haij, S. et al. In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc 
Receptor ITAM Signaling. Cancer Res. 70, 3209–3217 (2010). 
139. Boross, P. et al. FcR -Chain ITAM Signaling Is Critically Required for Cross-Presentation 
of Soluble Antibody-Antigen Complexes by DCs. J. Immunol. 193, 5506–5514 (2014). 
140. Graham, D. B. et al. ITAM signaling in DCs controls T helper cell priming by regulating 
MHC class II recycling. Blood 116, 3208–18 (2010). 
141. Takai, T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580–592 (2002). 
142. D’Ambrosio, D. et al. Recruitment and activation of PTP1C in negative regulation of 
antigen receptor signaling by Fc gamma RIIB1. Science 268, 293–7 (1995). 
143. Ono, M., Bolland, S., Tempst, P. & Ravetch, J. V. Role of the inositol phosphatase SHIP in 
negative regulation of the immune system by the receptor FeγRIIB. Nature 383, 263–
266 (1996). 
144. Ono, M. et al. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory 
signaling. Cell 90, 293–301 (1997). 
145. Schmidt, R. E. & Gessner, J. E. Fc receptors and their interaction with complement in 
autoimmunity. Immunol. Lett. 100, 56–67 (2005). 
146. Radeke, H. H. et al. Opposite regulation of type II and III receptors for immunoglobulin 
G in mouse glomerular mesangial cells and in the induction of anti-glomerular 
basement membrane (GBM) nephritis. J. Biol. Chem. 277, 27535–44 (2002). 
147. Tridandapani, S. et al. Regulated expression and inhibitory function of Fcgamma RIIb in 
human monocytic cells. J. Biol. Chem. 277, 5082–9 (2002). 
148. Blank, U., Launay, P., Benhamou, M. & Monteiro, R. C. Inhibitory ITAMs as novel 
regulators of immunity. Immunol. Rev. 232, 59–71 (2009). 
149. Getahun, A. & Cambier, J. C. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc 
receptor signaling. Immunol. Rev. 268, 66–73 (2015). 
150. Molfetta, R. et al. Regulation of Fc receptor endocytic trafficking by ubiquitination. 
Front. Immunol. 5, 1–9 (2014). 
151. Skokowa, J. et al. Macrophages induce the inflammatory response in the pulmonary 
Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor 
cooperation. J. Immunol. 174, 3041–50 (2005). 
152. Shushakova, N. et al. C5a anaphylatoxin is a major regulator of activating versus 
inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 110, 
1823–30 (2002). 
153. Seligman, V. A. et al. The Fcgamma receptor IIIA-158F allele is a major risk factor for the 
development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis 
Rheum. 44, 618–625 (2001). 
154. Nieto, A. et al. Involvement of Fcγ receptor IIIA genotypes in susceptibility to 
rheumatoid arthritis. Arthritis Rheum. 43, 735 (2000). 
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